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Summary
Vascular cell activation: mechanisms and consequences in human disease.
At sites of injury/inflammation local vascular cell activation occurs. This results in
the elaboration of cytokines, chemokines and, ultimately, the infiltration of
interstitial tissues by peripheral blood leukocytes. Recent advances in the
understanding of the paradigm of leukocyte trafficking and, in particular, the role of
adhesion molecules, chemokines and chemokine receptors in this process are
reviewed. Vascular cell activation, while essential in host defence, has pathological
consequences in a variety of human diseases. The immunopathology of these
processes in the development of atherosclerosis, vasculitis, thrombosis,
vasoconstriction and allograft rejection is discussed in detail. We develop the
concept that diverse stimuli perturb normal vascular homeostatic mechanisms and
initiate the cascade of inflammatory events which leads to the ultimate phenotypic
expression of these various diseases.
Growing evidence links systemic hypertension with the development of
atherosclerosis, and glomerular hypertension with glomerulosclerosis. Evidence has
been provided that mechanical strain acting on the vessel/glomerulus may be a
trigger for antigen-independent vascular cell activation in these diseases. In the
current study in vitro experiments were designed to focus specifically on the putative
modulation of immune mediator expression by mechanical strain. Results
demonstrate that mechanical strain can be either a proinflammatory or prosclerotic
stimulus depending on the cell type used. In ECV-304 cells cyclic mechanical strain
results in increased expression of chemokines (IL-8 and MCP-1), chemokine
x
receptor (CXCR4) and adhesion molecule expression (ICAM-1). In this study,
increased expression ofCOX-2 in ECV-304 cells was also demonstrated in response
to mechanical strain. The immunomodulatory effects of COX-2 following vascular
injury and in animal models of inflammation have been the focus of much recent
interest and the implications of such strain-induced increases in COX-2 expression,
given the available evidence to date, are discussed. In contrast, exposure of
mesangial cells to cyclic mechanical strain results in increased expression of the
prosclerotic mediators TGF-p and CTGF, supporting a role for this stimulus in the
ECM accumulation characteristic of glomerulosclerosis. No such increases occurred
in mesangial cell expression of cytokine, chemokine or chemokine receptors in
response to mechanical strain.
Finally, observations in both acute and chronic vascular disease suggest the existence
of endogenous regulatory systems that act to restore homeostatic vascular tone,
thrombogenicity and adhesiveness for leukocytes to normal. In this dynamic process
a large number of anti-inflammatory molecules are elaborated. Experiments focused
on the actions of lipoxins, a group of rapidly-acting anti-inflammatory eicosanoids -
specifically the signal transduction events triggered by the activation of lipoxin
receptors in endothelial and mesangial cells. The suppressors of cytokine signalling
(SOCS) proteins are a recently identified family of proteins which inhibit cytokine-
activation of the Janus kinase/signal transducers and activators of transcription
(JAK/STAT) cascade. The structural features of these proteins, their mechanisms of
action and possible physiological roles are reviewed. The role of the SOCS proteins
in inflammatory-based disease states is to date unknown. Experiments were therefore
undertaken to elucidate the role of SOCS in autoimmune inflammation using a rat
xi
crescentic nephritis model. Increases in SOCS-3 and CIS-1 were demonstrated which
appeared to correlate with disease activity. In addition, the profile of SOCS
expression was examined in a model of alloantigen-driven inflammation -
experimental cardiac transplant rejection. SOCS-3 expression was confined to the
rejecting cardiac allografts and occurred throughout the time course studied whereas
increases in SOCS-1 and CIS-1 expression, although present, were less sustained.
The expression of a representative array of immune mediators implicated in the
transplant immune response (cytokines, chemokines, chemokine receptors, adhesion
molecules and COX-2) was also profiled in this model. The demonstration of SOCS
expression in both these models implicates these endogenous inhibitors in the
modulation of cytokine bioactivities in inflammation and host defence.
xii
Aims
1. To assess the effect of cyclic strain on ECV-304 cell immune mediator (cytokine,
chemokine and adhesion molecule) expression.
2. To examine the potential activation of glomerular endothelial and mesangial cells
by cyclic mechanical strain.
3. To characterise the signal transduction events triggered by ligand-dependent
activation of endothelial lipoxin and leukotriene receptors; specifically to assess
putative MAP kinase activation.
4. To profile suppressors of cytokine signalling (SOCS) expression in glomerular
endothelial and mesangial cells in vitro.
5. To assess renal SOCS expression in an experimental nephrotoxic nephritis
model.
6. To profile the expression of SOCS in experimental acute cardiac transplant
rejection and to investigate the temporal expression of cytokines and leukocyte
trafficking determinants in this model.
Xlll
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Chapter 1
Regulation of vascular cell activation in health
1.1. Overview of endothelial cell, vascular smooth muscle cell and pericyte
physiology in health
1.1.1. Endothelial cells
The vascular endothelium, located at the interface between blood and the vascular
wall, is ideally positioned to modulate not only the activity of circulating blood
components, but also the structure and function of the vessel wall. In health, the
endothelium maintains vascular tone, provides a non-thrombogenic surface, is anti-
adhesive for leukocytes and is a permeability barrier across which there is
bidirectional exchange of nutrients and metabolites between blood and tissue
extracellular fluid. In addition, endothelial cells synthesise the basement membrane
collagens and proteoglycans upon which they rest, and, by the elaboration of growth
factors and cytokines, mediate important growth-regulatory and immuno-modulatory
effects (1). The endothelial surface is constantly exposed to humoral factors,
inflammatory mediators and haemodynamic forces and thus, by virtue of its strategic
position, is ideally placed to serve both as a sensor of these various signals and as an
effector of the biological responses to them.
Endothelial cells and structural integrity
The endothelial cells of normal arteries form a continuous single layer of flattened
cells, orientated with the long axis in the direction of blood flow. In areas of
turbulent flow or altered shear, the cells are altered in shape. In high shear, for
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example, they are elongated and, in low shear, cobblestone in shape (2, 3). The cell
shape is maintained by the endothelial cell cytoskeleton consisting of actin
microfdaments and microtubules. Cell-cell contact between endothelial cells is
maintained by unique calcium-dependent adhesion molecules of the cadherin family
in adherens junctions (4). Vascular endothelial (VE) cadherin, P-cadherin, E-
cadherin and N-cadherin are all expressed in endothelial cells. VE cadherin forms
complexes with catenins, some of which link the catenin/cadherin complex to actin
microfilaments (5). The cytoskeletal protein vinculin is co-localised with peripheral
actin microfilament bundles in the adherens junctions and, via specific actin-binding
sites, may facilitate the stable association of actin with the plasma membrane. In
addition, adhesion plaques containing vinculin are important sites for anchoring
endothelial cells to the sub-endothelium at focal adhesion sites (6). Disruption of
these junctions and/or adhesion plaques results in an immediate loss of endothelial
integrity due to subtle changes in intercellular adhesion, causing small gaps in the
endothelium or frank loss of endothelial cells. Under normal circumstances there is
very little turnover of endothelial cells suggesting that endothelial integrity is strictly
maintained in the normal resting state by quiescent endothelial cells. Following
denuding endothelial injury, the endothelial cell must undergo a transition from a
resting cell with a cytoskeleton organised for barrier function to one that promotes
cell translocation. Using in vitro models it has been established that, in small
wounds, adjacent endothelial cells rapidly extrude lamellopodia into the denuded
area (7, 8). If repair is incomplete, as in larger wounds, cell migration and eventual
proliferation occurs. These responses are accompanied by complex changes in
arrangements of the intra-cellular actin microfilament bundles, and stimulated by a
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variety of growth factors such as vascular endothelial growth factor and basic
fibroblast growth factor (9).
Endothelial control of vascular tone
Endothelial control of vasomotor tone occurs via its production of various vasoactive
mediators and it is the net balance of these mediators, i.e. their vasodilatory or
vasoconstrictive properties, that determines the local vascular tone and, hence, tissue
blood flow. The principal vasodilators produced by the endothelium are nitric oxide
(NO), prostacyclin (PGE), endothelial-derived hyperpolarising factor (EDHF),
adenosine and bradykinin. By contrast, endothelial production of endothelin (ET)-l,
angiotensin II (AT II) or endothelial-derived constricting factor (EDCF) results in
contraction of vascular smooth muscle cells (VSMC) and, ultimately,
vasoconstriction.
Endothelial-derived vasodilators
In 1980, landmark studies by Furchgott and Zawadzki showed that intact
endothelium is required for acetylcholine-induced vasorelaxation, and that acetyl¬
choline stimulates release of a potent vasodilator substance termed endothelial
derived relaxing factor (EDRF) (10). It is now known that EDRF is NO and that, in
addition to its potent vasodilator properties, NO is an important endogenous inhibitor
of leukocyte and platelet adhesion to endothelial cells (11, 12). NO is synthesised
constitutively in the endothelial cell from L-arginine by the actions of nitric oxide
synthase (NOS) through a five-electron oxidation. Three distinct isoforms of NOS
have been identified which catalyse the same redox reaction, but differ in
biochemical and structural properties (13). Type 1 NOS is constitutively expressed in
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neurons (neNOS) where its activity is regulated by calcium gradients. Type 2 NOS is
transcriptionally induced by cytokines, is independent of elevations of calcium and is
prototypically expressed in inflammatory macrophages. The type 3 isoform is
constitutive in endothelial cells (ecNOS). All NOS isoforms exhibit unique
complexity, but common to all is a flavin-containing reductase domain and a haem-
containing oxidase domain. This built-in electron transport system is used to oxidise
L-arginine to NO and the by-product L-citrulline. Tetrahydrobiopterin, flavin
mononucleotide and flavin adenine dinucleotide are cofactors in these reactions
while NADPH and molecular oxygen are necessary cosubstrates for optimal NOS
activity (14, 15). (Fig. 1.1).
Figure 1.1 NO synthesis (adapted from 16)
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ecNOS is dynamically regulated and can increase the production ofNO by more than
20-fold within seconds, presumably through the mobilisation of calcium. Chronic
increases in blood flow result in a more prolonged release of NO suggesting
induction of the NOS gene or of the cofactors necessary for the production ofNO by
EC. Stimuli that have been shown to increase NOS synthesis include a variety of
vasomediators including bradykinin, histamine, catecholamines, substance P,
serotonin, thrombin and vasopressin, as well as physical forces such as increased
shear stress and cyclic strain (17-19). There does not seem to be any control of NO
release as it rapidly diffuses out of the cell, either as free gas or by complexing with
carrier proteins, both into the vascular lumen and away from the lumen towards the
underlying cells. Before it reaches target cells, however, it may be inactivated by
oxygen radicals (O2" and OH") and iron containing compounds such as haemoglobin
(20).
NO stimulates soluble guanylate cyclase in target cells, leading to increases in
intracellular cGMP levels (21, 22). In vascular smooth muscle cells (VSMC), cGMP
activates cGMP-dependent protein kinase, which phosphorylates myosin light chain
kinase and in doing so lowers its affinity for the calcium-calmodulin complex (Fig.
1.2). This results in decreased phosphorylation of myosin light chain, enhanced
formation of the comparatively less active, dephosphorylated form of myosin, and
VSMC relaxation. Activation of the cGMP-dependent protein kinases can also result
in phosphorylation of calcium transporters and complexing of intra-cellular calcium,
again resulting in VSMC relaxation.
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In addition to NO, endothelial cells synthesise PGE from arachidonic acid via a
series of reactions initiated by the enzyme cyclooxygenase (23). PGI2 acts
synergistically with NO to produce vasodilation and relaxes VSMC by the activation




Endothelial-derived vasodilators: action on vascular smooth muscle cells (24).
Several laboratories have described an endothelial-derived vasodilating factor that is
distinct from NO or PGE This factor acts by opening calcium-activated potassium
channels and hyperpolarizing the smooth muscle membrane and is termed
endothelial-derived hyperpolarizing factor or EDHF (3, 25). The identity of EDHF
and the possibility of multiple EDHFs has received considerable attention. Recent
studies have shown that in animal coronary, cerebral and renal arteries, EDHF is a
cytochrome P450 metabolite of arachidonic acid, an epoxyeicosatrienoic acid or EET
(26). EETs are released by vasoactive substances such as acetylcholine or
bradykinin. Their activation of the calcium-activated K+ ion channels hyperpolarises
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and relaxes smooth muscle (Fig 1.2). It should be pointed out, however, that while
some vascular beds possess EDHF activity, they do not produce arachidonic acid
metabolites by the cytochrome P450 pathway (e.g. rabbit carotid artery and rabbit
aorta), implicating compounds other than EET as stimuli for smooth muscle
hyperpolarisation in these vascular beds (27).
The endothelial cells also possesses the requisite machinery to generate adenosine, a
potent vasodilator (28). Ecto-ATPase catalyses the hydrolysis ofADP to AMP. AMP
is then converted, by the actions of 5'nucleotidase, to adenosine. This pathway not
only produces a potent vasodilator but, in addition, the initial hydrolysis step ensures
that the platelet-aggregating effects ofADP are regulated. Bradykinin is generated in
endothelial cells by the actions of kallikrein on kininogens (29). Bradykinin exerts
potent vasodilating actions by stimulating endothelial production of NO, PGE and
EDHF. In addition bradykinin promotes release of tPA from endothelial cells, an
important mediator of fibrinolysis.
Endothelial-derived vasoconstrictors
The most potent vasoconstrictor produced by endothelial cells is endothelin (ET)
(30). ET-1 is the predominant isoform of the endothelin peptide family and regulates
vasoconstriction and VSMC growth in tissues through activation of Gi-protein-
coupled ETa and ETb receptors. ET-1 synthesis in the endothelial cells is enhanced
by angiotensin II (AT II) (31), vascular endothelial growth factor (VEGF) (32),
cytokines (33), and haemodynamic strain (34). Inhibitors of endothelin synthesis
include NO (35), PGE (36), atrial natriuretic peptides (37) and oestrogens (38). The
precursor peptide big ET-1 is processed to ET-1 through cleavage by either
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endothelin-converting enzymes (ECE), chymase or non-ECE metalloproteinases. ET-
1 binding to ETa and ETb receptors on smooth muscle mediates potent sustained
contraction, in addition to VSMC production of cytokines and growth factors (39).
Endothelial expression of angiotensin converting enzyme (ACE) results in the local
conversion ofAT I to the active peptide AT II (40) (Fig 1.3).
Angiotensinogen
Renin








A and N neural endopeptidase
prolylendopeptidase
Fig 1.3 Renin- angiotensin system
AT IV
AT II functions, mainly through the AT II type 1 receptor (ATi), as an acute
vasoconstrictor, regulating systemic blood pressure and vascular tone (41, 42). AT
III and AT IV are degradation products of AT II and also possess biological
functions. AT III, while possesssing most of the properties of AT II and sharing the
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same receptors, is particularly important in brain physiology. AT IV possesses its
own receptors distinct from ATi and AT2 and, in contrast to AT II, mediates renal
and cerebral vasodilatation although its exact physiological role remains uncertain.
Through an independent and parallel pathway, endothelial ACE also inactivates
bradykinin, a potent vasodilator.
A number of other factors, termed endothelial derived constricting factors (EDCF),
are released by endothelial cells. The composition of these factors is unknown, but
likely candidates include cyclooxygenase products of arachidonic acid and other cis-
unsaturated fatty acids (43).
Interplay of endothelial-derived vasodilators and vasoconstrictors
The vascular endothelium operates in concert with other systems such as sympathetic
neural networks to modulate vascular tone through a balance of vasodilating and
vasoconstricting stimuli and inhibitors. Interactions between these vasoactive
mediators ensure homeostasis in resting vascular tone as well as rapid responses to
the various physiological stimuli e.g. exercise, that necessitate changes in local
vascular tone or tissue blood flow (1). Indeed one of the primary manifestations of
endothelial dysfunction is the impairment of the endothelium-dependent vasodilator
response (44, 45). In addition vasodilators such as NO and PGI2 have important anti¬
platelet and growth inhibitory effects (46, 47), while vasoconstrictors such as ET-1
or AT II stimulate growth of the VSMC (48, 49). The anti-platelet and vasorelaxant
effects of NO and PGI2 appear to be synergistic (50), because NO activates
cyclooxygenase 1, the constitutive isoform of the enzyme responsible for
prostaglandin synthesis from arachidonic acid (51). NO and PGI2 (39) inhibit
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endothelial synthesis of ET-1, while AT II enhances synthesis of this peptide. The
vasoconstrictor effects of ET-1 acting through ETA and ETB receptors on VSMC are
modulated by its binding to endothelial ETB receptors which results in production of
the vasodilators NO and PGI2. ACE promotes vasoconstriction in two principal ways
(52). In addition to its involvement in the generation of AT II, ACE also, via an
independent and parallel pathway, inactivates bradykinin, thereby preventing
bradykinin-induced release of vasodilators (NO, PGI2 and EDHF). These various
interactions, stimulatory and inhibitory, between the endothelial vasoactive




Haemostasis is the physiologic mechanism that maintains blood in a fluid state
within the circulation. Coagulation of blood is mediated by cellular components and








Fig 1.4 Coagulation cascade (53)
The coagulation cascade involves an intrinsic and extrinsic pathway. The intrinsic pathway is initiated
by the activation of factor XII by contact with surface (CS), whereas the extrinsic pathway begins
with the activation of factor VII by tissue microsomal lipoproteins (TF). Physiologically, the two
pathways work together to provide maximum stimulation of factor X which in the presence of factor
V activates prothrombin to thrombin. The last step in the cascade is the activation of fibrinogen to
fibrin clot with factor XIII acing as a clot stabilising factor.
Endothelial cells maintain haemostasis and inhibit thrombus formation by a number
of specific anti-platelet, anti-coagulant and fibrinolytic effects. In addition, the
endothelial cell surface bears a negative charge at physiological pH due to heparin-
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like sulphated mucopolysaccarides and sialic acid groups of cell surface
glycoproteins. Sialic acid groups are also responsible for the negative charge
observed on the surface of circulating blood cells. This generates an electrostatic cell
repulsion which contributes to the non-reactivity of normal endothelium with
circulating blood cells and helps ensure a non-adhesive, non-thrombogenic
endothelial surface (54).
1. Endothelial anti-platelet activity
Endothelial production of NO and PGI2 further contributes to the maintenance of a
non-thrombogenic surface. By increasing platelet cGMP levels, NO inhibits both the
adhesion of platelets to endothelial cells and their aggregation (55). PGE produces
similar effects by increasing platelet cAMP levels (46). As previously discussed, the
anti-platelet and vasorelaxant effects of NO and PGE appear to be synergistic (50).
Both NO and PGI2 limit the vasoconstrictor effects of platelet-derived thromboxane
A2 (TXA2), the major product of platelet cyclooxygenase. Aggregating platelets also
release ADP which can be degraded by endothelial ecto-ADPase to AMP and
adenosine, another potent inhibitor of platelet function (56).
2. Endothelial anti-coagulant activity
The anti-coagulant activity of endothelial cells is mediated a number of mechanisms.
Heparin-sulphate proteoglycans are released by the endothelium and bind tightly to
its luminal surface (57). These proteoglycans attach, and subsequently activate,
antithrombin III (58). In this manner, the ability of this inhibitor to bind to and
neutralise thrombin and the other serine proteases of the clotting cascade is
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enhanced. A second anti-coagulant mechanism occurs via the binding of thrombin to
thrombomodulin on endothelial cells which alters the substrate specificity of
thrombin so that it no longer converts fibrinogen to fibrin and no longer activates
factor V (59). Moreover, thrombin binding to thrombomodulin also activates the
endogenous anticoagulant protein C (60).
3. Endothelial pro-coagulant activity
Endothelial cells also mediate a number of pro-coagulant effects which, in response
to vessel injury, assist in clot formation and excessive blood loss. Endothelial cells
release von Willebrand factor (vWF), an adhesive macromolecule which carries
factor VIII in plasma (61). vWF facilitates the adhesion of platelets to the exposed
sub-endothelium of injured vessels and also mediates inter-platelet interactions in the
formation of platelet-fibrin thrombi (62). In addition, endothelial cells express
receptors for cell-surface tissue factor, expose critical sites for coagulation-factor
complexes and attract platelets and monocytes to sites of tissue /endothelial damage.
4. Endothelial fibrinolytic activity
The dissolution of pre-formed clots, fibrinolysis, is also modulated by the
endothelium, through endothelial cell secretion of both plasminogen activators and
plasminogen activator inhibitors (63). Tissue-type plasminogen activator (t-PA) is
synthesised by vascular endothelial cells and results in the generation of plasmin
(from plasminogen), which then acts on fibrin to dissolve clots (Fig 1.5). Endothelial
cells express receptors for t-PA that further localise activation of plasminogen to the
endothelial cell surface (64). Plasminogen-activator inhibitor (PAI-1) is also
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produced and secreted by the endothelial cell, and as its name suggests, inhibits the
activation of plasminogen and antagonises fibrinolysis.
Under normal conditions, a delicate balance between the pro- and anti-coagulant
properties of the endothelium is achieved by a series of regulatory linking



















vascular tree, the endothelium is capable of shifting the haemostatic balance from
moment to moment. This, while providing enormous flexibilty, also makes the
endothelium vulnerable to focal dysfunction and pathophysiological disorders (as
will be discussed in later sections).
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Endothelial growth-regulatory effects
Endothelial cells produce substances that control growth of smooth muscle cells in
the vascular intima. In the normal state endothelial release of NO and PGE inhibit
VSMC growth (47, 65). These mediators are in themselves growth-inhibitory, and
moreover they exert indirect negative regulation in vitro via their inhibition of the
release of growth factors such as platelet derived growth factor (PDGF) and
epidermal growth factor (EGF) (66). Heparin sulphate proteoglycans on the surface
of the endothelial cell also inhibit growth of VSMC in vitro (67). Growth promoting
products of the endothelial cell include endothelin-1, AT II, basic fibroblast growth
factor (bFGF), PDGF, insulin-like growth factor (IGF) and cytokines (68).
The extra-cellular matrix (ECM) is composed of the scaffolding elements of
collagens (types I, III, IV and VI) and elastins embedded in a mixture of
glycoproteins (e.g. fibronectin) and proteoglycans (e.g. heparin sulphate). These
proteins not only provide structural support, but modulate cell function and growth
by interacting with growth factors (68). Endothelial cells produce matrix proteins
(including collagens, fibronectin, laminin and heparin sulphate), in addition to
enzymes which either promote matrix degradation (e.g. gelatinases) or inhibit it
(tissue inhibitor of metalloproteinases [TIMP]) (69). Many of these ECM-related
proteins are secreted preferentially in the basal direction in vitro, and secretion
occurs before the cells form a coherent layer. During periods of cell proliferation,
such as angiogenesis or vascular remodelling, initial proteolytic degradation of the
ECM is nececessary, followed by synthesis of ECM components and reconstruction
of the matrix scaffolding. It appears that endothelial cells are central to the
16
homeostatic control of these processes by the elaboration of the various proteases
and their inhibitors (69).
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1.1.2. Vascular smooth muscle cells
Blood vessels are comprised of three layers: the intima, media and adventitia. The
intima, the innermost layer, is made up of one cell type - the endothelium - which
lines the luminal surface. Intimal smooth muscle cells can also be found
occasionally, but their frequency depends on species, age and pathology. The media
is composed of multiple layers of vascular smooth muscle cells (VSMC) and is
separated from the intima by an internal elastic lamina. The outermost adventitial
layer consists of loose connective tissue and contains blood vessels and nerves. The
principal function of the VSMC is contraction and these cells have developed a
repertoire of appropriate contractile proteins, agonist receptors, ion channels and
signal-transducing molecules to carry out this specialised function. VSMC however
are also capable of a number of other functions that vary at different developmental
stages, during vascular repair and in vascular disease (70). Fully differentiated
VSMC in mature blood vessels proliferate at extremely low rates and produce only
small amounts of ECM matrix proteins. These processes are greatly accelerated
during development of the vascular system, during vessel remodelling, following
vessel injury and in atherogenesis (as will be discussed in section 1.3.1) (71).
A given VSMC can rapidly, and reversibly, acquire a broad spectrum of different
phenotypes (in terms of contractility, secretion of ECM components, proliferation
and migration) in response to these different physiological or pathological stimuli. If
an artery is injured, for example, some VSMC must be recruited to repair that injury,
while at the same time, the contractile function of the blood vessel must be
maintained for normal cardiovascular homeostasis (72). Endothelial-VSMC
interactions with the subsequent release of endothelial mediators (growth-inhibiting
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and growth stimulating), neuronal influences (such as sympathetic innervation) and
haemodynamic forces may all influence the phenotypic expression of VSMC. The
cellular and molecular mechanisms controlling the coordinate expression of genes
determining these various phenotypes are still poorly understood (70).
Mature VSMC express unique isoforms of a variety of contractile and cytoskeletal
proteins (actin, myosin, calponin, caldesmon, vinculin, tropomyosin, desmin and
vimentin) that are important for their differentiated function. The most abundant of
these is smooth muscle a-actin.which is the earliest known marker of differentiated
VSMCs expressed during vasculogenesis (73). There is also evidence that VSMC
from different vascular sites (and indeed within the same vessel) display phenotypic
and functional heterogeneity, with cells differing in size, organelle content, the
expression of cytoskeletal and contractile proteins and protein isoforms (74). This
has led to the concept of cell diversity which suggests that the vascular media is a
mosaic of functionally and morphologically unique cell types. If true, this would
explain regional variations in the response of vascular beds to vasoactive mediators
and how vessels localise remodelling in response to injury or hypertension.
19
1.1.3. Pericytes
Pericytes (also known as Rouget or mural cells) are associated abluminally with all
vascular capillaries and post-capillary venules. Most studies on pericyte function
have focused on retinal microvascular pericytes and mesangial cells. Differences in
pericyte morphology and distribution among vascular beds suggest vessel or tissue-
specific roles including phagocytosis, regulation of new capillary growth and control
of capillary blood flow. Evidence has also been provided which indicates that
pericytes behave both as multipotent mesenchymal cells and specific precursors to
VSMC (75).
Each pericyte possesses a cell body with a prominent nucleus and a small amount of
surrounding cytoplasm (76). Protruding from the cell body are long processes which
parallel the long axis of the capillary and taper to smaller processes which encircle
the capillary wall. Processes penetrate the surrounding ECM to directly contact the
underlying endothelium, as well as interdigitating among neighbouring cells.
Pericytes are embedded within a basement membrane that surrounds the capillary
tubes. In vitro evidence suggests that both endothelial cells and pericytes contribute
to basement membrane formation (77). Based on their location and their complement
of muscle cytoskeletal proteins (including a-smooth muscle actin, fibronectin,
myosin, tropomyosin), pericytes have been proposed to play a role in the regulation
of blood flow. In vitro studies demonstrating the contractile ability of pericytes
support this concept (78, 79). The marked similarity of pericytes to VSMC has led to
the theory that these cells are specific precursors of VSMC (80). A study of
mesenteric growth in rats, using intravital video and electron microscope analyses,
provided evidence that fibroblasts transform into capillary pericytes which, in turn,
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become VSMC (81). These authors speculate that as capillaries are remodelled into
larger vessels to meet an increased functional demand, pericytes are differentiated to
become true VSMC as needed. These cells appear to be multipotent, capable of
becoming adipocytes, osteoblasts and phagocytes (75). They are also thought to be
structurally similar to mesangial cells in the glomerulus, as discussed below.
Pericytes have been speculated to play a role in the regulation of capillary growth.
The exact mechanisms by which these cells promote vessel formation have yet to be
elucidated, but observations indicate that the endothelium can recruit undifferentiated
mesenchymal cells and direct their differentiaton into pericytes in microvessels and
VSMC in large vessels (82). Communication between endothelial cells and pericytes
(or their precursors) may take many forms. Bi-directional extracellular exchange of
soluble mediators takes place between the endothelial and mural cells. Amongst the
endothelially-derived mediators, candidate effectors for pericyte recruitment are
PDGF, bFGF and heparin-binding epidermal growth factor (HB-EGF) which is
similar to epidermal growth factor (83). Once pericyte precursors have been recruited
to the endothelial cell, the two cells make contact via cell-adhesion molecules
(CAMs), substrate adherence molecules, the ECM itself and gap junctions (84).
Although few data exist, it has been speculated that pericyte contacts, in addition to
the release of growth factors, may contribute to the growth and differentiation of
pericytes and smooth muscle cells. It appears that cell-cell contact, for example, is
necessary for the functioning of the cytokine TGF-p (85). This cytokine is secreted
in vitro in a latent form by both cell types and activated on endothelial-pericyte
contact. TGF-p induces the expression of a-SM actin (a VSMC marker) both in
myofibroblasts and in pericytes (86). Further, evidence that this cytokine is involved
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in the growth and differentiation of both endothelial cells and pericytes during vessel
formation was provided by the observation that mice lacking TGF-(3 display a
suppression of endothelial cell differentiation and insufficient vascular development
(87). The role of endothelial cell-pericyte contacts is almost certainly not limited to
vessel formation, and cell-cell interactions may also be vital to the maintenance and
functioning of the quiescent vessel. Endothelial/pericyte synthesis and secretion of
mediators which both stimulate and inhibit pericyte growth and differentiation
almost certainly occurs in vivo. The in vitro observation that conditioned media from
confluent endothelial cells inhibits the growth of pericytes supports this concept (88).
Mesangial cells
Mesangial cells (MC), together with their extracellular matrix material, constitute the
mesangium and are separated from the glomerular capillary lumen by the
endothelium. As noted earlier, it is generally accepted that glomerular MC are, in
effect, specialised pericytes (89). These cells possess many of the functional
properties of smooth muscle cells e.g. they provide structural support for the
glomerular capillary loops, produce growth factors and extra-cellular matrix
components and via their contractile properties, modulate glomerular
haemodynamics (90).
Mesangial cell structure
MCs are irregular in shape with numerous cytoplasmic processes arising from the
cell body (91). These processes run toward the perimesangial glomerular basement
membrane (GBM) and can extend around the capillary lumen, frequently insinuating
themselves between the basement membrane and the overlying endothelium. An
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extensive array of microfilament bundles, composed in part of actin, a-actinin and
myosin, are situated predominantly in the mesangial cell processes. These run mostly
transversely or diagonally from one side of a process to another and terminate by
connecting with the GBM either directly, or indirectly through the interposition of
extracellular microfibrils. The GBM plays the role of a "skeleton" in this system,
with the extracellular myofibrils functioning as "microtendons." The MC is also
surrounded by a matrix material that differs from the glomerular GBM in its "loose"
texture and the presence of small bundles of fine fibers. This matrix contains
sulphated glycosaminoglycans as well as fibronectin and laminin and, in addition to
providing structural support for the glomerular capillary tuft, has been implicated in
the adhesion, migration, proliferation and differentiation ofMCs.
Mesangial cell: contractile functions
The properties and functions of the MC have been defined largely from cell culture
studies. Contraction in vitro occurs in response to a variety of vasoactive agents,
including angiotensin II, vasopressin, norepinephrine, TxA2, leukotrienes and platelet
activating factor (PAF) (92). Furthermore, receptors for these mediators have been
demonstrated on the MC. Similar to smooth muscle, the signal transduction pathways
and ion-selective channels regulating MC contraction are dependent on the voltage-
gated Ca2+ influx. Relaxation in vitro occurs in response to such agents as
prostaglandin (PG) E2, atrial natriuretic peptides and dopamine, and involves
increases in cGMP in addition to the activation of plasmalemmal K+ channels which
9+
hyperpolarise the membrane potential and inhibit voltage-gated Ca entry (93). It is
generally held that MCs in situ will also respond to vasoactive substances although
this is based on indirect evidence derived from in vitro studies. The contractile
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properties of the MC suggest a regulatory role in role glomerular haemodynamics. It
has been speculated that contractile forces in the mesangium counterbalance the
ultrafiltration pressure, preserving the architecture of the capillary network (91). An
alternative theory proposes that MC contraction/relaxation can regulate the
glomerular filtration rate (GFR) by modulating the surface area of the capillaries
(94).
Mesangial cell: immune functions
In addition to their role in the maintenance of the structure and function of the
glomerulus MC are capable of macromolecular uptake and the generation of
autocoids and cytokines (89). Although evidence suggests that much of the
phagocytic ability of the mesangium resides in bone-marrow derived resident
monocyte/macrophages, it appears that MCs are themselves capable of phagocytosis.
In vitro, MC phagocytose opsonised zymosan in association with the production of
prostaglandins, reactive oxygen species and lipoxygenase products (95).
Phagocytosis of immune complexes by cultured MC also occurs and is accompanied
by the production of PGE2 and PAF (96). MCs express Fc receptors for IgG and
receptor expression is upregulated in vitro by interferon(IFN)-y, cAMP and
monocyte/macrophage colony stimulating factor (M-CSF-1) (97). In addition, uptake
of immune complexes is acutely increased by AT II and inhibited by cAMP. These
latter changes are independent of Fc receptor number, but are accompanied by
changes in the MC cytoskeleton. Uptake of tracers such as ferritin, colloidal carbon,
globin, aggregated proteins and immune complexes into the mesangium have been
demonstrated in animal models in vivo, but there is some controversy as to whether
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phagocytosis in these studies has been mediated by MC or resident bone-marrow
derived macrophages (92).
Many forms ofboth immune and non-immune glomerular injury are accompanied by
the glomerular recruitment and activation of macrophages. This requires prior
expression of cellular adhesion molecules, in addition to the generation of
chemokines, on resident cells. Stimulation of mesangial cells in vitro with immune
complexes and pro-inflammatory cytokines such as tumour necrosis factor(TNF)-a
or interleukin(IL)-l results in the appearance of adhesion molecules on MC
(intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1
(VCAM-1)), in addition to the elaboration of chemokines such as monocyte
chemotactic protein(MCP)-l, IL-8, regulated upon activation, normal T cell
expressed and secreted (RANTES) and macrophage inflammatory protein-(MIP)-2
(98, 99). Indeed MCP-1 expression is increased in MC in response to a variety of
stimuli including IFN-y, thrombin, low density lipoprotein (LDL) and phorbol esters
(100). Upregulation of chemokine expression in MC involves, at least in part, the
activation of the transcription factor NF-kB through protein tyrosine kinase-
dependent mechanisms. The ability of the mesangial cell to release not only
chemokines, but a wide range of growth factors and cytokines (such as PDGF,
insulin-like growth factor(IGF)-l, IL-1 and IL-6) suggests that, rather than a passive
target for the action of infiltrating cells, MC are themselves important participants in
glomerular injury, as will be discussed in later sections (2.5, 2.6) (101).
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Mesangial cells: proliferation and extracellular matrix production
MC elaborate a number of autocrine growth factors which both regulate cell function
and the production of extracellular matrix. MC can also respond to growth factors
released from neighbouring glomerular cells or from infiltrating cells and platelets
(102). Such responses include MC hypertrophy and proliferation and matrix
metabolism. PDGF mediates predominantly cell proliferation, while TGF-P mediates
MC matrix expansion. ECM has been implicated in the adhesion, migration,
proliferation and differentiation of MCs and indeed its composition may play an
important role in the regulation ofMC apoptosis (103).
Macrophage conditioned medium promotes a series of responses in cultured
mesangial cell. These include the upregulation of the MC genes and/or proteins for
the ECM components fibronectin, laminin and collagen IV, the modulators ofmatrix
turnover TIMP-1 and transin, in addition to genes for the growth factors TGF-P and
PDGF (104). With regard to fibronectin, treatment of MC with TNF-a, IL-ip or
TGF-P alone induces only modest increases in fibronectin protein levels. Combining
TGF-P with TNF-a or IL-ip however results in a marked synergistic increase in
fibronectin mRNA and protein levels, accompanied by down-regulation in
expression of the matrix proteinase transin and an increase in TIMP-1 expression.
These data suggest that complex interactions take place between cytokines in the
glomerulus to modulate MC matrix synthetic and degradation pathways. In theory,
alterations in the local cytokine network could potentially alter MC matrix
homeostasis and result in both MC proliferation and excess glomerular deposition of
extracellular matrix.
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In summary, the MC has several functions in the normal glomerulus, - producing
growth factors to allow a normal cell turnover, providing structural support via the
secretion of ECM, maintaining glomerular haemodynamics (by both contraction and
release of vasoactive mediators) and aiding in the clearance of immune complexes.
These functions are presumably tightly regulated and beneficial to the host. Evidence
now exists that MCs, activated during glomerular injury/inflammation, proliferate
and undergo a phenotypic modulation in which they markedly up-regulate their
expression of smooth muscle like proteins e.g. a-smooth muscle actin and produce
excess amounts of extra-cellular matrix. If this response is limited then it is
potentially reversible, otherwise glomerulosclerosis results. These consequences of
mesangial cell activation will be discussed in more detail in later sections.
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1.2. Mechanisms and consequences of vascular cell activation in
"appropriate" host defence
Mobilisation of the inflammatory response is primarily intended to neutralise the
initiating and "injurious" stimulus, limit tissue damage and initiate healing and
repair. Inflammation is a complex, highly orchestrated process involving many cell
types and molecules, some ofwhich initiate, amplify or sustain the process, some of
which attenuate it, and some of which promote its resolution. The importance of the
vascular endothelium in regulating these processes is well-established. Normally the
endothelium is in an "unactivated" state. At sites of injury or inflammation, however,
local endothelial "activation" occurs, either in response to the injuring stimulus itself,
in response to the inflammatory cytokines generated as a consequence of this injury
or in response to leukocyte-endothelial cell adhesion (105). Activated vascular
endothelium is hyperadhesive for leukocytes due to the up-regulated expression of a
number of membrane-associated leukocyte-endothelial cell adhesion molecules
(CAM) (106). It also secretes chemotactic factors (107) which attract peripheral
blood leukocytes and soluble factors which promote coagulation (108). Endothelial
activation occurs over a period of minutes to hours and is dependent on mobilisation
of stored intracellular proteins, such as P-selectin and vWF (109), and up-regulation
of gene expression and de-novo protein synthesis.
Inflammatory cytokines are intercellular signalling peptides produced by activated
cells in response to injurious stimuli such as endotoxin, immune complexes, and
physical and chemical injury (110). Most cytokines have multiple sources, multiple
targets and multiple functions. The cytokines that are produced during, and
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participate in, inflammatory processes are the chief stimulators of the acute phase
response (notably interleukin (IL)-6, IL-ip, tumour necrosis factor (TNF)-a and
interferon (IFN)-y). This response accompanies inflammation and is characterised by
a large number of changes, distant from the inflammatory focus, involving many
organ systems. The acute phase response is not discussed in detail here, but has been
reviewed extensively elsewhere (111). Cytokine production also promotes the
activation of vascular endothelium, leukocytes, platelets, fibroblasts and smooth
muscle cells, thereby initiating and propagating the cascade of vascular, cellular and
humoral events which comprise the inflammatory response.
1.2.1. Leukocyte trafficking
The histological hallmark of acute inflammation is the infiltration of interstitial
tissues by peripheral blood leukocytes - initially by neutrophils and, later,
mononuclear leukocytes. The movement of immune cells from the blood vessel
lumen into tissue occurs via a coordinated process involving directed movement up
concentration gradients of chemoattractants, adhesion to the endothelium,
penetration of endothelial cell tight junctions and finally migration through the
endothelium, basement membrane and extravascular tissue (112). The infiltrating
leukocyte population is, therefore, defined by the nature of the chemotactic cytokines
(chemokines) secreted by the cytokine-activated tissue cells surrounding the assault
and by the infiltrating cells themselves, and by the profile of adhesion molecules
expressed by leukocytes and resident tissue cells. The current model of leukocyte
trafficking holds that, following their chemotactic movement to the endothelium
surrounding the site of injury/inflammation, initial 'loose' tethering (so-called
"rolling") of circulating leukocytes is brought about by interaction between the
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selectins and various carbohydrate-containing counter-receptors located on immune
cells. This selectin-mediated adhesion in turn facilitates the immobilisation of
leukocytes - by the interaction of endothelial immunoglobulin-like adhesion
molecules (notably intercellular adhesion molecule-1, ICAM-1 and vascular cell
adhesion molecule VCAM-1) with leukocyte integrins - and the eventual movement
of these cells from the vessel lumen to the extravascular space (diapedesis) (Fig 1.6)
(113). The latter process is facilitated in some systems by adhesion of leukocytes to
endothelium and basement membrane through homotypic and heterotypic adhesion
processes involving another immunoglobulin-like adhesion molecule PECAM-1.
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Fig 1.6
Following chemotaxis (1), initial and attachment and rolling of leukocytes is mediated by selectins
binding their counter receptors (2). Neutrophils roll and decelerate on both activated endothelium as
well as other adherent neutrophils. Stable adhesion is mediated by adhesion between integrins present
on the leukocyte surface and Ig on the surface of activated endothelium (3). Transendothelial
migration is mediated by PECAM-l-PECAM-1 interactions as well as integrin-Ig bonds (4).
Chemokines may also promote diapedesis by activating leukocyte integrins or inducing chemotaxis.
Chemokines also direct the interstitial migration of transmigrated leukocytes and induce leukocyte
activation. Extravasated leukocytes may in turn generate more chemoattractants, thereby amplifying
the recruitment process.
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1.2.2. Leukocyte-endothelial adhesion molecules
Data derived from both in vitro (isolated leukocytes binding to monolayers of
cultured endothelial cells) or purified and immobilised adhesion proteins (114) and in
vivo (intravital microscopic examination of venules and gene "knock-outs") (115)
models of leukocyte-endothelial cell adhesion have revealed the relative
contributions of different leukocyte and endothelial cell adhesion molecules (CAMs)
to the adhesion responses elicited by various inflammatory stimuli. The various
leukocyte-endothelial adhesion molecules and their corresponding ligands are shown
in the table below (Table 1.1).
Cluster
Family Members des'anation Cellular distribution Counter-receptor / ligand








bearing structure(s) on leukocytes
Mucin-like PSGL-1 CD162 All blood leukocytes E-, L- and P-selectin
p-i integrins a4Pi CD29/CD49d Monocytes,lymphocytes
VCAM-1, fibronectin










(LPAM-1) Lymphocytes VCAM-1, fibronectin, MAdCAM-1






ICAM-2 CD102 Endothelium LFA-1
ICAM-3 CD50 Leukocytes LFA-1
VCAM-1 CD106 Endothelium,




Table 1.1 Cell adhesion molecules (105)
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Selectins
Selectins are trans-membrane glycoproteins which support leukocyte-endothelial and
leukocte-platelet rolling/adhesion. Three selectins have been identified and named
according to their cell of original discovery: P-selectin (platelet selectin), E-selectin
(endothelial cell selectin) and L-selectin (leukocyte selectin) (116, 117). L-selectin is
constitutively expressed by most leukocytes but not by other cell types. P-selectin is
expressed on the surface of activated endothelial cells and platelets (109). The
majority of P-selectin is stored in the Weibel-Palade bodies of endothelial cells and
in a-granules of platelets. Mobilisation of P-selectin to the cell surface occurs on
activation where it supports adhesion of granulocytes, monocytes and some
lymphocyte subsets. E-selectin is expressed, probably exclusively, by cytokine-
activated endothelial cells and, like P-selectin, supports the rolling of granulocytes,
monocytes and some T lymphocytes (117).
The physiological counter-receptors of selectins have not been fully elucidated, but
appear to be carbohydrate structures presented by glycoproteins on the surface of
vascular endothelium, leukocytes and platelets (118). The best characterised selectin
counter receptor is P-selectin glycoprotein ligand (PSGL)-l which is present on
neutrophils, monocytes and lymphocytes and binds P-selectin and possibly also L-
and E-selectin (119). Neutrophil-neutrophil adhesive reactions that occur during
neutrophil aggregation are also mediated by PSGL-1-L-selectin bonds. L-selectin
also binds to the mucin GlyCAM-1 expressed on high endothelial venules of lymph
nodes and this interaction may regulate normal recirculation of leukocytes through
lymph nodes in vivo (120).
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Integrins
Selectin-mediated interactions result in loose tethering and rolling of leukocytes on
endothelium and facilitate their subsequent immobilisation by the interaction of
leukocyte integrins with immunoglobulin-like molecules on the endothelium.
Integrins are transmembrane glycoproteins composed of non-covalently linked a and
P subunits and mediate diverse cell-cell and cell-matrix interactions. They are
classified according to their (1 chains and eight P chains have been identified to date.
The integrins associated with leukocyte adhesion belong to the pi, P2 and P7
subfamilies (121).
Members of the P2 subfamily contain one of four different a chains designated
CDlla, CDllb, CDllc and CDlld that are coupled to a common p chain, CD 18.
The heterodimer CDlla/CD18 is expressed on the surface of most leukocytes and
interacts with ICAM-1 and ICAM-2 on endothelial cells to cause firm adhesion
(112). CDllb and CDllc, expressed by granulocytes and monocytes, are stored in
granules and on phagocyte activation are rapidly mobilised to the cell surface by
fusion with the cell membrane (122). Activation by inflammatory mediators such
PAF or cytokines, such as TNF-a, result in a marked increase (10-30 fold) in
expression of these integrins on the cell surface. CDllb/CD18 interacts with
endothelial ICAM-1, while the ligand for CD1 lc/CD18 remains uncertain. A role for
the recently described CD 1 ld/CD 18 in leukocyte recruitment has not yet been
established (123). The adhesion of unstimulated leukocytes to endothelial cells is
mediated by CDl la/CD 18-ICAM-l interactions, while activated leukocytes bind to
endothelial ICAM-1 by both CDlla/CD18 and CDllb/CD18. The biological
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importance of the [32 integrins in the immune response was demonstrated by
identification of their deficiency in humans. Heterogeneous mutations of the CD18
gene result in defective surface expression of the entire CD11/CD18 complex. This
leukocyte adhesion deficiency (LAD) is characterised by defective leukocyte
trafficking, recurrent severe infections and impaired wound healing (124).
Heterodimers of the (31 and (37 subfamilies also contribute to recruitment of different
leukocyte populations. The (31 integrin a4(31, also known as very late antigen-4
(VLA-4) mediates the adhesion of lymphocytes, monocytes, eosinophils and natural
killer cells to activated endothelial cells expressing the counter-receptor VCAM-1
(125). The (37 integrin a4(37 is found on lymphocytes that colonise the gut and its
associated lymphoid tissue This mediates the normal homing of lymphocytes to
Peyer's patches, but, via its interaction with endothelial VCAM-1, it also facilitates
leukocyte adhesion under conditions of inflammation (126).
Immunoglobulin superfamily
Five members of the immunoglobulin supcrfamily act as adhesion molecules:
ICAM-1, ICAM-2, VCAM-1, platelet-endothelial cell adhesion molecule-1
(PECAM-1) and mucosal address in cell adhesion molecule-1 (MAdCAM-1) (127).
ICAM-1 is a glycoprotein constitutively expressed by many cell types including
vascular endothelium, fibroblasts, mesangial cells, epithelial cells and skeletal
myocytes. Its expression on these cells is up-regulated several fold by endotoxin and
inflammatory cytokines. This up-regulation varies from one vascular bed to another
and, in general, those beds with high constitutive expression like the lung show less
up-regulation than those with low constitutive expression (e.g. skeletal muscle or
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heart) (113). Cytokines can also induce ICAM-1 expression on other cell types such
as VSMC, mesangial cells and epithelial cells (112). ICAM-1 is also expressed by
lymphocytes and indeed lymphocyte-lymphocyte adhesion via ICAM-1 -
CD11 a/CD 18 binding may facilitate other lymphocyte functions such as antigen
recognition, lymphocyte co-stimulation and cytotoxicity. A soluble isoform of
ICAM-1 (sICAM-1) can be detected in the plasma during inflammation and
represents shed fragments of endothelial ICAM-1 (128). In a variety of inflammatory
and immune conditions serum levels of sICAM-1 have been found to correlate with
disease activity. ICAM-2 is constitutively expressed by endothelial cells and
lymphocytes and its expression by the endothelial cell is not influenced by the degree
of endothelial activation. ICAM-2 binds to CDlla/CD18, but with a lower affinity
than ICAM-1 (129).
VCAM-1 mediates the trafficking ofmonocytes and lymphocytes via binding to the
pi and P7 integrins (113). It is constitutively expressed at low levels predominantly
in endothelial cells, but also in VSMC and dendritic cells. Upregulation of VCAM-1
expression in these cells, and others such as mesangial and tubular epithelial cells,
occurs in response to cytokine stimulation.
PECAM-1 is constitutively expressed by vascular endothelium (mainly at tight
junctions), neutrophils, monocytes, some lymphocytes and platelets (130). It
mediates endothelial cell-cell adhesion, myeloid (neutrophil and monocyte) cell-
platelet adhesion and myeloid cell-endothelial adhesion by PECAM-l-PECAM-1
interactions. PECAM-1 was originally implicated in the transmigration of leukocytes
between intercellular junctions of vascular endothelium (131). However, some
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memory T-cells do not express PECAM-1 but are able to transmigrate successfully
and it now appears that this process is more complex than previously appreciated. In
vitro neutrophil adhesion to activated endothelial monolayers alters the molecular
composition and organisation of the endothelial cell VE-cadherin complex (probably
through selective proteolysis) which has been implicated in cell-cell adhesion and
cell-to-cytoskeletal integrity (132). This may facilitate the subsequent transmigration
of neutrophils. Another study challenged the long-dominant paradigm that
transmigrating neutrophils pass between endothelial cells and provided evidence that
in dermal venules neutrophils, in response to the chemoattractant fMLP, emigrated
by a transcellular route through both endothelial cells and pericytes (133). It remains
to be seen whether this observation can be extended to other inflammatory cells,
stimuli or vascular beds.
Platelet adhesion molecules
Platelets are crucial to the body's normal inflammatory response because of their
ability to form haemostatic platelet plugs very rapidly at the site of vascular injury, in
addition to their release of growth and chemotactic factors. The surfaces of platelets
are densely decorated with pi and P3 integrins which mediate both adherance to the
subendothelial matrix exposed by vascular injury and aggregation in response to
activation by various agonists such as ADP, adrenaline or thrombin (105). Platelet
adhesion is mediated by a2pi (binds collagen), a5pi (binds fibronectin), a6pi
(binds laminin) and allbp3 (also called gpIIb/IIIa). Platelet aggregation, on the other
hand, is mediated exclusively by the glycoprotein gpIIb/IIIa (134).
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1.2.3. Chemokines
Classical chemoattractants such as leukotriene B4, platelet activating factor and
complement components (e.g.C5a and its cleavage product c5a des arg) are generated
during the acute inflammatory response and mediate the migration of leukocytes to
sites of tissue injury (105). Chemokines (chemotactic cytokines) are a family of
peptides with potent leukocyte attractant and activating properties that exhibit
restricted and selective patterns of leukocyte attraction. Their production at the
inflammatory site therefore, both by resident cytokine-activated tissue cells and
infiltrating cells, defines the nature of the infiltrating leukocyte population (135).
Forty or so chemokines have been described to date and have been divided into four
subfamilies according to the relative position of the first two of their four cysteine
residues (135). In the C-C family cysteines are adjacent, while in the C-X-C family
they are separated by one amino acid. The only known C-chemokine family member
is lymphotactin, with two instead of four cysteines, while fractaline, with three amino
acids between the first two cysteines at the N-terminal of a mucin structure, is the
only known CX3C chemokine. Chief among the C-C family are the monocyte
chemoattractant proteins (MCP), regulated upon activation, normal T cell expressed
and secreted (RANTES) and macrophage inflammatory protein (MIP) attracting
monocytes, T cells, natural killer cells and some granulocytes but not neutrophils.
Principal C-X-C chemokines include interleukin(IL)-8 and growth related oncogene
(GRO) which, until recently, were thought to attract neutrophils but not monocytes.
There is increasing evidence, however, that, in certain instances these chemokines
may play a role in monocyte/macrophage recruitment e.g. to the atherosclerotic
plaque, and this is discussed in detail in section 1.3.1 (136). In contrast to the
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majority ofC-X-C chemokines which attract predominantly neutrophils, three C-X-C
proteins show a different spectrum of activity. Interferon-inducible protein of lOkd
(IP-10) and monokine induced by interferon-y (Mig) are selective for IL-2 activated
T lymphocytes (137), while platelet factor (PF)-4 can attract monocytes and
neutrophils (138). The major chemokines, their target cells and corresponding
receptors are shown in the table below (Table 1.2).
































CXCR2 Neutrophils, basophils, monocytes
GRO-a,-(3,-y CXCR2 Neutrophils, basophils, monocytes
IP-10 CXCR3 T lymphocytes
PF-4 CXCR3 Monocytes, neutrophils
SDF-1 CXCR4 T lymphocytes, monocytes, neutrophils
Table 1.2 Some chemokines and chemokine receptors
The effects of chemokines on leukocytes are mediated by heptahelical receptors
coupled to GTP-binding proteins. Within seconds of addition of a chemoattractant to
a leukocyte suspension dramatic shape changes occur. The formation and retraction
of lamellipodia, which function like the arms and legs of migrating cells, is
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dependent on the polymerisation and breakdown of actin. Upregulation and
activation of leukocyte integrins enables their adherence to vascular endothelial cells
prior to transmigration into tissues (139). Activation of the leukocyte also ensues, as
evidenced by rises in intracellular calcium, production of microbicidal oxygen
radicals and bioactive lipids, and release of lytic enzymes from intracellular granules
(140).
In the long-established paradigm of chemotaxis, leukocytes move "up" a
concentration gradient of chemoattractant. In vivo this concentration gradient may be
formed by "diffusion barriers" such as the vascular endothelium, the vessel wall and
interstitial spaces. It is becoming increasingly recognised however that cells
migrating within tissues encounter multiple chemoattractant signals in complex
spatial and temporal patterns. In vitro models have demonstrated that sequential
leukocyte migration through spatially distinct attractant fields is determined by the
nature and sequence of chemoattractants (141). It may be that multiple attractants
participate, in a hierachical manner, to guide leukocyte subsets to their tissue
destination and ensure ongoing leukocyte recruitment. This process is facilitated by
each of the many chemoattractant receptors expressed on the leukocyte surface
(142).
Most chemokines are produced under pathological conditions by tissue cells and
infiltrating leukocytes. Some chemokines seem to fulfil housekeeping functions,
however, such as leukocyte maturation within the bone marrow, the trafficking and
homing of particular lymphocyte subsets within lymphoid tissue and the renewal of


















Diverse roles of chemokines in leukocyte trafficking (adapted from (143)).
Chemokines play a role in:( 1) the maturation and differentiation of leukocyte subsets in the bone
marrow (2) the induction of leukocyte mobility and shape changes (3) the triggering of leukocyte-
endothelial adhesion and transmigration (4) generation of chemotactic gradients guiding leukocytes to
the inflammatory site (5) antigen presentation and co-stimulation of activation (6) leukocyte
activation.
The recently identified C-C chemokines thymus and activation regulated chemokine
(TARC), EBIl-Ligand chemokine (ELC) and secondary /ymphoid-tissue chemokine
(SLC) are constitutively expressed at high levels in the thymus, lymph nodes and
other lymphoid tissues and attract T lymphocytes and, to a variable degree, B
lymphocytes (144). The restricted, constitutive production of these chemokines in
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lymphoid tissue and their apparent selectivity for lymphocyte receptors implicates
their involvement in the regulation ofphysiological lymphocyte trafficking.
It is becoming apparent that, although originally identified as host defence proteins,
chemokines clearly have other functions, for example in growth regulation,
angiogenesis and tumour metastasis. PF-4 (145) and IP-10, for example, (146) inhibit
neovascularisation, tumour growth and metastasis. In contrast IL-8 promotes
angiogenesis and metastasis (147). Stromal-derived factor (SDF)-l is a C-X-C
chemokine which attracts T cells, monocytes and neutrophils expressing the receptor
CXCR4. In addition SDF-1 attracts progenitor B cells and it has been speculated that
it may be involved in directing progenitor cells into appropriate maturation sites in
the bone marrow and haematopoiesis (148). Support for this theory comes from the
observation that mice lacking SDF-1 have severely impaired lymphopoiesis and
abnormally low numbers of B and myeloid cell bone-marrow precursors (in addition
to a defective ventricular septum in the heart) (149). Mice lacking the receptor for
SDF-1, CXCR4, have a similar phenotype to those lacking SDF-1, but in addition
have central nervous system defects (premature and abnormal clustering of neurons)
and abnormal formation of blood vessels in the gastrointestinal tract (150, 151). It
has been speculated that the chemoattractant properties of chemokines may be useful
during morphogenesis to keep the cells that form tissues together, but research in this
field is still in its infancy and the mechanisms of these effects as yet unknown (135).
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1.2.4. Chemokine receptors
The biological effects of chemokines are mediated through interactions with seven
transmembrane, G-protein coupled receptors. Chemokine receptor genes are
expressed in a cell-type specific manner and this may be the basis for the specificity
of chemokines for leukocyte subsets (152). While most receptors bind more than one
chemokine, in general CC receptors bind only C-C chemokines and CXC receptors
bind only C-X-C chemokines (Table 1.2). A recent study, however, has demonstrated
that binding may not be necessarily so restricted to each sub-family in that C-C
chemokine 6-C-kine (also called Exodus 2) binds the CXC chemokine receptor
CXCR3 (153). Five human CXC chemokine receptors (CXCR1-5) and ten human
CC (CCR1-10) receptors have been identified (143). Although generally found on
leukocytes, chemokine receptors can also be present on other cell types such as
VSMC or endothelial cells, either constitutively or in response to inflammatory
stimuli (154, 155).
Binding of a chemokine to its receptor leads to a cascade of cellular activation which
may include the generation of inositol trisphosphate, the release of intracellular
calcium and the activation of protein kinase C (135). Many details are still unclear
and different kinases may be involved in signal transduction, including
serine/threonine kinases as well as tyrosine kinases. Most studies to date have
focused on IL-8 receptor signalling (156, 157). Upon IL-8 binding, receptor coupling
with a Bordetella pertussis toxin-sensitive G protein initiates a signalling cascade
which leads to activation of phospholipase C, protein kinase C, Src-related tyrosine
kinases, phosphatidylinositol-3-OH kinases and protein kinase B. Phospholipase C
activation, which results in the formation of inositol-1,4,5-trisphosphate, leads to
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increases in intracellular calcium levels, an event which is required for granule
release and superoxide production. In addition IL-8 binding results in the activation
of small GTPases; these proteins regulate cytoskeletal arrangements involved in
adhesion and chemotaxis such as membrane ruffling, pseudopod formation and
assembly of focal adhesion complexes. Receptor binding therefore activates the
intracellular pathways necessary to propel the cell towards the source of
chemoattractant.
The chemokine receptors CXCR4 and CCR5 serve as co-receptors for the human
immunodeficiency virus (HIV) (158). By facilitating entry into cells these receptors
determine viral tropism i.e.strains of HIV-1 that infect T cells (T-tropic strains) bind
to CXCR4 strains, while strains infecting macrophages and activated T-cells (M-
tropic) bind to CCR5. Entry of HIV into cells is blocked by the ligands for these
receptors-SDF-1, RANTES and MIPla/p (159, 160). The importance of chemokines
receptors in the pathophysiology of HIV infection is evidenced by the fact that
mutations in the CCR5 receptor, if homozygous confer resistance to HIV infection
and, if heterozygous, delay disease progression (161, 162).
Chemokines also interact with two types of non-signalling molecules. The
erythrocyte chemokine receptor called Duffy antigen receptor for chemokines
(DARC) is present on erthrocytes and endothelial cells (163). Although DARC is
structurally related to the chemokine receptors, it is distinctive in that both C-C and
C-X-C chemokines bind to it and ligand binding does not induce calcium flux. It has
been speculated that this receptor may serve as a reservoir for chemokines, thereby
serving to clear them from the circulation. Chemokines also interact with a group of
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negatively charged heparin sulphate proteoglycans found in the ECM and on
endothelial cells (164). It has been proposed that these interactions may serve to
establish a local concentration gradient from the source of chemokine secretion.
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1.3. Pathological consequences of "inappropriate" endothelial cell, vascular
smooth muscle cell and pericyte activation in human disease
1.3.1. Atherosclerotic phenotype
Atherosclerosis continues to be a leading cause of death in the United States, Europe
and much of Asia (165). It is now apparent that the lesions of atherosclerosis
represent a series of highly specific cellular and molecular responses resulting from
an intricate interplay between diverse factors such as lipid metabolism, blood
coagulation, behavioural risk factors, cytokines and haemodynamic stress (166). The
end result of this process is occlusive lesions affecting large and medium sized
arteries resulting in ischaemia or infarction of the organ concerned, most commonly
heart and brain.
The endothelial cells which line such blood vessels play a central role in both the
initiation and propagation of this process. The endothelium has numerous
physiological roles as discussed in detail in section 1.1.1. It provides a permeability
barrier through which there is exchange and active transport of substances into the
vessel wall. In addition it provides a non-thrombogenic surface and maintains the
basement membrane upon which it rests. By release of vasodilators (e.g.
prostaglandins, nitric oxide) or vasoconstrictors (e.g. endothelin-1) the endothelium
is an important regulator of vascular tone, whilst its ability to elaborate growth
regulatory factors and cytokines, although important in defence against injury, has
important implications in the fibroproliferative process that characterises
atherosclerosis.
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It now appears that endothelial dysfunction resulting from injury (and not necessarily
denudation as was previously thought), leads to compensatory changes that alter its
normal homeostatic properties (reviewed in (166)). This injury can take many forms
and includes such risk factors as elevated modified low density lipoprotein (LDL),
hypertension, diabetes mellitus, free radicals caused by cigarette smoking and
elevated homocysteine. It is proposed that endothelial injury (regardless of the
initiating cause) increases endothelial permeability, as well as enhancing its
adhesiveness for leukocytes and platelets. Increased expression of adhesion
molecules - selectins, ICAM-1 and VCAM-1 - results in firm attachment of
leukocytes to the endothelial surface while migration of leukocytes across the
endothelium occurs in response to chemokines, produced by activated endothelium,
smooth muscle cells and monocytes.
It is generally accepted that oxidation of LDL within the microenvironment of the
arterial wall is an important early step in atherosclerosis (167). Many of the cells
present in the arterial wall can oxidise LDL, including endothelial cells, vascular
smooth muscle cells and macrophages (168). Transition metals (present within
plaques), lipoxgenase enzymes, myeloperoxidase and reactive nitrogen species
(produced in vivo by the reaction of nitric oxide with superoxide) have all been
implicated in the oxidation of LDL within the arterial wall, an environment that is
relatively depleted of aqueous phase antioxidants (169-171). A recent study has
demonstrated that the 12/15 lipoxgenase enzyme in particular may play a key role in
these oxidative processes (172). In this study, homozygous disruption of the 12/15
lipoxygenase gene diminished atherosclerosis in apo-E deficient mice as compared to
their lipoxygenase expressing controls (without significant changes in plasma
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cholesterol levels). Other non-oxidative modifications of LDL including glycation,
carbamylation and modification by homocysteine, may also produce modified LDL
species that share some of the properties of ox-LDL (173). The oxidation of
polyunsaturated acids within LDL is followed by their fragmentation and the release
of aldehydes and ketones, such as malondialdehyde and 4-hydroxynonenal, which
can modify key lysine residues on apoprotein B (apoB) Modified apoB is no longer
recognised by the apoB receptor, but rather is taken up by the macrophage scavenger
receptors. This leads to dysregulated uptake of LDL cholesterol, the accumulation of
cholesterol esters within the macrophage and the formation of the characteristic foam
cell (166). The endothelium itself can also take up oxidised LDL via the recently
identified lectin-like ox-LDL receptor (LOX-1) (174). In vitro studies have shown
that, in human coronary artery endothelial cells, ox-LDL can increase its own
receptor (LOX-1) expression, while in vivo studies have confirmed LOX-1
expression on not only endothelial cells, but also intimal smooth muscle cells and
macrophages, within the atherosclerotic plaque (175, 176).
Oxidised LDL is a potent chemoattractant for circulating monocytes but inhibits their
further migration after they have entered the arterial wall and differentiated into
macrophages (177). In addition ox-LDL, as a result of its oxidative modification,
acquires a number of important biological activities which increase its atherogenicity
(166). It is cytotoxic to endothelial cells, promotes production of a wide range of
cytokines and growth factors from lesional macrophages, increases platelet
aggregation and interferes with the actions of nitric oxide. It can also result in the
upregulation of endothelial genes such as macrophage colony stimulating factor (M-
CSF) and the chemokine MCP-1. Finally, via increases in cellular adhesion
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molecules, LDL has been implicated in promoting the leukocyte-endothelial cell
adhesion which is central to the initiation and growth of atherosclerotic lesions.
Cell adhesion molecules have been discussed in detail in section 1.2.2. Levels of
soluble cell adhesion molecules are increased in patients with dyslipidaemia and
appear to be regulated by plasma cholesterol levels (178). Moreover
histopathological studies have shown increased VCAM-1, ICAM-1, P- and E-
selectin in atherosclerotic lesions and have defined increased adhesion molecule
expression as temporally preceding intimal accumulation of macrophages and T-
lymphocytes (179-182). Interestingly a recent study using mice doubly deficient in
the LDL receptor and P-selectin has confirmed the importance of this adhesion
molecule in the development of early atherosclerotic lesions (183). These
observations are supported by in vitro and in vivo studies indicating that ox-LDL
induced endothelial-leukocyte hyperadhesiveness is mediated by P-selectin, L-
selectin, VCAM-1, as well as ICAM-1 and its integrin counter-receptor CD11/CD18
(184). Also, native LDL binding to the LDL receptor has been shown in vitro to
activate human endothelial cells, as evidenced by increases in intracellular calcium
which then acts as a second messenger to induce VCAM-1 and E-selectin expression
(185). Generation and uptake of ox-LDL therefore helps to drive the inflammatory
process by stimulating activation ofmacrophages and the entry of new monocytes/T
lymphocytes into the arterial wall, eventually resulting in fatty streak formation, the
first phase of an atherosclerotic lesion.
The elaboration of cytokines and growth factors also stimulates migration and
proliferation of smooth muscle cells which become intermixed with the
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inflammatory cells. As a result of this patho-immune response, progressive
atherosclerotic lesions are characterised by the infiltration of immune competent
cells (macrophages and T lymphocytes), the proliferation of intimal cells of the
arterial wall (smooth muscle), the accumulation of lipid and the deposition of
extracellular matrix components (166). Cycles of cellular accumulation, macrophage
death by apoptosis and their deposition of extracellular lipid and subsequent
formation of fibrous tissue leads to enlargement and restructuring of the lesion so
that it becomes covered by a fibrous cap overlying a core of lipid - the so-called
atherosclerotic plaque. This encroaches into the blood vessel lumen with resulting
narrowing and obstruction to blood flow. Lesion complication often culminates in
rupture of the fibrous cap, exposing circulating blood components to the tissue factor
rich core and inciting thrombosis, as occurs during the acute coronary syndromes or
myocardial infarction.
Factors affecting plaque stability have been the focus of many recent studies. A
plaque prone to rupture is generally one with a thin fibrous cap overlying a large
thrombogenic lipid core rich in lipid laden macrophages (186). The integrity of the
fibrous cap, and thus its resistance to rupture, depends on the extracellular matrix and
the balance between the synthesis and degradation of the macromolecules that
constitute it (principally collagen, elastin and proteoglycans). A family of enzymes
known as matrix metalloproteinases are expressed by plaque macrophages and can
contribute to weakening of the fibrous cap by degradation of all its major
constituents.
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As with all inflammatory processes no single factor works alone in the process of
atherogenesis. Complex cellular networks exist whereby the release of one molecule
can lead to expression of a second molecule which itself causes gene upregulation in
an autocrine or paracrine way (187). II-1 or TNF-a for example are released by
activated lesion macrophages exposed to ox-LDL. In culture these cytokines can
induce PDGF gene expression in smooth muscle cells, which can in turn result in
further smooth muscle cell stimulation and growth. Many such mediators have been





































Figure 1.8 Mediators in atherosclerosis.
The principal products of platelets, macrophages and smooth muscle cells that may affect the
endothelium and promote atherogenesis are shown in this schematic diagram In turn the endothelial
cells can themselves express genes for and synthesise a number of growth-regulatory molecules,
cytokines, chemotactic factors and vasoactive mediators (adapted from(187)).
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CD40: CD40L interactions and atherosclerosis
Cells in human atherosclerotic lesions have been demonstrated to express the
immune mediator CD40 and its ligand CD40L (188). CD40L is an important
immunomodulatory signalling molecule previously considered to be restricted to
activated CD4+ T lymphocytes. Recent studies have identified its coexpression with
its receptor CD40 on endothelial cells, smooth muscle cells and macrophages in the
atherosclerotic plaque (188). In hyperlipidaemic mice (lacking the receptor for LDL
and fed a high-cholesterol diet), inhibition of CD40 signalling by anti-CD40
antibody limited atherosclerosis. Lesions were smaller, had reduced lipid content,
contained significantly fewer macrophages and lymphocytes and demonstrated
reduced expression of VCAM-1. Stimulation in vitro of human vascular smooth
muscle and endothelial cells with CD40L activates interleukin 1 ^-converting enzyme
(ICE) activity and promotes elaboration of active interleukin 1 (1 (189). In addition,
stimulation of human monocytes/macrophages through CD40 (using either
membranes of activated T cells or recombinant CD40L) has been reported to induce
expression of the chemokines MCP-1 and IL-8, the pro-inflammatory cytokines IL-1
and TNF-a, tissue factor and the matrix metalloproteinases collagenase and
stromelysin (190). The matrix metalloproteinase stromelysin-3 mRNA and protein
has been subsequently shown to co-localise with CD40 and CD40L in atherosclerotic
plaques (191). In keeping with this observation, interruption of CD40/CD40L
signalling in LDL receptor deficient hyperlidaemic mice has been reported to
substantially reduce expression of this enzyme in atherosclerotic plaques. These
findings suggest a crucial role for CD40-CD40L T cell independent interactions in




The migration of immune cells from blood vessel lumen into the atherosclerotic
plaque is central to atherogenesis. Chemokines, as discussed in section 1.2.3, are
members of a superfamily of small polypeptides that mediate not only migration, but
also the growth and activation of leukocytes and a variety of other cells (135). The
biological effects of chemokines are mediated through interactions with seven
transmembrane, G-protein coupled receptors and binding of a chemokine to its
receptor activates the intracellular pathways necessary to propel the cell in its chosen
direction. A number of recent investigations have implicated certain chemokines, and
their receptors, in the promotion of atherogenesis (192, 193).
The expression of IL-8 by lesional macrophage-derived foam cells has been detected
at various stages of the atherosclerotic process (194). Its corresponding receptor
CXCR-2 has also been detected in the intima of human atherosclerotic lesions (136).
In LDL-receptor deficient mice the murine homologue of this receptor (mIL-8R) was
abundant in the macrophage rich areas of established atherosclerotic lesions.
Moreover, the functional importance of this receptor was confirmed when its absence
on bone marrow derived-peripheral blood leukocytes was associated with reduced
lesion size and reduced macrophage recruitment, implying a role for its cognate
ligands (IL-8, growth-related oncogene (GRO) and neutrophil activating protein-2
[NAP-2]) in the localisation of macrophages to these lesions (136). 11-8 and its
related chemokines were originally thought to be predominantly chemotactic for
neutrophils which are scanty in human atherosclerotic lesions. The increasing
evidence indicating a role for this chemokine in monocyte/macrophage recruitment
to the atherosclerotic plaque, together with the recent in vitro finding that IL-8 is a
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potent trigger for firm adhesion of monocytes to vascular endothelium expressing
cell adhesion molecules under flow conditions, strongly suggests that this chemokine
is also a potent chemoattractant for mononuclear cells (195).
Expression of the CC chemokine MCP-1 is also upregulated in human
atherosclerotic plaques (196). Studies in vitro have demonstrated MCP-1
upregulation in endothelial cells, smooth muscle cells and monocytes in response to
various stimuli known to be present in lesions (192). These include oxLDL,
minimally modified LDL, the pro-inflammatory cytokines IL-1 and TNF-a, the
growth factors PDGF and basic FGF and binding of CD 40 ligand to its receptor CD
40. MCP-1 modulates not only monocyte (and T lymphocyte) recruitment but also
monocyte activation, including expression of some complement proteins, IL-1 and
the procoagulant tissue factor. In atherosclerotic prone mice lacking the receptor for
MCP-1, CCR2, there was markedly decreased lesion formation and macrophage
recruitment without changes in cholesterol levels or distribution of lipoprotein
particles (197). This identified CCR2 as a possible genetic determinant of murine
atherosclerosis and provided evidence for the role of MCP-1 in macrophage
recruitment and atherogenesis. Further confirmation of this was achieved when
deletion of the MCP-1 gene in transgenic mice expressing human apolipoprotein B
(causing elevated plasma cholesterol levels) provided protection from macrophage
recruitment and lesion formation, without altering lipoprotein metabolism (198).
Conversely, when bone marrow cells from mice overexpressing a murine MCP-1
transgene were transplanted into irradiated apolipoprotein E-knockout mice,
macrophages expressing the transgene were found in several tissues including the
aorta (199). Atherosclerotic lesions in these mice showed increased oxidised lipid
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content and macrophage infiltration providing further evidence that MCP-1
expression by leukocytes, mainly macrophages, may increase the progression of
atherosclerosis by facilitating both macrophage infiltration and oxidised lipid
accumulation.
Platelet factor 4 (PF 4) and interferon-inducible protein- lOkDa (IP-10) are C-X-C
chemokines which bind to the chemokine receptor, CXCR3. PF-4 selectively binds
to regions of active endothelial cell migration (and angiogenesis) and inhibits
endothelial cell proliferation (192). It also inhibits thrombin-induced matrix
metalloproteinase MMP-1 and MMP-3 expression by endothelial cells in vitro but
does not affect TIMP expression. It has been speculated therefore that PF4 may
interfere with vascular wall remodelling in atherosclerosis. IP-10, like PF-4, inhibits
endothelial proliferation. IP-10 mRNA is induced in the rat carotid artery after
balloon angioplasty (200). The capacity of IP-10 to modulate arterial remodelling is
further supported by its expression in VSMC in vitro and its chemotactic and
mitogenic actions on these cells (200).
Other C-C chemokines which have been demonstrated in atherosclerotic plaques are
pulmonary and activation regulated chemokine (PARC), ELC, RANTES and MIP-
la (201). While PARC was restricted to macrophages, ELC is present on both
macrophages and smooth muscle cells. Furthermore ELC mRNA levels in vitro have
been demonstrated to be upregulated in aortic smooth muscle cells stimulated with
TNF-a and IFN-y. These chemokines have a highly selective activity on
lymphocytes leading to speculation that they may be involved in the recruitment of T
cells into the atherosclerotic plaque. Although RANTES mRNA has been detected in
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atherosclerotic tissue (202), its presence also in normal aortic tissue makes the
significance of this finding unclear (154).
Chemokine receptors and atherosclerosis
Chemokine receptors have also been demonstrated on the various cells present in the
atherosclerotic lesion. Chemokine receptor mRNA for CCR-1 and CCR-2 have been
demonstrated on human vascular smooth muscle cells (154). Endothelial cells
express CXCR-4 (155) but conflicting reports exist as to the presence of CCR1,
CCR2 and CXCR2 on these cells (155, 203-205). The constitutive nature of such
receptors and their chemokines (stromal derived factor(SDF)-l in the case ofCXCR-
4) may be important in the early recruitment of monocytes and T lymphocytes as
opposed to the inducible chemokines such as MCP-1 which are generally not
expressed on normal arteries. Moreover, the expression of these receptors can be
regulated by pro-inflammatory cytokines (155). Further studies will help to clarify
the role of these chemokines and chemokine receptors in atherogenesis.
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1.3.2. Vasculitic phenotype
Vasculitis is defined simply as blood vessel inflammation. A broad and
heterogeneous group of syndromes result from this process, since any type, size and
location of blood vessel may be involved. Patients typically present with symptoms
related to inflammation/ischaemia in the particular vascular bed affected; disease
may be confined to a single organ or it may simultaneously involve several organ
systems (206).
Classification of the vasculitic syndromes has been plagued by their variability and
overlap, but in general relies principally on the size of the primary blood vessel
affected (Table 1.3).
Evidence for the immunopathogenenic mechanisms underlying vasculitic disease is
for the most part indirect and may reflect epiphenomena as opposed to true causality.
It is generally held, however, that an initiating stimulus leads to vascular injury
(often segmental or localised), resulting in inappropriate activation of the normally
tightly regulated immune response and subsequent vessel damage. Putative stimuli
include immune complex deposition in response to exogenous antigens, complement
activation, infectious agents and anti-neutrophil cytoplasmic antibodies (ANCA)/
anti-endothelial cell antibodies (AECA).
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Classification of Vasculitic Syndromes
Clinical Syndrome Predominant Vessels Affected
Takayasu arteritis Large arteries (aorta & primary branches)
Giant cell (temporal) arteritis Large and medium arteries (aorta, primary, andsecondary branches)
Systemic necrotizing vasculitis
Medium and small muscular arteries and
arterioles (diverse distributions and locations)
Systemic necrotizing vasculitis
Polyangiitis nodosa




Vasculitis in rheumatic disease (eg,
rheumatoid arthritis. Behcets
syndrome)










Cutaneous vasculitis associated with
other diseases
(eg, biliary cirrhosis, ulcerative colitis)
Hypersensitivity vasculitis (cutaneous
leukocytoclastic vasculitis)
Small vessels (arteries capillaries, venules)
Large vessel refers to the aorta and the largest branches directed toward major body
regions (eg, to the extremities and the head and neck): medium vessel refers to the main
visceral arteries (eg. renal, hepatic, coronary, and mesenteric arteries): and small vessel
refers to venules, capillaries, arterioles, and the intraparenchymal distal arterial radicals
that connect with arterioles. Some small and large vessel vasculitis may involve medium
arteries, but large and medium vessel vasculitis do not involve vessels smaller than
arteries. (206)
Table 1.3 Classification of Vasculitic Syndromes
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It may be that in certain forms of vasculitis, some form of persistant immune
challenge or chronic antigen exposure induces the formation of immune complexes
in excess of the capacity of normal immune system clearance mechanisms (207).
Such complexes, when formed in excess, are deposited in vessel walls where they
stimulate complement activation. C5a generation, for example, results in neutrophil
recruitment to the site of immune complex deposition; basophil/mast cell
degranulation also occurs with subsequent release of vasoactive amines and
associated increases in vascular permeability. Neutrophils, activated as they try to
phagocytose immune complexes, release inflammatory mediators and proteolytic
enzymes. This results in endothelial damage, exposure of the sub-endothelium and
activation of the intrinsic coagulation pathway. In addition, platelets bind at sites of
endothelial damage, interact with immune complexes and aggregate at these sites.
Uncontrolled these events lead to the formation ofmicrothrombi, vascular occlusion
and necrosis.
Antibodies recognising antigens in the cytoplasm of ethanol fixed neutrophils
(ANCA) have been detected in various forms of vasculitis and have been classified
according to their pattern of immunofluorescent staining (208). Cytoplasmic anti-
neutrophil antibodies (c-ANCA) bind to the enzyme proteinase-3 and stain
leukocytes in a granular cytoplasmic manner. Conversely, perinuclear anti-neutrophil
antibodies (p-ANCA) generally recognise the enzyme myeloperoxidase (less
commonly recognised antigens include elastase, cathepsin G, lactoferrin and
lysozyme) and show perinuclear staining of leukocytes. c-ANCA has a high
specificity for Wegener's granulomatosis (WG) with antibody level fluctuating with
disease activity; p-ANCA is most frequently detected in patients with microscopic
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polyangiitis. In vitro c-ANCA increases the expression of E-selectin and VCAM-1
on endothelial cells, as well as E-selectin-dependent neutrophil adhesion (208). In
addition, the proinflammatory cytokines TNF-a, IL-lp and IFN-y result in the
translocation of cytosolic proteinase-3 to the cell membrane of endothelial cells in
vitro (209). Subsequent stimulation of such cytokine-primed cells with c-ANCA
results in a dose-dependent induction of the phosphoinositide hydrolysis signal
transduction pathway, concomitant with an increase in trans-endothelial protein
leakage and loss of barrier function (209). ANCA have also been reported to
stimulate neutrophil activation and degranulation and it has now been established
that, at least in vitro, the Fc region of ANCA interacts with Fc receptors on
neutrophils (210). Neutrophils constitutively express the Fc receptors FcyRIIa
(CD32) and FcyRIIIb (CD16); c-ANCA and p-ANCA can bind to both these
receptors resulting in neutrophil activation, degranulation and increases in adhesion
molecule (CDllb/CD18) expression. Taken together, the above studies suggest that
these antibodies, acting via multiple mechanisms, may be important in the
pathogenesis of the vasculitic process in patients in whom they are detected.
Patients with systemic autoimmune disease associated with vasculitis, and some
primary vasculitic processes (e.g. Takayasu's arteritis) have a high prevalence of
anti-endothelial cell antibodies (AECA), the titre of which has been shown to
correlate with disease activity (211). These antibodies, frequently associated with
anionic phospholipids, activate endothelial cells in vitro, leading to adhesion
molecule expression and, in some cases, induction of endothelial apoptosis (212,
213). In Kawasaki vasculitis, IgM anti-endothelial antibodies directed against
endothelial surface antigens inducible by cytokines have been found. Thus, in some
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forms of vasculitis, inducible antigens may lead to a subsequent antibody response
which can lead to vascular injury.
Hepatitis B antigen, streptococcal, staphylococcal and mycobacterial antigens have
been identified in certain vasculitic lesions, most commonly polyarteritis nodosa
(PAN). In selected cases ofPAN circulating immune complexes, containing hepatitis
B surface antigen linked to specific IgG and IgM, have been demonstrated both in
the circulation and in vasculitic lesions (206). Several viral infections in humans are
also capable of causing direct cytopathic injury to arterial endothelium (214). Interest
has also recently focused on bacterial superantigens which, by virtue of their
structure, have the ability to stimulate a large portion of the T cell pool. It has been
speculated that such antigens may stimulate T cells, autoreactive to some vascular
wall component, to mediate autoimmune vessel wall destruction (215). Furthermore
such antigens may activate autoreactive B cells to produce auto-antibodies such as
ANCA, or anti-endothelial cell antibodies or indeed others, as yet unidentified.
Molecular studies in giant cell arteritis indicate that T cells are recruited to the vessel
wall and are activated locally; subsequent production of IL-2 and IFN-y regulates the
activity of tissue infiltrating macrophages (216). Growth factors are instrumental in
the process of intimal hyperplasia, leading to lumen obstruction and tissue ischaemia.
The levels of IL-2, IFN-y and PDGF in vascular lesions varies according to the
clinical manifestations of the disease e.g. ischaemic optic neuritis or stroke is
characterised by high IFN-y and PDGF, while dominant IL-2 production is
associated with polymyalgia rheumatica. It has been speculated that these different
inflammatory pathways may reflect differences in the contribution of the arterial
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wall, or may be due to the presence of multiple disease-inducing antigens with
different tissue distributions or tropisms (216).
The prognosis of Henoch-Schonlein purpura (HSP), unlike some of the other forms
of vasculitis, is excellent, with most patients recovering completely, and in some
cases without the need for therapy (207). The underlying pathogenesis is presumed to
be immune-complex deposition and a number of inciting antigens have been
suggested including upper respiratory tract infections, various drugs, foods, insect
bites and immunisations. IgA is most commonly found in the immune complexes,
and this in addition to alterations in circulating serum terminal complement
complexes (decreased properdin, increased C3d), suggests IgA-mediated alternate
pathway complement activation. Whether the IgA complexes trigger this
complement activation is still unclear. IgG anti-mesangial cell antibodies have also
been detected in patients with HSP where levels have been reported to parallel the
course of the renal disease (217).
It is important to note, however, that to date in most cases of vasculitis, definitive
identification of causative agents has not yet been made. It is also unclear why
certain individuals develop vasculitis in response to antigenic stimuli, whereas others
do not. It is likely that a number of factors are involved in the ultimate expression of
a vasculitic syndrome such as genetic predisposition and the regulatory mechanisms
associated with the immune response to certain antigens. In addition, the size and
physicochemical properties of immune complexes (if present), the relative degree of
turbulence in blood flow, the haemostatic pressure in different vessels and the pre¬
existing integrity of the endothelium may all play a role in determining why only
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certain immune complexes cause vasculitis and why vasculitis is selective for only
certain vessels in individual patients.
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1.3.3. Thrombotic phenotype
Blood coagulation is mediated by cellular components and soluble plasma proteins
(reviewed in (218)). In response to vascular injury, circulating platelets adhere,
aggregate, and provide cell-surface phospholipid for assembly of blood-clotting
enzyme complexes. A series of enzymatic reactions then leads to the conversion of
soluble fibrinogen to a fibrin clot (219)(Fig 1.9).
Figure 1.9 Coagulation cascade (adapted from 219) refer to following text for details
HMWK=high molecular weight kinogen: PK=prekallikrein: PL=phospholipid: PT=prothrombin: TF
=tissue factor: Th=thrombin
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All of the enzymes (factors) within the pathways (except factor VIII) are serine
proteases and hydrolyse peptide bonds. In the extrinsic pathway, tissue factors
(lipoproteins released from damaged cells) bind to activated factor VII and the
resulting enzyme complex activates factors IX and X of the intrinsic and common
pathways respectively. Factor IX in turn activates additional factor X in a reaction
accelerated by a cofactor, factor VIII. Factor VIII is a complex protein made up of a
small protein molecule (VIII:C) with coagulant activity and a larger protein molecule
(VIIIR:Ag) which is associated with platelet function, particularly their adhesion to
exposed collagen. (Von Willebrand's factor is part of the VIIIR:Ag molecule).
Once activated, factor X converts prothrombin to thrombin (in a reaction catalysed
by factor V), and thrombin in turn cleaves fibrinogen to form fibrin monomers.
Polymerisation and linking of fibrin (via factor XIII) then occurs to form a
chemically stable clot. Feed-back loops exist whereby thrombin itself can activate
cofactors V and VIII resulting in amplification of this cascade. In essence then, the
extrinsic pathway initiates coagulation, while the intrinsic pathway amplifies the
response through feed-back mechanisms.
Platelets have a number of functions in, and are crucial to, thrombus formation (105,
218). Adherence of platelets to the subendothelial matrix, exposed by vascular
injury, results in their activation which in turn causes recruitment and adherance of
further platelets - platelet aggregation. Fibrinogen and von Willebrand factor form
crossbridges between adjacent glycoprotein (GpIIb/IIIa) molecules on adjacent
activated platelets thereby resulting in this platelet aggregation which in itself can
form a haemostatic plug. This process is enhanced by platelet production ofADP and
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thromboxane A2 (TXA2). TXA2 is also a potent vasoconstrictor resulting in the
retention of both platelets and clotting factors at the site of endothelial injury.
Prostacyclin (PGI2), synthesised by the vascular endothelial cell, promotes
vasodilatation and inhibits platelet aggregation. PGI2 production is also stimulated by
thrombin and may play a role in limiting coagulation to the site of damage.
These cascades have the ability to transduce a small initiating stimulus/injury into a
large fibrin clot and their potentially explosive nature is offset by natural
anticoagulant mecanisms. Antithrombin III is a plasma protein that inhibits the
activity of the serine-proteases of the intrinsic and common pathways by forming
stable complexes with them. Heparin sulphate, released from endothelial cells, binds
to antithrombin III and greatly potentiates its ability to inactivate these enzymes (58).
Thrombin complexes with the endothelial cell via a receptor protein,
thrombomodulin (59). This increases the generation of activated protein C which
cleaves activated factors V and VIII and destroys their coagulant properties (60).
This reaction can also be accelerated by a cofactor, protein S (Fig 1.10).
Coagulation Inactivation of Va, Villa






Activation of protein C.
Figure 1.10 (220)
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Inhibition of the extrinsic pathway occurs via tissue factor pathway inhibitor which is
a lipoprotein-associated plasma protein that forms a quaternary complex with tissue
factor and factors VII and X, thereby preventing their activity. Finally the generation
of plasmin from plasminogen, via another series of linked enzymatic reactions,
results in the dissolution ofpre-formed clots by fibrin breakdown (Fig 1.5)
The mechanisms that underlie the thrombotic phenotype are defined by Virchow's
triad: a decrease in blood flow (the deep veins of the leg, for example, are
particularly at risk of thrombosis in conditions of decreased flow/stasis such as the
peri- and post-operative period), injury to the vessel wall and a change in the
systemic balance of procoagulant and anticoagulant factors. It is interesting,
however, that systemic changes in haemostatic mechanisms, whether congenital or
acquired, typically give rise to local thrombotic lesions in discrete segments of the
vascular tree, leading to speculation that the endothelium integrates different
extracellular signals and responses according to its location within the vasculature
(218).
Hypercoagulable states
Congenital deficiencies of antithrombin III, protein C and protein S are associated
with an increased risk of lower limb deep-vein thrombosis (221). Resistance to
activated protein C (APC) is the most common inherited hypercoagulable state found
to be associated with venous thrombosis. It is caused by a single point mutation in
the factor V gene. The occurrence of this mutation results in loss of one of the three
factor V cleavage sites for APC and hence resistance to its anticoagulant effects. This
so-called Factor V Leiden is associated with a 5-10 fold increased risk of deep
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venous thrombosis in the legs, as well as an increased risk of cerebral thrombosis.
Most studies have not confirmed an association between factor V Leiden and arterial
thrombosis, but it may confer an increased risk of myocardial infarction in young
female smokers (222). The second most common inherited risk factor for thrombosis
is a point mutation in the prothrombin gene (G20210A) which is associated with
increased prothrombin activity (221). This also predisposes to venous thrombi in legs
and brain and may be a genetic risk for coronary and cerebral arterial thrombosis,
although this needs further confirmation (223, 224).
Inherited abnormalities of the coagulation system such as those described above may
interact with environmental/acquired factors to potentiate the risk of thrombosis.
Trauma, surgery, immobilisation, pregnancy, the puerperium and the use of oral
contraceptives are important risk factors for venous thrombosis. Oral contraceptive
use, for example, results in alterations in the concentrations ofmany haemostatic and
fibrinolytic components of the blood. In patients with the factor V Leiden mutation
and prothrombin G20210A mutation, the risk of cerebral and lower limb venous
thrombosis is significantly increased by concomitant oral contraceptive use (225).
Several acquired hypercoagulable states also occur. Paroxsymal haemoglobinuria is a
rare condition in which an abnormal stem cell clone leads to a proportion of red cells
which are sensitive to activated complement, resulting in intravascular haemolysis
(218). In addition, the production of abnormal platelets leads to a tendency to
thrombosis, but interestingly, this most commonly affects the hepatic, portal and
mesenteric veins. In polycythaemia and myelofibrosis elevated levels of abnormal
platelets which have an increased tendency to aggregate, predispose to both arterial
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and venous thrombi (218). In the anti-phospholipid antibody syndrome (APAS) there
is a propensity to form clots within particular venous and arterial segments of the
arterial tree including retina and placenta. The mechanisms of thrombus formation by
these antibodies is not completely understood, although in vitro they can inhibit
protein C activation and activate endothelial cells (226). Furthermore in a mouse
model ofmicrocirculation, antibodies introduced from patients with APAS results in
enhanced thrombus formation (227).
Haemolytic uraemic syndrome (HUS) and thrombotic thrombocytopenic purpura
(TTP) are microvascular syndromes in which microangiopathic haemolytic anaemia,
thrombocyopaenia and platelet clumping lead to microvascular thrombosis in all
organs except liver and lungs (228). HUS is mostly due to verotoxin producing E.
Coli (E.Coli 0157:H7), while the cause ofTTP is still uncertain although associations
with malignancy, bone marrow transplantation and HIV infection have been
documented (229). Endothelial cell injury and intravascular platelet aggregation have
been implicated in the pathogenesis of both syndromes. Immunohistochemical
studies have demonstrated the presence of abundant von Willebrand factor in the
thrombotic lesions and, particularly in the chronic relapsing forms of these
syndromes, unusually large circulating multimers of von Willebrand factor occur
which are capable of agglutinating platelets (230). It has been speculated that
systemic endothelial injury may lead to release of excessive amounts of these
abnormal multimers which, under normal circumstances, are processed to smaller
forms by vonWillebrand factor cleaving protease. Recent studies have indicated that,
in the case of TTP, familial forms are associated with a constitutional deficiency of
this enzyme, whereas in the non-familial forms the presence of an antibody inhibitor
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to the protease can be demonstrated (230, 231). These abnormalities were not
detected in HUS and the pathogenesis of this disease remains unclear.
The acute inflammatory response in meningococcaemia leads to activation of the
cytokine and complement networks, in addition to activation of the homeostatic
cascades of procoagulation, anti-coagulation and fibrinolysis (232). This
disseminated coagulopathy results in an acquired deficiency of the anti-coagulants
protein C, protein S and antithrombin III. Protein C activity is reduced to a greater
extent than the other anticoagulants and there is a correlation between the severity of
the acquired protein C deficiency, the extent of thrombotic skin lesions and adverse
outcome (233). Mortality in this disease is greater than 50%, and in survivors skin
grafts, amputation and end-organ failure are not uncommon. A recent study showed a
decrease in mortality and morbidity in response to early protein C replacement (in
additional to conventional therapy) in patients with meningococcal septicaemia and
associated disseminated coagulopathy (232). Study numbers however were small and
additional randomised controlled trials are necessary to confirm these preliminary
results.
Elevated plasma homocysteine levels are typically caused by genetic defects in the
enzymes involved in homocysteine metabolism or nutritional deficiencies in vitamin
co-factors (folate, vitamin B12 and vitamin B6) (reviewed in (234)). Elevated levels
also occur in chronic renal failure, in association with certain malignancies, and
occasionally secondary to drugs (methotrexate, phenytoin, theophylline). In
homocysteinuria (homozygous for cystathionine [1-synthase deficiency) where there
is marked elevations of plasma homocysteine levels, there is, in addition to skeletal
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abnormalities and mental retardation, severe premature atherosclerosis and increased
incidence of arterial and venous thrombosis (234). Multiple studies have also
confirmed that moderately elevated homocysteine levels are an independent risk
factor for atherothrombotic disease and venous thrombosis. The precise molecular
mechanism underlying this is unknown, but homocysteine does cause endothelial
dysfunction at several levels. In relation to coagulation, homocysteine enhances the
activity of factor V, induces the expression of tissue factor, depresses the activation
of protein C, inhibits the expression of thrombomodulin, and suppresses endothelial
production of heparin sulphate. In aggregate these effects facilitate the production of
thrombin and create a prothrombotic environment.
Vascular bed specific hyper-coagulable states
In all of these situations, a systemic defect in the haemostatic pathway, caused by
absence of a circulating endogenous anticoagulant or the presence of an activated
cell surface, results in an increased risk of localised thrombosis. The endothelium
within a given area of the vasculature, and the microenvironment surrounding it, is
crucial to maintaining the balance of pro-coagulant and anti-coagulant forces. In this
scenario, not only does the microenvironment vary from one vascular bed to another
in terms of the array of extracellular signals regulating the haemostatic properties of
the endothelium, but there is also increasing evidence to suggest that endothelial cells
from different vascular beds respond differently to the same signals in terms of their
pro- and anti-coagulant activity (218).
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Microenvironment: extra-cellular mediators, haemodynamic forces, cell-cell
interactions
Growth factors and cytokines, constitutive to the microenvironment surrounding an
endothelial cell, or produced by infiltrating cells in response to injurious stimuli, are
important in defining the balance between a pro-thrombotic and anti-thrombotic
phenotype. IL-1, TNF-a, and TGF-P all decrease the expression of thrombomodulin
in vitro (235) and, in addition, the latter two cytokines increase expression of the
plasminogen activator inhibitor type 1 (PAI-1) (236). Vascular endothelial growth
factor (VEGF) increases the expression of thrombomodulin (237), PAI-1 and tissue
type plasminogen activator (238), while PDGF increases expression of von
Willebrand factor (part of the factor VIII complex) (239). These effects obviously
have potential to shift towards the thrombotic phenotype, although the effects in vivo
have yet to be clarified.
Haemodynamic forces may also be important regulators of the thrombotic
phenotype. These forces will be discussed in more detail in chapter 2; suffice to say
here that such forces, consisting of both shear stress - as blood flows along the
endothelial surface - and cyclic strain - elongation of the cells as they undergo the
rhythmic distension of the vessel, - are higher in arteries than veins. Shear stress is
accentuated at sites just distal to bifurctations in vessels, cyclic strain is increased in
hypertension and both forces increase during cardiac systole and exercise. Many in
vitro studies have documented shear stress-dependent induction of endothelial genes
including thrombomodulin, tissue plasminogen inactivator, tissue factor and ecNOS
(218). Similarly, cyclic strain upregulates endothelial transcription of the genes for
tissue plasminogen activator and inactivator and ecNOS (240). In view of these
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findings, it has been speculated that changes in haemodynamic forces may contribute
to the different patterns of expression of pro- and anti- coagulant factors in different
vascular beds.
Communication between different cell types may also be important in this process. In
vitro, for example, expression of PAI-1 in endothelial cells is down-regulated by
conditioned medium from pulmonary artery smooth muscle cells, but up-regulated
by smooth muscle cells from aorta and umbilical vein (241, 242). In another study
the expression of von Willebrand factor in the endothelial cells of the heart was
shown to be induced by a cardiomyocyte-dependent pathway (243).
Endothelial cell responsiveness: origin-dependent
An important component to differential endothelial responses to the extra-cellular
stimuli within their microenvironment is the uneven distribution of the various pro-
and anti- coagulant factors throughout the vascular tree. Levels of von Willebrand
factor, for example, vary from one vascular bed to another, while
immunohistochemstry has revealed high levels of the thrombomodulin receptor in
the endothelium of the lungs and heart, with barely detectable levels within the
blood-brain barrier (218). Gene targeting studies in mice have provided proof of this
concept in that mice deficient in either thrombomodulin or tissue-type plasminogen
activator have characteristic patterns of thrombus distribution, with some organs
being spared (244).
The response of a given endothelial cell to a stimulus also varies. In vitro, for
example, plasma derived from patients with TTP mediates differential effects on the
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production of prostacyclin and apoptosis in endothelial cells derived from various
vascular beds (245). IL-la inhibits expression of VCAM-1 in dermal microvascular
endothelial cells but not other endothelial cell types where it induces expression of
this molecule (246). Furthermore, stimulation of blood vessels ex vivo with thrombin
has been shown to mediate an endothelial-dependent relaxation of the internal
thoracic artery but causes contraction of the saphenous vein (247). The expression of
von Willebrand factor within the endothelial microvessels of the heart is governed by
a signalling pathway mediated by cardiomyocyte dependent PDGF AB heterodimer.
PDGF AB is not detectible in other vascular beds such as lung, and even within the
cardiac microvasculature, only certain endothelial cells have receptors for PDGF-a
and thus are able to transduce the signal (239). Modulation of tissue factor activity by
the pro-inflammatory cytokine, TNF-a varies in vitro according to the origin of the
endothelial cell, be it aorta, umbilical vein or dermal microvessels (218).
A final mechanism underlying the expression of vascular-bed-specific phenotypes
may be found at the level of transcription, with endothelial genes being controlled by
different pathways. In transgenic mice for example, a short 733-bp region of the von
Willebrand promoter directs expression only in cerebral endothelium, whereas a
promoter containing additional upstream and downstream elements directs
expression in the endothelium of heart and skeletal muscle (243, 248).
In summary then, regional networks of pro and anti-coagulant mechanisms yield a
net balance in hemostasis. In hypercoagulable states, abnormalities of the
coagulation factors, either congenital or acquired and often interacting with
environmental factors, predispose to thrombosis. The endothelium plays a crucial
74
role in the maintenance of haemostasis and it is now apparent that endothelial cells
from different vascular beds respond differently to the same signals in terms of their
pro- and anti-coagulant activity. This, in addition to the various extra-cellular
mediators, haemodynamic forces and cell-cell interactions occuring in the
microenvironment within a given vascular bed, explains why systemic defects in the
haemostatic pathways generally result in localised thrombosis.
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1.3.4. Vasoconstrictive phenotype
A variety of human diseases are characterised by vasoconstriction e.g. ischaemic
acute tubular necrosis, Raynaud's phenomonen, sclerodermic crisis and pre¬
eclampsia. In these diseases diverse stimuli, through injury to endothelium,
jeopardise the endothelial-dependent control of vascular tone. In addition, as has
been extensively discussed, endothelial activation-injury promotes the adaptation of
a pro-inflammatory phenotype by these cells (249-251). For the purposes of this
discussion, pre-eclampsia will be used to illustrate the characteristics of the
vasocontrictive phenotype.
Pre-eclampsia refers to the development of hypertension and proteinuria during the
second and third trimesters of pregnancy. This condition is most common in, but not
exclusive to, primigravidae and occurs in about 1% of this group. In addition to
increased foetal risks of intrauterine growth retardation or intrauterine death, it poses
significant threat to the mother as it may precede eclampsia. Eclampsia is
characterised by convulsions and coma and carries increased risks ofmaternal death
from cerebral ischaemia/haemorrhage, renal, hepatic and cardiac failure. While the
pathogenesis of this disease remains poorly understood, there is now abundant
circumstantial evidence supporting the concept of endothelial dysfunction and
activation in this multisystem disorder, in addition to a systemic activation of
maternal inflammatory responses (249). Indeed most clinical aspects of pre¬
eclampsia could potentially be explained by generalised maternal endothelial cell
dysfunction: intense vasoconstriction and hypertension through disturbed endothelial
control of vascular tone, fluid retention resulting from increased endothelial
76
permeability and clotting dysfunction due to abnormal endothelial procoagulant
production.
It has been speculated that the pathogenesis of pre-eclampsia is related to an
imbalance of oxidative homeostasis. Maternal dyslipidaemia, which may be in part
related to fatty acid mobilisation for the increased energy demands of pregnancy, and
altered iron kinetics may both contribute to the increased oxidative load (252).
Increased levels of lipid peroxides have been detected both in the placenta and in the
circulation of pre-eclamptics and these can result in activation of maternal
endothelial cells and circulating leukocytes (253). Endothelial activation results in
upregulation of adhesion molecules; a concurrent upregulation of the corresponding
receptors on neutrophils results in increased neutrophil-endothelial binding and
transmigration (254). Upon activation neutrophil granules are released, leukotrienes
are synthesised and superoxide is generated in a respiratory burst. In addition,
complement activation and increased monocyte production of the cytokines TNF-a,
IL-6 and IL-8 have also been demonstrated (255). These processes both promote and
sustain vascular damage. Loss of endothelial integrity and increases in vascular
permeability can be demonstrated in patients who have increased circulating levels of
the endothelial cell markers fibronectin, von Willebrand factor, tissue plasminogen
activator and plasminogen activator inhibitor-1 (PAI-1) (256). Increases in levels of
endothelin-1 may also contribute to the intense vasoconstriction and hypertension
that characterises this disease (257).
Placental tissue is essential to to generate the end stages of the syndrome of pre¬
eclampsia. Furthermore, in the rare case of extrauterine pregnancy where delivery of
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the foetus does not lead to delivery of the placenta, signs of the disease persist post¬
partum. It has been speculated that defective placentation may cause uteroplacental
arterial insufficiency and subsequent placental hypoxia (249). This may result in
release of cytokines, proteolytic enzymes and free radicals into the maternal
circulation leading to endothelial and leukocyte activation as described previously.
Increasing placental damage also results in release of syncytiotrophoblastic
microvillus fragments which may themselves initiate an inflammatory response.
Pregnancy has long been regarded as a state of relative immunosuppression, but
some interesting recent observations have suggested that normal pregnancy is also
associated with a degree of immune activation. Using flow cytometric techniques,
leukocytes from women with normal pregnancies showed higher surface expression
of the integrin CD lib and the IgG receptor CD64 as compared with non-pregnant
women (256). Intracellular reactive oxygen species were also significantly increased,
though not to the degrees observed in pre-eclampsia. This has led these authors to
suggest that a generalised, intravascular, inflammatory response occurs in normal
pregnancy and that pre-eclampsia is not an intrinsically different state of pregnancy,
but rather represents the extreme end of a universal maternal response to pregnancy.
Decompensation might result when the inflammatory stimulus is too strong (e.g.
placental hypoxia) or the maternal response to it is too intense (e.g. genetic
susceptibility to inflammatory stimuli). These are complex issues and important
questions remain unanswered such as the preponderance of pre-eclampsia in first
pregnancies and the occurrence of marked vasoconstriction/hypertension in this
disease. Acute sepsis for example, the classical paradigm of systemic inflammation,
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Allograft Rejection: Major histocompatibility complex
The ability to distinguish self from non-self is the basis for the rejection process.
Allograft rejection, both acute and chronic, represents the end result of a complex set
of immunological processes arising from the recognition of non-self antigens
(peptides) on transplanted tissues (258). Major histocompatibility complex molecules
(MHC) are the most potent of the histocompatibility antigens that serve as targets for
allograft rejection. The MHC, first described in the mouse by Gorer (259) and Snell
(260), is a closely linked series of genes encoding the major antigens responsible for
organ rejection in all mammalian species studied to date. In humans this polymorphic
set of membrane proteins are known as the human leukocyte antigens (HLA),
homologous to RT1 in the rat and H-2 in the mouse (Table 1.4).
MHC Antigens
Class I Class II
Human HLA ABC DQ DR DP
Rat RT1 A B D
Mouse H-2 KDL I-A l-E
Table 1.4 MHC antigens
MHC antigens are divided into two groups: class I and class II. Class I molecules are
expressed on all nucleated cells; class II antigens are expressed on B lymphocytes,
activated T lymphocytes, some monocytes/macrophages and dendritic cells. Human
endothelium or epithelium does not generally express class II molecules but these
can be induced rapidly by injury and inflammatory stimuli. In the context of
transplantation the expression of both classes ofMHC antigens on resident allograft
cells is not constant and is modified by the rejection process (258).
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The remarkable polymorphism ofMHC antigens, due to the presence ofmany alleles
encoded by at least six loci (located on the short arm of chromosone 6 in humans),
makes it extremely unlikely that two unrelated individuals will carry identical
antigens (261). The direct recognition of intact MHC molecules, although focused on
polymorhic MHC epitopes, is also strongly influenced by the presence of peptides
bound in the MHC groove. Because a given MHC molecule can bind many different
peptides, including some derived from self-MHC, a high number of possible MHC-
peptide combinations can occur that provide a great diversity of MHC binding
regions for presentation to the T cell pool. Further it has been speculated that, in
addition to the vast number ofMHC alloantigen epitopes, the natural high affinity of
the T cell receptor-MHC interaction is a key determinant in defining the
characteristic intensity of the allogeneic immune response. The histocompatibility
immune response is as much as 100-fold stronger than the response to the more
common environmental antigens e.g. viruses. It is not surprising, therefore, that
organ rejection is the ultimate result.
Allorecognition
It is generally accepted that there are two principal mechanisms of allorecognition;
the so-called direct and indirect pathways (262). In the former, T cells recognise
intact allo-MHC molecules on the surface of donor cells; peptides derived from
endogenous proteins bound in the antigen binding groove of the MHC play an
important role in this mode of recognition. In the indirect pathway, self antigen
presenting cells (APC) process allo-MHC molecules and present the resultant
peptides in the context of their own MHC for T cell recognition. Both mechanisms of
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recognition initiate the immune response that characterises the rejection process
(Fig 1.11).











Figure 1.11 Allorecognition: direct and indirect mechanisms
(See text for details. Adapted from reference (263))
Allograft rejection: T helper cells
Two major subsets of T cells, the CD8+ cytotoxic T cells (Tc) and CD4+ T helper
(Th) cells recognise processed antigen on MHC class I and class II, respectively (Fig
1.11). The activation of a T cell requires two principal signals. One signal is
transduced by the antigen specific T cell receptor when it recognises the antigen in
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the context of MHC molecules on the APC and this defines the specificity of the T
cell response. The second signal is mediated, via a separate pathway, by a co-
stimulatory molecule that is independent of antigen. The best characterised
costimulatory molecule is CD28 which is expressed on all T helper and some
cytotoxic T cells and binds a family of counter receptors termed B7 expressed by the
APC (263). Both pathways interact at a transcriptional level to regulate gene
expression and, hence, T cell activation and function. One of the main effects of
these signals is to induce the Th cell to produce interleukin (IL)-2, a cytokine that
activates the Th cell, enabling it to proliferate and interact with B cells and cytotoxic
T cells (Fig 1.12).
Figure 1.12 T cell co-stimulation: CD28-B7 interactions (from Reference (263).)
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CD40 is a member of the TNF receptor family and is expressed on most immune
cells and endothelial cells (264). It binds to CD40L, a type II membrane-protein
member of the TNF family, present on endothelial cells, activated B cells, APC and
platelets. In the context of cardiac rejection, CD40/CD40L interactions can induce
expression of costimulatory molecules (B7) on APC and can activate endothelial
cells to express adhesion molecules and cytokines that promote the inflammatory
response (188, 265).
In addition to CD28, Th cells express a second higher affinity ligand for B7, CTLA4.
In contrast to CD28 this delivers a negative signal to the T cell leading to cell cycle
arrest (263). Mice deficient in CTLA4 die of a generalised lymphoproliferative
disorder within two or three weeks of birth, highlighting the importance of the
CTLA4 "off' signal. Blockade of the CD28-B7 interaction by anti-CTLA4 prevents
T cell activation and prolongs allograft survival. (Fig 1.13) (266, 267).
Antigen activation
Inhibition
Figure 1.13 CTLA4: inhibition ofT cell costimulation and
clonal expansion
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Allograft rejection: endothelial cells
Endothelial cells of vascularised allografts are the first obligate cells that interact
with host lymphocytes. Graft endothelium can influence rejection in two important
ways. Firstly, as described above, endothelial cells may participate directly in the
activation of alloreactive T lymphocytes via the presentation of alloantigen and
effective costimulation of activation. Secondly, the endothelium is critical for the
recruitment of T cells into allograft tissue. The movement of immune cells from the
blood vessel lumen into allograft tissue is likely to occur via the multistep paradigm
of leukocyte-endothelial interactions described previously in section 1.2.1.
Endothelial E-selectin expression tends to occur early following transplantation and
precedes rejection episodes, whereas ICAM-l/VCAM-1 on endothelial cells tend to
be more temporally associated with T cell infiltrates and the rejection process itself
(264).
Allograft rejection: chemokines
A large body of evidence suggests that chemokines (discussed in section 1.2.3)
participate in leukocyte trafficking into allografts, with documented expression
following ischaemia/reperfusion injury, during acute or chronic rejection episodes
and in association with viral infections (143). The infiltrating leukocyte population is
defined both by the nature of the chemokines secreted by, as well the specific
chemokine receptors expressed on the cytokine-activated allograft cells and the
infiltrating cells themselves. The elaboration of cytokines and chemokines by Th,




While signalling through the T cell receptor and co-stimulatory molecule is sufficient
to activate the T cell to produce and secrete IL-2, these signals alone are not
sufficient to promote T cell proliferation. Cytokines affect the proliferation,
differentiation and the functioning of immune cells in numerous physiological
processes and are central to the generation of an immune response (261). These
mediators are produced by multiple different cell types including T cells, B cells,
monocytes/macrophages and APC as well as various non-immune cells such as
endothelial cells. Subsets of Th cells, namely Thl and Th2 cells, which exhibit
characteristic cytokine production profiles are central to the immune response (268).
Thl cells exert broadly pro-inflammatory actions via their secretion of IL-2, TNF-a
and IFN-y (269). As previously mentioned IL-2 is a powerful autocrine T cell growth
factor, activating T cells, stimulating their growth and giving rise to clonal
expansion. By contrast, TNF-a and IFN-y on the other hand exert activating effects
on monocytes and resident cells. These cytokines induce class I and class II antigen
expression, modulate adhesion molecule expression and stimulate the release of
further cytokines, chemokines and growth factors from monocytes, T cells and
endothelial cells. Interleukin IL-1 production by macrophages activated by TNF-a
and IFN-y further enhances the immune response by activating T cells, promoting
chemotaxis of additional macrophages into the allograft and by stimulating growth
factor and chemokine production by resident cells. Th2 cytokines, principally IL-4,
IL-6, IL-10 and IL-13 exert anti-inflammatory effects via their suppression of Thl
cell activation. It is important to note however that Th2 cytokines can "switch on"
humoral immnuity via their activation of B lymphocytes. Thus, in the context of
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allograft rejection, cytokines both sustain and amplify the immune response by
promoting lymphocyte activation, increasing adhesion molecule expression, and
regulatingMHC expression (268, 269).
Allograft rejection: cytotoxic T cells
In addition to the activation and proliferation of Th cells, the generation of allograft
specific CD8+ cytotoxic T cells which recognise donor antigens in the context of
MHC Class I results in further destruction of graft tissue (261). Multiple mechanisms
may come into play in cytotoxic lymphocyte mediated target cell destruction. Certain
cytotoxic lymphocytes have within their cytoplasm lytic granules containing pore
forming material. Following binding to target cell lytic granules fuse with the T cell
membrane and release their contents into the lymphocyte-target cell intercellular
space. Among the granule constituents are the pore forming protein perforin,
lysosomal enzymes and serine esterases termed granzymes. It has been speculated
that, in the presence of calcium ions, perforin forms non-selective trans-membrane
pores resulting in disruption of electrochemical gradients and subsequent colloid
osmotic collapse of the affected cell. Cytotoxic T cell-dependent apoptosis of
resident cardiac cells is also thought to occur (270). There is now substantial
evidence that cytotoxic CD8+T cells can also produce produce cytokines, such as IL-
2 and IFN-y, at levels sufficient to provide autocrine growth. Thus in some
circumstances CD8 + cells may provide their own help and function independently of
the Th cell subset (258).
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These various processes underlying allograft rejection are shown schematically in the













Figure 1.14 Allograft rejection (261).
Schematic illustration of the immunological components of rejection. Activated CD4 T helper cells
proliferate and secrete a variety of cytokines that serve as growth and activation factors for CD8
cytotoxic T cells, B cells and macrophages, which cause destruction of the graft by direct lysis of
target cells, antibody production and cell-mediated cytotoxicity.
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Types of Transplants
Transplanted organs are divided into four categories based on their origin and, hence,
genetic relation to the recipient.
1. Autogeneic graft. This is performed within the same individual and is not rejected
e.g when skin, blood vessel or bone is moved from one site and grafted to another.
2. Syngeneic graft. A graft is transferred within genetically identical individuals e.g.
identical twins or an inbred animal colony and is not rejected.
3. Allogeneic graft. A graft is transferred between individuals belonging to the same
species but differing in their genetic repertoire. This is the commonest mode of
transplantation in both humans and experimental animals and is frequently associated
with rejection.
4. Xenogeneic graft. A graft is transferred from one species to another and is
invariably associated with acute rejection.
Clinical syndromes of graft rejection
The rejection of cardiac allografts can be divided into three clinical syndromes on the
basis of the pathological process and the kinetics of the rejection response:
hyperacute, acute and chronic rejection (reviewed in (258)).
1. Hyperacute rejection.
This occurs within minutes to hours and is caused by pre-existing antibodies to graft
antigens, usually AB blood group or HLA class I molecules. Antibodies binding to
vascular endothelium of the graft activate complement and cause cell destruction.
Activation of endothelial cells also results in alteration in the expression of adhesion
molecules which in turn facilitates the movement of phagocytic immune cells into
the graft tissue, as well as the activation of platelets and fibrin deposition/thrombus
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formation. Current protocols for blood group matching and the screening for prior
sensitisation against HLA in recipients have greatly reduced the incidence of
hyperacute rejection, but once initiated this process is generally irreversible and
results in graft oedema, haemorrhage, vascular thrombosis, ischaemia and,
ultimately, allograft rejection. With the continuing shortfall in donor grafts
xenotransplantation is once more emerging as a possible alternative, e.g. pig to
human transplants, and much work is presently focusing on the development of
techniques to avert hyperacute xenograft rejection.
2. Acute rejection
Episodes of acute rejection in humans commence 3 to 7 days after transplantation
and occur with decreasing frequency after three months. Acute rejection can,
however, occur months to years after transplantation and is frequently associated
with the withdrawal of immunosuppressive regimes. The effector mechanisms of
graft destruction in acute rejection are multiple and involve cell- mediated
cytotoxicity by CD8+cytotoxic T cells, activation and proliferation of CD4+ Th cells,
cytokine production, and macrophage activation. The 3-7 days required for the
initiation of this process is the time required for presentation of donor antigen by
antigen presenting cells in the lymph nodes and spleen, the activation and
proliferation of graft specific host T cells and the differentiation, migration and
infiltration of effector cells back into the graft. Ischaemia-reperfusion injury
associated with the harvesting of a donor graft and its subsequent revascularisation,
is also a determinant in graft outcome (271). The response to injury results in the
upregulation of MHC molecules, adhesion molecules and increase in expression of
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cytokine and growth factor genes. This in turn results in more immune recognition
and promotion of the allograft directed immune response.
3. Chronic rejection
A steady rate of attrition of allografts occurs months to years after transplantation
and is attributed to chronic rejection (258, 261). The exact immune mechanisms
remain poorly understood and pathogenesis appears to be multifactorial. Mild to
moderate lymphocytic infiltrates lend support to a cell-mediated process while in
some cases graft specific antibodies have been detected. Non-specific factors which
are not antigen driven e.g. ischaemia-reperfiision injury are also important. Activated
graft infiltrating T cells/macrophages, as well as activated resident endothelial cells
secrete growth factors such as platelet derived growth factor (PDGF) and fibroblast
growth factor (FGF) which stimulate smooth muscle cell proliferation. The resultant
sustained activation of the inflammatory response, despite immunosuppressive
therapy, results in interstitial fibrosis and intimal proliferation in arteries and
arterioles i.e. graft atherosclerosis (272). Cardiac transplants are particularly sensitive
to the vascular changes of chronic rejection because of myocardial dependence on
coronary blood flow with ensuing graft dysfunction and cardiac failure.
In practice these syndromes of rejection are frequently overlapping and are often not
totally distinct. All forms of rejection involve a combination of antigen-specific cell-
mediated mechanisms, humoral mechanisms, cytokine elaboration and non-immune
factors such as ischaemia, infection, age and comorbidities in both donor and
recipient. It is generally accepted, however, that the degree of MHC mismatch
correlates positively with the degree of acute rejection and that the number of acute
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It is apparent that, among these various phenotypes, shared mechanisms of vascular
pathogenesis exist. The inflammatory response, while primarily intended to
neutralise the initiating and "injurious" stimulus and promote healing and repair, can
itself result in extensive tissue damage and organ dysfunction when inappropriate
and sustained activation occurs. Inflammation is a complex, highly orchestrated
process involving many cell types and molecules, some of which initiate, amplify or
sustain the process, some of which attenuate it, and some of which promote its
resolution. Although the initiating stimuli may differ, many of these diverse
phenotypes share certain features at a cellular level: vascular cell activation and
subsequent cell adhesion molecule upregulation, leukocyte infiltration of the
vessel/tissue and the elaboration of cytokines and chemokines. It is not surprising
therefore that some of these conditions also share certain features at a phenotypic
level. The association, for example, between atherosclerosis and thrombosis has led
to the term atherothrombosis which emphasises the importance of atherosclerotic
plaque in the formation of thrombi and vice versa (273). Ischaemic acute tubular
necrosis is mediated by a combination of vasoconstriction and inflammation
occuring within the kidney, while hyperacute rejection on the other hand represents a
cross-over between the alloreactive and thrombotic phenotypes. Many additional
examples of such cross-over phenotype exist but the following discussion will focus
specifically on the above.
The nature of the chronic inflammatory response underlying atherogenesis is
discussed in detail in section 1.3.3. Individual atherosclerotic lesions often fall into
two categories: stable and vulnerable. Both types may coexist within a given arterial
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tree. Stable plaques, which are often more stenotic, may cause ischaemia and, hence,
produce warning symptoms before thrombotic complications occur. Disruption of
vulnerable plaques, however, exposes thrombogenic surfaces within the plaque to
circulating blood and may result in thrombotic occlusion of the affected vessel,
giving rise to an acute coronary syndrome or myocardial infarction. In cigarette
smokers these effects are enhanced by an impairment of acute endothelial tPA
release, a crucial event if endogenous fibrinolysis within the vessel is to be effective
(274). Plaque stability is determined by the composition (and hence strength) of the
fibrous cap. Several inflammatory mediators (section 1.3.3), by modulating vascular
cell production of matrix metalloproteinases (which degrade all major plaque
constituents), can contribute to weakening of the fibrous cap and its subsequent
rupture (186). In addition, mural thrombi can be incorporated into the plaque,
enhancing the evolution of atherosclerotic lesions by the release of coagulation
factors, such as thrombin, which can promote vascular smooth muscle proliferation
and cytokine release (273). For these reasons, most therapeutic regimes for patients
with ischaemic heart disease incorporate an anti-platelet agent in addition to standard
anti-anginal therapy.
Elevated plasma homocysteine levels are associated with premature atherosclerosis
in the coronary, cerebral and peripheral vasculature, as well as recurrent venous and
arterial thrombosis (234). Evidence suggests that the atherogenic propensity
associated with hyperhomocysteinemia is a consequence of endothelial dysfunction
and injury, followed by platelet activation and thrombus formation. Although the
exact mechanisms underlying homocysteine-mediated endothelial dysfunction are
unknown, there is growing evidence that homocysteine exerts its effects by
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promoting oxidative damage. Homocysteine is rapidly oxidised with the subsequent
generation of potent reactive oxygen species and this process has been shown to
support the oxidation of LDL. In addition, homocysteine alters the normal anti¬
thrombotic phenotype of the endothelium by enhancing the activities of factor XII
and factor V and depressing the activation of protein C. Homocysteine also inhibits
the expression of thrombomodulin, induces the expression of tissue factor and
suppresses the expression of heparin sulphate by the endothelium. All of these effects
facilitate the formation of thrombin and create a prothrombotic environment, thereby,
and at least partially, explaining the propensity to both venous and arterial
thrombosis characteristic of this disease.
A wide spectrum of clinical conditions result in a generalised or localised reduction
in renal blood flow. These include intravascular volume depletion such as occurs in
haemorrhage/GI fluid losses, decreased effective intravascular volume e.g.
congestive cardiac failure/cirrhosis, large and small vessel renal vascular disease and
a variety ofmedications and toxins. In the ischaemic kidney, the local production of
inflammatory mediators such as cytokines, complement-activation products, platelet
activating factor and leukotrienes is associated with increased expression of
endothelial adhesion molecules such as ICAM-1 and selectins (251). This
upregulation facilitates the extravasation of neutrophils into ischaemic tissue.
Interestingly, in animal models of renal, myocardial or intestinal ischaemia the
depletion of neutrophils, blockade of neutrophil adhesion to the endothelium and
inhibition of the complement system all reduce tissue injury (275-277). In addition
intrarenal vasoconstriction may result from a variety of vasoactive agents acting on
the blood vessels of the kidney. Such insults can be systemic e.g. cyclosporin,
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tacrolimus and radioactive contrast agents - all of which result in vasoconstriction of
small renal vessels, or local e.g vasoactive eicosanoids such as leukotrienes. The
resulting ischaemia can directly alter endothelial cell function with subsequent
imbalance in the endothelial production of, and response to, vasoactive mediators.
Such vasoconstriction, when combined with enhanced local inflammatory responses,
may aggravate injury in the post ischaemic kidney.
Ischaemic injury to an allograft can lead to delayed graft function which has been
associated with acute rejection and decreased graft survival (258). Hyperacute
rejection occurs within minutes to hours and is caused by pre-existing antibodies to
graft antigens usually AB blood group or HLA Class I molecules (258). Antibody
binding to the vascular endothelium of the graft can result in complement activation
and cell destruction. Endothelial cell activation also results in increased adhesion
molecules expression which, as has been discussed, facilitates the movement of
immune cells into the graft tissue. In addition, the activation of platelets and fibrin
deposition/thrombus formation results in a thrombotic microangiopathy. This cross¬
over between the alloreactive and thrombotic phenotypes results in graft oedema,
haemorrhage, vascular thrombosis, ischaemia and, ultimately, allograft rejection.
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2.1. Pathophysiology of systemic hypertension
2.1.1. Overview
An elevated arterial blood pressure is common, generally asymptomatic, and often
leads to lethal complications if left untreated (1). Patients with hypertension are at
increased risk for a variety of cardiovascular sequelae including angina pectoris,
myocardial infarction, stroke, heart failure and sudden death, in addition to renal and
retinal complications (2). Clinical studies have demonstrated that treatment of this
disorder reduces the incidence of such complications. In 90% of cases the aetiology
of hypertension is still largely unknown and a diagnosis of so-called essential
hypertension is made after exclusion of the known causes (most commonly renal and
adrenocortical disorders) (3). It is probable that essential hypertension itself does not
arise from a single pathology, but rather is the clinical presentation of a number of
different disease processes which can each result in elevated blood pressure. The end
result, however, despite pathophysiologically divergent aetiologies, is a relatively
uniform effect on the arterial wall in terms of both vascular hypertrophy and the
development and progression of atherosclerosis.
In long-standing essential hypertension, the fundamental abnormality is an increase
in peripheral vascular resistance due to a decrease in lumen diameter in small
arteries, arterioles and pre-capillary sphincters (resistance vessels). This occurs even
when vessels are maximally dilated, indicating an underlying alteration in vessel
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structure rather than functional "overactivity." A complex interplay between genetic
and environmental factors which control cell growth and the neurohormonal milieu
within the vasculature, results not only in medial smooth muscle
hypertrophy/hyperplasia, but endothelial dysfunction with reduced endothelium-
dependent relaxation (4). The subsequent decrease in vessel lumen diameter
produced by these changes leads to increases in peripheral vascular resistance and,
ultimately, hypertension. With the development of hypertension, ongoing changes in
the production of vasoactive mediators and alterations in the various haemodynamic
forces within the vascular lumen, promotes further structural changes in a self-
























Figure 2.1 Hypertensive vessel wall: structural and functional characteristics
(adapted £rom(4))
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The endothelium in hypertension
The concept that endothelial function is disturbed in hypertension and perpetuates
high blood pressure, remodelling and atherogenesis, relies on a number of
observations. The best characterised alteration is diminished endothelium-dependent
relaxation in response to acetylcholine. This has been demonstrated in both
mesenteric vessels of hypertensive rats (5) and in the forearm circulation of
hypertensive patients (6). This dysfunction is related to a decrease in the effective
concentration of endothelial derived relaxing factors (EDRF), the most important of
which is nitric oxide (NO). NO has been discussed in detail in section 1.1.1 and it has
been established that in the hypertensive state there is decreased basal production of
NO (7). In addition, however, administration of superoxide dismutase (an enzyme
that destroys the superoxide radical) decreases blood pressure in spontaneously
hypertensive rat (SHR), leading to speculation that the presence of increased free
radicals in hypertension may result in increased destruction of NO. Finally, NO
exerts its vasodilating effects by increasing cGMP which inhibits myosin
phosphorylation and subsequent smooth muscle contraction. It appears that this
series of events may be altered in smooth muscle cells exposed to chronic
hypertension, as shown by the decreased relaxation in the aorta and carotid of the
SHR on administration of a variety of compounds that donate NO, e.g. nitroprusside,
and thereby stimulate cGMP (8).
In addition to decreased nitric oxide production, the endothelium may release
increased amounts of constricting factors such as the potent vasoconstrictor
endothelin-1 (ET-1). ET-1, secreted mainly by the endothelium but also by vascular
smooth muscle cells, acts in a paracrine or autocrine fashion on blood vessels by
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binding to endothelin receptors A and B (ETa and ETb) on smooth muscle to mediate
contraction (9). This effect is modulated by endothelial ETb receptors where ligand
binding results in production of the vasodilators NO and prostacyclin. Production of
ET-1 is enhanced in several experimental rat models of hypertension (10), and while
plasma ET-1 levels are generally not elevated in essential hypertension, there may be
an increase in its local concentrations. Endothelin-dependent vascular tone has been
demonstrated in studies of forearm blood flow and enhanced expression of ET-1
mRNA has been shown in the endothelium of small arteries of patients with
moderate to severe hypertension (11).
2.1.2. Vascular smooth muscle cells (VSMC) in hypertension
Increases in vessel wall thickness in hypertension result from increases in smooth
muscle cell size (cell hypertrophy), increases in smooth muscle cell number (cell
hyperplasia) and increases in matrix deposition (4). These changes are initially
adaptive in that they act to return the increased wall stresses occuring in hypertension
to normal. Furthermore, the increased macrovascular pressures in hypertension, if
transmitted unabated to arterioles and capillaries, could potentially damage the
endothelium of the microcirculation. This is particularly critical in the cerebral
circulation where increased vascular permeability would rapidly lead to cerebral
oedema. VSMC (section 1.1.2) are clearly a heterogeneous group. Contractile VSMC
are spindle-shaped, located in the media, contract in response to agonists and express
high levels of the contractile proteins a-actin and smooth muscle cell specific
myosin. Synthetic phenotype VSMC are round, may be present in the intima, do not
contract and do not express a-actin and myosin. These cells are characterised by
large amounts of rough endoplasmic reticulum, secretion of large amounts of tissue
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matrix proteins and a proliferative phenotype in vitro. Contractile smooth muscle
cells, by contrast, do not initially proliferate in culture, but can undergo a process of
phenotypic modulation in which they take on the appearance of synthetic cells and
begin to proliferate in response to mitogens.
Various growth factors have been implicated in VSMC responses to elevated
pressures and the following discussion will focus on the most important of these.
It has now been established that the entire renin-angiotensin system is present within
the wall of normal vessels and its activity is dynamically,regulated, resulting
ultimately in the production of angiotensin II (AT II) (12). AT II functions
(predominantly through the AT II type 1(AT 1) receptor) as an acute vasoconstrictor,
regulating systemic blood pressure and vascular tone. Furthermore AT II is also
involved in cardiac and vascular growth processes (13). It induces smooth muscle
hypertrophy in vitro through increased expression ofPDGF-A, TGF-P and the proto-
oncogenes c-myc, c-fos and c-jun (14). AT II-induced VSMC growth appears to be
mainly due to PDGF production, as was evidenced by the attenuation of AT II
dependent effects by antisense oligonucleotides to PDGF-A mRNA (15). In this
study, TGF-p 1 appeared to negatively modulate the mitogenic effect of PDGF since,
in the presence of neutralising antibody to TGF-pi, PDGF treatment of rat VSMC
resulted in enhanced AT II-induced DNA synthesis and proliferation of these cells.
In the light of these findings, it has been speculated that AT II is a bifunctional
growth factor, capable of activating (through PDGF) or modulating (through TGF-P)
cellular growth.
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The concept that the renin-angiotensin system may be of crucial importance in both
hypertension and atherogenesis has recently gained support from studies of candidate
genes of hypertension (14). Genetic analysis of a restriction fragment length
polymorphism of genomic DNA has recently established a linkage between
polymorphisms of the angiotensin-converting enzyme (ACE) gene and salt-induced
hypertension in stroke-prone SHRs. Although conflicting reports on such an
association exist in human essential hypertension, a deletion polymorphism of this
gene results in higher plasma ACE levels in affected subjects and appears to confer
an increased risk of related pathologies including atheroscelerosis, myocardial
infarction and sudden death. Two allelic variants of the angiotensinogen gene have
been linked to hypertension in a sib-pair linkage analysis of two ethnically different
populations, and in one of these variants there was increased angiotensinogen levels.
Interest recently has focused on polymorphisms of the AT I receptor, and indeed an
A-C tranversion at nucleotide position 1166 located in the 3'untranslated region of
the ATI-receptor gene(All66C) is associated with human essential hypertension (16).
No clear human phenotype has yet been identified with this genotype.
Other classic vasoconstrictors such as catecholamines have also been implicated in
hypertension. In patients with pheochromocytoma a marked increase in plasma
catecholamine levels are associated with both sustained and episodic hypertension. In
vitro noradrenaline stimulates VSMC hypertrophy and hyperplasia (17), and in
carotid injury models al-adrenergic stimulation caused PDGF A chain expression
(18). As yet however no convincing evidence exists which demonstrates a role for
abnormal catecholamine secretion or metabolism in human essential hypertension.
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A number of peptide growth factors are synthesised locally in the blood vessel and
are involved in VSMC growth. As has been discussed, PDGF is a potent smooth
muscle cell mitogen. PDGF is a heterodimeric protein composed of two distinct
polypeptide chains, PDGF-A and PDGF-B. Elevated PDGF-A mRNA levels have
been demonstrated in both small and large blood vessels in various rat models of
hypertension (14). Furthermore, the recent finding of increased plasma levels of
PDGF-AB and PDGF-BB in patients with never-treated mild hypertension suggests a
role for PDGF in the vascular changes associated with this process (19).
Insulin-like growth factor 1 (IGF-1) promotes hypertrophy and matrix deposition by
VSMC in vitro, and also enhances the mitogenic effects of PDGF. IGF-1 mRNA
expression is increased in the rat aorta above the coarctation site in infrarenal aortic
coarctation, although the precise effect of this increase remains to be determined
(20). IGF-1 mRNA expression is also induced in VSMC in vitro in response to AT
II, suggesting that IGF-1 may participate in the AT II growth pathway. This may be
of particular relevance to those patients with a strong genetic predisposition to a
combination of essential hypertension, insulin resistance and hyperinsulinaemia.
Whether insulin acts as a growth factor via its own receptors, or via the IGF-1
receptors for which it has a relatively weak affinity, remains to be determined.
ET-1, in addition to causing vasoconstriction, can also function as a mitogen for
VSMC in vitro. However when administered in serum-free conditions ET-1 displays
only weak mitogenic activity, and it has been speculated that its importance is as a
co-mitogen with other growth factors present in the vessel wall (21).
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2.1.3. Extra-cellular matrix - changes in hypertension
The extra-cellular matrix (ECM) is a complex protein-carbohydrate network
consisting of collagens, elastins, proteoglycans and glycopeptides which is a critical
regulator of blood vessel function and its physical characteristics The composition of
the matrix influences how vascular cells percieve the forces applied to the vessel
wall. This role takes several forms: firstly the three dimensional structure of the
matrix and the resulting "stiffness" influences the extent to which cells within the
matrix may be physically deformed. Cells within a highly collagenous vessel for
example may be less susceptible to deformation than those in a more elastic vessel.
Secondly, the matrix may influence the alignment of cells within it, biasing the
extent and direction of the force to which cells in the vessel wall are exposed. Finally
all vascular cells are able to generate tension through their cytoskeleton, and this
ability to contract and the tension generated depends on the nature of the matrix
surrounding the cells. Forces generated by a cell as it contracts can influence its
cellular activity and response to growth factors. Increases in collagen, elastin and
fibronectin levels have been demonstrated in the aorta ofhypertensive rats (4).
Production of these molecules is regulated by a variety of enzymes and growth
factors produced by VSMC and endothelial cells that alter both the structure of the
ECM and its ordered dissolution and reassembly. Collagenase activity, for example,
is tightly regulated in VSMC. Expression ofVSMC collagenase in vitro is stimulated
by growth factors via a phorbal ester response element, while heparin limits its
induction (22). Proteases such as urokinase and tissue plasminogen activator are
induced during mitogenesis of VSMC in vivo, and their expression, at least in vitro,
is also blocked by heparin (23). The composition of the ECM may also influence
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smooth muscle cell phenotype. Culture of VSMC on a fibronectin matrix, for
example, promotes the adoption of a synthetic proliferative phenotype when cells are
placed in culture, whereas laminin maintains smooth muscle cells in a contractile
form for a prolonged period (24). The binding of fibrogenic growth factors such as
TGF-|3 and FGF to matrix components also regulates their activity. Binding of TGF-
(3 to the matrix protein decorin results in the inactivation of this cytokine, while the
binding of FGF to ECM heparin-sulphate proteoglycans is thought to provide both a
reservoir of FGF and, in addition, protect this growth factor from proteolytic
degradation (25).
The ECM therefore is a critical regulator of vessel growth and structure by virtue of
its own dynamic regulation as well as its ability to modulate the activity of both
growth-promoting and growth-inhibiting factors. Although, to date, the hypertension-
associated changes occuring in the composition of the extra-cellular matrix or its
growth-factor binding capacity remain largely undefined, it is obvious that any
alterations in these factors could have profound effects on both vessel structure and
the phenotypic expression of VSMC, thereby determining the vascular remodelling
that is pathognomic of this disease.
2.1.4. The hypertensive phenotype
Several abnormalities of signal transduction and ion transport leading to increased
VSMC responsiveness to growth factors and alterations in sensitivity to contractile
agonists have been proposed in the development of the hypertensive phenotype. One
such abnormality - enhanced Na+/H+ exchange - is present consistently in both
human essential hypertension and animal models of hypertension (4).
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The growth-activated Na+/H+ exchanger (NHE-1) is a member of a multigene family
which exchanges one H+ ion for one Na+ ion when decreases in extracellular pH
occur. In addition increases in intracellular Na+ occur via this exchanger in response
to cell shrinkage, restoring cell volume by obligate water entry. It appears that the
NHE-1 participates in signal transduction pathways by which vasoactive agents
modulate vascular tone and regulate smooth muscle proliferation. Evidence for
dysfunction of the exchanger in hypertension is provided by the observation that its
activity is increased in cells from hypertensive patients (26). In addition, several
studies indicate that both cultured VSMC and intact mesenteric arteries from SHR
demonstrate enhanced exchanger activity (27). To date there is no evidence for
mutations or altered regulation of this gene in hypertensive populations, and studies
in the SHR have demonstrated no changes at mRNA level. It may be then that this
enhancement in exchanger activity may be a consequence of post-translational
modification Such increased exchange activity may result in an enhanced sensitivity
to mitogens, thereby facilitating VSMC proliferation. Increased vascular tone
secondary to this elevation in NHE-1 activity could occur by two potential
mechanisms. First, increased Na+ entry into the cell could activate Na+/Ca2+
exchange, leading to increased intracellular calcium. Second, increased intracellular
2+
pH would enhance the Ca sensitivity of the contractile apparatus leading to an
9+
increase in contractility for a given intracellular Ca concentration (28).
In addition many alterations in downstream effectors have also been demonstrated in
SHR-derived cells as compared to cells derived from their normotensive counterparts
(4). For example, phospholipase C-mediated phosphoinositide turnover is stimulated
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by significantly lower concentrations of thrombin and angiotensin II in the SHR.
Increased PKC activity and increased intracellular calcium have also been
demonstrated in VSMC from the SHR. The fact that these abnormalities persist in
culture has led to speculation that there may be genetic abnormalities in the
regulation of these enzymes. Although no such abnormality has been detected to date
in human essential hypertension, it may be that enhancement of such intracellular
mediators in hypertensive VSMC alters common regulatory events such as ion fluxes
and cell cycle genes leading to both increased vessel tone and increased VSMC
growth (29).
2.1.5. Hypertension-induced atherosclerosis
The molecular mechanisms underlying atherosclerosis are discussed in detail in
section 1.3.1. Hypertension is an established risk factor for atherosclerosis, but the
underlying molecular mechanisms have not yet been clearly elucidated. A great deal
of experimental, epidemiological and clinical evidence suggests an important role for
the renin-angiotensin system in atherogenesis. Hypertensive patients with elevated
AT II levels show a five-fold increase in their incidence of myocardial infarction
(30). ACE inhibitors reduce atherosclerotic formation in several experimental animal
models, such as Watanabe heritable hyperlipidaemia (WHHL) rabbits, cholesterol-
fed mice and monkeys (31). In addition, treatment of patients with left ventricular
dysfunction with ACE inhibitors, reduces the incidence of recurrent myocardial
infarction and sudden death, implying an anti-ischaemic role for these drugs (32). In
addition to its vasoactive role, AT II directly induces oxidative stress in the
vasculature by generating superoxide anions through the activation of
NADH/NADPH oxidase. This has been demonstrated in cultured rat aortic smooth
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muscle cells and in aortas of rats made hypertensive by infusion of AT II (33, 34).
Moreover, AT II may also contribute to the inflammatory axis of atherogenesis.
Treatment of rat vascular smooth muscle cells with AT II resulted in a dose-
dependant increase in MCP-1 gene expression, and, in keeping with this observation,
MCP-1 mRNA expression was increased almost four-fold in the aortas of rats
rendered hypertensive by either AT II or norepinephrine infusion (33, 34). This was
accompanied by recruitment of monocytes/macrophages into the media and
adventitia of the hypertensive aorta. In a double transgenic rat (dTGR) model of high
human renin hypertension in which rats are transgenic for the both the human
angiotensinogen and renin genes, rats develop moderately severe hypertension and
die of end-organ cardiac and renal failure by week 7 (35). The hearts of the animals
are necrotic and fibrotic, whereas vasculopathy in the kidneys resembles that of the
haemolytic uraemic syndrome. There is an early increase in cell adhesion molecules
(ICAM-1, VCAM-1) in the interstitium, intima and adventitia of small cardiac and
renal vessels while leukocyte infdtration into the vessel wall accompanies PAI-1,
VEGF and MCP-1 vascular expression. Expression of TGF-(3 and extracellular
matrix proteins then follows. In this model treatment with ACE inhibitors and ATI
receptor blockers lower blood pressure and, when combined, prevent vasculopathy
(36). The up-regulation of NF-kB in the kidney of this model has led the authors to
speculate that AT II, via activation of this transcription factor, may initiate cytokine
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Figure 2.2 Hypothetical schema of vascular injury in the dTGR model.
(adapted from reference (35))
Recent studies also suggest an interaction between hyperlipidaemia, activation of the
renin-angiotensin system and atherosclerotic disease (31). LDL upregulates
expression of the AT II receptor (ATi) in cultured VSMC and ATi protein
expression is increased two-fold in hypercholesterolaemic rabbits. AT II, in turn,
facilitates oxidation of LDL and its uptake by scavenger receptors on
monocytes/macrophages. The endothelial receptor for ox-LDL, LOX-1, is
upregulated in the SHR. It has also been shown that human coronary artery
endothelial cells (HCAEC) express the ATI receptor, and that AT II increases the
uptake of ox-LDL by HCAEC in vitro in a concentration-dependent manner (37).
This increased uptake is due to the upregulation of the LOX-1 receptor on HCAEC.
As previously described in section 1.3.1, ox-LDL uptake via LOX-1 on vascular
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endothelium may cause endothelial activation/dysfunction, initiating the
inflammatory process that is characteristic of atherosclerosis. The molecular
mechanisms by which AT II upregulates LOX-1 expression and indeed how ox-LDL
injures endothelial cells are, as yet, unknown. Although limited to in vitro findings
these studies suggest that cross talk between ox-LDL and AT II may be relevant in
atherosclerosis and may provide a long-sought molecular link between hypertension,
hyperlipidaemia and atherogenesis.
2.1.6. Mechanical deformation of the arterial wall in hypertension: a
mechanism for vascular pathology
It has become increasingly apparent that mechanical deformation of the arterial wall
is an important proximal signal in the development of hypertensive vasculopathy.
The increased haemodynamic forces occuring in hypertension induce expression of a
variety of growth-stimulating and pro-inflammatory gene products which mediate
both the altered vessel growth characteristic of hypertension and its pro-atherogenic
effects (38).
Early ex-vivo work demonstrated that increases in luminal pressure of arteries
resulted in increased vessel radius and subsequently wall tension. At higher arterial
pressures there is a greater incremental increase in wall tension for a given increase
in pressure (38). This acute effect can be balanced by the development of vascular
hypertrophy, with a resulting increase in wall thickness and a decrease in wall stress.
In an attempt to dissociate mechanical and humoral factors workers employed an in
vivo aortic coarctation model in which the blood pressure below the coarctation
remains relatively normal, while above the coarctation it is elevated (39). Although
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the entire aorta was exposed to the same humoral milieu, only the aorta above the
coarctation demonstrated hypertrophy, implying that mechanical forces contributed
to the pathogenic manifestations of hypertension. In another study bifurcating
arteries from cholesterol-fed rabbits were cast in acrylic at low pressure to reduce
wall stress, thereby facilitating the dissociation of wall strain-dependent effects (40).
Arterial segments treated in this way exhibited a complete absence of atherosclerotic
lesions. In this model however, atherosclerosis does not normally occur without
cholesterol feeding, and therefore, while the authors concluded that wall stress is a
necessary component of atherogenesis, it is unlikely that this stimulus alone is
sufficient to initiate this pathogenic process.
Available data support the concept that pressure-induced wall stress is a potentially
important factor in the development of hypertrophy and atherosclerosis. The pulsatile
component of the arterial pressure, and the cyclic alterations in wall stress in
response to these pulsatile changes, may also be critical in the development of
hypertensive vasculopathy. In animal studies using SHR the media/lumen ratio in
resistance vessels (a measure of vascular wall hypertrophy) correlated more closely
to pulse pressure than any other parameter studied, including systolic, diastolic or
mean arterial pressure (38). In support of this finding, a recent study identified pulse
pressure (as opposed to mean, peak or diastolic pressure) as the stongest predictor of
all-cause and cardiovascular mortality in 19,000 French males undergoing routine
physical examinations (41).
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2.2. Biomechanical forces: triggers for endothelial cell activation
Endothelial cells are constantly exposed to a spectrum of haemodynamic forces
generated by pulsatile blood flow and, by virtue of their strategic position, are ideally
placed to serve both as a sensor of these various signals and as effectors of the
biological responses to them (42). In vivo vascular walls are exposed to three main
haemodynamic forces: (1) shear stress, a tangential factional force due to blood
flow; (2) transmural hydrostatic pressure, a perpendicular cyclic force due to blood
pressure; and (3) mechanical stretch, a cyclic tensile stress caused by blood pressure.
The recognition therefore that the native condition of the endothelial cells is one of
continuous mechanical deformation drove the development of in vitro models to
investigate these forces and their effects on endothelial function. On the basis of
studies in these models, there is increasing evidence that these biomechanical stimuli
can directly influence endothelial structure and function, acutely and chronically,
thus constituting a novel paradigm of endothelial activation (42, 43)(Fig 2.3).
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2.2.1. Endothelial cells and fluid shear stresses
Shear stress is the frictional force applied along the endothelial cell surface as blood
flows through the vessel lumen. This flow can be uniform laminar or turbulent.
Investigators have designed flow chambers which can generate various forms of
shear stress and facilitate studies into the effects of this force on the endothelium
(44). Culturing endothelial cells in dynamic conditions which mimic physiologically
relevant degrees of shear results in a spectrum of structural and functional changes
(45). These include striking morphological changes in cell shape (polygonal to
ellipsoidal), realignment (in the direction of flow) and cell architecture. At a basic
cell biology level, many of these changes could be viewed as the in vitro readaptation
of the cultured endothelial cell to biomechanical stimuli normally present in vivo.
Real-time visualisation of a cultured endothelial cell monolayer exposed to
unidirectional laminar shear stress (LSS) using tandem scanning confocal
microscopy reveals a dynamic remodelling of the focal contact sites along its basal
aspect (46). Moreover, these focal adhesion complexes, as well as adhesion
molecules such as platelet-endothelial cellular adhesion molecule (PECAM)-1 which
are localised to lateral cell-cell junctions, have also been shown to demonstrate
increased phosphorylation. These internal changes in cytoskeletal architecture and
external changes in tomography presumably reflect generalised cellular adaptations
to applied mechanical stresses, such that the endothelial cell is in equilibrium with its
ambient fluid environment.
In addition to these structural adaptations, biomechanical forces such as shear stress
also stimulate endothelial production of a large and diverse array of biological
mediators (43, 45). Such responses include the acute release of NO and PGE,
133
activation of transcription factors NF-kB, c-fos, c-jun and SP-1, and the
transcriptional activation of genes including ICAM-1, MCP-1, GRO, tissue factor,
PDGF (A and B), TGF-pi, cyclooxygenase (COX)-2 and endothelial NOS. It has
been recently established that shear stress is capable of activating the MAP kinase
signal transduction pathway in vascular endothelial cells (47). Considerable progress
has also been made in defining some of the molecular mechanisms involved,
including the identification of positive and negative shear stress responsive elements
(SSREs) in the promoters ofbiomechanically responsive genes. (Table. 2.1)








PDGF-B 5'-GAGACC-3' NF-kB 9p50-p65) Transient Upregulation (48, 49)
PDGF-A Egr-1 sites Egr-1 Transient Upregulation (50)
MCP-1 TRE(AP-1) site AP-1 (c-fos, c-jun) Transient Upregulation (51)
Tissue factor Sp 1 sites Sp1 Transient Upregulation (52)
TGF-p ND ND Transient Upregulation (53)
ICAM-1 ND ND Transient Upregulation (54)




* Biomechanical stimulus = uniform laminar shear stress in physiological range; for the genes listed,
the putative SSREs have been identified by analysis of mutated promoter-reporter genes in vitro.
ND, not defined
Table 2.1 Shear stress responsive genes (43)
It appears that the endothelial cell is capable of responding not only to the magnitude
of applied forces, but also their temporal and spatial fluctuations - steady versus
pulsatile flow, uniform laminar, disturbed laminar or turbulent flow regimes. Most
studies to date have used relatively simple in vitro fluid mechanic systems to
generate uniform laminar shear stresses on cultured endothelial monolayers. In
attempts to better model in vivo haemodynamics, investigators have devised unsteady
flow systems to generate these fluctuations in shear stress and have even combined
shear stress, pressure and circumferential stretch in the same in vitro systems (54,
57).
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Pathophysiological relevance of endothelial activation by fluid shear stress
The most striking example of flow-related changes in vessel wall biology is provided
by nature - the non-random distribution of early atherosclerotic lesions in humans
and experimental animals. Lesion-prone areas are characteristically those where
disturbed flow patterns (flow separation, flow reversal, fluctuating shear stresses)
occur such as arterial bifurcations, curvatures and ostial openings. Lesion-protected
areas, on the other hand, generally experience uniform laminar flow and relatively
constant shear stress such as the straight tubular part of the aorta (43). These patterns
also occur in animal models of atherogenesis in whom systemic risks factors such as
markedly elevated lipoprotein levels have been deliberately induced. These
observations led to speculation that endothelial cells in these lesion-prone areas
might be responding differentially to their fluid mechanical environment.
Experiments using RT-PCR-based differential display technology examined the
patterns of genes regulated (positively and negatively) by various shear stresses (58).
Uniform LSS (as in lesion-protected areas) selectively induces the sustained up-
regulation of such genes as manganese superoxide dismutase, COX-2 and NOS. It
has been speculated that the antioxidant, anti-thrombotic and anti-adhesive activities
of these genes are potentially atheroprotective. Turbulent shear stress (TSS), in
contrast, does not induce these genes. Other genes, such as ICAM-1 and MCP-1, do
not exhibit sustained LSS-selective upregulation. Counter-intuitive to this theory was
the finding that TSS (all be it short term for 6 hours) did not result in the up¬
regulation of genes which are potentially pro-inflammatory/proatherogenic such as
ICAM-1 or MCP-1. In another study however the influence of three different flow
profiles was investigated - ramp flow (shear stress smoothly transited at flow onset),
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step flow (shear stress abruptly applied at onset), and impulse flow (shear stress
abruptly applied for 3s only) (59). Impulse flow and the onset of step flow (i.e.
temporal gradients in shear) produces marked increases in MCP-1 and PDGF-A
expression, while ramp flow and the steady component of ramp flow (steady shear)
diminishes their expression, implying a role for temporal gradients in shear in
atherogenesis. In addition, further work has demonstrated that oscillatory shear
stress, as opposed to static shear stress, resulted in a more sustained activation of pro-
oxidative processes as indicated by increased levels of NADH oxidase activity and
induction of the redox-sensitive gene heme-oxygenase-1 (60). These authors suggest
that differences in the endothelial redox state, orchestrated by different regimens of
shear stress, may contribute to the focal nature of atherosclerosis. Finally the recent
development of a disturbed laminar shear stress model, which incorporates regions of
significant spatial shear stress gradients similar to those found in atherosclerosis
prone arterial geometries in vivo, has demonstrated increases in levels of nuclear
localised NF-kB, Egr-1, c-Jun and c-Fos, as compared with cells exposed to uniform
LSS (54). In addition, individual cells demonstrated marked heterogeneity in their
responsiveness to disturbed flow as measured by the amounts of these transcription
factors in their nuclei. These results imply a role for spatial shear stress gradients in
the modulation of endothelial cell gene expression at anatomic sites predisposed to
atherosclerotic development.
In summary then, the effects of fluid shear stress to date have been derived from
relatively simplified in vitro model systems attempting to mimic the in vivo setting. It
has become apparent that complex flow patterns exist and that it is the nature of these
flow profiles in terms of laminar or turbulent flow and their spatial and temporal
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fluctuations which may be the determining feature in altering endothelial gene
expression.
2.2.2. Transmural hydrostatic pressure
The total transmural hydrostatic pressure to which endothelial cells are exposed to in
vivo is complex, and is not the same as "blood pressure" as measured with a
sphygmomanometer. The hydrostatic pressure, as reviewed by Stronberg and
Weiderhielm, is the net sum of several pressures including the vascular hydrostatic
pressure (i.e. the force containing blood within the vessels), components of the
vascular hydrodynamic pressure ("blood pressure"), plasma and tissue oncotic
pressures and the tissue hydrostatic pressure (61). Within a given vascular bed, the
hydrostatic pressure is directly correlated with, but generally lower than, arterial
blood pressure. A change in blood pressure exposes endothelial cells to changes in
hydrostatic pressure. Of the various haemodynamic forces, this is the least
investigated. One model of hydrostatic pressure involves growing cells in pressure
chambers consisting of cylinders to which medium is then added to attain the desired
hydrostatic pressure head. Endothelial cells in one such study were exposed to 1.5-
15cm H2O sustained hydrostatic pressure for up to seven days and exhibited
elongation, cytoskeletal reaarangements, increased cell proliferation and bilayering
(62). This was accompanied by endothelial release of basic fibroblast growth factor
(bFGF). A further study (using the same model) demonstrated increased cell
proliferation and increases in av integrin expression and altered distribution of focal
adhesion plaques (63).
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In a different model static or pulsatile pressure was applied to the cells cultured on
rigid substrates from above their medium by delivering a mixture of compressed
air/C02 into specially designed pressure chambers. Higher pressures were used in
this study and while endothelial cells demonstrated no gross morphological changes,
their proliferation rates decreased (64). The significance of these findings and the
intra-cellular signalling pathways underlying them are still uncertain.
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2.3. Mechanical strain: a trigger for vascular cell activation in systemic
hypertension
Cyclic strain (also known as mechanical stress/mechanical stretch) describes the
elongation and circumferential stresses experienced by cells as the blood vessel
rhythmically distends. In vivo measurements in patients and animals and in vitro
models simulating the major geometric features of blood vessels indicate that there is
a 5% to 6% wall excursion at peak systole under normal physiological conditions,
which can be as much as 10% under hypertensive conditions (65, 66). In addition to
increased mechanical strain occurring in the setting of hypertension, recent
observations have shown that in the arterial tree, this force is significantly higher at
bifurcations and curvatures than in straight segments (67). These considerations
suggest that cyclic mechanical stretch may play an important role in atherogenesis.
The in vitro model most widely used to examine the effects of cyclic strain is the
Flexercell unit.
2.3.1. The Flexercell unit
The Flexercell unit (Flexcell International Corporation, McKeesport, PA, USA) is a
modification of a unit originally described by Banes et al (68). and consists of a
manifold and gasket with eight vacuum ports to receive eight 6 well plates. The
culture plates are centred over the vacuum ports, one per port. The strain unit has a
fitting to which a vacuum hose is attached. Valves allow adjustment of the ingress
and egress of atmosphere and therefore control the degree of elongation of the
culture plates. The vacuum hose is connected to a control module which contains
pressure transducers, solenoid valves and signal processors and is computer
controlled. The computer controls the duration and frequency of the applied stress or
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relaxation, while the control module regulates the maximum deformation and strain
rates. This allows changes to be made in any of these parameters while holding other
variables constant. Cells are grown on specially manufactured culture plates
(FlexerCell, McKeesport, PA, USA) that have bottoms made of a flexible silicone
rubber material which is then coated with various compounds (collagen, elastin,
negatively charged carboxyl coating or positively charged amino hydrophilic
coating) depending on the growth requirements of the cells being studied. These
bottoms have been tested with stretching up to 200%. Cells therefore on the inner
surface of the culture dish experience the same force as applied to the silicone rubber
bottoms and real-time video experiments substantiate that the cells remain attached
during the cyclic stretching procedure. Control cells are grown in static, but
otherwise identical, conditions by culture on non-flexible bottomed coated plates.













Several investigators have used this system to assess the effects ofmechanical strain
on cultured cells. Various stretch regimens have been used. In endothelial studies
pressures of between -5 kPa and -20 kPa are generally applied to the underside of
the membrane at a frequency of 60 cycles/min (0.5 s of deformation alternating with
0.5 s of relaxation). It is important to point that the degree of stretch across the plate
is non-uniform and is maximum at 9.5 mm from the centre of a 25 mm diameter
well, decreasing exponentially towards the centre and periphery of the well. -20 kPa
results in a deformation ranging from 0% at the centre to a maximum of 24% at the
periphery, -5 kPa results in a deformation ranging from 0% in the centre to a
maximum of 6% in the periphery. In view of this some investigators have collected
cells at the centre and periphery of the wells separately for subsequent analyses.
In vitro studies employing such models of cyclic strain have provided important
insights into disease pathogenesis in two major areas. Firstly the exposure of vascular
cells, mainly endothelial but also vascular smooth muscle cells, to pathogenic cyclic
strain has helped define how the increases in this biomechanical force in
hypertension might contribute to arterial hypertensive vasculopathy and, in
particular, atherosclerosis (38). Secondly, many forms of glomerular injury are
accompanied by compensatory hypertrophy and hyperfiltration of remaining
nephrons, resulting in glomerular hypertension and, ultimately, the production of
excess extra ECM components by mesangial cells - glomerulosclerosis. Studies into
the influence of excessive cyclic strain on mesangial cell function have provided
important mechanistic insights into how glomerular hypertension might result in
glomerulosclerosis, as will be discussed later in section 2.6 (69).
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2.3.2. Endothelial cells and in vitro cyclic strain
Endothelial cells subjected to cyclic strain elongate and align themselves so that their
long axis is perpendicular to the strain force (70). In addition these cells demonstrate
pseudopods and actin stress fibers not found on their statically cultured counterparts.
Cyclic strain also stimulates proliferation of endothelial cells (71).
In addition to these structural adaptations, cyclic strain also stimulates endothelial
production of a diverse array of biological mediators, as discussed below.
Endothelin-1 secretion from endothelial cells is increased five to six-fold by cyclic
strain (72). Experiments demonstrate not only an early response to strain (at 20
minutes), but also a later peak in endothelin-1 production. The latter was found to be
blocked following treatment with actinomycin-D, suggesting that de-novo synthesis
of ET-1 was responsible. Although these studies in bovine aortic endothelial cells
showed an increase in endothelin-1 release in response to cyclic strain, they were not
able to confirm an increase in transcription of endothelin-1 mRNA. By contrast,
another group demonstrated that in human umbilical vein endothelial cells
(HUVEC), in addition to a two-fold increase in endothelin-1 release, cyclic strain
also induced a two-fold increase in endothelin-1 mRNA levels (73). These authors
also provided evidence that this up-regulation was PKC-dependent. The reason for
this discrepancy is not clear, but it may indicate species dependancy. ET-1 (section
1.1.1) is released in vivo from endothelial cells and binds to endothelin receptors on
smooth muscle to mediate contraction. Production of ET-1 is enhanced in several
experimental rat models of hypertension (10), and while plasma ET-1 levels are
generally not elevated in essential hypertension, there may be an increase in its local
concentrations. Endothelin-dependent vascular tone has been demonstrated in studies
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of forearm blood flow and enhanced expression of ET-1 mRNA has been shown in
the endothelium of small arteries of patients with moderate to severe hypertension
(11). ET-1, in addition to causing vasoconstriction, may also function as a co-
mitogen for VSMC in vivo (21). Given these observations, it is possible that
increased haemodynamic forces and cyclic strain, occuring in the setting of
hypertension, potentiate endothelin-1 release from endothelial cells. Subsequent ET-
1 induced vasoconstriction could theoretically result in further elevation of blood
pressure while mitogenic actions on VSMC could promote hypertensive
vasculopathy.
In vitro cyclic strain also causes a sustained increase in the expression of the
chemokine monocyte chemotactic protein (MCP)-l in endothelial cells (74). This is
accompanied by increases in MCP-1 secretion and a corresponding increase in
monocyte chemotactic activity (as measured by monocyte migration assays).
Inhibitor studies suggest that the strain-induced MCP-1 expression is predominantly
mediated by the PKC pathway and that gene induction requires Ca2+, but is not
dependent on cytoskeletal reorganisation. MCP-1 is a potent chemoattractant for
monocytes/macrophages and evidence for its role for the recruitment ofmacrophages
into the vessel wall in atherosclerosis has been discussed in detail in section 1.3.1. It
has been speculated therefore that strain-induced MCP-1 production might be
relevant in hypertension and its contribution to atherosclerosis.
Endothelial activation in response to humoral factors such as cytokines is an
established paradigm by which increases in endothelial cell adhesion molecule
expression results in increased leukocyte-endothelial adhesion. It is now apparent
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that increases in biomechanical stimuli such as shear stress or cyclic strain can also
alter adhesion molecule expression. Cyclic strain in endothelial cells increases
mRNA levels for ICAM-1 and the release of soluble ICAM-1 from cells (75). Using
flow cytometric analysis, increases in ICAM-1 surface expression are both strain and
time-dependent and correlated with strain dependent increases in adhesion of
monocytes to strained cells. This increase in monocyte adhesion could be partially
inhibited by pre-treatment of cells with antibody to ICAM-1. Endothelial expression
of E-selectin also increases in response to physiologically relevant levels of cyclic
strain, and again, strain-induced monocyte adhesion is substantially inhibited by pre-
treatment with anti-E-selectin antibody (76). In contrast, levels of VCAM-1
expression are unchanged in stretched cells over a 24 hour period. As discussed in
section 1.3.1, P-selectin mediated adhesion of monocytes to endothelial cells has
been implicated both in the early development of atheroma (fatty streak formation)
and in ongoing atherosclerosis. In animal models of atherosclerosis endothelial
ICAM-1 expression occurs in regions predisposed to atheroma formation as well as
on endothelial cells in the atheroscelerotic plaque. Strain-induced expression of
endothelial adhesion molecules may contribute to the adhesion of monocytes to
localised areas of vascular walls where strain is high (bifurctations, ostia) and
therefore to the initiation of atherogenesis. Furthermore, increases in such forces in
hypertension may, in part, explain the well-documented association between
hypertension and atherosclerosis.
Cyclic strain, like shear stress, increases PDGF-B expression in endothelial cells in a
time and amplitude-dependent manner (77). This strain-amplitude dependence was
supported by enhanced PDGF-B immunostaining in the high-strain membrane
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preriphery relative to cells in the low-strain centre region. The mechanism
underlying this up-regulation is still unknown. PDGF (section 2.1.3), a heterodimeric
protein composed of two distinct polypeptide chains (PDGF-A and PDGF-B), is a
potent smooth muscle cell mitogen. The recent finding of increased plasma levels of
PDGF-AB and PDGF-BB in patients with never-treated mild hypertension suggests a
role for PDGF in the vascular changes associated with this process (19).
Furthermore, PDGF-B gene transcript levels are elevated in human atherosclerotic
lesions compared to normal arteries (78). The observation therefore that cyclic strain
produces increases in PDGF-B gene and protein expression provides further possible
mechanisms for the aetiology of smooth muscle hypertrophy and hyperplasia in
hypertension and hypertension-induced atherosclerosis.
Oxidative stress (section 1.3.1) plays an important role in atherosclerosis and is
mediated by a variety of reactive oxygen species (ROS) such as superoxide, H2O2 and
hydroxyl radical. The origin of these intracellular ROS remains unclear. They may
derive from several sources, including the mitochondrial electron transport system
and NADPH oxidase. ROS appear to participate in inflammatory responses by
activating transcription factors such as NF-kB which can then induce transcription of
a variety of redox sensitive genes such as MCP-1 and ICAM-1. Cyclic strain induces
an oxidative stress in endothelial cells as measured by FFCF production, release of
lipid peroxidation products and activity ofNADH/NADPH oxidase (79). Continuous
non-cyclic stretching did not induce an oxidative stress suggesting that the pulsatile
component of strain is an important feature of the oxidative stimulus. Further studies
have suggested that the increases in MCP-1 and ICAM-1 mRNA/protein levels
occuring in response to cyclic strain are mediated by strain-induced increases in ROS
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(80, 81). In the case of MCP-1, ROS modify the AP-1 binding site in the MCP-1
promoter region, while for ICAM-1 the exact mechanism has yet to be established.
Early growth response-1 (Egr-1), a transcription factor and an immediate early gene,
is an important regulator for gene expression by competing with the transcription
factor Sp-1 in binding to the GC-rich region in the promoter of several
atherosclerosis associated genes, including tissue factor, PDGF and ICAM-1 (82).
Application of cyclic strain to bovine endothelial cells induces Egr-1 expression
prominantly via the Ras/Raf/ERK pathway and strain-induced ROS are involved in
the modulation of this signalling pathway (83).
The anti-coagulant and fibrinolytic activity of the endothelium has been previously
discussed in section 1.1.1. Cyclic strain results in an increase in endothelial tissue
plasminogen activator (tPA) mRNA, immunoreactive tPA protein and tPA activity in
the supernatent (84). This seems to occur through the activation of multiple
intracellular signalling pathways, including PKA and PKC. These in turn result in the
binding of different nuclear factors to the tPA promoter (AP-2 and CRE-like) to
initiate new tPA transcripts. Endothelial release of plasminogen activator inhibitor
(PAI)-l also occurs in response to cyclic strain and appears to involve ROS (85).
Small areas of denudation and thrombus formation are a common finding on the
surface of atheromatous plaques and are usually sub-clinical. In the presence of an
imbalance in the coagulation or fibrinolytic systems, such microthrombi may
propagate leading to arterial occlusion. TPA initiates fibrinolysis and, in the scenario
outlined above, is essential to the dissolution of thombi. PAI-1, on the other hand,
inhibits fibrinolysis by forming a complex with tPA and inhibiting free tPA activity.
The significance of cyclic strain-induced increases in both these factors is as yet
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unclear, but obviously any potential alterations in the endogenous balance of
tPA/PAI-1 induced by cyclic strain could have profound implications for thrombosis
versus fibrinolysis.
Endothelium-derived nitric oxide (NO) is a potent endogenous vasorelaxant with
anti-platelet and anti-leukocyte properties (section 1.1.1). Synthesis of NO in
endothelial cells is by nitric oxide synthase (ecNOS). Cyclic strain upregulates the
expression of ecNOS transcripts and protein levels in endothelial cells in a strain-
dependent manner (86). In cells subjected to 10% cyclic strain increased expression
of the ecNOS gene occurred rapidly, 15 minutes after commencement of strain. The
mechanisms underlying the regulation of ecNOS by cyclic strain are as yet unknown.
Recent studies have demonstrated that sustained dynamic exercise reduces the
incidence of cardiovascular events, lowers blood pressure and improves exercise
tolerance in patients with ischaemic heart disease. Chronic exercise in dogs increases
the release of nitric oxide from large coronary arteries and microvessels and
specifically increases ecNOS expression in aortic endothelial cell extracts (87). In
humans sustained exercise leads to increased urinary nitrate excretion which
indicates an increased NO production (88). It has been speculated therefore that
increases in the various biomechanical forces during exercise, including rhythmic
distension of the arterial wall, may play a role in the regulation of ecNOS and,
ultimately, NO in vivo.
An earlier study examined the endothelial production of the vasodilator PGR in
response to cyclic strain. It appears that while cyclic strain does not increase basal
production of PGP by bovine aortic endothelial cells, it does enhance their ability to
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produce PGI2 when exogenous arachidonic acid (AA) is added (89). TXA2
production was similar in static and stretched groups in the presence or absence of
AA, suggesting that it may be the activity of PGI2 synthase that is regulated by the
repetitive deformation stimulus. The authors of this study conceded that there was
marked variability of PGI2 production by endothelial cells depending on their
species, site of origin, passage and confluency. In addition, a deformation regime of
3 cycles/minute was used in this study (as opposed to the more widely used and, in
the case of the endothelial cell, more physiologically relevant, 60 cycles/minute), so
it is difficult to explain the in vivo significance of these results or indeed compare
them with other studies.
2.3.3. Mechanical strain to functional response: putative signal transduction
mechanisms
Two alternative theories attempt to explain the process of transduction of mechanical
strain to biochemical signal (reviewed in (73) and references contained therein). The
first paradigm proposes that mechanical strain sensed by cell surface adhesion
plaques and cytoskeletal proteins, could mobilise a second-messenger cascade. The
second theory relates to the observation that stretch can activate mechanosensitive
ion channels in the cell membrane. Potassium, calcium and possibly other ion fluxes
across these channels could potentially activate second-messenger signal cascades.
Multiple second messenger pathways have been implicated in the transduction of
cyclic strain in endothelial cells, as discussed in preceding sections; these include
protein kinase C, protein kinase A, calcium, ROS, the Ras/Raf/ERK and the
p21ras/phosphatidylinositol-3 kinase/ERK pathways.
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Focal adhesion plaques and the cytoskeleton
Mechanical forces will exert their greatest effect at the points of attachment of the
cell to the underlying extracellular matrix (ECM). These sites of attachment are
known as focal adhesion plaques. They comprise cell surface associated integrin
receptors and specific proteins such as paxillin, talin, moesin and focal adhesion
kinase (FAK) which mechanically couple the integrins to the cytoskeleton (Fig 2.5a).
Figure 2.5a Cell at rest: focal adhesion plaques and cytoskeleton
Cytoskeletal proteins including actin, myosin and actinin are tethered to focal
adhesion plaques and project from them to span the cell cytosol, inserting into distal
aspects of the cell or nuclear membrane. These microfilament bundles experience
stretch and deformation in response to external mechanical strain. In short, the
cytoskeletal network together with focal adhesion plaques and integrins, form a
mechanism, "hard-wired" into cellular architecture, which facilitates the transmission
of external physical forces to the internal cell environment including the nucleus
(Fig. 2.5b(see over).
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Independent groups have highlighted the significance of this pathway. In an intricate
series of experiments, Maniotis et al. has demonstrated that when endothelial cell
integrins are physically deformed using micropipette techniques, cytoskeletal
filaments reorientate, nuclei distort and nucleoli redistribute along the axis of the
applied tension (90). These effects are mediated by direct linkages between the








Figure 2.5b Stretched cell: focal adhesion plaques and cytoskeleton
These workers have also reported discovered that cell binding to ECM can result in
relocation of mRNA and ribosomes to the focal adhesion plaques (91). These
findings, they suggest, demonstrate for the first time, a new mechanism by which
integrins may mediate gene regulation. Endothelial cells subjected to periods of
cyclical mechanical strain demonstrate increased tyrosine phosphorylation of FAK,
paxillin and the small GTP-binding protein rho, as well as a redistribution of FAK
and paxillin within the cell. Tyrosine kinase inhibition resulted in loss of the normal
pattern of strain-induced EC morphological change and migration, implicating this
phosphorylation in the cellular response to mechanical strain (92, 93).
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The effects of stretch on ion channels
The existence of specific stretch-activated (SA) cation channels was first proposed in
the context of cerebral blood flow autoregulation (94). The channels were described
in cerebrovascular smooth muscle cells and were noted for their resistance to the
effects of recognised calcium channel blocking agents (95). Since then SA cation
channels have been described in several cell types including endothelial and
mesangial cells (96, 97). Influx of calcium through stretch-mediated channels has
been implicated as the main source for the raised intracellular calcium levels reported
with cyclical stretch/relaxation. However a novel stretch activated intracellular
calcium store in endothelial cells has recently been identified which may also
contribute to the elevated calcium levels (98).
It may be that the ion flux and cytoskeletal based paradigms are not mutually
exclusive alternatives. The correct paradigm is likely to contain elements ofboth.
2.3.4. Regulation of transcription factor activation and gene expression by
mechanical forces
Cyclic strain in human umbilical vein endothelial cells (HUVECs) results in
induction of the immediate early genes c-jun, c-fos and, as already discussed, Egr-1.
Activation of transcription factors NFkB and AP-1 has also been demonstrated to
occur in response to cyclic strain in human endothelial cells (73). While these results
confirm transcription factor activation and gene induction by mechanical strain, they
do not directly link cyclic strain with gene promotor activation. A common sequence
(GAGACC) in the promoter region of platelet-derived growth factor (PDGF) is
required for shear stress- induced upregulation of this gene in endothelial cells. This
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consensus sequence has been named the Shear Stress Response Element (SSRE)
(48). Originally it was reported that activation of the SSRE in stretched endothelial
cells occurred within 30 minutes of commencement of 10% cyclical strain. However
subsequent studies have indicated that the SSRE was not necessary for inducible
gene expression in strained endothelial cells. Work is ongoing to determine if there is
a consensus sequence in promoter regions of strain-sensitive genes that specifically
modulates the cyclic strain effects in endothelial cells.
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2.4. Influence of mechanical strain on cytokine-adhesion molecule networks
in ECV-304 cells
2.4.1. Introduction
There is increasing evidence that biomechanical forces can directly influence
endothelial structure and function, thus constituting a novel antigen-independent
paradigm of endothelial activation (section 2.2, 2.3). The main haemodynamic forces
acting on the vasculature in vivo include shear stress, transmural (hydrostatic)
pressure and cyclic mechanical strain. In hypertension, the latter two forces are
increased and result in increased vascular wall stretch. These forces, by inducing
expression of a variety of growth-stimulating and pro-inflammatory gene products,
could potentially mediate both the altered vessel growth and the pro-atherogenic
effects characteristic of this disease. The inflammatory axis of atherosclerosis is
discussed in detail in section 1.3.1; in brief, the normally intact and anti-thrombotic
endothelium undergoes injury/activation following which monocyte recruitment into
the vessel wall occurs via the classical paradigm of leukocyte trafficking. It is
hypothesised that increases in cyclic strain, occuring in association with
hypertension, may facilitate monocyte recruitment into the vessel wall by acting as a
pro-inflammatory stimulus capable of modulating immune mediator expression. The
purpose of the current investigation was, therefore, to evaluate whether cytokine,
chemokine and adhesion molecule expression in endothelial cells was modified by
cyclic strain.
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2.4.2. Materials and methods
Cell culture
ECV 304 cells have been previously characterised and were obtained from the
EATCC (no. 92091712) (99). All cell culture reagents were obtained from Gibco
Life Technologies (Paisley, Scotland) unless otherwise stated. These cells were
maintained in Ml99 medium (Sigma, Dorset, England), supplemented with 1%
glutamine, 100 U/ml penicillin, 100 pg/ml streptomycin and 10% heat-inactivated
foetal calf serum. As the effects of mechanical strain on endothelial cells have been
previously shown to be serum-independent, cells were not rendered quiescent prior
to exposure to cyclic mechanical stretch.
Mechanical Stretch
ECV 304 cells were seeded at a density of 2xl05/well onto elastin-coated, flexible
and rigid based six-well plates, (Flex I and II plates respectively, FlexerCell,
McKeesport, PA, USA). Vacuum pressure was applied to the underside of these
supports by the FlexerCell unit (FX-2000) described in detail in section 2.3.1. Cells
were subjected to repetitive deformation with -15 kPa vacuum, i.e. maximum strain
17%, at 60 cycles/min for 24 and 48 hours.
RT-PCR
ECV 304 total RNA was isolated using Trizol reagent (Gibco Life Technologies,
Paisley, Scotland) according to the manufacturers' instructions. Total RNA (2pg) was
treated with DNase I and OHgo(dt)i2-i8 was then used to generate first strand cDNA.
Reverse transcription was carried out using Superscript II RNase H (all from Gibco).
Sequence specific primer pairs were either obtained from Biosource (Camarillo,
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CA), Continental Laboratories Products Incorporated (CLP, San Diego, CA) or









P1= Primer 1 P2= Primer 2
Adhesion molecules
ICAM-1 60 237
P1 5-TAT GGC AAC GAC TCC TTC T -3'
P2 5-CAT TCA GCG TCA CCT TGG-3'
VCAM-1 60 259
P1 5-ATG ACA TGC TTG AGC CAG G-3'
P2 5-GTG TCT CCT TCT TTG ACA CT-3'
E-Selectin 60 435
P1 5'-GGG TAG GAA CCC AGA AAC CT-3'
P2 5'-CCA GAG GAC ATA CAC TGC AT-3'
Chemokines
MCP-1 60 279
Obtained from BioSource Int. CA, USAIL-8 60 227
RANTES 60 197
Cytokines
IL-1 p 60 331
P1 5'-CTT CAT CTT TGA AGA AGA ACC TAT-3'
P2 5'-AAT TTT TGG GAT CTA CAC TCT CCA-3'
TNF-a 60 325
P1 5'-CAG AGG GAA GAG TTC CCC AG-3'
P2 5'-CCT TGG TCT GGT AGG AGA CG-3'
IFN-y 60 510
P1 5'-ATG AAA TAT ACA AGT TAT ATC TTG GCT TT-3'
P2 5'-GAT GCT CTT CGA CCT CGA AAC AGC AT-3'
IL-6 60 501 Obtained from BioSource Int. CA, USA
Chemokine Receptors1
CCR1 56 327
P1 5'-ACC TGC AGC CTT CAC TTT CCT CAC-3'
P2 5'-GGC GAT CAC CTC CGT CAC TTG-3'
CCR2 56 255
P1 5-CCA ACT CCT GCCTCC GCT CTA-3'
P2 5-CCG CCA AAA TAA CCG ATG TGA TAC-3'
CXCR2 57 385
P1 5'-CCG GGC GTG GTG GTG AG-3'
P2 5'-TCT GCC TTT TGG GTC TTG TGA ATA-3'
CXCR4 60 499
P1 5'- TTC CTG CCC ACC ATC TAC TC-3'
P2 5'-CCA TGA TGT GCT GAA ACT GG-3'
COX'
COX-1 56.5 309
P1 5'-CTT GAC CGC TAC CAG TGT GA-3'
P2 5'-AGA GGG CAG AAT ACG AGT GT-3'
COX-2 55 539
P1 5'-AAG CCT TCT CTA ACC TCT CC-3'
P2 5'-TAA GCA CAT CGC ATA CTC TG-3'
GAPDH
GAPDH 60 495
P1 5'- ACC ACA GTC CAT GCC ATC AC-3'
P2 5'- TCC ACC ACC CTG TTG CTG TA-3'
1. Reference (100). 2.Reference (101)
Table 2.2 Primer sequences and product sizes
Amplification was as previously described, typically 94°C for 3 minutes; 35-40 cycles
of 94°C for 30 seconds (denaturing), 55°C-60°C for 1 minute (annealing) and 72°C for
1 minute (extension); followed by a final extension step of 72°C for 7 minutes. cDNA
samples were subjected to parallel PCR reactions with primers for GAPDH to control
for equivalency of loading. The presence of genomic DNA was determined by control
reactions in which amplification was conducted in complete reaction mixture lacking
template cDNA or with RNA samples from RT reactions carried out in the absence of
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Superscript II. PCR products were visualised by ethidium bromide staining following
electrophoresis on 1.2% agarose gels. Subsequent quantification for each gene studied
in comparison to the GAPDH loading control was conducted using the GelWorks ID
software package (UVP, Cambridge UK).
2.4.3. Results and Discussion
In vivo measurements in patients and in in vitro animal models simulating the major
geometric features of blood vessels indicate that there is a 5% to 6% wall excursion
at peak systole under normal physiological conditions, which can extend to 10% in
the scenario of hypertension. To determine the effects of pathogenic cyclic strain,
cells were stretched at -15 kPa which corresponds to a maximum strain of 17%,
(average strain 11%), at a physiologically relevant frequency of 1 Hz (60
cycles/min). While cyclic strain has not been as extensively studied as shear stress,
studies to date in endothelial cells have demonstrated the upregulation of a diverse
array of genes. These include those for the adhesion molecules ICAM-1 and E-
selectin, the chemokine MCP-1, the vasoactive mediator ET-1, the fibrinolytic
protein tPA and the growth factor PDGF-B. The implications of these in vitro
findings, with emphasis on their potential relevance to hypertension-induced
atherosclerosis, are discussed in detail in section 2.3.
Human umbilical vein endothelial cells (HUVEC) have been used extensively to
study the biology and pathobiology of the human endothelial cell. While the main
advantage of HUVEC culture is the wide availability of these cells, there are
disadvantages to their use. These include their time-consuming isolation, fastidious
growth factor requirements, relatively short life-span and long population doubling
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time. These limitations drove a search for transformed endothelial cell lines. In 1990,
the establishment of an immortalised HUVEC cell line, ECV-304 was reported (99).
A number of groups demonstrated that these cells exhibited classical endothelial
properties including the expression of characteristic markers (UEA-1 lectin, PHM5
and HAM 56), organelles (Wiebel-Palade bodies) and the ability to form blood
vessels (angiogenesis) (102). It must be pointed out however that the use of a cell
line rather than freshly isolated primary cells involves accepting the caveat that the
acquisition of the transformed phenotype may alter key cellular characteristics of the
former. For example ECV-304 lack vonWillebrand factor and express cytokeratins
usually associated with cells of an epithelial origin. Despite these discrepancies,
ECV-304 have been employed as a valid model of endothelial cell function by
numerous investigators.
In order to validate the current experimental model, the expression of the adhesion
molecule ICAM-1 and the chemokine MCP-1 were first examined, since cyclic strain
has been reported to modulate endothelial expression of both these genes (74, 75). In
the present study, constitutive expression of ICAM-1 in ECV-304 cells was apparent
and mRNA levels for this species were increased by exposure to cyclic mechanical
stretch for 24 and 48 hours. (Fig 2.5). MCP-1 was also constitutively expressed in
these cells but, in contrast to ICAM-1, no upregulation was apparent after 24 hours
of cyclic strain. Exposure to mechanical stretch for 48 hours, however, resulted in a
marked increase in MCP-1 mRNA expression as compared with control cells which
were grown under identical, but static conditions (Fig 2.6). This is in agreement with
previous studies and the ability to reproduce these results validated the chosen
experimental parameters chosen for the current study.
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Figure 2.6. ICAM-1 expression in ECV-304 cells is upregulated by cyclic strain
Constitutive expression of ICAM-1 is apparent, but mRNA levels for this species are elevated
following 24 and 48 hours of cyclic mechanical strain. Positive control is TNF-a treated ECV-304
cells. Result shown is representative of three separate experiments (Appendix 1 A).
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Figure 2.7.MCP-1 expression in ECV-304 cells is increased by cyclic strain
Constitutive expression of MCP-1 is apparent, but mRNA levels for this species are elevated
following 48 hours of cyclic mechanical strain. Positive control is TNF-a treated ECV-304 cells.
Result shown is representative of three separate experiments (Appendix 1A).
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The emerging role of chemokines, and in particular IL-8, in the inflammatory axis of
atherogenesis has been discussed previously (section 1.3.1). The expression of IL-8
and its corresponding receptor CXCR-2 has been detected in human atherosclerotic
lesions. The absence of the murine homologue of this receptor (mIL-8R) on bone
marrow derived-peripheral blood leukocytes in LDL-receptor deficient mice has
been reported to result in reduced atherosclerotic lesion size and attenuated
macrophage recruitment, implying a role for IL-8 receptor binding chemokines in the
localisation of macrophages to these lesions. IL-8 and its related chemokines were
originally thought to be predominantly chemotactic for neutrophils which are scanty
in human atherosclerotic lesions. Recent work however has suggested that IL-8 may
facilitate macrophage recruitment into the atherosclerotic plaque via other, non-
chemotactic, mechanisms. It has been demonstrated, for example, that IL-8 is a
potent trigger for firm adhesion of monocytes to vascular endothelium expressing
cell adhesion molecules under flow conditions; in this study IL-8-induced monocyte
arrest was significantly blocked a monoclonal antibody to (32 integrin (103).
These studies implicate IL-8 in monocyte recruitment to the atherosclerotic plaque
by translating initial monocyte tethering into firm adhesion through activation of
leukocyte integrins. IL-8 has also been recently identified in human coronary
atherectomy specimens where its presence has been implicated in angiogenesis as
assessed using in vivo assays (104). The corneal neovascular response was markedly
positive in response to pellets from atherectomy specimens as compared with
controls and was completely abrogated by IL-8 neutralising antibody. In addition, IL-
8 is a potent chemoattractant and mitogen for VSMC in vitro (105). Increased
endothelial IL-8 expression in response to mechanical stretch therefore, in addition to
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facilitating macrophage influx/adhesion, might also provide a potential mechanism
whereby increased cyclic strain, occuring in the setting of hypertension, could
mediate the medial smooth muscle hyperplasia characteristic of this disease.
We chose to examine therefore whether cyclic mechanical strain could modulate IL-
8 expression in ECV-304 cells. mRNA for IL-8 was expressed under basal
conditions in these cells and cyclic strain led to increased expression of this C-X-C
chemokine (Fig. 2.8). This was most pronounced following 24 hours of mechanical
strain, but was still evident at 48 hours. ECV-304 cells treated with TNF-a at a
concentration of 100 ng/ml for 4 hours served as a positive control.
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Figure 2.8. IL-8 expression in ECV-304 cells is increased by cyclic strain
Constitutive expression of IL-8 is apparent, but mRNA levels for this species are elevated following
24 and 48 hours of cyclic mechanical strain. Positive control is TNF-a treated ECV-304 cells. Result
shown is representative of three separate experiments (Appendix 1 A).
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Regulated upon activation, normal T cell expressed and secreted (RANTES) is a C-C
chemokine that attracts monocytes, T lymphocytes and eosinophils into sites of
inflammation (1.2.2). In keeping with this role, RANTES expression has been
identified in a wide range of inflammatory diseases including endotoxaemia,
inflammatory bowel disease, acute pulmonary disease and rheumatoid arthritis. In
one study RANTES expression was found to be elevated in the cells of
atherosclerotic lesions of carotid endarterectomy specimens. However, while
RANTES expression was identified in a number of atherosclerotic sites (abdominal
aorta, iliac and carotid arteries) by other investigators (106), this chemokine was also
detected in apparently normal aortic control tissue (100); the role ofRANTES in the
pathogenesis of atherosclerosis is, therefore, still unclear. RANTES expression can
be induced in vascular smooth muscle and endothelial cells in vitro in response to
pro-inflammatory cytokines (TNF-a, IFN-y) (107). On the basis that cyclic strain is
a putative pro-inflammatory stimulus, the expression of RANTES in ECV-304 cells
exposed to cyclic strain was examined. In contrast to IL-8, the expression of
RANTES, although constitutive, was not upregulated in ECV-304 cells following 24
or 48 hours of cyclic strain (Fig 2.9). There was, however, a marked upregulation in
the expression of this chemokine following stimulation of these cells with TNF-a
(100 ng/ml for 4 hours). The observation in the current study that cyclic strain does
not modulate RANTES expression, but does increase expression of both IL-8 and
MCP-1, demonstrates differential chemokine responses in ECV-304 cells exposed to
cyclic strain. The data do not, however, rule out a role for RANTES in hypertension-
associated atherosclerosis since its expression may be modulated by additional
classic pro-inflammatory stimuli present in the vascular milieu.
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Figure 2.9 RANTES expression in ECV-304 cells is unaltered by cyclic strain
Constitutive expression of RANTES is apparent, but mRNA levels of this chemokine remain
unchanged following 24 and 48 hours of cyclic mechanical strain. Positive control is TNF-a treated
ECV-304 cells. Result shown is representative of three separate experiments (Appendix 1 A).
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The biological effects of chemokines are mediated through interactions with their
corresponding chemokine receptors which are expressed in a cell-type specific
manner (section 1.2.4). Chemokine receptor expression can be modulated by a
variety of pro-inflammatory stimuli. Ligands for CCR1 are the C-C chemokines
RANTES, MlP-la, MCP-2 and MCP-3, while MCP-1-4 bind CCR2.
The functional importance of the CCR2 receptor was demonstrated recently when
homologous recombination was used to "knock-out" its expression in atherosclerotic
prone mice (108). Apolipoprotein E null mice (which develop severe atherosclerosis)
deficient in the CCR2 receptor exhibited markedly decreased lesion formation and
macrophage recruitment (discussed in section 1.3.1). These results identified CCR2
as a possible genetic determinant of murine atherosclerosis and provided evidence
for the role of MCP-1 in macrophage recruitment and, hence, atherogenesis.
Conflicting reports exist as to the presence of the C-C chemokine receptors on
endothelial cells (section 1.3.1). A number of groups have been unable to detect
CCR1 and CCR2 expression; a recent study, however, demonstrated endothelial
expression of CCR2, in addition to MCP-1 induced migration of endothelial cells in
vitro. Similarly, conflicting reports exist as to the expression of the IL-8 receptor on
endothelial cells. The presence of this receptor would not be unexpected, given the
finding that IL-8 increases endothelial proliferation and migration in vitro and
promotes angiogenesis in vivo, presumably through a receptor-mediated mechanism.
The expression of CXCR4 on endothelial cells has been demonstrated previously
(109). The constitutive nature of this receptor and its ligand, stromal derived factor
(SDF)-l, led to speculation that together they may play an important role in the early
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recruitment of monocytes and T lymphocytes, particularly since inducible
chemokines such as MCP-1 are generally not expressed on normal arteries. In
addition, the expression of CXCR4 in endothelial cells is modulated by various pro¬
inflammatory mediators implicated in the pathogenesis of atherosclerosis. IFN-y for
example results in a down-regulation of CXCR4 expression in endothelial cells,
while IL-ip and TNF-a produce a biphasic response eliciting an immediate decrease,
followed by a subsequent reversal and increase in steady state levels of CXCR4
mRNA (109).
In light of the above findings, basal expression of the chemokine receptors CCR1,
CCR2, CXCR2 and CXCR4 in ECV 304 cells was investigated. The influence of
mechanical strain on receptor expression levels was also examined. Neutrophil and
mononuclear cell total RNA served as a positive control for these experiments.
CCR1 and CCR2 are expressed by monocyte/macrophages, while CXCR2 is
expressed by neutrophils (110). These controls were used in the relevant PCR
reactions.
CCR1, CCR2 and CXCR2 were not expressed in ECV-304 cells, nor was mRNA for
these species induced by cyclic strain (Fig 2.10). CXCR4, however, was expressed
constitutively in ECV-304 cells. Expression of this receptor, as compared to control
cells, exhibited a biphasic pattern; at 24 hours expression was decreased while at 48
hours expression was elevated over control (Fig 2.11). Comparisons may be drawn
between these observations and the biphasic response of endothelial CXCR4
expression previously demonstrated by other investigators in response to IL-ip and
TNF-a. The latter, however, occurs over a different time period, with initial
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decreases occuring in the first three to five hours following cytokine stimulation,
while increased expression is apparent by 24 hours. Increases in CXCR4 expression
in endothelial cells by cyclic strain could be potentially relevant to the in vivo
recruitment of monocytes and T cells to the vessel wall in hypertension-induced
atherosclerosis. However, it is recognised that RT-PCR is a semi-quantitative
technique and that these preliminary results must be confirmed using more
quantitative methods such as Northern blotting.
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Figure 2.10 Chemokine receptor expression in EVC-304 cells
The chemokine receptors CCR1 and CCR2 are not expressed by ECV-304 cells under basal
conditions or in response to cyclic strain. Human monocytes served as a positive control in these
experiments. Result shown is representative of two separate experiments
168
24 HR 48 HR
C24 S24 C48 S48
Figure 2.11 Expression of the chemokine receptor CXCR4 in ECV-304 cells is
modulated by cyclic strain
The receptor CXCR4 was constitutive in ECV-304 cells. Expression of this receptor, as compared to
control cells, appeared to be downregulated and then upregulated following 24 hours and 48 hours of
cyclic strain, respectively. Human monocytes served as a positive control for this receptor. Result
shown is representative of three separate experiments(Appendix 1 A).
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While endothelial expression of the adhesion molecules E-selectin and ICAM-1 can
be modified by cyclic strain, conflicting reports exist as to modulation of VCAM-1
mRNA levels by cyclic strain. One study demonstrated upregulation of VCAM-1 by
approximately 30% following 24 hours of cyclic strain in HUVEC (111) while
another group was unable to reproduce this increase (76). Strain-induced expression
of such endothelial adhesion molecules in vivo may facilitate the adhesion of
monocytes to localised areas of vascular walls where strain is high (bifiirctations,
ostia) and, therefore, to the initiation of atherogenesis. Furthermore, increases in such
forces in hypertension may, in part, explain the well-documented association
between hypertension and atherosclerosis. Given these observations, it was of
interest to us to explore the influence of cyclic mechanical strain on the expression of
E-selectin and VCAM-1 in ECV-304 cells. E-selectin was not expressed in these
cells under basal conditions or, indeed, in response to 24 or 48 hours of cyclic strain.
TNF-a (100 ng/ml for 4 hours) resulted in a slight increase in mRNA levels as
detected by RT-PCR. VCAM-1 was not expressed under basal conditions in these
cells nor in response to cyclic strain, but once again was detected in TNF-a-treated
cells (Fig 2.12).
Growing evidence implicates cytokines, in addition to their chemokine sub-group, in
the formation and development of atherosclerotic lesions. Their role in this process,
mediated predominantly by their effects on cell proliferation and lipid/protein
synthesis, is discussed elsewhere (1.3.1). On the basis that cyclic mechanical strain is
a putative pro-inflammatory stimulus, the effects of this force on the expression of
the cytokines TNF-a, IL-1, IFN-y and IL-6 in ECV-304 cells were examined.
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Figure 2.12 VCAM-1 and E-selectin in ECV-304 cells are unaltered by cyclic strain
VCAM-1 and E-selectin are not expressed by ECV-304 cells under basal conditions or following
exposure to cyclic strain; in contrast, in TNF-a treated ECV-304 cells, faint expression of these
adhesion molecules is detected. Result shown is representative of three separate experiments
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Figure 2.13. Expression of the cytokines IL-6 and IL-ip in EVC-304 cells are
unaltered by cyclic strain
IL-6 and IL-ip are expressed in ECV304 cells under basal conditions but mRNA levels are unaltered
by cyclic strain. Result shown is representative of two separate experiments.
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IFN-y is not expressed in ECV-304 cells under basal conditions nor in response to
cyclic mechanical strain. By contrast, TNF-a, IL-|3 and IL-6 were found to be
expressed constitutively in ECV-304 cells. As was found for IFN-y however, mRNA
levels for the cytokines remain unaltered following 24 and 48 hours of cyclic strain
(Fig 2.13).
Cyclooxygenase (COX) catalyses the first, rate-limiting step in the formation of
prostaglandin and thromboxane eicosanoids from phospholipase A2-released
arachidonic acid. The "inducible" fonn of the enzyme, COX-2, is absent from most
cells under basal conditions, but is rapidly and transiently expressed in response to a
diverse range of stimuli. As might have been anticipated from its in vitro induction
by lipopolysaccharide and pro-inflammatory cytokines, COX-2 has been found to be
important in a wide variety of inflammatory disorders; indeed, the development of
selective COX-2 inhibitors as therapies for inflammatory disease represents a key
area of current pharmacological research (112). A close correlation between the
inflammatory response and COX-2 activity is supported by the observation that its
expression is induced by inflammatory cytokines such as interferon-y and tumour
necrosis factor-a (113) and downregulated by the anti-inflammatory cytokine IL-10.
Further, examination of synovia from patients suffering from osteo- and rheumatoid
arthritis has confirmed the presence of COX-2 in mononuclear cells, blood vessel
endothelial cells and sub-synovial fibroblast-like cells (114) supporting the
contention that the major portion of inflammatory prostaglandins are derived from
COX-2. COX-2 "knockout" mice have, however, provided unexpected results in a
number of inflammatory assays (115). These studies indicated that inflammatory
responses in the carrageenan, phorbol ester and arachidonate models were COX-2
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independent and moreover, these animals were observed to exhibit normal
inflammatory responses to bacterial invasion of the peritoneum. It has been recently
demonstrated in vitro, however, that COX-1 ~ and COX2~ ~ cells derived from these
animals exhibit substantially enhanced basal and inducible expression of the
remaining functional COX gene, in addition to increased expression of cytosolic
phospholipase A2 (CPLA2), another key enzyme in prostaglandin synthesis (116).
Such compensatory COX-1 production in the COX2 ~~ mice almost certainly explains
the counter-intuitive findings regarding the inflammatory responses of these animals.
Inducible COX-2 was initially regarded as a pro-inflammatory enzyme as evidenced
by its increased expression and bioactivity in disorders such as rheumatoid arthritis.
However, evidence is accumulating that in certain scenarios this enzyme may also
elicit anti-inflammatory effects (117). In carrageenin-induced pleurisy in rats, COX-2
protein expression in inflammatory exudate cells peaked at 2 hours and again at 48
hours (time points that in this model are associated with predominant PMN and
mononuclear cell infiltration, respectively). While the initial peak was associated
with maximal PGE2 synthesis, the second, and more pronounced peak, coincided
with minimal PGE2 production and increased levels of PGD2 and 15-deoxy-PGJ2.
Furthermore, the selective COX-2 inhibitor NS-398 and the dual COX-1/COX-2
inhibitor indomethacin, while inhibiting inflammation at 2 hours, significantly
exacerbated inflammation at 48 hours (as measured by increases in cellular infiltrates
and exudative volume). This exacerbation was associated with reduced production of
PGD2 and 15-deoxy-PGJ2 in exudates and reversed by the exogenous addition of
these prostaglandins. On the basis of these observations, it has been suggested in this
model COX-2 may be pro-inflammatory during the early PMN-dominated phase, but
174
may aid inflammatory resolution in the later mononuclear cell- dominated stage by
generating alternative anti-inflammatory prostaglandins. Similarly in a model of
experimental glomerulonephritis COX products (athough in this case predominantly
COX-1 -derived) have been implicated in the endogenous repression of the
chemokine MCP-1, an event that coincides with a reduction in glomerular monocytes
and resolution of this disease (118).
In the vascular scenario, it appears that COX-2 may also have immunomodulatory
effects following vessel injury (reviewed in (119)). In animal vessels in vivo and in
vitro COX-2 expression can be induced in vascular smooth muscle cells in response
to physical injury and pro-inflammatory cytokines. Moreover, this upregulation is
associated with increases in PGI2 and PGE2 production that are able to compensate
for the loss of prostaglandin synthesis (via constitutive COX-1) by injured
endothelial cells. PGI2, as discussed in section 1.1.1, is a vasodilator with potent
inhibitory actions on platelet function and is essential in the maintenance of normal
vascular homeostasis. Studies in vitro demonstrate that COX-2, induced in response
to cytokines, limits VSMC adhesion molecule expression (ICAM-1 and VCAM-1)
and GM-CSF release. On this basis, it has been proposed that the induction ofCOX-
2 in VSMC may represent a defence mechanism compensating for COX-1 loss in the
endothelium which, via suppression of cytokine and adhesion molecule expression,
limits further vascular damage. The expression of COX-1 and COX-2 in human
atherosclerotic lesions has recently been examined (120). While normal arteries
demonstrated COX-1 (but not COX-2) mRNA and protein in the endothelial and
medial smooth muscle cells, atherosclerotic lesions contained both COX-1 and COX-
2 in macrophages, and to a lesser extent in VSMC and endothelium. The role of
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COX-2 in the pathogenesis of atherosclerosis has not been definitively established
and, indeed, based on current evidence this enzyme could potentially either promote
atherosclerosis via its pro-inflammatory effects or be produced in response to pro-
atherosclerotic stimuli to limit plaque progression and prevent further vessel injury.
To date, it may be only speculated as to whether its effects result in a positive or
negative modulation.
On the basis of the hypothesis that cyclic strain is a pro-inflammatory stimulus, the
putative influence of this force on the expression of COX-1 and its inducible
isoform, COX-2, in ECV-304 cells was examined. COX-1 is expressed in ECV-304
cells under basal conditions, but levels remain unchanged by cyclic strain (Fig. 2.14).
In contrast, mRNA for COX-2, while also present in these cells under basal
conditions, increases following 48 but not 24 hours of cyclic strain (Fig 2.15). COX-
2 is serum-inducible, so, as expected, expression levels in the control cells decline
over the time course studied (Fig 2.15). Based on the current available evidence
regarding COX-2 bioactivity within the vasculature, it is speculated that the strain-
induced upregulation ofCOX-2 in ECV-304 could potentially modulate the response
to this stimulus by influencing the expression of leukocyte trafficking determinants
(chemokines and leukocyte adhesion molecules).
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Figure 2.14 COX-1 expression in EVC-304 cells is unaltered by cyclic mechanical
strain
COX-1 is expressed in EVC-304 cells under basal conditions, but mRNA levels for this species















Figure 2.15. COX-2 expression in ECV-304 cells is increased by cyclic strain
mRNA for COX-2 is present in ECV-304 cells under basal conditions. Increases in COX-2 expression
occur following 48 but not 24 hours of cyclic strain. COX-2 is serum-inducible, so, as expected,
expression levels in the control cells decline over the time course studied. Result shown is
representative of three separate experiments (Appendix 1A).
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As this work neared completion, results obtained from PCR-based single locus
fingerprinting studies questioned the origin of ECV-304 cells. In June 1999 a
directive was issued from the European Collection of Cell Cultures (EATCC), from
whom these cells had been initially obtained by our laboratory, which suggested that
ECV-304 had the same DNA fingerprint as the T24 cell line (human bladder
carcinoma (epithelial)).
This discovery has obvious implications for the findings of the current study. For
example, our inability to reproduce the previous finding that cyclic strain induced
upregulation of E-selectin is most likely explained by the fact that ECV-304 cells are
epithelial in origin. The observation in the current study that TNF-a can induce
expression of E-selectin mRNA in ECV-304 cells is interesting, since E-selectin has
been previously considered to be expressed almost exclusively by activated
endothelial cells. A recent study however has identified E-selectin expression in
colonic epithelial cells (121).
Irrespective of source however this cell line provides a useful model for the
regulation of immune mediators by mechanical strain. Although we cannot speculate
on the basis of these results on the pro-atherogenic potential of cyclic strain, a
number of interesting observations can still be made. Inadvertently, this study has
identified strain-induced genes in epithelial cells. The results described here outlining
the modulation of chemokine and adhesion molecule expression by cyclic strain in
ECV-304 cells are otherwise in broad agreement with the results described by other
groups working with other cell types. The upregulation of ICAM-1 and MCP-1 have
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been previously demonstrated in endothelial cells and, indeed, were used in the
current study to validate the in-vitro conditions. During the course of this work,
cyclic strain induced upregulation of IL-8 mRNA in endothelial cells was
demonstrated simultaneously by another group (122). IL-8 expression, therefore, in
both endothelial and epithelial cells, is increased by cyclic mechanical stretch.
Likewise, the observation in the current study that cyclic strain increases expression
of COX-2, but not COX-1, in epithelial cells has been previously documented in
mesangial cells and bladder smooth muscle cells (123, 124). Furthermore, increases
in COX-2 promoter activity in response to cyclic strain have recently been
demonstrated in endothelial cells. Investigators elsewhere have demonstrated that
cyclic mechanical stretch increases expression of the growth factor PDGF-B in both
endothelial cells and vascular smooth muscle cells (in the latter PDGF-A is also
upregulated in a strain-dependent manner) (77, 125). In addition, in agreement with
the current study, other groups have failed to demonstrate increases in mRNA for the
cytokines TNF-a, IL-1 and IL-6 in response to cyclic strain in HUVEC (122). It
would appear that distinct cell types share "strain-inducible" genes (Table 2.3).
The observation that specific genes are upregulated in a number of different cell
types in response to cyclic mechanical stretch raises the possibility that these
responses are, to some degree, a strain-specific phenomenon. A cell specific level of
control may also exist, however, since IL-8 expression was found to be negatively
modulated by cyclic strain in mesangial cells (section 2.6).
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Table 2.3 "Strain-inducible" genes common to different cell types.
A number of alternative theories have attempted to explain the process of
transduction of mechanical strain to biochemical signal. (Section 2.3.3). One such
theory proposes that mechanical strain, sensed by cell surface adhesion plaques and
cytoskeletal proteins, could mobilise second-messenger cascades. In support of this
theory both endothelial and mesangial cells subjected to periods of cyclical
mechanical strain demonstrate increased tyrosine phosphorylation and redistribution
of focal adhesion plaque proteins FAK and paxillin (69, 73). Multiple second
messenger pathways have also been implicated in the responses of endothelial cells,
mesangial cells and vascular smooth muscle cells to mechanical strain. These are
discussed in detail elsewhere. In brief, the activation of PKC and PKA, stretch-
induced calcium fluxes and mitogen activated protein (MAP) kinases appear to play
a role in the strain-induced responses of all three cell types. Downstream to such
signalling cascades the induction of various immediate early genes including c-fos
and egr-1 occurs following the exposure of these cell types to cyclic strain.
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These findings lend further support to the theory of strain-dependent transcription,
mediated by a common strain-responsive consensus sequence in the promoter region
of target genes. A recent study in vascular smooth muscle cells exposed to cyclic
mechanical strain identified a GC-rich region in the proximal 92 bp of the PDGF-A
promoter as a putative strain-responsive element (125). These authors presented
evidence that this region contains mechanical strain responsive elements that bind the
transcription factors Egr-1, and possibly Sp-1. To date, a common consensus
sequence in promoter regions of other strain-sensitive genes in any other cell type
remains to be identified.
Recently another theory has emerged on how mechanical stimuli are converted into
biochemical stimuli which may also explain the presence of strain-responsive genes
common to diverse cell types. Workers using vascular smooth muscle cells showed
that cyclic strain evoked activation of MAP kinases followed by enhanced DNA
binding activity of the transcription factor AP-1 (126). In addition, this force rapidly
induced phosphorylation and activation of PDGF receptor-a. Conditioned medium
from the vascular smooth muscle cells exposed to mechanical strain did not result in
PDGFR-a phosphorylation and antibodies binding to all forms of PDGF did not
block strain-induced PDGFR-a activation. These authors speculated that mechanical
stresses, by directly perturbing the cell membrane, may alter receptor confirmation,
thereby initiating signalling pathways normally activated following ligand-dependent
receptor activation. While this has yet to be demonstrated for other cell types or
indeed other receptors, in theory, simple deformation of the membrane and activation
of receptors in this manner could induce the expression of a variety of mediators,
irrespective of the cell type.
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The current study demonstrated the upregulation of ICAM-1, MCP-1, IL-8, COX-2
and CXCR4 expression in ECV-304 cells in response to cyclic strain. These findings
support the original hypothesis that cyclic strain is a pro-inflammatory stimulus
capable of modulating immune mediator expression, although these effects may
occur independently of cell type.
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2.5. Role of glomerular hypertension in the pathophysiology of
glomerulosclerosis
Glomerular filtration and subsequent modifications of the filtrate by tubule epithelial
cells are in large part responsible for fluid and electrolyte balance in the organism,
thereby ensuring that the final urine volume and composition are matched to the
daily intake of fluid and food. In patients with chronic renal disease and overall
reductions in glomerular filtration rate (GFR), salt and water excretion is still
accomplished without major dietary changes, and indeed may be achieved until such
time as the GFR approaches 10% of normal. The ability of the injured/diseased
kidney to adapt to these changes suggests that compensatory mechanisms occur in its
remaining functioning nephrons to ensure fluid and electrolyte homeostasis. If,
therefore, the initial complement of nephrons (around 2 million in humans) is
damaged by disease, and diet is unchanged, then the rate of solute and water
excretion per individual remaining nephrons must increase. In support of this
concept, experimental studies have shown that disease processes reduce the GFR in
some nephrons, whereas in less damaged nephrons compensatory changes occur to
elevate the GFR and promote enlargement of tubules (reviewed in (127) and
references contained therein).
2.5.1. Glomerular hyperfiltration in response to reduced nephron number
The simplest model of reduced nephron number is surgical ablation of renal tissue. In
humans who have donated a kidney for renal transplantation, and in rats subjected to
experimental uninephrectomy, the GFR in the remnant kidney increases by about
40%-60% above its preoperative value. Most of these changes occur in the first week
following surgery. This could be potentially caused by either an increase in the
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single-nephron GFR (SNGFR) of remaining nephrons, or by an increase in the actual
number of nephrons in the remnant kidney. It is generally held, however, that new
nephrons are not formed in mature animals, and increases in remnant kidney GFR
are entirely due to increases in SNGFR. This has in fact been confirmed in the rat
uninephrectomy model by micropuncture and glomerular counting techniques.
Similar measurements in rats following removal of 2/3-5/6 of renal tissue shows that
these adaptive increases occur similarly in superficial and juxtaglomerular nephrons.
Increases in SNGFR in both animals and humans are accompanied by increases in
total renal blood flow of a similar magnitude, and this in turn represents increased
perfusion of the individual glomerulus. Indeed, in the rat uninephrectomy model
micropuncture techniques have demonstrated that the majority of SNGFR is due to
elevation of glomerular plasma flow. Elevation of mean glomerular hydraulic
pressure and alterations in the glomerular coefficient (as determined by the product
of the hydraulic permeability of the glomerular capillary wall per unit surface area
and the glomerular capillary surface area available for filtration) also contribute. In
rats in whom greater proportions of renal mass are removed (75-90%) SNGFR of
remnant nephrons was found to have increased further, and these remarkable
increases were accompanied by equally prominent increases in plasma flow. This is
achieved by further dilation of afferent and to a lesser extent efferent arterioles.
Systemic blood pressure in this scenario, but not after uninephrectomy, is generally
elevated, and accompanies an elevation in mean glomerular transcapillary pressure.
This change therefore in glomerular transcapillary pressure is, therefore, important in
the remarkable increases in SNGFR observed after extensive renal ablation in the rat.
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The stimuli responsible for glomeruli hypertension, hyperperfusion and
hyperfiltration following extensive renal ablation in the rat remain to be identified.
Chronic administration ofACE inhibitors in this model has been shown to normalise
the glomerular transcapillary pressure, implicating AT II in the causation of
glomerular hypertension in remnant glomeruli (128). Whether the effects of AT II
can occur acutely are still uncertain, and it has been speculated that AT II increases
glomerular pressure in remnant glomeruli in this model by promoting Na+ retention
and promoting systemic hypertension, rather than by direct actions on the renal
microcirculation (127).
Atrial naturietic peptide (ANP) contributes to elevated SNGFR in rats with reduced
nephron number maintained on a liberal salt diet (129). ET-1 activity, although
constant in the first week following renal ablation begins to rise thereafter (130). The
significance of this is unknown. Altered prostaglandin synthesis also occurs in the
remnant kidney, with increased glomerular synthesis of PGf, PGE2 and TXAo, and
increased nephron excretion of the latter two (131). It has been speculated that
remnant glomerular haemodynamic function may be altered by increased renal
production of both vasodilator and vasoconstrictor prostanoids. In support of this,
inhibition of prostaglandin synthesis both reduces remnant nephron plasma flow and
SNGFR in rat renal ablation models (132) and total renal plasma flow and GFR in
patients with renal insufficiency (133).
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2.5.2. Compensatory renal hypertrophy in response to reduced nephron
number
Both cell hypertrophy and cell hyperplasia accompany loss of renal mass and it has
not been definitively determined whether hypertrophy causes hyperfiltration or vice
versa. The contribution of the various structural components of the glomerulus to its
expansion have been much debated (127). Overall, studies indicate that the fractions
of glomerular volume occupied by its various components (capillary lumens,
endothelial cells, epithelial cells and mesangium), remain constant, but it is still
unclear as to what extent the different glomerular cell types increase in number and
volume. Increases in proximal tubule size, and to a lesser extent distal tubule, also
occur in proportion to the extent of loss of nephron number, enabling an increase in
tubular reabsorption and the preservation of glomerulotubular balance. In vitro
studies suggest, however, that in addition to increased tubule size, intrinsic
adaptation of tubule transport mechanisms may also facilitate increased fluid
readsorption following reduction in nephron number (127).
The observation that compensatory renal hypertrophy does not require renal
innervation prompted the search for circulating agents or hormones which could
control renal growth. No renal-specific factor has been identified to date, but IGF-1,
EGF, PDGF, PGE2, in addition to the hormones thyroxine, hydrocortisone,
vasopressin and AT II have all been shown to promote growth of renal cells in
culture, in particular mesangial and proximal tubule cells (127). It has been
speculated that these factors may participate, in a non-specific way in renal
hypertrophy, after growth has been triggered by some, as yet unidentified, signal.
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2.5.3. Function of intact nephrons in parenchymal renal disease
Compensatory elevation of SNGFR must be accompanied by increased proximal
water and solute reabsorption to avoid inappropriate diuresis and circulatory
collapse. The converse is also true with a reduction in SNGFR (134). Micropuncture
studies in various models of experimental glomerulonephritis and tubulointerstitial
damage have confirmed maintenance of this so-called glomerulotubular balance over
a wide range of SNGFR values (135). In the case of experimental GN, alteration in
Starling forces governing peritubular capillary reabsorption have been shown to
account for the appropriate coupling of proximal Na+ and water retention to
glomerular filtration. Oncotic pressure in the efferent arteriole was found to vary
directly with SNGFR, while the hydraulic pressure was similar throughout the
peritubular capillary network. Structural changes then in the proximal tubule and
peritubular capillary network appear to act in concert with changes in Starling forces
to achieve glomerulotubular balance.
Studies in human renal disease are generally in agreement with the above concepts,
although information is less complete. It has been demonstrated, for example, that
hypertrophied tubules are most often attached to hypertrophied glomeruli and
shrunken tubules to shrunken glomeruli.
2.5.4. Adverse effects of glomerular capillary hypertension:
glomerulosclerosis
Patients with established renal insufficiency generally display progressive loss of
renal function. Those in whom the GFR has been reduced to about 25% of normal
can expect to eventually require dialysis or transplantation (127). It appears then, that
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after a certain point, reduction in functioning nephron numbers, irrespective of the
cause, leads to progressive failure of remaining units through a final common
pathway of injury. Mounting evidence suggests that the haemodynamic changes
causing remnant glomerular hypertension and hyperfiltration, although initially
adaptive, may eventually cause injury to residual glomeruli. In the rat renal ablation
models, early glomerular hypertension, hyperfiltration and hypertrophy is
accompanied by ultrastructural changes in epithelial cells including fusion of their
foot processes (136). Following this focal detachment of endothelial and epithelial
cells from the GBM occurs. Finally, progressive accumulation of subendothelial
hyaline material and collapse of capillary lumens eventually results in the appearance
of focal and segmental glomerulosclerosis. The numbers of sclerotic lesions
increases with time and progression to global sclerosis is observed while the pace of
the injury, like the degree of increase in SNGFR, increases in proportion to the loss
of renal mass (136).
Restriction of dietary protein lowers GFR in normal animals. Studies investigated
whether this dietary regimen could effect a lowering of the glomerular pressure and
flow in rats following extensive renal ablation. Restriction of dietary protein was
found to reduce proteinuria and early glomerular morphological changes as
compared to rats following ablation fed on standard chow (137). This paradigm also
holds in models of less extensive renal ablation where protein restriction results not
only in functional improvements, but a longer life-span. Late institution of protein
restriction also limits the progression of established renal injury and studies indicate
that this is via a reduction in glomerular capillary pressure, without a reduction in
remnant glomerular hyperfiltration and hyperperfusion (138). In support of the role
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of increases in glomerular capillary pressure in the development of
glomerulosclerosis, in a rat remnant kidney model in which animals develop
glomerular hyperfiltration without glomerular hypertension, glomerular injury is
absent (139).
Glomerulosclerosis is a characteristic of animal models of experimental hypertension
where increases in systemic pressure are transmitted to the glomerulus and cause
capillary hypertension. Blockade of nitric oxide synthesis, or sustained infusion of
AT II, cause systemic and glomerular hypertension and the rapid development of
glomerulosclerosis in intact rats with normal nephron number (128, 140). In the two-
kidney one-clip model of hypertension, rats develop glomerular hypertension and
glomerulosclerosis only in the undipped kidney (141). In contrast, in models where
the glomerular pressures remain normal despite elevated systemic pressures (SHR,
Milan hypertensive rats) early glomerulosclerosis is not prominent (142). Use of
ACE inhibitors in rats subjected to renal ablation has been shown to control systemic
blood pressure, normalise glomerular capillary pressure and prevent glomerular
injury. Interestingly, ACE inhibitors have been shown to provide some protection
against glomerular injury in every model of renal disease in which they have been
tested to date.
A number of other non-haemodynamic mechanisms may also contribute to remnant
nephron injury (127). The finding of lipid droplets in glomerulosclerotic lesions led
to the hypothesis that glomerular deposition of circulating lipids could contribute to
progressive glomerular injury in renal disease (143). Lipid feeding in rabbits and
guinea-pigs causes glomerular inury. In the rat renal ablation model and in rats with
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hereditary obesity, hyperlipidaemia is also associated with progressive glomerular
injury and, indeed, lipid lowering in these models limits glomerulosclerosis (127).
The lipoproteins causing injury are as yet unidentified and indeed the observation
that cholesterol feeding itself can increase glomerular pressure causes some difficulty
in the interpretation of these findings.
Capillary microthrombi also occur after reduction in nephron number (127). It has
been speculated that these are precipitated by early endothelial cell injury in the
remnant glomeruli and contribute to progressive injury and glomerulosclerosis by
occlusion of capillary lumens and release of platelet-derived factors. This prompted
studies of anti-coagulant drugs in the rat renal ablation model and, while heparin
largely prevents glomerulosclerosis, warfarin and aspirin are less effective. Heparin
may have other effects in this model such as a reduction in blood pressure, so the role
of capillary thrombosis in this glomerulosclerosis requires further clarification.
2.5.5. Glomerular hypertension: cellular mechanisms of glomerular injury
The different mechanisms suggested for glomerular injury are not mutually exclusive
and it is probable that each contributes, to a greater or lesser degree, to the
development of glomerulosclerosis. Initial theories suggested that increases in
glomerular pressure resulted in the movement of macromolecules into the
mesangium. This was subsequently demonstrated in the rat renal ablation model
where proteinuria is due to defects in the charge and size selective properties in the
capillary wall (as measured by dextran sieving studies) (144). Once present in the
mesangium, it has been speculated that these macromolecules may stimulate
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mesangial cell proliferation, recruit mononuclear cells into the mesangium and alter
production of extra-cellular matrix components.
Movement of proteins through the glomerular capillary wall may also cause
tubulointerstitial damage. Many progressive glomerulopathies have in common
persistently high levels of urinary protein excretion and tubulointerstitial lesions at
biopsy (145, 146). The functional importance of tubulointerstitial events in
progressive renal failure is supported by evidence that that the severity of
tubulointerstitial damage and in particular macrophage infiltration correlates strongly
with the risk of progressive renal dysfunction, even more so than glomerular lesions
(145, 146). Because more severe proteinuria is associated with more severe lesions
and faster progression of renal damage, and high protein loads on the kidney
experimentally causes structural parenchymal injury and interstitial macrophage
accumulation, it has been speculated that proteins filtered through the glomerular
capillary may have intrinsic renal toxicity (so-called "protein overload hypothesis").
In support of this concept, studies have shown that in remnant kidneys following 5/6
renal mass ablation, albumen and IgG accumulation by proximal tubular cells was
apparent at early time points and preceded interstitial infiltration ofMHC-II-positive
cells and macrophages (147). Using double-staining techniques, infiltrates were
visualised at or near tubules containing intracellular IgG or luminal casts. Further
studies also showed the colocalisation of complement (C3) and the chemokine
osteopontin to these regions. Interestingly, similar patterns were found in an immune
model (passive Heymann nephritis) (147), suggesting that the interstitial
inflammatory reaction develops at sites of protein overload, regardless of the type of
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glomerular injury. The mechanisms underlying the proinflammatory response of
tubular cells to protein challenge have yet to be established.
Other processes of injury in response to glomerular hypertension are shown in the
figure below (Fig 2.16).
Figure 2.16.Potential mechanisms of glomerular injury in the development of
glomerulosclerosis (adapted from (127)).
Serial studies in rats subjected to renal ablation suggest that all these processes occur
in parallel and at this time it is impossible to identify any one particular initiating or
predominant feature in the development of glomerulosclerosis.
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In a recent study screening for genes upregulated in the 5/6 nephrectomised mouse
kidney using a PCR-based subtraction method, 10 known and 9 novel genes were
identified. 12 clones showed a 1.5- to 6-fold upregulation by northern blot analyses,
while the remaining seven were rarely expressed (148). The known genes included
kidney androgen-related protein, major urinary protein, lysozyme M,
metalloproteinase-3 tissue inhibitor, chaperonin 10, cytochrome oxidase I, epsilon-
sarcoglycan, ribosomal protein S3a, G-proteingammalO subunit and splicing factor
9G8. These suggest a possible role for androgen action, mitochondrial functions,
matrix metabolism, cell-matrix interactions and intracellular signalling events in the
initial hyperfiltration and hypertrophy of remnant kidney.
2.5.6. Putative link between glomerular hypertension and immune cell
infiltration
It has been speculated that immune cell infiltration of the hypertensive glomerulus
may promote glomerular injury. Certainly in animal models, leukocytes accumulate
in the mesangium of injured remnant glomeruli (149). Interestingly, depletion of
leukocytes in rats by irradiation delays the onset of glomerular injury after renal
ablative surgery while mycopenolate mofetil, an immunosuppressive agent selective
for T lymphocytes, results in partial remission of renal injury in this model. (149,
150). In human diabetic glomerulosclerosis (which is preceded by glomerular
hyperfiltration), macrophage (but not T or B cell) infiltration appears to occur in the
stage of moderate diabetic glomerulosclerosis (as opposed to the mild or advanced
stages) and it has been suggested that this transient macrophage infiltration may
contribute to irreversible structural damage by the augmentation of ECM production
or the production of inflammatory mediators (151). Potential cytokines participating
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in glomerular injury include all those made by the native glomerular cells in addition
to those released by infiltrating immune cells.
Evidence has been presented which supports the upregulation of cellular adhesion
molecules within the remnant glomeruli as a potential mechanism for mononuclear
cell recruitment. Levels of glomerular ICAM-1 expression are significantly increased
in the 5/6 nephrectomised rat model as compared to sham operated controls and
correlate with mononuclear leukocyte infiltration. Anti-ICAM-1 monoclonal
antibody effectively prevents this infiltration of macrophages into the glomerulus
following nephrectomy (152). Treatment of streptozotocin-induced diabetic rats with
an aldose reductase inhibitor, which reduces glomerular hyperfiltration but does not
affect glucose levels, reduces ICAM-1 protein expression and mononuclear cell
infiltration (153). Moreover, mononuclear cell infiltration into the diabetic
glomerulus has also been shown to be prevented by anti-ICAM monoclonal
antibody, and both ICAM-1 protein expression and cellular infiltration were
decreased by insulin treatment. These results suggest that glomerular hypertension
and hyperfiltration may promote glomerular macrophage infiltration by the
induction of ICAM-1 expression.
2.5.7. Glomerular pressure and cyclic mechanical strain
Under normal conditions, because glomeruli are exposed to only small pulse pressure
variations and not to the low frequency oscillations in systemic pressure, volume
remains stable. The contractile activity of the afferent arteriole provides effective
autoregulation and tight control of intra-glomerular pressure. The pre-glomerular
dilatation that characterises a wide range of renal diseases, however, facilitates the
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delivery of a greater fraction of the systemic pressure, normal or elevated, to
glomerular capillaries. In many models of progressive renal disease such as the
remnant and diabetic kidney, autoregulatory glomerular protection is impaired and
marked augmentation of the moment to moment variations in pressure occurs within
the glomerulus (154). This, in turn, results in wide swings in glomerular volume,
which can be further exacerbated by the systemic hypertension that often co-exists
with renal disease. In normal glomeruli with intact autoregulation moment to
moment volume varies by a mere 0.4%, while volume changes of up to 7.4% can
occur in glomeruli from remnant kidneys of hypertensive animals (154). These
changes in overall volume are associated with parallel changes in all the glomerular
structural components. In the case of a mesangial cell, which is anchored via
cytoplasmic projections to the peripheral basement membrane, pressure induced
glomerular expansion and distended capillaries will displace these anchoring points
and produce intense mesangial cell stretch. It has been suggested, therefore, that
cyclic changes in glomerular volume result in repeated episodes of mesangial stretch
and relaxation.
The degree to which elevated intraglomerular pressure will deform or stretch an
endothelial or mesangial cell depends on the mechanical compliance of the
glomerulus and supporting structures; the greater the compliance, the greater the
stretch. Studies on the glomeruli of subtotally nephrectomised rats have shown
changes in their elastic properties that result in increased mechanical compliance
(154). As a consequence, any increase in intraglomerular pressure will tend to
subject mesangial cells to a greater degree of deformity or mechanical strain. In
addition, at any given glomerular pressure, larger, hypertrophied glomeruli are more
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distensible than smaller glomeruli, most likely secondary to increased capillary wall
tension in hypertrophied capillaries. Consequently, glomerular hypertrophy, whether
induced by nephron loss or diabetes, magnifies the deleterious effects of altered
glomerular haemodynamics (69).
ECM accumulation is the principle pathognomic hallmark of glomerulosclerosis
(127). The expanded mesangial matrix contains normal matrix components including
laminin and type IV collagen as well as atypical components such as types I and III
collagen. Matrix accumulation results both from increased production and decreased
degradation of ECM components. Matrix breakdown is the function of the matrix
metalloproteinases (MMPs). The activity of the MMPs is inhibited by the Tissue
Inhibitors ofMetalloproteinases (TIMPs), a group of endogenous regulatory proteins.
Increased production of ECM components, diminished metalloproteinase activity or
increased TIMP activity may contribute to, and/or, individually cause ECM
accumulation.
How increased biomechanical forces, in particular cyclic stretch-relaxation, are
translated into extracellular matrix accumulation and glomerulosclerosis has been the
focus of recent investigations. Working with glomeruli isolated from rat kidneys,
Riser and co-workers undertook a series of microperfusion experiments (155).
Changes in volume in microdissected rat glomeruli perfused ex vivo at increasing
flows, were recorded and plotted against the corresponding intraglomerular pressure.
At perfusion pressures known to occur pathologically in vivo, a 16% increase in
glomerular volume was observed. Using this information, Riser subjected cultured
rat mesangial cells to cycles of 16% stretch using the Flexercell unit (described in
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detail in section 2.3.1) (155). The strained mesangial cells increased their synthesis
of types I and IV collagen, laminin and fibronectin, suggesting that corresponding
pathological mechanical strain in vivo may produce a similar response. Interestingly,
the accumulation of ECM induced by cell stretch is markedly enhanced when the
ambient glucose concentration is increased.
2.5.8. Mesangial cell mediators released in response to mechanical strain
Evidence is mounting, of a pre-eminent role TGF-(3 in the accumulation of ECM in
glomerulosclerosis. Isaka and co-workers have shown that transfection of TGF-
P1 results in expansion of the mesangial matrix in an in vivo rat model (156), while
inhibition of TGF-P has been shown to protect against scarring in experimental
models of renal disease (157). TGF-p has been specifically implicated in the
development of DN (158), where production by mesangial cells has shown to be a
consequence of both mechanical (159) and biochemical stimuli (160). Participation
of TGF-P in the mesangial cell response to mechanical strain has been demonstrated
by several investigators. Increases in TGF-p 1 mRNA can be detected following 24
hours of cyclical strain of rat MCs, while increases in TGF-P 1 protein can be
demonstrated by 48 hours (159). In the same set of experiments, Northern blot
analysis showed increases in mRNA for matrix proteins types I, III and IV collagen,
laminin and fibronectin to be maximal after 12 hours of cyclical strain suggesting
that other factors in addition to TGF-p are involved in the early regulation ofmatrix
protein accumulation. Northern blot analysis also revealed a significant decrease in
mRNA for matrix metalloproteinase-2 (MMP-2) within 6 hours of initiation of
stretch/relaxation. In contrast, expression of tissue inhibitor of metalloproteinase-2
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(TIMP-2) was found to be increased within 12 hours of stretch/relaxation. The net
effect of these two changes would be a significant reduction in the rate of matrix
breakdown, facilitating overall matrix accumulation. It seems likely that net matrix
accumulation occurs as a result of a shift in the balance between these opposing
trophic and degradative factors.
Some clues as to the mechanism of action of TGF-p were provided by Hori et al
(161). TGF-p is secreted as a large latent complex (LLTC) associated with latent
TGF-P binding protein-1 (LTBP-1), the latter molecule being known to bind ECM.
LTBP-1 mRNA expression in rat MCs has been shown to be elevated during the first
24 hours of stretch and then decreased over the next 12 hours. Moreover anti-LTBP-
1 antibodies inhibited fibronectin and laminin mRNA expression normally induced
by stretch-induced TGF-p. Of note the antibodies did not prevent TGF-P interacting
with its receptor nor did they diminish its production by the MCs suggesting the
target of inhibition may be at the stage of TGF-P activation through inhibition of the
LTBP-ECM association.
2.5.9. Mechanical strain to functional response: putative signal transduction
mechanisms
Two alternative theories attempt to explain the process of transduction ofmechanical
strain to functional response in the stretched mesangial cell. These are discussed in
detail in an earlier section (2.3.3) focusing on endothelial cells and cyclic strain, but
the underlying concepts are broadly similar. The first paradigm relates to the
observation that stretch can activate mechanosensitive ion channels in the cell
membrane. Stimulation of ion fluxes (potassium, calcium and possibly other) across
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these channels could also potentially activate signal transduction cascades. The
second theory proposes that mechanical strain sensed by cell surface adhesion
plaques and cytoskeletal proteins, leads to second-messenger mobilisation.
Specific stretch-activated (SA) cation channels have been described in mesangial
cells. Akai and co-workers recorded the presence of stretch-induced calcium fluxes
in mesangial cells and linked Ca2+ influx to the induction of the protooncogenes c-fos
and egr-1 via protein kinase C activation (123). Moreover, the combination of
nifedipine (a calcium channel blocker) and gadolinium chloride (a specific SA
channel blocker) has recently been shown to prevent stretch mediated upregulation of
c-fos, indicating L-type voltage-gated calcium channels may also be involved in
stretch-induced calcium mobilisation. These results have also led to speculation that
ion channel blockers may hold promise as therapies for ameliorating hypertension
induced glomerular damage (162).
Working with rat mesangial cells, Craelius et al. assessed the potential role of
mechanically-activated potassium and sodium ion channels (MACs) as signal
transducers in the alteration of mesangial cell morphology known to occur in
response to mechanical stretch (163). MACs have been identified on numerous cell
types and have been implicated in the electromechanical coupling which mediates a
depolarisation which in turn triggers stretch-induced contraction (164). Mesangial
cells are richly endowed with MACs and these channels have been suggested to play
a role in mesangial cell response to hyperosmolar states. Craelius et al. demonstrated
that cell swelling or stretching of small portions of the cell membrane such as would
occur in glomerular hypertension led to MC MAC activation. The channels carry a
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large current composed of potassium and sodium. The authors proposed this could
confer mesangial cells with both osmosensitive and mechanosensitive properties,
allowing them to respond to intraglomerular physical forces. In support of the role of
ion channels in mediating glomerular hypertension-induced pathology, ion channel
regulation has recently been linked causally to hyperfiltration during the early stages
of diabetes mellitus (165). However, the exact role of ion channels in the
development of glomerulosclerosis remains to be elucidated.
Mechanical forces will exert their greatest effect at the points of attachment of the
cell to the underlying ECM, - focal adhesion plaques. Rapid tyrosine phosphorylation
of FAK and paxillin, protein components of the focal adhesion plaques, has recently
been reported for stretch-stimulated rat mesangial cells (166). Clustering of (31-
integrin toward the periphery of the mesangial cell and stress fibre formation was
demonstrated in the same study. While inhibition of integrin-ECM binding failed to
suppress this process, inhibition ofPKC and PLC and use of the intracellular calcium
chelator BAPTA-AM completely blocked it. Activation of PKC and PLC and
intracellular calcium mobilisation (possibly via stretch-activated ion channels) seem
to be required to facilitate the focal adhesion and cytoskeletal response to mechanical
strain. It would appear therefore, the ion flux and cytoskeletal based paradigms may
not be mutually exclusive alternatives. The correct paradigm is likely to contain
elements of both.
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2.5.10. Regulation of transcription factor activation and gene expression by
mechanical forces in mesangial cells
Cyclic strain has been demonstrated to activate protein kinase C, increase
intracellular calcium concentrations and induce tyrosine kinase phosphorylation of
focal adhesion plaque proteins in mesangial cells. Stimulation of resting mesangial
cells by serum or vasoconstrictors results in a rapid and transient expression of the
protooncogenes c-fos and zif 268/egr-l (167). Akai et al have demonstrated
stretch/relaxation induced-expression of these protooncogenes, as well as the
mitogen-inducible cyclooxygenase (COX-2), in cultured rat mesangial cells (123).
The induction of these immediate early genes was preceded by activation of protein
kinase C (PKC) and calcium influx. By 24 hours of cyclical stretch/relaxation, PKC
activity had returned to basal levels and its distribution was similar to that in
unstimulated cells. Inhibition of PKC had a profound inhibitory effect on subsequent
stretch/relaxation induced gene expression. Stimulating the mesangial cells in
medium deficient in calcium also diminished protooncogene production. Taken
together the results suggest an important role for both PKC and calcium dependent
mechanisms in mesangial cell responses to mechanical strain. In addition to protein
kinase C activation and calcium influx, stimuli that lead to c-fos induction, also
require activation ofmitogen activated protein (MAP) kinase pathways. Of the three
MAP kinase pathways described in mammalian cells, work from Ingram et al. has
revealed only ERK 1/2 and p38 MAPK are activated in stretched mesangial cells
(168).
202
2.6. Influence of cyclic mechanical strain on glomerular endothelial and
mesangial cell activation in vitro
2.6.1. Introduction
How increased biomechanical forces occuring in glomerular hypertension, in
particular cyclic stretch-relaxation, are translated into glomerular injury, and,
ultimately, glomerulosclerosis have not been fully elucidated. Increased
intraglomerular pressure promotes glomerular expansion and, it has become widely
accepted, compliant stretching of resident glomerular cells. In addition, the pre-
glomerular dilatation that characterises a wide range of renal diseases facilitates the
delivery of a greater fraction of the systemic pressure, normal or elevated, to
glomerular capillaries. In many models of progressive renal disease such as the
remnant and diabetic kidney, autoregulatory glomerular protection is impaired and
marked augmentation of the moment to moment variations in pressure occurs within
the glomerulus (69). This in turn results in wide swings in glomerular volume, which
can be further exacerbated by the systemic hypertension that often co-exists with
renal disease. In vitro studies have provided evidence for the involvement of
increased cyclic mesangial cell stretch in the sclerotic processes of glomerular injury
(155, 159). Evidence has also been presented which suggests that leukocyte
infiltration of the glomerulus, an event critical to the pathogenesis of inflammatory-
based glomerular diseases, may play a role in the development of glomerulosclerosis
(149, 151). The importance of mechanical stretch, however, as a putative pro¬
inflammatory stimulus capable of the modulation of immune mediator expression
and leukocyte trafficking determinants within the glomerulus, has not yet been
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examined. The aim of this study was to examine the influence of cyclic mechanical
strain on glomerular endothelial and mesangial cell activation in vitro.
2.6.2. Materials and Methods
Cell Culture
All cell culture reagents were obtained from Gibco Life Technologies (Paisley,
Scotland) unless otherwise stated. SV40 transformed human mesangial cells (tHMC)
(169) were a kind gift from Dr. Ann McGinty. These cells were routinely cultured in
RPMI 1640 (BioWhitaker, Maryland, USA), supplemented with 5% FCS, 100 U/ml
penicillin and 100 pg/ml streptomycin.
Transformed rat glomerular endothelial cells (RGEC) were a generous gift from Dr.
Harry Holthofer and have been characterised previously (170). These cells were
routinely cultured in Dulbecco's Modified Eagle's Medium (DMEM) containing L-
alanyl-L-glutamine, sodium pyruvate, 1000 mg/L glucose and pyridoxine and
supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin and
100 pg/ml streptomycin.
Application ofCyclic Mechanical Stretch to tHMC and RGEC
tHMC (6x105 cells / well) were seeded on elastin-coated, flexible and rigid based six-
well plates, (Flex I and II plates respectively, FlexerCell, McKeesport, PA, USA).
Growth media was replaced with RPMI, containing 0.5% FCS 1 Hr prior to
application of cyclical mechanical stretch.
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RGEC were seeded on to on collagen-coated, flexible and rigid based six-well plates,
(Flex I and II plates respectively, FlexerCell, McKeesport, PA, USA). Prior to
experiments RGEC were not rendered quiescent, since they were found to detach
under conditions of serum restriction.
Stretch was induced using the Flexercell Strain Unit (FX-2000). This instrument,
described in detail in section 2.3.1, provides precisely timed, negative pressure cycles
of controlled magnitude, deforming the base of the culture plate and stretching the cells
growing on the upper surface of the well. Previous work from Riser et al has shown
microdissected rat glomerular volume to increase by 17% over a pathophysiological
intraglomerular pressure range likely to occur in vivo in the setting of glomerular
hypertension (155). Thus to mimic conditions of cyclical pulsatile strain present in the
glomerulus in hyperfiltration states, we exposed the cultured tHMC and RGEC to
continuous cycles of stretch/relaxation at a rate of 60 cycles per minute (using alternate
cycles of 0.5 seconds stretch followed by 0.5 seconds of relaxation) at a vacuum
pressure of-15 kPa to induce maximal elongation of 17%.
Northern Blot Analysis and RT-PCR
Total cellular RNA was isolated using Trizol reagent according to the manufacturer's
instructions. Total RNA (5pg) from tHMC was subjected to Northern blot analysis for
fibronectin expression exactly as described previously (171). Product quantification
was achieved by normalisation to GAPDH, by means of phosphorimaging. Total RNA
(2pg) (tHMC and RGEC) was treated with DNase I and 01igo(dt)i2-i8 was then used to
generate first strand cDNA. Reverse transcription was carried out using Superscript II
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RNase H. Sequence specific primer pairs were either obtained from Biosource









PI= Primer 1 P2= Primer 2
Chemokines
MCP-1 60 279




P1 5'-CAG AAA TAC AGC AAC AAT TCC TGG 3'
P2 5'-TTG CAG TGT GTT ATC CGT GCT GTC 3'
CTGF 58 348
P1 5'-GGT TAC CAA TGA CAA CGC CT-3'
92 5'- AAG ATG TCA TTG TCT CCG GG-3'
IL-1 p 60 331
P1 5'-CTT CAT CTT TGA AGA AGA ACC TAT-3'
P2 5'-AAT TTT TGG GAT CTA CAC TCT CCA-3'
TNF-a 60 325
P1 5'-CAG AGG GAA GAG TTC CCC AG-3'
92 5'-CCT TGG TCT GGT AGG AGA CG-3'
IFN-y 60 510
P1 5'-ATG AAA TAT ACA AGT TAT ATC TTG GCT TT-3'
P2 5'-GAT GCT CTT CGA CCT CGA AAC AGC AT-3'
IL-6 60 501 Obtained from BioSource Int. CA, USA
Chemokine Receptors1
CCR1 56 327
P1 5'-ACC TGC AGC CTT CAC TTT CCT CAC-3'
P2 5 -GGC GAT CAC CTC CGT CAC TTG-3'
CCR2 56 255
P1 5-CCA ACT CCT GCC TCC GCT CTA-3'
P2 5-CCG CCA AAA TAA CCG ATG TGA TAC-3'
CXCR2 57 385
P1 5-CCG GGC GTG GTG GTG AG-3'
P2 5'-TCT GCC TTT TGG GTC TTG TGA ATA-3'
GAPDH
GAPDH 60 495
P1 5'- ACC ACA GTC CAT GCC ATC AC-3'
92 5'- TCC ACC ACC CTG TTG CTG TA-3'
1. Reference (100)
Table 2.4. Human primer sequences and product sizes.
Amplification was as previously described, typically 94°C for 3 minutes; 35-40 cycles
of 94°C for 30 seconds (denaturing), 56°C-60°C for 1 minute (annealing) and 72°C for
1 minute (extension); followed by a final extension step of 72°C for 7 minutes. cDNA
samples were subjected to parallel PCR reactions with primers for GAPDH to control
for equivalency of loading. The presence of genomic DNA was determined by control
reactions in which amplification was conducted in complete reaction mixture lacking
template cDNA or with RNA samples from RT reactions carried out in the absence of
Superscript II. PCR products were visualised by ethidium bromide staining following
electrophoresis on 1.2% agarose gels. Subsequent quantification for each gene studied
206
in comparison to the GAPDH loading control was conducted using the GelWorks 1D









Pl= Primer 1 P2= Primer 2
Adhesion Molecules
ICAM-1 60 600
P1 5-TTC TGC CAC CAT CAC TGT GT-3'
P2 5'-TTC TCC ATC TCC AGG GTC TG-3'
VCAM-1 60 451
P1 5-GAC CTG TCA GCG AAG GAA AC-3'
P2 5'-TGA GCA GGT CAG GTT CAC AG-3'
Chemokines
GRO-a 60 180
P1 5'-AGA CAG TGG CAG GGA TTC AC-3'
P2 5'-ACT TGG GGA CAC CCT TTA GC-3'
Cytokines
TGFp 60 552
P1 5'- GTC AAC TGT GGA GCA ACA CG-3'
P2 5'-TGG TTG TAG AGG GCA AGG AC -3'
Chemokine Receptors
CCR1 60 503
P1 5'- AAA CCT ACC CCA CAA CCA CA-3'
P2 5-CTG GGC CTT GAA AAA GCA TA -3'
CCR2 60 350
P1 5'-TTT GAT CCT GCC CCT ACT TG-3'
P2 5-TTT TGG CAA TGT GCT TTC TG-3'
CXCR2 60 197
P1 5-AGT TCT GAC CCG CCC TTT AC-3'
P2 5'-GCC AGG TTC AGC AGG TAG AC-3'
GAPDH
GAPDH 60 495
P1 5'- ACC ACA GTC CAT GCC ATC AC-3'
P2 5'- TCC ACC ACC CTG TTG CTG TA-3'
Table 2.5 Rat primer sequences and product sizes.
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2.6.3. Results and discussion
In order to validate the conditions chosen for cyclic mechanical stretch in the current
study, tHMC were subjected to a maximum elongation of 17% using alternate 0.5 s
cycles of stretch and relaxation for 24, 48 and 72 Hr. Total cellular RNA was then
isolated and subjected to Northern blot analysis using a cDNA probe for fibronectin,
a gene previously shown to be upregulated in mesangial cells in response to this
stimulus (159). As can be seen (Fig. 2.17), under these conditions of cyclic
mechanical stretch fibronectin expression was increased in tHMC at 24, 48 and 72
Hr (1.78, 1.82 and 1.61 fold over control, respectively).
Mesangial cell expression of the cytokine TGF-P has also been shown increase in
response to cyclic strain. In the current study, therefore, expression of this cytokine
in tHMC following exposure to cyclic strain was examined. For this and subsequent
studies, total cellular RNA was isolated and subjected to RT-PCR. mRNA levels for
this species were increased by 48 and 72 hours exposure to cyclic mechanical stretch
(2.0 and 2.8 fold/basal respectively) (Fig 2.18). The finding that two stretch
responsive genes, fibronectin and TGF-p, were upregulated in tHMC in response to
cyclic mechanical stretch validated the experimental parameters chosen for the
current study.
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Figure 2.17 Fibronectin expression is increased in tHMC cells in response to cyclic
strain.
Expression of fibronectin under basal conditions is apparent, with increases in mRNA for this species
occuring following exposure to 24, 48 and 72 hours of mechanical strain. Result shown is
representative of three separate experiments.
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Figure 2.18 TGF-(3 expression is increased in tHMC in response to cyclic strain
Basal expression of TGF-p is apparent in tHMC with increases in mRNA for this cytokine occuring in
response to 48 and 72 hours of cyclic strain. Result shown is representative of three separate
experiments (Appendix IB).
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ECM accumulation is the principle pathognomic hallmark of glomerulosclerosis. The
findings presented above are consistent with the hypothesis that glomerular
hypertension, via increases in glomerular expansion and mesangial stretch, is a
profibrotic stimulus. The induction of TGF-P and its subsequent actions in an
autocrine/paracrine manner enhance ECM synthesis and deposition by mesangial
cells and, in agreement with these observations, increases in TGF-P expression have
been demonstrated in various forms of proliferative glomerulonephritis. The complex
actions of this cytokine are discussed in detail in section 3.5.1 but it has been
suggested that in the context of glomerulosclerosis the pro-fibrogenic effects of this
cytokine, rather than its anti-inflammatory properties, predominate.
Expression of the cytokine connective tissue growth factor (CTGF) is potently
induced by TGF-P and is a putative downstream mediator of TGF-p action on
mesangial cells and fibroblasts, where it stimulates synthesis ofECM via increases in
collagen type 1 and fibronectin production (172). Our group has recently
demonstrated that high glucose stimulates mesangial CTGF expression in vitro by
TGF-P- and protein kinase C-dependent pathways (173). Moreover, glomerular
CTGF expression is elevated in steptozotocin-induced diabetes (174). On this basis,
it was speculated that CTGF may be a mediator of TGF-P-driven matrix production
in diabetic glomerulosclerosis The demonstration that CTGF mRNA is upregulated
in several human glomerulopathies suggests that CTGF may also be an important
stimulus for glomerulosclerosis in other forms of progressive renal disease (175).
Induction of CTGF (mRNA and protein) in rat glomeruli has been demonstrated at 8
and 12 weeks post-renal ablation (a model of glomerular hyperfiltration), while
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studies in vitro have demonstrated increases in mesangial CTGF expression and
secretion in response to the cytokines IL-ip, IL-4, TNF-a and TGF-(3 (176).
Given the evidence supporting a role for CTGF in the pathogenesis of
glomerulosclerosis, the influence of cyclic mechanical strain on expression of this
species in tHMC was examined. Although the expression of this mediator was not
increased following 24 hours of cyclic strain, dramatic elevations in mRNA do occur
in response to 48 and 72 hours of this stimulus (Fig 2.19). Strain-induced CTGF
expression in primary human mesangial cells has recently been demonstrated in our
laboratory (Gupta et ah, unpublished observations) and by other investigators (177).
The increases in CTGF expression at 48 and 72 hours occur in tandem with strain-
induced increases in TGF-P expression; work is ongoing to establish whether these
effects are mediated by TGF-p. These results provide evidence that increased
biomechanical forces occuring in the setting of glomerular hypertension could
potentially, via increases in CTGF, result in the ECM accumulation characteristic of
glomerulosclerosis.
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Figure 2.19 CTGF expression in tHMC is increased in tHMC following cyclic strain.
Basal expression of CTGF is apparent with increases in mRNA levels for this species occuring in
response to 48 and 72 hours of cyclic strain. Result shown is representative of three separate
experiments (Appendix IB).
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The glomerular and interstitial infiltration of leukocytes is a common phenomenon
found in most renal diseases, independent of whether they are immune or non¬
immune in origin. In the scenario of glomerular hypertension, leukocyte infiltration,
predominantly macrophages, has been demonstrated in experimental models of
hyperfiltration and in certain human renal diseases which progress to
glomerulosclerosis (section 2.5). The role of these cells, however, in the development
of human glomerulosclerosis is still unknown. Conditions that determine the cellular
infiltrate at the site of injury include the local production and release of chemokines
in addition to the activation of both infiltrating inflammatory cells and resident renal
cells. A role for chemokines in renal diseases has been suggested in experimental
animal models where chemokine mRNA is increased in timely concordance with
macrophage infiltration (e.g, elevated MCP-1 in anti-Thy 1 nephritis and nephrotoxic
nephritis) (178, 179). Furthermore, in human kidney disease, the expression of
various chemokines in biopsy specimens at both mRNA and protein level (MCP-1,
RANTES, IL-8) correlates with immune cell infiltration (180).
It is apparent that mesangial cells, as discussed in section 2.5, rather than being a
passive target for the action of infiltrating cells, are themselves important participants
in glomerular injury. Indeed studies in vitro have demonstrated the upregulation of
mesangial cell adhesion molecules and their elaboration of cytokines/chemokines in
response to various pro-inflammatory stimuli. On the basis that cyclic strain is a
putative pro-inflammatory stimulus, the expression of the chemokines IL-8,
RANTES and MCP-1 in tHMC in response to this stimulus was examined.
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Expression of IL-8 is reduced following 24 and 48 hours of cyclic mechanical stretch
(with levels in stretched cells decreasing by 1.8 and 2.4 times, respectively as
compared to control levels)(Fig. 2.20). In contrast, RANTES expression was not
detected in tHMC under basal conditions nor was this gene upregulated in response
to cyclic strain. Modulation of the expression of the chemokine MCP-1 in these cells
was also examined in view of the observation that cyclic strain is a positive
modulator of MCP-1 expression in endothelial cells. Consistent results concerning
the effects of cyclic strain on MCP-1 mRNA levels in tHMC proved elusive (data not
shown). However, the reasons for this variability remain unclear.
IL-8 and its related C-X-C chemokines were originally thought to be predominantly
chemotactic for neutrophils. A recent study has demonstrated, however, that IL-8 is a
potent trigger for firm adhesion of monocytes to vascular endothelium expressing
cell adhesion molecules under flow conditions. Cyclic strain has been shown to
upregulate the expression of this chemokine in ECV-304 cells (section 2.3) and
endothelial cells. It was somewhat unexpected, therefore, that given these responses
and the putative role of glomerular monocyte/macrophage infiltration in glomerular
hypertension-induced glomerulosclerosis, that exposure of tHMC to cyclic
mechanical strain negatively modulated expression of this chemokine.
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Figure 2.20 IL-8 expression in tHMC is decreased following cyclic strain.
Basal expression of IL-8 is apparent with decreases in mRNA levels for this chemokine occuring in
response to 24 and 48 (but not 72) hours of cyclic strain. Result shown is representative of three
separate experiments (Appendix IB).
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Mesangial cell production of IL-8 occurs in response to TNF-a and IL1-P in vitro
and increased IL-8 expression has been demonstrated in certain experimental and
human glomerulnephritides (181). Because of emerging evidence concerning the
expression of chemokine receptors on many non-immune cells, it is becoming
apparent that chemokines have many effects in addition to the attraction of
leukocytes (section 1.2.3). IL-8, for example, has been shown to promote migration
and proliferation of endothelial cells and VSMC in vitro, and promotes angiogenesis
in vivo. No such effects on mesangial cells have been demonstrated however, and
studies to date have focused on the chemotactic role of IL-8 in the various forms of
immune-based renal diseases. The constitutive expression of this chemokine in
tHMC is intriguing and it may be speculated that the down-regulation of its
expression in response to cyclic strain represents a defence mechanism which
protects the glomeruli from further injury by limiting monocyte infiltration.
Alternatively, it may be that IL-8 exerts a specific and possibly non-chemotactic role
in the kidney thereby explaining the apparently counterintuitive findings presented
here.
IL-ip and IL-6 were expressed constitutively in tHMC but levels were unchanged
following 24, 48 and 72 hours of cyclic mechanical strain. mRNA for the pro¬
inflammatory cytokines TNF-a and IFN-y was not present in these cells under basal
conditions, nor was expression of these species induced by cyclic strain at any time
point studied (data not shown). These results concur with those of a previous study in
which no changes in TNF-a and IL-lp expression were documented following
exposure of rat mesangial cells to cyclic mechanical stretch (182). Mesangial cell
production of IL-ip and IL-6 in response to pro-inflammatory stimuli has been
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demonstrated in vitro and evidence suggests that these cytokines, acting in an
autocrine way, promote the mesangial proliferation that is characteristic of various
forms of glomerulonephritis (183). In addition, cytokine-modulated
cytokine/chemokine/adhesion molecule expression in mesangial cells both promotes
and sustains the inflammatory process in these diseases. In the context of the current
study however it appears that differential responses in cytokine mRNA expression
occur in tHMC exposed to cyclic mechanical stretch. Elevations in TGF-P and CTGF
mRNA are not paralleled by increases in expression of the pro-inflammatory
cytokines or IL-6. How these differential responses are mediated is as yet unknown.
Interestingly, studies in ECV-304 cells (section 2.4) and endothelial cells (122) were
also unable to demonstrate changes in expression of IL-ip, IL-6, TNF-a and IFN-y
in response to cyclic strain.
In contrast to the ample information concerning chemokines and renal injury, so far
little is known regarding the expression and distribution of chemokine receptors in
normal and diseased kidneys. In addition the mechanisms regulating expression of
these receptors are not well-defined. It has been established, however, that in
leukocytes (PMN and monocytes) and endothelial cells chemokine receptor
expression can be modulated by pro-inflammatory cytokines in vitro. Expression of
the receptors CCR1, CCR2, CCR3 and CCR5 has been detected in normal murine
kidney, and levels are upregulated in animals with anti-GBM nephritis. Studies in
human mesangial cells have shown that while there is no expression of the
chemokine receptors CCR1-CCR8 under basal conditions, mRNA for CCR1 and
CCR7 could be induced by pro-inflammatory cytokines (184).
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Basal expression of the chemokine receptors CCR1, CCR2 and CXCR2 in tHMC
was therefore investigated in the current study. In addition, the influence of
mechanical strain on receptor expression levels was examined. In order to provide a
positive control for these experiments, neutrophil and mononuclear cells were
isolated from human peripheral blood using standard techniques and total RNA
isolated as described in the preceding experimental section. CCR1 and CCR2 are
expressed by monocyte/macrophages, while CXCR2 is expressed by neutrophils.
These controls were used in the relevant PCR reactions. CCR1, CCR2 and CXCR2
were not expressed in tHMC cells, nor was mRNA for these species induced by
cyclic strain (Fig 2.21).
Evidence has been presented by other investigators in our group which indicates that
the strain-induced modulation of mesangial protein expression may occur
independently of transcriptional and translational mechanisms. These studies have
demonstrated that while levels of VCAM-1 and ICAM-1 mRNA are not increased in
response to cyclic mechanical stretch, surface expression of the latter is increased
significantly (as measured by FACS analysis) following exposure to 24, 48 and 72
hours of cyclic strain (185). Another study has suggested that the increase in TGF-P
secretion that occurs when mesangial cells are exposed to cyclic mechanical strain in
conjunction with a high glucose environment may occur via non-transcriptional
mechanisms (182).
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Figure 2.21 Chemokine receptor expression in tHMC cells.
mRNA for the chemokine receptors CCR1, CCR2 and CXCR2 are not expressed on tHMC mesangial
cells under basal conditions or in response to 24, 48 and 72 hours of cyclic strain. Human monocytes
served as positive controls for CCR1 and CCR2 while neutrophils served as CXCR2 positive control.
Result shown is representative of two separate experiments.
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This establishes a precedent that stretch-induced increases in protein surface
expression/secretion may not in fact be due to increased expression of target genes.
It will be necessary, therefore, to investigate whether the surface expression of
leukocyte trafficking determinants such as the chemokine receptors are increased in
response to cyclic mechanical strain in a manner independent of
trancription/translation.
Glomerular hypertension, in addition to causing increased mesangial cell stretch,
also results in changes in the cyclic mechanical forces experienced by the
endothelium lining the glomerular capillaries. The effects of cyclic strain on the
modulation of macrovascular endothelial gene expression in vitro are well-
established (section 2.3), however no data exists concerning the responses of
microvascular endothelial cells such as glomerular endothelial cells to this stimulus.
Endothelial activation is pivotal in the pathogenesis of many disease processes and
within the glomerulus these are the first obligate cells to come into contact with
circulating leukocytes. The influence of cyclic mechanical stretch on the expression
of leukocyte trafficking determinants and immune mediators in a rat glomerular
endothelial cell line was therefore examined.
VCAM-1, but not ICAM-1, was expressed at low levels in RGEC under basal
conditions. Expression levels of both adhesion molecules remained unchanged
following 24 and 48 hours of cyclic strain, in contrast to TNF-a stimulation which
resulted in increased mRNA levels for both species. Similarly mRNA for the
chemokine GRO-a (the rat homologue of IL-8) and TGF-(3, although upregulated in
TNF-a-treated RGEC, were not detected under basal conditions and remained
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unchanged following cyclic strain. The chemokine receptors CCR1, CCR2 and
CXCR2 were not present constitutively or in response to 24 and 48 hours of
mechanical strain. (Data not shown).
Thus, while the pro-inflammatory cytokine TNF-a elicits the characteristic features
of endothelial activation in RGEC (increased expression of cell adhesion molecules,
cytokines and chemokines), no such responses however could be demonstrated
following exposure of these cells to cyclic mechanical strain. This is in contrast with
our results presented here in tHMC, primary human mesangial cells and ECV-304,
and indeed with that of previous investigators using macrovascular endothelial cells.
The reason for the absence of strain-induced responses in RGEC is as yet uncertain.
In the current study RGEC were plated onto collagen as elastin matrices did not
sustain cell growth for these experiments. Prevous studies using other cell types have
demonstrated that responses to mechanical stretch can be both integrin dependent
and matrix specific (186). It would be of interest therefore to examine the response of
RGEC grown on other types ofmatrix to mechanical stretch.
In summary, then, exposure of mesangial cells to cyclic mechanical strain results in
increased expression of the prosclerotic mediators TGF-(3 and CTGF, supporting a
role for this stimulus in the ECM accumulation characteristic of glomerulosclerosis.
No such increases, however, occured in mesangial cell expression of cytokine,
chemokine or chemokine receptors in response to mechanical strain. Indeed mRNA
levels for the chemokine IL-8 appeared to decrease following exposure of cells to
this stimulus. ICAM-1 however, while not increased at mRNA level, demonstrates
increased mesangial cell surface expression in response to cyclic mechanical strain
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indicating that stretch-induced increases in protein surface expression/secretion may
not in fact be due to increased expression of target genes. Work is ongoing to
establish whether the modulation of other mesangial cell leukocyte trafficking
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3.1. Overview: mechanisms of the resolution of vascular disease
3.1.1. Evidence that vascular disease is reversible
Many acute inflammatory processes within the vasculature resolve without the need
for specific immunosuppressive therapy. Infections, for example, once treated with
appropriate antimicrobial therapy to eliminate microorganisms, are, in general,
quickly acompanied by a return of tissue architecture and endothelial function to
premorbid levels. The same is true of certain inflammatory conditions occuring in the
absence of infection. The small vessel vasculitis, Henoch-Schonlein purpura (section
1.3.2) has an excellent prognosis with most patients recovering completely, and in
some cases without the need for therapy. Similarly, in eclampsia there is no specific
treatment, apart from delivery of the baby and supportive measures to treat blood
pressure and seizures and while the maternal mortality continues to be significant,
the multi-system abnormalities that accompany this disease quickly resolve post¬
partum as endothelial structure and function return to normal.
There is some evidence too for reversibility in chronic inflammatory processes such
as atherosclerosis. In animal models, a low cholesterol diet results in significant
plaque regression. Studies in human atherosclerosis have tended to combine a low
cholesterol diet with drug therapy such as inhibitors of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase (statins) to lower cholesterol. It is now
recognised that statins have, in addition to their cholesterol lowering properties, anti¬
thrombotic and anti-atherogenic effects that are independent of their lowering of
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plasma-LDL (1). The regression of atherosclerosis in such trials is well-documented
and would appear to be attributable to the various actions of these drugs and not
endogenous anti-inflammatory mechanisms. A number of trials have attempted to
assess the role of lifestyle modifications (smoking cessation, low cholesterol diet,
exercise) in the progression/regression of atherosclerosis (2). Although the numbers
of patients in these trials were small, these modifications, in addition to delaying
progression of atherosclerosis, also resulted in significant regression as measured by
coronary angiography. Removal of the injurious stimuli, therefore, appeared to
promote reversal of atheroma and vessel healing, which in the absence of
pharmacological intervention, is likely to be due to endogenous recovery
mechanisms. In aggregate, these observations in acute and chronic vascular diseases
suggest the existence of endogenous systems which actively restore vascular tone,
thrombogenicity and adhesiveness for leukocytes to normal.
3.1.2. Mechanisms of resolution
It is now apparent that the resolution phase of such inflammatory processes, like the
initiation phase, is a dynamic process in which a large number of anti-inflammatory
molecules are elaborated under well-ordered programs that act as "braking signals"
for leukocyte recruitment and subsequent tissue injury and promote healing and
repair.
These so-called "defence" molecules counteract the inflammatory response at all
levels, extracellular, cell surface and intracellular. Some have very specific targets
e.g. cytokine inhibitors, proteinase inhibitors, complement regulatory proteins, anti¬
thrombotic molecules, antioxidants and cyclin kinase inhibitors. Conversely
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mediators such as the anti-inflammatory cytokines, anti-inflammatory eicosanoids,
glucocorticoids, heparin, adenosine and nitric oxide have a wide range of targets.
Some of these molecules are expressed constitutively, while others are inducible in
response to a local inflammatory milieu. These various mediators and their
mechanisms of action are reviewed extensively elsewhere (3). Of particular
relevance to the work described here are the lipoxins, a group of rapid-acting anti¬
inflammatory eicosanoids will be discussed in detail in section 3.2. In addition, the
anti-inflammatory cytokines and endogenous inhibitors of cytokine bioactivity are
reviewed in section 3.5. Particular emphasis will be placed on a recently identified
family of proteins, the suppressors of cytokine signalling (SOCS) which effectively
act as cytokine inhibitors. The actions of the SOCS proteins and the evidence
supporting a role for them in the modulation of cytokine bioactivity in health and
disease are examined in section 3.6.
In summary then, the observation that many inflammatory reactions resolve
spontaneously indicates the presence of endogenous 'braking systems' that 'turn-off
leukocyte-mediated inflammation and limit tissue injury. Defining the molecular
basis for these various anti-inflammatory mediators is critical to the further
understanding of the inflammatory response in addition to the possibility of
exploiting their activities for therapeutic gain.
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3.2. Lipoxins: putative braking signals for acute polymorphonuclear
leukocyte (PMN)-mediated vascular injury
Recruitment ofpolymorphonuclear leukocytes (PMN) from blood to an extravascular
inflammatory focus is an essential feature of host defense against bacterial and
fungal infection. PMN recruitment from blood vessel lumen into target tissue occurs
via the classical paradigm of leukocyte trafficking described in previous sections.
Having reached the target tissue, PMN eliminate invading microorganisms by
phagocytosis and subsequent release of free radicals and lytic enzymes into
phagolysomes. Inappropriate leukocyte trafficking and activation, such as occurs in
the various phenotypes described in section 1.3, can result in extensive tissue damage
and organ dysfunction in the absence of infection. Many inflammatory reactions
resolve spontaneously suggesting that endogenous 'braking systems' exist that 'turn-
off leukocyte-mediated inflammation and limit tissue injury (4). Evidence is
reviewed that the lipoxins serve this purpose.
3.2.1. Lipoxin biosynthesis in vitro
The lipoxins (LX) are eicosanoids that carry a trihydroxytetraene structure and are
structurally and functionally distinct from other families of arachidonic acid-derived
bioactive products. In suspensions of activated granulocytes in vitro, the sequential
actions of 15- and 5-lipoxygenase on arachidonic acid yields 5,6-epoxytetraene, an
unstable epoxide intermediate, which is converted by epoxide hydrolases to the two
major bioactive lipoxins LXA4 and LXB4 (5, 6). The latter are positional isomers: the
structure of LXA4 being 5S, 6R, 15S-trihydroxy-7,9,13 trans-11-cis-eicosatetraenoic
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acid and the structure of LXB4 being 55,14/?, 155 hydroxy-6,10,12-trans-8-cis-
eicosatetraenoic acid (7) (Fig. 3.1).




Lipoxin biosynthesis is augmented greatly in vitro if granulocytes are activated in the
presence of platelets (8-12). In this setting, platelets convert PMN-derived LTA4 to
5,6-epoxytetraene through the action of platelet 12-lipoxygenase. The latter enzyme
functions as a 15-lipoxygenase (LX synthase) when its substrate is LTA4.
Intriguingly, aspirin triggers production of lipoxin 5-epimers during coincubations of
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PMN and cytokine-activated endothelial cells in vitro (13, 14). When acetylated by
aspirin, cyclooxygenase 2 (COX-2) retains the enzymatic capacity to convert
arachidonic acid to 15(i?)-HETE. During cell-cell interactions, some endothelial-
derived 15(7?)-HETE is converted by PMN 5-lipoxygenase to either 15 epi-LXA4 or
15-epi LXB4 which display properties similar to native lipoxins (14). (see below).
Lipoxin production is boosted in vitro by several mechanisms that may be relevant to
lipoxin generation in human disease. Cell-cell adhesion through P-selectin promotes
transcellular biosynthesis of lipoxins during PMN-platelet interaction probably by
enhancing the transfer of arachidonate intermediates between different cell-types and
by priming lipoxygenase pathways (15, 16). Disruption of platelet cell membranes,
which occurs over time within an inflammatory or thrombotic microenvironment,
also enhances lipoxin production (10). The balance of lipoximleukotriene generation
during PMN-platelet interaction is also influenced by local redox potential.
Specifically, a fall in cellular levels of reduced glutathione, as occurs during PMN-
mediated or ischaemic injury, augments lipoxin levels at the expense of leukotriene
generation (9).
Finally, 'in-vitro' experiments predict that cytokines are important local regulators
of lipoxin biosynthesis. During PMN-platelets interactions, transcellular lipoxin
generation is also boosted by GM-CSF and PDGF. IL-4 and IL-13 induce 15-
lipoxygenase expression in alveolar macrophages, granulocyte, monocytes and
epithelial cells, activities that may promote transcellular lipoxin generation (17, 18).
Of note, these T„-2 derived cytokines have been implicated as negative regulators of
the inflammatory response.
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The pathways for lipoxin metabolism are still being defined. Lipoxins can be
metabolised rapidly in vitro through either dehydrogenation or co oxidation (19, 20).
It is likely that the former represents the major pathway for lipoxin degradation in
vivo. With a view to probing the bioactions of lipoxins further and to possible drug
design, lipoxin analogues have been designed and synthesized which are resistant to
degradation and retain the biological activity of native lipoxins (21, 22). These have
shown promising results in preliminary studies in experimental animal models of
acute inflammation.
3.2.2. Lipoxin generation in vivo
Lipoxins have been detected in tissue, blood or body fluids in a variety of human
diseases including asthma, glomerulonephritis, rheumatoid arthritis, psoriasis,
pneumonia, post-coronary angioplasty, sarcoidosis, and allergic rhinitis (7, 23, 24).
Interestingly, platelet-PMN transcellular pathways appear to be an important source
of lipoxin generation during renal glomerular inflammation (25) and after
angioplasty (24) in vivo confirming predictions from in vitro experiments. It is
likely that PMN also interact with other cell-types to generate lipoxins as
inflammation progresses and cytokines induce 15-lipoxygenase expression in
resident tissue cells (see above).
3.2.3. Lipoxins: potent modulators of leukocyte-endothelial cell adhesion
The spectrum of biological activities of lipoxins is still expanding. Lipoxins
attenuate many pro-inflammatory effects of leukotrienes and other mediators in vitro.
In particular, they inhibit PMN-endothelial cell adhesion, a critical step for PMN
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recruitment in vivo (26). The various leukocyte-endothelial adhesion molecules and
their corresponding ligands are discussed in detail in section 1.2.2.
Leukotrienes are established proinflammatory mediators and modulate PMN
trafficking, vascular permeability and blood flow (27). LTB4 is a potent stimulus for
PMN chemotaxis and PMN-endothelial cell adhesion supported by CD11/CD18
integrins. LTC4 and LTD4, in contrast to LTEf show limited bioactivity towards
human PMN, but act on smooth muscle cells to induce vasoconstriction and
bronchoconstriction. In addition, LTC4 and LTD4 trigger PMN-endothelial cell
adhesion in vitro by inducing formation of endothelial cell mediators that promote
PMN adhesion (e.g. platelet-activating factor) and by stimulating mobilization of P-
selectin to the cell surface (26, 28, 29). Mice transgenic for the LTB4 receptor have
demonstrated that over-expression of this receptor dramatically increases PMN
trafficking both to skin microabscesses and to lungs in a hindlimb tourniquet model
of second organ reperfusion injury (30). This was associated with selective increases
in the expression of 5-lipoxygenase and its product 5S-HETE in inflammatory
exudates, leading the authors to speculate that receptor overexpression amplifies pro¬
inflammatory circuits. In contrast, mice deficient in 5-lipoxygenase showed
diminished PMN accumulation in lungs, indicating the importance of both the LTB4
receptor and the 5-lipoxygenase enzyme in reperfusion-initiatiated PMN trafficking
to remote organs.
Lipoxins antagonise many of the actions of leukotrienes in vitro (see Table 3.1).
LXA4 and LXB4 themselves do not provoke chemotaxis, adhesion, degranulation or
free radical generation at biologically relevant concentrations (5). In contrast, LXA4
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and LXB4 inhibit LTB4-induced PMN chemotaxis and PMN-endothelial cell
adhesion supported by CD 11 /CD 18 integrin (26). LXA4 and LXB4 also attenuate
LTC4- and LTD4 -triggered endothelial hyperadhesiveness for PMN, at least in part
by inhibiting mobilisation of P-selectin from Weibel-Palade bodies to the endothelial
cell surface (26)(Fig 3.2). In addition, LXA4 can attenuate the contraction of smooth
muscle and mesangial cells produced by LTC4 and LTD4-induced vasoconstriction
(31,32).
Bioactivity modulated by lipoxins Lipoxin Stimulus Ref
Leukocytes
PMN chemotaxis lxa4, lxb4 LTB4, fMLP (33)
PMN endothelial cell adhesion lxa4, lxb4 LTB4 (not C5a, fMLP) (26)
PMN migration across endothelium lxa4, lxb4 LTB4 (not C5a, fMLP) (26)





PMN homotypic aggregation lxa4 fMLP (35)
Upregulation of CD11/CD18 lxa4 fMLP (35)
PMN margination and diapedesis lxa4 Topical LTB4 (34)
PMN infiltration of glomeruli lxa4 immune complex GN (15)
Endothelial Cells
P-selectin mobilization lxa4, lxb4 LTC3, LTD4 (not histamine, thrombin) (26)
Increased adhesiveness for PMN lxa4, lxb4 LTC4, LTD4 (not histamine, thrombin) (26)
Mesangial Cells
Mesangial Cell adhesiveness lxa4 ltd4 (27)
Mesangial Cell contractility lxa4 ltd4 (36)
Table 3.1. Some actions of lipoxins.
The 'anti-inflammatory' actions of lipoxins are not confined to leukotriene-triggered
responses. LXA4 also antagonises fMLP-induced PMN chemotaxis (33), eosinophil
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chemotaxis induced by platelet activating factor, (37) and IL-8 release from TNFa
primed colonic cell lines (38). In addition, lipoxins attenuate PMN transmigration
across epithelial monolayers activated by TNF a (34). It has also been demonstrated
that both LXA4 and aspirin triggered 15-epi-LXA4 inhibit the release of superoxide
anion and IL-ip from TNF-a-stimulated neutrophils in vitro (39). A recent study
from our group shows that LXA4 stimulates tissue factor (TF) activity in monocytes
and endothelial cells in vitro although the in vivo importance of LXA4 as a modulator
of TF-related vascular events during inflammation and thrombosis is still unclear
(40).
In keeping with in-vitro observations, LXA4 inhibits LTB4-induced PMN
margination and diapedesis in hamster cheek pouch model of the microcirculation
(41). In the mouse ear model of inflammation, epi-lipoxins and stable lipoxin
analogues inhibit PMN infiltration evoked by topical application of LTB4 (14).
Furthermore in the inflammatory murine air pouch model, a stable analogue of
lipoxin, 15R/S-methyl-LXA4t inhibits neutrophil recruitment. Interestingly this is
with associated a decline in MIP-2 and ILip and an increase in IL-4 production in
the pouch exudates (30). In mice transgenic for the LTB4 receptor, topical
application of lipoxin is protective in acute dermal inflammation, while intravenous
injection of aspirin-triggered 15-epi-lipoxin diminishes PMN trafficking in the lung
in a model of second organ reperfusion injury (39). Exposure of PMN to LXA4 ex
vivo attenuates their recruitment to inflamed renal glomeruli in the Con A/Ferritin
model of glomerulonephritis (15). Finally, defective LXA4 biosynthesis is associated
with exaggerated PMN infiltration in experimental immune complex-mediated




















Stimulus LTB, Stimulus LTB, Stimulus LTB,
Figure 3.2. Modulation of leukocyte trafficking by lipoxins.
Lipoxins attenuate (1) Chemotaxis (2) Selectin-mediated adhesion (3) Integrin-mediated
immobilisation.
3.2.4. Cellular mechanisms of lipoxin actions
The molecular basis for these lipoxin-evoked responses is still being elucidated.
PMN, monocytes, gastrointestinal epithelial cells, renal mesangial cells and
endothelia express high affinity binding sites for lipoxins (35, 38, 42). The cloning
and characterisation of these lipoxin receptors suggest that many are members of the
seven transmembrane spanning superfamily of G-protein coupled receptors. cDNA
cloning and subsequent sequence analysis of the human myeloid LXA4 receptor
reveals it to be homologous to members of the chemokine receptor superfamily
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which also includes the fMLP receptor and the recently cloned LTB4 receptor (14,
38). This PMN receptor has also been cloned from monocyte and epithelial cDNA
libraries (14).
Engagement of the monocyte and PMN LXA4 receptor causes mobilisation of
intracellular calcium, activation of phospholipases A2, C and D, and arachidonic acid
release. These responses are blunted by pertussis toxin (PTX) further supporting
involvement ofheptahelical G protein-coupled receptors (35, 42, 43). Downstream of
these signalling pathways are the mitogen activated protein (MAP) kinase cascades.
In response to extracellular stimuli, MAP kinases regulate the transcriptional activity
of several transcription factors, thereby initiating the expression of a variety of
immediate and delayed early response genes. Data from our laboratory has
demonstrated that in mesangial cells, LXA4 stimulates phosphorylation and
activation of specific MAP kinases in a PTX insensitive manner; in contrast, LTD4
activation of these pathways appears to be PTX sensitive (44). The structure and
function of the mesangial cell and endothelial receptors are under investigation. It
has been suggested that LXA4 attenuates the proinflammatory effects of LTD4 in
mesangial cells by acting as a partial agonist at an LTD4 binding site (36). To date
the LXB4 receptor has not been cloned. Pharmacological evidence suggests that it is
distinct from the LXA4 receptor (7).
In aggregate, these observations suggest that the leukotrienes and lipoxins are
notably distinct from other eicosanoids both in terms of their functional activities and
their cell signalling pathways. The homology of lipoxin receptors to chemokine
receptors is particularly interesting and suggests that the lipoxin/leukotriene
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pathways may have evolved prineipally to raodu,ate granulocyte traffickmg during
host defence.
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3.3. Mitogen-activated protein (MAP) kinases
Mitogen-activated protein kinases are serine-threonine protein kinases that, in
response to a diverse array of extracellular signals, initiate a variety of cell-signalling
outcomes. Five mammalian MAP kinase families have been identified to date, each
with distinct biological functions; extracellular signal related kinase (ERK) 1/2, p38
MAPK, c-Jun-N-terminal kinase (JNK), ERK3/4 and ERK5 (45). A common feature
of all MAP kinase isoforms is the requirement for phosphorylation of both threonine
and tyrosine regulatory sites by a specific upstream protein kinase for activation. The
basic assembly of MAP kinase pathways is a three-component module comprising
three kinases which establish a sequential activation pathway: MAP kinase kinase
kinase (MKKK), MAP kinase kinase (MKK) and MAP kinase. In response to
stimuli, this sequence is activated such that the ultimate activation of the tertiary
MAP kinase results in the phosphorylation of either stimulatory or inhibitory
transcription factor sites, thereby modulating the expression of a variety of
immediate and delayed early response genes. This, in addition to the phosphorylation
and regulation of cytosolic and nuclear targets, is critical in producing the various
cellular responses which typify MAP kinase activation including proliferation,
differentiation, adaptation to environmental stress and apoptosis (Fig 3.3).
3.3.1. ERK Pathway
There are five MAP kinases defined as ERK, however amino acid sequence
comparisons indicate that these proteins belong to different families ofMAP kinases.
Of this collective group known as ERK, ERK 1 and ERK 2 (44- and 42-kDa
isoforms respectively) are the most extensively studied. The other ERK are less well
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Figure 3.3. Overview MAP Kinase pathways (46).
by PKC isoforms, ERK 4 which is activated in response to nerve growth factor
(NGF) and EGF via a Ras-dependent pathway and the least known pathway, ERK 5,
which in response to oxidative stress/hyperosmolality/serum translocates from the
cytosol to the nucleus where it activates the transcription factor MEF2C which
induces expression of c-Jun (45). For the remainder of this discussion, however, the
term ERK will refer to ERK 1 and 2.
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Many different receptor types activate the ERK pathway. These include receptor
tyrosine kinases (which bind growth factors), cytokine receptors, G-protein coupled
receptors and the engagement and clustering of integrins. Ligation ofmany receptors
leads to activation of ERK through the activation of Ras (47). Ras in the GTP-bound
form binds to Raf 1 which functions as the activated MKKK in this pathway.
MKKKRafl in turn activates the MKKs, MEK 1 and 2, although these appear to be
differentially activated depending on cell type studied. These kinases then
phosphorylate and activate ERK. There have been some reports that ERK activation
can occur in the absence of Raf activation suggesting that other MKKK may function
in the ERK signalling modules. Upon activation, ERK phosphorylates substrate
proteins on serine or threonine residues within a proline-directed motif. The
cytoplasmic proteins known to be substrates for ERK include the S6 kinase p90rsk,
phospholipase A2 and several microtubule associated proteins (48). Following
activation ERK is also capable of translocation to the nucleus where it can result in
the phosphorylation of several transcription factors including Elk-1, Ets-1 c-Myc, c-
Jun, Sap la, Tal and signal transducer and activator of transcription (STAT) proteins.
Given these many diverse substrates, it is not surprising that the biological effects of
ERK activation are wide ranging. In cell culture systems however there is a good
evidence to support a role for ERK in cell proliferation, differentiation, regulation of
cell cycle activity and protection from apoptosis.
3.3.2. JNK pathway
The c-Jun-N-terminal kinase (JNK) is so named because of its ability to regulate c-
Jun transcriptional activity by phosphorylation of the N-terminal activating domain
(whereas ERK phosphorylates the inhibitory C-terminal site). JNK is activated by
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extracellular stress (UV-light, heat shock, osmolality), cytokines (TNF-a, IL-1) or
growth factors (45, 46). 10 different isoforms exist but to date a definitive analysis of
their expression patterns in vivo has not been carried out. While the pathways that
lead from cell stress to activation of this cascade remain largely uncharacterised, the
JNK response to extracellular ligands has been studied extensively. Activation of this
pathway can occur in response to stimulation of a variety of different receptor types
including the TNF receptor family, G-protein coupled receptors, tyrosine kinase
receptors and cytokine receptors. MKK 4 and MKK7 have been implicated in the
phosphorylation and activation of JNK. These kinases are in turn activated by several
MKKK (up to 10 have been demonstrated to act in the JNK signalling module).
Other signalling proteins that act as upstream activators of the JNK pathway are the
small GTP-binding proteins of the Rho and Rac family. In studies, for example, in
which mutation of the native genes results in constitutively active protein varients of
Rac and Cdc 42, JNK activation ensues. The JNK substrates identified to date are
exclusively transcription factors (in contrast to ERK which has substrates outside the
nucleus), and include c-Jun, ATF-2, Elk-1, p53, DPC4 and NFAT4. JNK activation
results in diverse responses depending on cell type, but evidence suggests that this
signalling pathway may exert anti-proliferative and pro-apoptotic effects in addition
to promoting T-cell activation.
3.3.3. p38 MAP kinase
This family consists of at least four different homologous proteins - p38 a, p, y and 5
(45). Once again p38 MAP kinase activation occurs in response to a variety of
stimuli - cellular stress (UV irradiation, osmotic shock, LPS), cytokine receptor
binding and G protein coupled receptors, and a similar ordered activation module
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exists. A number of MKKK and MKK have been implicated in the subsequent
activation ofp38 MAP kinase. (Fig 3.3).
Interestingly the MKKK Pak (also known as p21-activated kinase) can be activated
by Cdc 42 and Rac, G proteins which are also implicated in the upstream signalling
of the JNK pathway. Activated p38 MAP kinase phosphorylates a variety of
substrates. These include the transcription factors ATF2, Elk-1, Chop and Max. In
addition, p38 activation can result in the phosphorylation of small heat-shock
proteins. This MAP kinase pathway is important in the production of cytokines by
haematopoietic cells, IL-2 mediated cellular proliferation and promoting apoptosis.
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3.4. Differential effects of lipoxins on endothelial and mesangial cell MAP
kinase pathways
3.4.1. Introduction
The activation of the endothelium and its subsequent interaction with circulating
blood cells is a pivotal event in the pathophysiology of inflammation, allograft
rejection, atherosclerosis and thrombosis. The robust acute inflammatory response
which is initiated by endothelium:PMN interaction is typically self-limiting and
tissue architecture and function normally return to premorbid levels. These
observations suggest that the resolution phase of inflammation is a dynamic process
and that endogenous anti-inflammatory agents are elaborated that can act as "braking
signals" for leukocyte recruitment and subsequent tissue injury. The actions of
lipoxins in this regard are discussed in the preceding section (2.4). In brief, lipoxins
attenuate many pro-inflammatory effects of leukotrienes (and indeed other
mediators) in vitro. Moreover in vivo, they inhibit PMN-endothelial cell adhesion, a
critical step for PMN recruitment. Although, these effects appear to be regulated via
high affinity G protein coupled receptors, the more downstream cell signalling events
mediating these novel bioactions remain undefined. The neutrophil LXA4 receptor
has been previously shown to be coupled to phospholipase activation and increases
in intracellular calcium levels (35, 42). In mesangial cells, it has been suggested that
LXA4 attenuates the proinflammatory effects of LTD4 by acting as a partial agonist at
an LTD4 binding site (36) but it is not known whether this is the case for endothelial
cells. The structure of the endothelial cell LXA4 receptor and the sequence of events
following its engagement have not been elucidated. The aim of this study therefore
was to characterise the signal transduction events triggered by activation of
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endothelial lipoxin and leukotriene receptors, and specifically to examine whether
MAP kinase activation (section 3.3) occurred in response to these stimuli.
3.4.2. Materials and Methods
Cell Culture
ECV 304 cells have been previously characterised (49) and were obtained from the
EATCC (Cat no. 92091712). All cell culture reagents were obtained from Gibco Life
Technologies (Paisley, Scotland) unless otherwise stated. These cells were
maintained in Ml99 medium (Sigma, Dorset, England), supplemented with 1%
glutamine, 100 U/ml penicillin, 100 pg/ml streptomycin and 10% heat-inactivated
foetal calf serum. Cells were grown in 100 mm dishes and growth media was
replaced with Ml99, containing 0.5% FCS 48 hours prior to stimulation.
Cell Treatments
All materials were obtained from Sigma (Dorset, UK) unless otherwise stated. The
cells were stimulated with LTD4, LXA4, (Cascade, USA) alone or in combination at
10"7 M for the times indicated. Stimulations with phorbol 12-myristate-13-acetate
(PMA) (100 nM) and anisomycin (100 nM) were carried out in the relevant
experiments. The appropriate vehicle controls were included in all experiments.
Following stimulation the media was aspirated and the cells washed with ice cold
Dulbecco's PBS (without calcium or magnesium). Cells were lysed in 500 pi of ice
cold whole cell extract buffer (20 mM FIEPES, 75 mM NaCl, 2.5 mM MgCU, 0.1
mM EDTA, 0.05% Triton X-100, 0.5 mM dithiothreitol, 20 mM [^-glycerophosphate,
0.1 mM sodium orthovanadate, 2 pg/ml leupeptin, 100 pg/ml phenylmethylsulfoflyl
fluoride). Following incubation on ice for 5 minutes, lysates were scraped from each
257
dish and transferred to microfuge tubes. These samples were left at 4°C for a further
10 minutes and then centrifuged at 4°C at 20,000g for 10 minutes. Supernatants were
removed and stored at -20°C for further analysis.
Protein Determination
The protein concentration in each sample was determined using a Bradford Assay
(Bio-Rad, Hercules, CA). The absorbance of each sample was measured at a
wavelength of 595 nm (Ultraspec 3000, Pharmacia Biotech. Inc., Almeda, CA). A
standard curve was prepared using bovine serum albumin standards (0. 1, 2, 4, 6, 8,
10 pg/ml) and this was used to estimate the concentration of protein present in a
sample aliquot.
Western Blot Analysis
Lysates standardised for protein were mixed with 5X Laemmli buffer and heated for
5 minutes at 95°C. Typically 40 pg protein/sample was subjected to SDS-PAGE
using 4 and 10% acrylamide for stacking and resolving gels respectively. Protein was
electrotransferred to polyvinylidene difluoride (PVDF) membranes at 40 V for 4
hours or 10 V overnight. To confirm equivalence of both protein loading and
transfer, a strip of membrane was cut well above the expected location of the
phosphorylated proteins. This membrane was stained using Coomassie stain for 2
minutes, followed by Coomassie destain (50% methanol, 10% acetic acid) for 30
minutes and dried. The remaining membrane containing the proteins of interest was
washed with TTBS (Tris Buffered Saline, pH 7.6, 0.1% Tween-20) and blocked for 1
hour in blocking buffer (TTBS, pH 7.6, 5% nonfat dry milk [w/v]). An accepted
method of detecting phosphorylated, and hence active, MAP kinases involves
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immunoblotting using anti-phospho-MAP kinase antibodies. For the purposes of this
study, the membranes were probed with a primary antibody specific for either
phosphorylated ERK, p38 MAPK or JNK (New England Biolabs, MA, USA). The
membranes were incubated with the primary antibody at a dilution of 1:1000 in
TTBS, pFI 7.6, 5% Bovine Serum Albumin (w/v) overnight at 4°C. Following three
five minute washes in TTBS, incubation was carried out with goat anti-rabbit
alkaline phosphatase (Bio-Rad, Hercules, CA), at a dilution of 1:3000 in TTBS, pH
7.4. 3% nonfat dry milk (w/v) for 1 hour. This was followed by two further 5 minute
washes in TTBS and a final 5 minute wash with TBS. The blots were developed
using 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT)
liquid substrate system.
3.4.3. Results and discussion
ECV 304 cells, a spontaneously transformed cell line isolated from human umbilical
vein endothelial cells, were chosen for use in these studies. These cells appeared to
be a well-established in vitro model system, whose stable phenotype was ideally
suited for studies of endothelial cell signalling. The subsequent identification of these
cells as T24 cells (human bladder carcinoma cell line) is discussed in detail in section
2.4. This may in part explain the problems pertaining to the experiments about to be
described. In addition, because of the epithelial nature of these cells, it is not possible
to directly correlate between any responses demonstrated here and those occuring in
endothelial cells.
Experiments focused initially on studies into the putative activation of the MAP
kinases ERK, JNK and p38 MAPK in ECV-304 cells in response to lipoxin and
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leukotriene stimulation. To this end, phosphorylation (i.e. activation) of these
proteins was detected by means of Western blotting using phospho-specific
antibodies. Attempts were made to establish the temporal kinetics and dose
dependence of both lipoxin A4 (LXA4) and leukotriene D4 (LTD4)-dependent ERK,
JNK and p38 MAPK activation. Initial time course experiments were carried out at
10"7 M for both ligands since prior studies indicated that these were likely to be
optimal doses for both LXA4 and LTD4. LTD4 for example provokes a rapid increase
in endothelial P-selectin at 10"7 M, an effect which is maximally inhibited by lipoxin
n
at a concentration of 10" M (26).
Activation of ERK in ECV-304 cells in response to LTD4 treatments at 10"7 M for 2,
5, 10, 20 and 30 minutes was examined (Fig.3.4). Fully phosphorylated and non
phoshorylated MAP kinase control proteins (NEB) confirmed that primary antibody
specifically detected the modified MAPK (Lanes 1 and 2). Cells treated with PMA
(10~7 M, 15 minutes), a known activator of ERK, served as a positive control (Lane
6). ERK activation occurred under basal conditions and at all time points studied.
Equivalence of both protein loading and transfer was confirmed in all experiments
(data not shown). The presence of activated ERK under basal conditions was such
that even PMA, a known potent activator of ERK, appeared to give only a moderate
response. It is not surprising therefore that the effects of a (presumably) weaker
stimulus such as LTD4 on ERK phosphorylation were undetectible. Indeed, in the
current study, it was not possible to demonstrate increases in ERK activation in
response to LTD4 over the time course studied.
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Figure 3.4. ERK activation in ECV-304 cells occurred under basal conditions and at
all time points studied.
ERK activation in ECV-304 cells in response to LTD4 (107 M) for 2, 5, 10, 20 and 30 minutes. Fully
phosphorylated and non phoshorylated MAP kinase control proteins (NEB) confirmed that primary
antibody specifically detected the modified MAPK (Lanes 1 and 2). Cells treated with PMA (10~7 M,
15 minutes), a known activator of ERK, served as a positive control (Lane 6); vehicle control was
ethanol (0.1% v/v). ERK activation occurred under basal conditions and at all time points studied.
Lanes 3 and 4 refer to the negative control (C=control) and cells in which extra care was taken to
avoid excessive movement of the medium (M=medium), respectively.
Figure 3.5 ERK activation in ECV-304 cells in response to LTD4 at concentations of
10'11 Mto 10-6
High constitutive levels of phosphorylated ERK were apparent, with no obvious increase in response
to LTD4 at any dose tested. PMA and vehicle (0.1% v/v ethanol) controls were included as before.
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A number of practical steps were taken in an effort to reduce basal ERK activation.
There had been concern that ERK activation might be sensitive to perturbation of the
cells during handling and addition of stimuli. The levels of phosphorylated ERK
were therefore measured in cells in which extra care had been taken to avoid
excessive movement and from which no medium was removed or stimulant added.
(Lane 3, M=medium). There was however no apparent decrease in the basal levels in
these cells when compared to those from whom medium had been removed and
readded (Lane 4, C=control) or the vehicle control (Lane 5, V=vehicle, ethanol 0.1%
[v/v]). These stimulations were repeated on a number of occasions with broadly
similar results. (Figure 3.4 shows a representative experiment). Attempts were made
to establish a dose-response curve for ERK activation in response to LTD4 at
concentrations ranging from 10"11 M to 10~6 M for 5 minutes (Fig. 3.5). Once again,
these were frustrated by high constitutive levels of phosphorylated ERK, with no
apparent increase in response to LTD4 at any dose tested. Treatment of ECV-304
with LXA4 at 10"7 M over the same time course produced similar results (data not
shown).
The results outlined are broadly similar with respect to p38 MAPK and JNK
activation over the same time course. Anisomycin (10" M, 15 minutes), a known
activator of these kinases, served as a positive control in these experiments. Total cell
extracts from control and anisomycin C-6 glioma cells treated served as positive and
negative controls respectively, for phosphorylated and hence activated p38 MAPK
(New England Biolabs, MA, USA). Experiments were performed a number of times
and representative blots are shown in figures 3.6 and 3.7. Once again, high
constitutive levels of the active kinases were apparent with no increases by LTD4.
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Figure 3.6. p38 activation in ECV-304 cells in response to LTD4 and LXA4
stimulation
p38 activation in ECV-304 cells in response to LTD4 (10"7 M) for 2, 5, 10, 20 and 30 minutes. In
addition the effects of LXA^ (10"7 M for 15 minutes) either alone or followed by LTD4 stimulation for
10 minutes was investigated, (lanes 10 and 11). .Total cell extracts from control and anisomycin C-6
glioma cells treated served as positive and negative controls respectively, for phosphorylated and
hence activated p38 MAPK (Lanes 1 and 2). Cells treated with anisomycin(10"7 M, 15 minutes), a
known activator of p38, served as a positive control (Lane 12); vehicle control was ethanol (0.1%
v/v). p38 activation occurred under basal conditions and at all conditions and time points studied
Figure 3.7.JNK activation in ECV-304 cells in response to LTD4 occurred at all time
points studied.
Positive (anisomycin) and vehicle controls were included as before. JNK activation occurred at all
time points and conditions studied.
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Preliminary investigations into the actions of lipoxins on p38 MAPK and JNK
activation were incorporated into these experiments. LXA4 (10~7 M, 15 minutes) or
LXA4 (10~7 M, 15 minutes) followed by LTD4 (10"7 M 10 minutes) had no apparent
effects on kinase activation when compared to controls.
One of the major difficulties in demonstrating increased MAP kinase activity in
response to LXA4 and LTD4 in ECV-304 cells appeared to be high constitutive levels
of kinase activation. Strenuous attempts were made to overcome this, but despite
exhaustive efforts, all proved ineffective. Although the original study outlined here
had undeniable merits, it became increasingly apparent that continued investigations
into lipoxin- and leukotriene-mediated MAP kinase activation in ECV-304 cells were
unlikely to yield sufficient data. In addition, further studies into both the upstream
mediators linking ligand stimulation to kinase activation and the downstream
consequences of this activation in these cells seemed inappropriate. These difficulties
also precluded studies using lipoxin analogues in this particular cell line.
The subsequent identification of ECV-304 cells as T24 cells is discussed in section
2.4. No reports can be found concerning the activation status ofMAP kinases in T24
cells either constitutively or in response to stimuli. One study however using ECV-
304 cells in a model of endothelialisation following denuding injury documented
increased expression of ERK, p38 MAPK and JNK following injury (50). The exact
reasons for these discrepancies and the findings in the current study are not entirely
clear.
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Ongoing investigations in our laboratory to establish the signal transduction
pathways evoked by lipoxins and leukotrienes in mesangial cells have proved more
successful. It appears that in these cells both LXA4 and LTD4 activate the MAP
kinases (ERK, p38 MAPK and JNK) by a pertussis toxin sensitive pathway (44).
This was inhibited by GF109203X, implicating PKC in this process. Only LTD4-
induced MAPK activation was associated with increased activity of
phosphoidylinositol-3 (PI-3) kinase, a known upstream activator of ERK, and
treatment with a specific LTD4 receptor antagonist (SKF 104353) blunted both
LTD4-induced MAPK and PI-3 kinase activity. A component of LXA4-induced ERK
activation, however, was insensitive to SKF 104353, pertussis toxin and wortmannin
(an inhibitor of PI-3 kinase). It maybe, therefore, that LXA4-induced MAPK activity
is mediated by binding at two distinct receptors: one shared with LTD4 and coupled
to a pertussis-toxin sensitive G-protein (G;) and a second coupled via an alternative
G protein such as Gq or G12 to ERK activation. In keeping with this hypothesis,
evidence has been provided which demonstrates the expression of both the LXA4 and
LTD4 receptors on mesangial cells.
Recent studies in experimental animal models have confirmed the importance of
lipoxins and their stable analogues as potent anti-inflammatory mediators in vivo (30,
39, 51). Despite the disappointing results in the current study, given the critical role
of endothelial activation in inflammatory events, research should continue to be
directed towards defining the molecular mechanisms of lipoxin bioactivity in
endothelial cells. ECV-304 cells, used world-wide as an endothelial cell model, were
chosen for this study in good faith in an attempt to avoid some of the pitfalls of
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primary HUVEC culture. The problems experienced in the current investigation may
be avoided by using primary endothelial cells such as HUVEC for further studies.
266
3.5. Endogenous inhibitors of cytokine bioactivity
Many inflammatory reactions resolve spontaneously suggesting that endogenous
"braking systems" exist that "turn-off' leukocyte-mediated inflammation and limit
tissue injury. As with the initiation of inflammation, resolution of the inflammatory
process occurs via elaboration of a well ordered array ofmediators acting at all levels
- extracellular, cell surface and intracellular, to down regulate or halt further immune
activation and promote recovery. Cytokines, generated from both immune and
resident cells, have pleiotropic cellular effects and are central to the generation of the
inflammatory response. It is now apparent that, in addition to the generation of
certain cytokines which are themselves anti-inflammatory, a number of endogenous
inhibitors of cytokine bioactivity exist which are important in inflammatory
resolution. For the purposes of this discussion glomerulonephritis (GN) will be
viewed as a paradigm of pathogenic inflammation and reference made to in vivo and
in vitro studies which have attempted to characterise the mechanisms which limit
such immune-mediated damage within the glomerulus.
The different varieties of GN may be distinguished on the basis of their initiating
stimuli, histological features and the nature of their progression, but in all forms the
normal, and usually tightly regulated, immune response undergoes inappropriate
activation. In the most simplistic of terms the process may be divided into four
stages: initiation (immune complex formation and antigenic-stimulation of T cells),
leukocyte recruitment (the extravasation of circulating monocytes/macrophages from
the blood vessel lumen into the glomeruli and/or tubulointerstitum), proliferation
(predominantly of resident mesangial cells) and and either scarring (as a result of
extracellular matrix accumulation) or resolution. Throughout the inflammatory
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process is sustained and amplified via the release of cytokines and monocyte/T cell
chemotactic factors by both activated resident cells and infiltrating immune cells.
3.5.1. Anti-inflammmatory cytokines
The cytokines interleukin (IL)-4, IL-10 and IL-13 are produced mainly by T helper
type 2 (Th 2) cells and exert broadly anti-inflammatory effects (reviewed in (3) and
references contained therein). These so-called Th2 cytokines have multifunctional
roles, the most important of which is the modulation of macrophage function. Th 2
cytokines have been documented to inhibit macrophage release of reactive oxygen
species (ROS), proinflammatory cytokines and chemokines. In addition, these anti¬
inflammatory mediators down-regulate leukocyte growth factors (granulocyte
macrophage colony-stimulating factor (GM-CSF) and granulocyte colony
stimulating stimulating factor (G-CSF). All of these effects result in a marked
attenuation of the inflammatory process. Administration of IL-4, for example, in a
murine model of crescentic glomerulonephritis induced by anti-glomerular basement
membrane (anti-GBM) antibody, has been shown to reduce crescent formation,
attenuate macrophage/T cell infiltration and decrease proteinuria. Conversely
deletion of the IL-4 gene in mice by homologous recombination (i.e. "knock-out"
technology) exacerbates nephritis. In addition to its effects on macrophages, IL-4 can
inhibit release of ROS from neutrophils and modulate the function of resident cells
e.g. inhibition of IL-1-induced proliferation of mesangial cells. IL-10 has also been
shown to have immuno-suppressive effects in the anti-GBM model of GN. Renal
expression of IL-13 has also been demonstrated in experimental models of
glomerulonephritis, although the putative anti-inflammatory role of this cytokine in
vivo in the resolution of kidney disease has yet to be clarified. Interestingly, in a
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murine model of collagen-induced arthritis, treatment with vector cells engineered to
secrete IL-13 resulted in attenuation of inflammation.
IL-6 is produced in almost all inflammatory states, often in conjunction with the pro¬
inflammatory cytokines TNF-a and IL-1. IL-6 is critical to the generation of
immunity against chronic intracellular infections, and, together with TNF-a and IL-
1, is required for the induction of acute phase reactions (fever, corticosterone release
and hepatic production of acute phase proteins). Up until recently it was unclear
whether IL-6 made any additional contribution to acute inflammatory responses, and
indeed conflicting reports existed as to its pro- or anti-inflammatory effects. IL-6 for
example has been shown to induce proliferation of mesangial cells in vitro and in
vivo and administration of IL-6 exacerbates murine lupus nephritis, while blockade
of the IL-6 receptor promotes disease resolution (3). Subsequent investigations
however failed to demonstrate IL-6 induction of mesangial cell proliferation and in
nephrotoxic serum nephritis IL-6 administration has been reported to reduce
glomerular thrombosis, leukocyte infiltration, expression of cytokines/chemokines
and proteinuria. A recent study investigating the role of IL-6 in animal models of
endotoxic lung/endotoxaemia in IL-6+/+ and IL-6"7" mice has helped to clarify its role
in acute inflammation (52). Aerosol exposure ofmice to endotoxin induced a release
of TNF-a and MIP-2, in addition to a neutrophil response, in the lungs of IL-6+ +
mice. These effects however were significantly greater in the lungs of IL-6"" mice.
Systemic responses following intraperitoneal delivery of endotoxin were also more
pronounced in the IL-6"" mice, as demonstrated by increased circulating levels of
TNF-a, MIP-2, GM-CSF and IFN-y. Administration of recombinant IL-6 to IL-6"7"
mice abolished these differences. Importantly, the anti-inflammatory cytokine IL-10
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was induced to a similar degree in both sets ofmice following endotoxin challenge.
This provides strong evidence that endogenous IL-6 plays an important anti¬
inflammatory role in both local and systemic acute inflammatory responses by
controlling the level of pro-inflammatory cytokines.
Leukaemia inhibitory factor (LIF), an IL-6 family member, is another pleiotropic
cytokine produced by many different cell types including endothelial and mesangial
cells. Low levels are expressed in normal rat glomeruli but increase rapidly and
dramatically in response to induction of nephritis. Administration of LIF in
experimental anti-GBM nephritis results in amelioration of disease with reduced
macrophage infiltration and decreases in MCP-1, IL-1 and TNF-a mRNA
expression.
The complex actions of the cytokine TGF-P are essential in a wide range of
pathophysiological processes (3). Constitutive expression is essential for the
maintenance of normal immune and tissue function; TGF-P "knock-ouf' mice
demonstrate immune dysregulation, multiorgan inflammation and early death (53).
TGF-P is upregulated in many diseases particularly autoimmune disorders where it
exerts anti-inflammatory actions. TGF-P 1 is upregulated in many forms of
experimental and human glomeronephritis (54). Production appears to be mainly
from the mesangial cell and can be enhanced in vitro by diverse stimuli such as
angiotensin II, thrombin, high glucose, oxidised LDL, immune complexes and
mechanical strain. In vitro studies have also demonstrated that, in addition to
functioning as an autocrine inhibitor of the cytokine response in mesangial cells (IL-
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1(3 and TNF-a), TGF-(31 production from these cells inhibits production of IL-la,
TNF-a, interferon (IFN)-y and MCP-1 by activated macrophages. This has been
borne out by studies using an ex vivo gene transfer approach for TGF-P 1 delivery
where a sustained increase in TGF-P 1 glomerular expression was associated with a
decreased glomerular cell proliferation in experimental mesangial proliferative
glomeruonephritis. TGF-P however is a double-edged sword in that, in addition to its
immunosuppressive actions, this cytokine also exerts potent fibrogenic effects.
Introduction of the TGF-P into the kidney induces glomeruloscelerosis in vivo (55),
while in vitro studies have confirmed increased mesangial cell synthesis of collagen,
fibronectin and proteoglycans in response to TGF-p, concomitant with a decreased
catabolism of these compounds. Indeed it has become accepted that the accumulation
of extracellular matrix, the characteristic hallmark of glomerulosclerosis, is
predominantly due to the pro-fibrogenic/anti-proteolytic consequences of excess
TGF-P production in renal inflammation.
3.5.2. Inhibition of cytokine bioactivity by anti-inflammatory eicosanoids
The activation of monocytes/macrophages and polymorphonuclear cells (PMN) in
inflammatory states is accompanied by production of a number of arachidonic acid
derived metabolites which have important immunomodulatory effects (56). In the
majority of cases these are pro-inflammatory and include thromboxane A2,
prostaglandin (PG) F2a, leukotrienes B4, C4 and D4. These mediators trigger
leukocyte infiltration, coagulation, and proliferation/matrix production by resident
cells. In some cases however eicosanoids function as anti-inflammatory agents and
these include prostacyclin (PGE2, PGI2) and lipoxins (LX). The latter compounds
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exert a number of anti-inflammatory actions (section 3.2). With particular reference
to cytokine bioactivity, PGE2 and PGI2 inhibit production of IL-ip and TNF-a from
activated macrophages. Production of PGE2 in vivo occurs in many inflammatory
states, while in vitro studies e.g. with mesangial cells, have shown increased
production in response to a variety of inflammatory stimuli (IL-1 p, TNF-a, ROS,
angiotensin II, thrombin, immunoglobulins).
3.5.3. Cytokine inhibitors: antagonists
The ability to elaborate a set of natural inhibitors against specific cytokines is another
important contributor to the resolution of established inflammation. IL-1 receptor
antagonist (IL-lra) is one such mediator (56). IL-lra (which is homologous to IL-la
and ILip) competes with IL-1 for binding at its receptors but, in contrast to IL-1,
fails to induce interiorisation of receptor-ligand complexes and stimulate intracellular
responses. This antagonism by IL-lra results in the attenuation of the potent pro¬
inflammatory effects of IL-1. The expression of IL-lra has been demonstrated in
many inflammatory diseases and attempts have made to utilise its anti-inflammatory
effects by upregulating its expression either by administration of recombinant IL-lra
protein or by gene transfer techniques. Injection of IL-lra limits glomerulonephritis
in a number of experimental models at various stages of the disease process, while
transfer ofmesangial cells expressing IL-lra to glomeruli results in their insensitivity
to IL-1. In vitro studies also indicate that IL-lra expression in macrophages is
upregulated not only by IL-1, but also by the anti-inflammatory cytokines IL-4, IL-6
and TGF-p.
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Decorin is a proteoglycan that binds TGF-(3 isoforms and neutralises their activity
(3). In acute anti-Thy 1 glomerulonephritis systemic administration of decorin, or
indeed intramuscular transfer of its gene, results in inhibition of matrix expansion
and proteinuria. No information exists on whether decorin inhibits the positive
immunosuppressive effects ofTGF-p.
3.5.4. Cytokine inhibitors:soluble receptors/decoy receptors
Bioactivity of the pro-inflammatory cytokines IL-1 and TNF-a may also be
modulated by naturally occuring soluble binding proteins (56). In the case of IL-1
two receptors, type I and type II, (RI and RII) are co-expressed in different cell types.
IL-1 signalling occurs principally via RI while RII has no signalling properties and
acts as a "decoy" for IL-1. This results in an inhibition of IL-1 activity by preventing
its binding at the active RI receptor. In addition, activated inflammatory cells secrete
a soluble form of both receptors that retain the ability to bind IL-1 and, hence,
compete with its membrane receptors for binding. The efficacy of these molecules as
potential therapeutic agents has been assessed in experimental glomerulonephritis
where their administration limits glomerular injury.
Soluble TNF receptors (sTNFRp55 and sTNFRp75) have also been identified (56).
These are truncated forms of membrane TNF-a receptors which appear to function
as antagonists by competitively inhibiting TNF interaction with cell-surface
receptors. In vivo recombinant analogues of the soluble TNF receptors show potent
TNF-neutralising activity e.g. in the rat model of acute nephrotoxic serum nephritis
administration results in blunting of the inflammatory response with reduced
expression of glomerular adhesion molecules and decreased leukocyte infiltration.
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Subsequent to these changes, a suppression of histopathological changes
(intracapillary thrombi and crescent formation) and preservation of renal function.
The presence of soluble TNF receptors has been identified in the urine of patients
with chronic glomerular nephritis and it has been speculated that these may be
produced in response to inflammatory stimuli in the glomerulus to limit the action of
TNF-a.
3.5.5. Intracellular inhibitors of cytokine cell signalling events
Cytokines initiate their pleiotropic cellular effects through their interactions with
specific receptors on the surface of target cells. Once bound to the surface receptor
various intracellular signal transduction pathways are activated and these lead
ultimately to the transcription of specific genes. Cytokine signalling from receptor to
nucleus occurs through three principal pathways - the Janus kinase / signal
transducers and activators of transcription (JAK/STAT) cascade, mitogen-activated
protein kinases and NF-kB activation. In the JAK/STAT pathway binding of
cytokine to receptor results in the juxtaposition and activation (presumably by
transphosphorylation) of the receptor associated JAKS (57). The activated JAKS
phosphorylate a number of key tyrosine residues in the cytoplasmic portion of the
cytokine receptor subunits. These phosphotyrosines are then believed to act as
docking sites for the src homology 2 (SH2) domains of STAT transcription factors.
The recruited STATs are activated, via JAK mediated phosphorylation, and they then
dislocate from the receptor complex and form homo- or heterodimers. Finally, the
STAT dimers translocate to the nucleus where they bind to specific DNA elements in
gene promoters and thus induce transcription of cytokine dependent genes (Fig 3.8).
Recently a family of inhibitors of JAK/STAT signalling have been reported, the
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Figure 3.8. Cartoon summarising the key elements of the JAK/STAT pathway
(see text for details).
suppressors of cytokine signalling (SOCS) family (58-61). The SOCS proteins are
products of JAK/STAT-inducible early genes and function, via a classic negative
feedback loop, to down regulate this pathway. In essence, cytokine-mediated
activation of the JAK/STAT pathway leads to the transcription of various genes,
including those encoding SOCS proteins; thus, by activating the JAK/STAT cascade,
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cytokines are also initiating the process by which they will be eventually 'switched
off. The SOCS proteins will be discussed in detail in section 3.6.
In addition to SOCS, another family of proteins have been identified which inhibit
STAT mediated gene transcription - protein inhibitor of activated STAT (PIAS)
proteins (62). These proteins exist constitutively in the cytoplasm of cells and upon
cytokine binding preferentially associate with phosphorylated STATS. In the case of
PIAS 1 and PIAS 3, their association with STAT 1 and STAT 3, respectively,
inhibits STAT-mediated gene activation, most likely by blocking their DNA-binding
ability. It has been suggested that the striking specific in vivo association between
individual PIAS and STAT proteins may indicate the presence of a specific PIAS
inhibitor in every STAT signalling pathway, but this remains to be clarified.
Activation of the various MAPKs results not only in their phosphorylation of
cytoplasmic proteins, but also in their translocation to the nucleus where
phosphorylation can activate various transcription factors (section 3.3).
Phosphorylation in these systems is a dynamic process balanced by the actions of the
kinases which catalyse phosphorylation and the phosphatases which catalyse
dephosphorylation. MAP kinase phosphatase (MKP)-l is one such phosphatase.
MKP-1 suppresses the activity of the MAPK family and has recently been shown to
be upregulated in the glomeruli of anti-Thy 1 glomerulonephritis (3). In addition,
MKP-1 has been implicated in the very early stages of anti-GBM GN. Injection of
anti-GBM antibodies to rats resulted in an increase in MKP-1 levels as early as 30
min, that returned to basal levels after 24 hours. The significance of these findings is
still unclear.
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The transcription factor NF-kB resides normally in the cytoplasm of resting cells, but
enters the nucleus in response to various stimuli such as infection, ultraviolet
irradiation and pro-inflammatory cytokines such as TNF-a and IL-ip. In the cytosol
NF-kB is complexed with its inhibitor IkB and its activation is controlled by
inhibitory IkB kinases (IKK) (63). Signal-induced phosphorylation of IkB by IKK
initiates its conjugation to ubiquitin and subsequent degradation by the proteasome.
The liberated NF-kB can then translocate to the nucleus and activate gene expression
(Fig. 3.9).
Figure 3.9. NF-kB activation.
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The activity of IKK resides in two subunits IKKa and IKKp which share significant
homology and contain identical structural domains, but mediate quite different NF-
Kp dependent effects. In recent studies IKKa7" mice died shortly after birth and
demonstrated striking limb and skeletal abnormalities (64). The mediators
controlling IKKa activity early in development are unknown, but are unlikely to be
IL-ip or TNF-a because both these cytokines can activate NF-Kp in cells from the
IKKa7" mice. IKKp on the other hand appears to control the NF-kp responsive genes
involved in the inflammatory response e.g. TNF-a and IL-ip. It has been shown that
inhibition of TNF-a induced NF-kP activation by salicylate (the hydrolysis product
of aspirin) occurs via suppression of IKKp activity. Cells lacking NF-kB activity
have also been shown to undergo apoptosis in response to TNF-a and, in support of
IKKp control of TNF-a induced effects, IKKp7" mice died in utero of TNF-a-
induced hepatocyte apoptosis (65). Because of the potential toxicity and
pathophysiology associated with prolonged NF-kB activation, it is important not
only to activate this system rapidly in response to infection, but also to decrease its
activity once the infectious challenge disappears. The mechanisms involved in down
regulation of this pathway are still unknown but it has been suggested that IKKp may
be a site for negative regulation of IKK, and hence, NK-kB activity (66). IKK-p is
rapidly activated through phosphorylation at its activation (T) loop and also at a
COOH-terminal serine cluster. The region encompassing the serine cluster appears to
be an intrinsic activator of the kinase and it has been speculated that the - COOH-
terminal portion of the molecule folds back to contact the kinase domain and induces
a conformational change that enhances catalytic activity. Progressive
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phosphorylation of the serine cluster may weaken these interactions and act as a
timing device that limits the period of IKK activation.
3.5.6. The acquisition of an anti-inflammatory phenotype
In addition to anti-inflammatory cytokines or inhibitors of proinflammatory
cytokines, a large number of other mediators exist which result in down-reguation of
the immune response in other ways These include complement inhibitors, anti¬
thrombotic molecules, heat shock proteins, antioxidant enzymes and cyclin kinase
inhibitors and are discussed in detail elsewhere (3). Many of these so-called
"defence" molecules are constitutively expressed in normal tissues and may be
involved in the prevention/limitation of injury and the maintenance of tissue
integrity. Others are inducible in response to a local inflammatory milieu and
contribute to the resolution of inflammation. It is interesting that one defending
molecule may trigger the expression of another or act in synergism with it against the
inflammatory stimulus. IL-1 and TGF-P for example trigger the expression of their
specific inhibitors IL-lra and decorin. TGF-P induces IL-10, while IL-10 itself
upregulates IL-lra and sTNFR. IL-4 and IL-13 stimulate expression of IL-lra, IL-1
decoy receptor and 15-lipoxygenase (the enzyme responsible for lipoxin formation).
The acquisition of this so-called "anti-inflammatory phenotype" has been supported
by ex vivo data. In the regeneration phase (day 7) of acute anti-thy 1
glomerulonephritis, glomeruli have been reported to show blunted responses to pro¬
inflammatory stimuli (67). When normal glomeruli were stimulated with IL-1 P the
expression of the cytokine-responsive matrix metalloproteinase stromelysin was
induced. This expression was blunted however in nephritic glomeruli, which also
showed reduced expression of other cytokine inducible molecules including
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gelatinase B and MCP-1. In nephritis blunted glomerular responses were also
observed in response to lipopolysaccaride and TPA. In the light of these findings, it
has been speculated that the elaboration of defending molecules such as those
detailed above in previous sections contributes to this reduced responsiveness,
leading the authors to hypothesise that such desensitisation of resident tissue
represents an "anti-inflammatory phenotype" which both limits cell damage and
facilitates disease resolution.
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3.6. Suppressors of cytokine signalling (SOCS) proteins
Cytokines are secreted proteins which regulate the proliferation, differentiation and
activation state of many different cell-types. They are important modulators of
diverse homeostatic processes such as development, haematopoiesis and host
defence. Inappropriate cytokine release contributes to tissue injury and organ
dysfunction in patients with autoimmune disease. Cytokines initiate their pleiotropic
effects through interaction with specific cell surface receptors on target cells.
Receptor engagement activates intracellular signal transduction pathways that evoke
diverse functional responses, including transcription of new genes. A recently
identified family of proteins, the suppressors of cytokine signalling (SOCS), which
act as negative regulators of a key cytokine-activated signalling pathway, the Janus
kinase/signal transducers and activators of transcription (JAK/STAT) cascade,
appear to be important regulators of cytokine bioactivity in health and disease (58-
61).
3.6.1. The JAK/STAT pathway
Over the past decade the importance of the JAK/STAT signal transduction cascade in
linking activation of cytokine receptors to gene transcription has been established
(57). In unstimulated cells JAKS are associated with cytokine receptors. Following
cytokine binding, receptor aggregation results in the juxtaposition and activation
(presumably by transphosphorylation) of the associated JAKS. The activated JAKS
phosphorylate a number of key tyrosine residues in the cytoplasmic portion of the
receptor subunits. These phosphotyrosines are then believed to act as docking sites
for the src homology 2 (SH2) domains of STAT transcription factors. The recruited
STATs are activated via JAK mediated phosphorylation of a phosphotyrosine residue
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carboxyl to the SH2 domain (Tyr-701 in the case of STAT 2) and they then dislocate
from the receptor complex and form homo- or heterodimers via reciprocal
interactions between their SH2 domains and the phosphotyrosine residue. Finally, the
STAT dimers translocate to the nucleus where they bind to specific DNA elements in
gene promoters and thus induce transcription of cytokine dependent genes. Most
definitive studies on JAK/STAT activation have been carried out using with
interferon (a and y) and have identified two major prototypic sequences in the genes
upregulated by these cytokines - the interferon a stimulated response element
(ISRE) and the interferon y inducible element, or GAS element (68).
Receptor
3.6.2. SOCS: discovery, structural features and regulation of expression
Whereas the key events in cytokine-mediated JAK/STAT activation have been
relatively well-defined (Fig 3.10),
-i a until recently little was known of the
mechanisms of inactivation of this
signal transduction pathway.
Over the past four years a family of
inhibitors of JAK/STAT signalling
has been characterised, the
suppressors of cytokine signalling
(SOCS) family - alternatively termed
cytokine inducible SH2-containing
sequence, CIS/ STAT-induced STAT
inhibitor, SSI / JAK binding protein,
Figure 3.10. JAK/STAT pathway.
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JAB (58-61). The SOCS proteins are products of JAK/STAT-inducible immediate






Figure 3.11. SOCS proteins
The SOCS proteins are products of JAK/STAT-inducible early genes and function, via a classic
negative feedback loop, to down regulate this pathway. In essence, cytokine-mediated activation of
the JAK/STAT pathway leads to the transcription of various genes, including those encoding SOCS
proteins; thus, by activating the JAK/STAT cascade, cytokines are also initiating the process by which
they will be eventually 'switched off
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To-date the SOCS family comprise at least eight members, SOCS-1-7 and CIS-1.
CIS-1, the first member identified, is the product of a cytokine-inducible gene and
binds to the phosphorylated IL-3 and erythropoietin (Epo) receptors (61). Epo, while
historically classified as a hormone, is a member of the growth hormone family of
cytokines and the Epo receptor a member of the class 1 cytokine receptor family
(57). SOCS-1 was subsequently identified almost simultaneously by four
independent groups using a variety of experimental approaches, a discovery that was
quickly followed by the identification ofmultiple murine and human SOCS members
(69, 70).
Basal and cytokine induced SOCS expression exhibits striking tissue- and cell-type
specificity; for example, interleukin (IL)-6 is capable of upregulating the expression
of SOCS-1, -2 and -3 in mouse liver, while this cytokine induces only SOCS-1 in
murine monocytic Ml cells (60). Similarly, although CIS-1 induction was originally
thought to be IL-6 independent (61), it has since been shown to be upregulated in a
cell- and tissue-type specific manner in response to this cytokine.
SOCS over-expression and promoter analysis studies support the theory that
cytokine-mediated SOCS upregulation is due to STAT-dependent transcription. A
dominant-negative STAT 3 mutant has been shown to block IL-6 and leukaemia
inhibitory factor (LIF)-dependent SOCS-1 upregulation (71). The rat SOCS-1
promoter contains several GAS consensus motifs (72). Four STAT 5 consensus
binding sites located on the CIS-1 promoter close to the transcription initiation site
are also required for Epo-dependent upregulation of this gene (73) and
characterisation of the murine SOCS-3 promoter has revealed a STAT-l/STAT-3
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binding element essential for LIF-dependent transcription (74). Whereas cytokines
appear to be the principal mediators of JAK/STAT-driven SOCS upregulation, other
ligands capable of initiating STAT transcriptional activation e.g. epidermal growth
factor and platelet derived growth factor, are also potential inducers of these negative
regulators. Interestingly, there is evidence that SOCS-3 is upregulated by IL-10 via a
STAT-independent mechanism, implying that additional cytokine-activated
transcription factors are involved in SOCS upregulation (75). Moreover, the recent
intriguing observation that SOCS-2 is physically associated with the activated
insulin-like growth factor-1 receptor (76) has led to speculation that the role of SOCS
as regulators of intracellular signalling may extend beyond their inhibition of
JAK/STAT activity.
3.6.3. Structural elements
The most striking structural feature of the SOCS family members is a novel
conserved C-terminal motif of approximately 40 amino acids containing a core
conserved sequence - (K/R)(D/E)(Y/F). This has been alternatively termed the
SOCS box, the CIS homology (CH) domain or the SSI C-terminal motif (SC motif).
The SOCS box is conserved among family members both at the level of its amino
acid sequence and its position within individual SOCS molecules, suggesting that
this motif may serve a similar function in each protein (77). SOCS-1-7 and CIS-1
have a Src homlogy 2 (SH2) domain amino terminal to the SOCS box. The latter
observation has prompted speculation that these members of the SOCS family may
bind to phosphorylated tyrosine residues on target proteins via this region. Indeed,
SOCS-1 has been reported to bind to the kinase domain of JAK2 as a result of
SH2:phosphotyrosine interactions (58). A further 8 proteins containing the SOCS
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box and featuring additional amino terminal protein-protein interaction motifs
(specifically WD-40/ankyrin repeats and SPRY domains) have also been identified
(77). In addition, two small GTPases and two small sequences of unknown structural
class which contain a C-terminal SOCS box have also been reported.
Contrary to initial predictions the SOCS box does not appear to be required for
inhibition of cytokine signalling (78-80). Evidence has been provided that the SOCS
box may be involved in preventing the proteolytic breakdown of SOCS proteins in
some systems; whereas the SOCS box may be responsible for targeting SOCS
proteins for proteosomal degradation in others (81). In support of the former, SOCS-
1 mutants lacking the SOCS box are expressed at lower levels in cultured cells than
the full length protein; a phenomenon that is reversible in the presence of proteasome
inhibitors (79). Elongins B and C are proteases that putatively target proteins to
proteasomal destruction and SOCS proteins appear to interact with the Elongin BC
complex via a BC interaction motif located within the SOCS box. In one study
Elongin BC-SOCS interaction stabilises SOCS-1 levels by rendering the molecule
relatively resistant to proteolytic degradation (78). In contrast, Zhang et al. have
reported that proteasome inhibition prolongs cytokine-induced SOCS-3 upregulation
and suggested that the proteasomal complex, and by inference the Elongin BC
proteins, may facilitate the degradation of endogenous SOCS proteins (81). Clearly,
further research in this area is required to clarify these apparently contradictory
findings.
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3.6.4. Mechanisms of inhibition of JAK/STAT signalling
SOCS have been reported to inhibit cytokine-triggered JAK/STAT signal
transduction pathways through several mechanisms. SOCS-1 appears to associate
directly with JAKS and thereby inhibit kinase activity and STAT-dependant gene
transcription. In contrast, CIS-1 does not appear to physically interact with JAK-2
but inhibits binding of STAT-5 to cytokine receptors (73). Furthermore, SOCS-3
interacts with JAK-2 in vitro (58) but suppresses JAK activity weakly (82, 83) even
though it inhibits cytokine bioactivity. In the case of SOCS-1 and SOCS-3, intact
SH2 and N-terminal sequence are also required for inhibition of IL-6 signalling (79,
80), further highlighting the complexity of this system.
SOCS-1 has also been demonstrated to inhibit cytokine-dependent activation of the
non-receptor tyrosine kinase Tec (82), although the role of this kinase in JAK/STAT
signalling remains to be clarified. In the latter study, SOCS-1 over-expression
suppressed both Tec kinase and JAK-2 activity in haematopoietic cells; however the
suppression of JAK-2 was more consistent. These observations led the authors to
speculate that SOCS-1 has a higher binding affinity for JAK-2 than Tec, and that
JAK-2 was the more likely target of SOCS-1.
3.6.5. Physiological roles
Complementary experimental approaches using (a) analyses of SOCS expression
under basal conditions and following cytokine stimulation, (b) SOCS over-
expression systems and, (c) SOCS 'knockout' mice, have begun to yield valuable
insights into the function of these proteins in health and disease. Most studies point
to SOCS as important negative regulators of JAK/STAT signalling triggered by
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hormones and cytokines. Growth hormone (GH), for example, produces a rapid
transient induction of SOCS- 3 in fibroblasts in vitro (84). Intraperitoneal
administration of GH to mice in vivo causes induction of SOCS-3 in the liver.
Transfection of Chinese hamster ovary (CHO) cells with SOCS-1 and -3 blocked
GH-induced transactivation of a GH responsive gene promoter, evidence which
strongly implicates SOCS-1 and 3 as inhibitors ofGH-JAK 2 signalling (84).
SOCS-3 also regulates leptin signalling in vivo (85). Leptin administration to leptin-
deficient mice rapidly induces SOCS-3 mRNA in the hypothalamus and over-
expression of SOCS-3 blocks leptin receptor-mediated signal transduction in COS-1
cells (86). Furthermore, in the lethal yellow mouse (AY/a), a model characterised by
hyperleptinaemia and resistance to both central and peripheral leptin administration
(86), basal SOCS-3 mRNA are increased in hypothalamic nuclei. It has been
speculated that excessive SOCS-3 activity in leptin resistant neurons might be a
potential mechanism for this pathology in the Ay /a mouse, and indeed other
syndromes of obesity. SOCS-3 is also a negative regulator of leukaemia inhibitory
factor (LIF)-induced proopiomelanocortin gene expression and subsequent ACTH
secretion in vitro and in vivo (87).
The growth, differentiation and functions of immune and haematopoietic cells are
controlled by multiple cytokines. The importance of SOCS in modulating the effects
of cytokines on haematopoietic cell lines has been the subject of intense study.
SOCS-1 is strongly induced by IFN-y in mouse myeloid leukaemia (Ml) cells (88).
Over-expression of SOCS-1 in these cell lines causes resistance to interferon-induced
growth arrest. It has been postulated that this may be a contributory mechanism
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underlying IFN resistance, for example in the late phase of chronic myeloid
leukaemia (89). The expression of CIS-1 mRNA and protein has also been
demonstrated in haematopoietic cell lines. CIS-1 protein interacts with the IL-3
receptor and with the tyrosine phosphorylated erythropoietin receptor. The over-
expression of CIS-1 in various haematopoietic cell lines suppresses cell growth (61)
implicating CIS-1 protein as a negative regulator of cytokine growth signals.
Mice deficient in SOCS-1 protein exhibit stunted growth and abnormalities in a
range of organs (71, 90). Although normal at birth, the mice die before three weeks
of age. Histological examination of the liver revealed fatty degeneration of
parenchymal cells, as well as generalised infiltration of the liver by immature
haematopoietic cells. These changes were also present, though less marked, in
pancreas, lungs and heart. Conversely, the lymphoid organs, thymus and spleen,
showed markedly reduced cellularity with progressive depletion of pre-B and B cells.
Indeed, while the differentiation of lymphocytes lacking SOCS-1 appeared to be
normal, these cells exhibited accelerated apoptosis with ageing, the number of
lymphocytes in SOCS-1 homozygous deficient mice at 10 days being 20-25% of
their wild type counterparts. These authors found that expression of the pro-
apoptotic protein Bax was elevated in spleen- and thymus-derived lymphocytes of
SOCS-1 deficient mice, leading them to speculate that SOCS-1 might function to
prevent lymphocyte apoptosis by inhibiting the expression of this molecule.
3.6.6. Summary
In summary, cytokine-triggered phosphorylation of STATs induces the transcription
of SOCS genes. The SOCS proteins, in turn, inhibit cytokine signal transduction and
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represent a classical negative feedback loop. They are also ideally placed to
participate in crosstalk among cytokine signals because the SOCS genes induced by
one cytokine could potentially modify the intensity of other cytokine signals. This
paradigm has been suggested as a possible mechanism underlying the inhibition of
IFN-dependent gene induction by IL-10 (91) and a recent publication has provided
evidence that IFN-dependent SOCS-1 upregulation may be, at least partially,
responsible for the inhibitory effect of this cytokine on IL-4-dependent gene
expression (92).
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3.7. Regulation of SOCS expression in glomerular endothelial and
mesangial cells in vitro and in vivo
3.7.1. Introduction
Glomerulonephritis (GN) can be viewed as a paradigm of autoimmune inflammation
in which the normal, and usually tightly regulated, immune response undergoes
inappropriate activation. In the most simplistic of terms the process may be divided
into four stages: initiation (immune complex formation and antigenic-stimulation of
T cells), leukocyte recruitment (the extravasation of circulating
monocytes/macrophages from the blood vessel lumen into the glomeruli and/or
tubulointerstitum), proliferation (predominantly of resident mesangial cells) and
either scarring (as a result of extracellular matrix accumulation) or resolution.
Throughout the inflammatory process is sustained and amplified via the release of
cytokines and monocyte/T cell chemotactic factors by both activated resident cells
and infiltrating immune cells. Considerable efforts have been made to characterise
the mechanisms which limit such immune-mediated damage within the glomerulus
and these are discussed in more detail in section 3.5. Since the role of cytokines in
the pathology of GN is well established (93), and the potent inhibition of JAK/STAT
signaling by SOCS establishes their importance as endogenous regulators of key
cytokine-mediated biological processes, the present study was undertaken to
elucidate the role of SOCS in renal inflammation.
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3.7.2. Materials and methods
Cell Culture
Transformed rat glomerular endothelial cells were a generous gift from Dr. Harry
Holthofer and have been characterised previously (94). All cell culture reagents were
obtained from Gibco Life Technologies (Paisley, Scotland) unless other wise stated.
These cells were routinely cultured in Dulbecco's Modified Eagle's Medium
(DMEM) containing L-alanyl-L-glutamine, sodium pyruvate, 1000 mg/L glucose
and pyridoxine and supplemented with 10% heat-inactivated fetal bovine serum, 100
U/ml penicillin and 100 pg/ml streptomycin. Prior to stimulation RGEC were not
rendered quiescent, as they were found to detach under conditions of serum
restriction. Cytokines were obtained from R&D systems (Oxford, UK) and all
treatments were carried out at a concentration of 100 ng/ml for 2 hours.
Primary cultures of rat mesangial cells were isolated as described previously (95) and
were a kind gift of Dr Ann McGinty. Cells were cultured in RPMI ((Biowhittaker,
Wokingham, UK), 17% heat-inactivated fetal bovine serum 100 U/ml penicillan and
100 pg/ml streptomycin. Cells were plated onto 6-well plates and when 80%
confluent rendered quiescent overnight in RPMI, containing 0.5% fetal bovine
serum. Cytokines were obtained from R&D systems (Oxford, UK) and all treatments
were carried out at a concentration of 100 ng/ml for 2 hours.
Rat Crescentic Nephritis Model
Crescentic GN was induced in male Wistar Kyoto (WKY, 200-250 g) rats by a single
injection (0.1 ml) of rabbit anti-rat GBM nephrotoxic serum which had been
prepared as described previously (96); control animals received 0.1 ml of normal
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rabbit serum. The kinetics of leukocyte infiltration and glomerular injury associated
with injection of this antiserum have been reported previously (97). In the present
study animals were sacrificed at 2 (n=4) and 7 days (n=4) following the
administration of nephrotoxic serum. The latter group of animals received either 4.8
pg intravenous IL-4 (obtained from the conditioned media of a CHO-K1 cell line
transfected with rat IL-4 cDNA and quantified by ELISA, Biosource, U.K.) (n=4) or
media from untransfected parental CHO-K1 cells (n=4) twice daily intravenously
from day 4 to day 7 post-induction of nephritis. For all animals glomeruli were
isolated by standard sieving techniques (97). Samples of kidney were either placed
in optimal cutting temperature (OCT) compound and snap frozen in liquid nitrogen
cooled isopentane or used for the isolation of glomeruli by standard sieving
techniques.
RT-PCR
Transformed RGEC, primary rat mesangial cell or glomerular total RNA was
isolated using Trizol (Gibco) according to the manufacturers' instructions. Total
RNA (2pg) was treated with DNase I and 01igo(dt)i2-is was then used to generate first
strand cDNA. Reverse transcription was carried out using Superscript II RNase H.
Sequence-specific primer pairs were designed and obtained from Sigma-Genoys
(Cambridge, UK) (Table 3.2) Amplification was as previously described, typically
94°C for 3 minutes; 35-40 cycles of 94°C for 30 seconds (denaturing), 55°C for 1
minute (annealing) and 72°C for 1 minute (extension); followed by a final extension
step of 72°C for 7 minutes. cDNA samples were subjected to parallel PCR reactions
with primers for GAPDH/p-actin to control for equivalency of loading. The presence
of genomic DNA was determined by control reactions in which amplification was
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conducted in complete reaction mixture lacking template cDNA or with RNA samples
from RT reactions carried out in the absence of Superscript II. PCR products were
visualised by ethidium bromide staining following electrophoresis on 1.2% agarose
gels. Subsequent quantification for each gene studied in comparison to the GAPDH










P1= Primer 1 P2= Primer 2
SOCS
SOCS-1 55 273
P1 5'-TCC GCT CCC ACT CTG ATT AC-3'
P2 5'-CGA AGA GGC AGT CGA AGG T-3'
SOCS-2 55 333
P1 5'-AAA TTA AAA GAG GCG CCA GA-3'
P2 5'-AAT GCT GAG TCG GCA GAA GT-3'
SOCS-3 55 200
P1 5'-GCT ACC CTC CAG CAT CTT TG-3'
P2 5-GGC TGG ATT TTT GTG CTT GT-3'
CIS-1 55 201
P1 5'-TCT CCT ACC TCC GGG AAT CT-3'
P2 5'-CCA GTC GGA AGC TAG AGT CG-3'
Table 3.2 Rat SOCS primers.
Immunohistochemistry
Paraffin sections were used for immunohistochemical staining for SOCS-3 and CIS-
1. Goat polyclonal SOCS-3 and CIS-1 antibodies (Santa Cruz Biotechnology) were
used at a concentration of 5pg/ml, overnight at 4°C. In both cases detection of
primary antibody was via biotinylated horse anti-goat IgG (1:500, Vector Labs) and
streptavidin-biotin-peroxidase conjugates (1:500, Boehringer Mannheim).
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3.7.3. Results
As has previously been stated, cytokine-dependent upregulation of SOCS exhibits a
marked cell-type and tissue-type specificity. For this reason, although a number of
the cytokines used in the present study have been shown to upregulate various SOCS
in haematopoietic tissue and cell lines, liver and pituitary it was necessary to
determine the pattern of SOCS upregulation in response to these mediators in renal
cells. The role of resident mesangial cells in glomerular inflammation is well
established, as is the pivotal role of endothelial activation in many inflammatory
conditions. These two cell types were therefore chosen as a cell culture model in
which to begin the investigations. Initial experiments were carried out to determine
which SOCS species were basally expressed in these cells. RT-PCR analysis using
sequence specific primers for CIS-1, SOCS-1, -2 and -3 was carried out on total
mRNA isolated from RGEC and rat mesangial cells. In both cell types SOCS-3 and
CIS-1, but not SOCS-1 and SOCS-2, were found to be constitutive under basal
conditions. Following cytokine stimulation SOCS 3 and CIS-1 expression in RGEC
was upregulated, to varying degrees, in response to the cytokines IL-ip, IL-4, IL-6
and TNF-a and IFN-y (Fig 3.12, 3.13). In contrast, no significant upregulation of
SOCS-3 in response to these cytokines occurred in rat mesangial cells, while
increases in CIS-1 mRNA were apparent only after stimulation with TNF-a. (Fig
3.14, 3.15). Expression of SOCS-1 and SOCS-2 in these two cell types was not
induced in response to these cytokines.
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Figure 3.12. SOCS-3 expression in RGEC in response to cytokine stimulation.
SOCS-3 is expressed in RGEC under basal conditions (c=control). mRNA levels of SOCS-3 in RGEC
are increased in response to the cytokines IL-1 (2 fold), IL-4 (1.8 fold), IL-6 (2.0 fold), TNF-a (2.1
fold) and IFN-y(3 fold). Result shown is representative of three separate experiments (Appendix 1C).
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Figure 3.13. CIS-1 expression in RGEC in response to cytokine stimulation.
CIS-l is expressed in RGEC under basal conditions (c=control). mRNA levels for CIS-1 in RGEC are
increased in response to the cytokines IL-1 (1.9 fold), IL-4 (2.3 fold), IL-6 (1.8 fold), TNF-a (3 fold)
and IFN-y ( 5.5 fold). Result shown is representative of three separate experiments (Appendix 1C).
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c IL-1 IL-4 IL-6 TNF-a IFN-y
Figure 3.14 SOCS-3 expression in primary rat mesangial cells in response to
cytokine stimulation.
SOCS-3 expression in primary rat mesangial cells occurs under basal conditions (c=control) and
demonstrates no significant upreguation in response to the cytokines IL-1, IL-4, IL-6, TNF-a and
IFN-y. Result shown is representative of three separate experiments (Appendix 1C).
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Figure 3.15 CIS-1 expression in primary rat mesangial cells in response to cytokine
stimulation.
CIS-1 is expressed in primary rat mesangial cells under basal conditions (c=control). Levels of CIS-1
mRNA are increased in response to TNF-a (1.9 fold), but not in response to any other cytokine
studied. Result shown is representative of three separate experiments (Appendix 1C).
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Interferon-y resulted in a marked upregulation of SOCS-3 expression (3 fold), while
3 and 5.5 fold increases in CIS-1 mRNA occurred in response to TNF-a and IFN-y,
respectively in these cells. Less dramatic increases in SOCS-3 and CIS-1 expression
occurred in response to the other cytokines studied; SOCS-3 expression in response
to IL-ip (2.0 fold), IL-4 (1.8 fold), IL-6 (2.0 fold) and TNF-a (2.1 fold): CIS-1
expression in response to IL-1 (1.9 fold), IL-4 (2.3 fold) and IL-6 (1.8 fold). In
contrast, while CIS-1 mRNA in mesangial cells increased 1.9 fold following TNF-a
treatment, no significant increases in either CIS-1 or SOCS-3 expression in these
cells occurred in response to any other cytokine studied. Obviously in view of the
limitations of semi-quantitative RT-PCR, these results will be confirmed using
Northern analysis.
In summary, increases in the expression of SOCS-3 and CIS-1 in RGEC appeared to
occur in response to both pro- (IL-1 p, TNF-a and IFN-y) and anti-inflammatory (IL-
4 and IL-6) cytokines. Rat mesangial cells appeared less responsive to cytokine-
induced SOCS-upregulation, with only TNF-a producing a modest increase in CIS-1
expression in these cells.
Other investigators in our group have examined the role of cytokines in the
modulation of SOCS expression in another cell culture model - an SV-40
transformed murine mesangial cell line, MES 13 (ATCC, Maryland, USA) (98).
MES 13 cells also express SOCS-3 and CIS-1 under control conditions while
increases in SOCS-3 and CIS-1 mRNA occur in response to TNF-a and IL-1 p
stimulation of these cells. IFN-y has no significant effects on cytokine-induced
300
SOCS-3 and CIS-1 upregulation in these cells. The anti-inflammatory cytokines IL-4
and IL-13 increased expression of CIS-1, but not SOCS-3. This study also examined
whether IL-6 and its family members could modulate SOCS expression in MES 13
cells. In brief, significant upregulation of SOCS-3 and CIS-1 occur in response to IL-
6 and the related cytokines, LIF and IL-11.
Since studies in RGEC (and previously in MES 13) cells indicated that SOCS were
upregulated in vitro in response to both pro- and anti-inflammatory cytokine
stimulation, it was unclear whether SOCS expression levels in vivo would correlate
with the extent or the resolution of inflammation. In order to assess this, the
glomerular expression of SOCS-2, -3 and CIS-1 in a rat model of crescentic nephritis
was determined.
Total glomerular RNA was isolated from control animals and from those animals to
whom nephrotoxic serum had been administered 2 and 7 days previously. Analysis
of SOCS expression was by means of RT-PCR using sequence specific primers
(Table 3.2). As can be seen, SOCS-3 and to a variable extent CIS-1 were basally
expressed in normal rat glomeruli. By day 7 post-induction of GN, however, CIS-1
and SOCS-3 expression were markedly increased over control levels in these animals
(Fig. 3.16, 3.17).
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Figure 3.16. SOCS-3 expression in a rat model of crescentic nephritis.
SOCS-3 was basally expressed in normal rat glomeruli. By day 7 post-induction of GN, however,
SOCS-3 expression was markedly increased over control levels. IL-4 administration led to an
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Figure 3.17. CIS-1 expression in a rat model of crescentic nephritis.
Basal expression of CIS-1 in rat glomeruli varied between barely apparent to completely absent from
animal to animal. By day 7 post-induction ofGN, however, CIS-1 expression was markedly increased
over control levels. IL-4 administration led to an attenuation in disease activity and glomerular
expression of CIS-1 was also reduced in animals receiving IL-4.
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In order to assess whether treatment of GN with IL-4, having delayed the
administration of this cytokine until inflammation was established, would have any
effect on glomerular expression of CIS and SOCS-3, a group of rats were given i.v.
IL-4 twice daily from day 4 - day 7. IL-4 administration led to an attenuation in
disease activity (as indicated by significantly reduced proteinuria and fibroid necrosis
when compared to day 7 nephritic animals receiving no cytokine therapy (99).
Glomerular expression of CIS and SOCS-3 was also reduced in animals receiving
IL-4 (Fig. 3.16, 3.17).
On the basis of these results, immunohistochemical staining for SOCS-3 and CIS-1
was carried out on paraffin sections of the kidneys from these animals. To date
staining for CIS-1 has not been successful and work is ongoing overcome these
technical difficulties. In the normal kidney, SOCS-3 is present in distal tubules, but
undetectible in glomeruli (Fig. 3.18a and b). By day 2 faint glomerular SOCS-3
staining is apparent with definite glomerular staining occurring at day 7 (Fig 3.18c
and d). Staining appeared to occur in cells with the morphology of macrophages,
however, no double-staining techniques were used in this study, so the possibility
that some SOCS-3 staining is occuring in intrinsic glomerular cells cannot be
excluded. Immunohistochemistry revealed no clear differences between SOCS
expression at day 7 in the IL-4 treated rats and in those animals receiving no cytokine
therapy (Fig. 3.18e and f).
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Figure 3.18a SOCS-3 staining in normal kidney
Figure 3.18b SOCS-3 staining in normal kidney


















Figure 3.18c SOCS-3 staining at day 7 in crescentic nephritis.
Figure 3.18d SOCS-3 staining at day 7 in crescentic nephritis
In addition to SOCS-3 staining in distal tubules, definite staining occurs in glomeruli at day 7 in
crescentic nephritis.
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Figure 3.18e. SOCS-3 staining at day 7 in crescentic nephritis following IL-4
Figure 3.18f. SOCS-3 staining at day 7 in crescentic nephritis following IL-4
Immunohistochemistry revealed no apparent differences between SOCS-3 expression at day 7 in the
IL-4 treated rats and in those animals receiving no cytokine therapy.
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3.7.4. Discussion
The current study attempted to define the role of SOCS in renal inflammation. In
vitro studies employing various renal cells (RGEC, MES 13) determined that
upregulation of these species was a consequence of both pro-inflammatory (TNF-a,
INF-y and IL-1(3) and anti-inflammatory (IL-4 and IL-6) cytokine stimulation,
suggesting that CIS-1 and SOCS-3 upregulation was a pleiotropic negative
regulatory mechanism whereby cytokine-dependent Jak/STAT signaling was
blunted. In agreement with these findings, in vivo investigations employing a rat
model of nephrotoxic nephritis found that SOCS-3 and CIS-1 upregulation correlated
with disease activity. Taken together these in vitro and in vivo findings imply that, in
the scenario of renal inflammation, the expression level of a given SOCS species is
likely to reflect the total load of cytokines (both pro- and anti-inflammatory) within
the site of inflammation capable of upregulating its expression.
As has been previously stated, both the specificity of SOCS expression and the
kinetics which this expression follows appear to be regulated at the transcriptional
level in a cell and tissue-dependent fashion. Cytokine-receptor interaction, the
particular JAKS which this activates, or indeed the STAT dimers which are
consequently utilised to initiate transcription, do not appear to define SOCS
expression with the same certainty as has been evidenced for other cytokine-
inducible genes. For this reason it was necessary to define the pattern of basal and
induced SOCS expression in the in vitro and in vivo models used in the current study.
Interestingly, the basal expression of SOCS-3 characteristic of all the cell types
studied here was also found in glomerular RNA samples. However, while CIS-1
expression was constitutive in these cell types, normal rat glomeruli did not
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consistently express this transcript. In our hands basal expression of CIS-1 in rat
kidney - both cortex and purified glomeruli - varied (between barely apparent to
completely absent) from animal to animal. While it has been reported that murine
kidney exhibits pronounced basal CIS-1 expression (61), it also appears that
unstimulated CIS-1 expression in murine tissues (liver, thymus and, to a lesser
extent, kidney) is gender-dependent, with female animals exhibiting significantly
enhanced levels (60). Since male rats were used in the present study, this remains as
a possible explanation for the observed variability.
While only significant TNF-a induced upregulation of CIS-1 could be demonstrated
in rat mesangial cells, both CIS-1 and SOCS-3 were determined to be the relevant
agonist-inducible SOCS in RGEC and MES 13. Treatment of these cells with various
pro- and anti-inflammatory cytokines resulted in the upregulation of one, other or
both of these transcripts. Similarly, CIS-1 and SOCS-3 were amplified from nephritic
glomeruli cDNA. It must be pointed out, however, that while mesangial cells in
particular may be taken as an indicator of the responses of the predominant resident
cell in the glomerulus, in the scenario of renal inflammation, the situation becomes
much more complex due to the accumulation of mononuclear cells. Regardless, the
data demonstrate a broad correlation between the pattern of basal and inducible
SOCS expression in an in vitro and in vivo model of renal inflammation. This
parallels other studies in which the in vitro expression of a SOCS species in tissue-
derived cells corresponded to its in vivo expression in the originator organ; SOCS-3,
for example, was found to be the predominant basally-expressed and LIF-induced
species in both a pituitary tumor-derived corticotroph cell line and in murine
pituitary in vivo (87).
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WKY rats have been shown to be reliably susceptible to the induction of severe
crescentic GN in response to a single i.v. dose of anti-GBM containing serum (97,
100). This model is, therefore, consistent and reproducible since the requirement for
pre-immunisation associated with most animal models of accelerated GN is removed
and potential variations in disease progression arising from differences in individual
immune responses are no longer an issue. SOCS expression was investigated over
seven days following the administration of nephrotoxic serum, since it was reasoned
that this time course incorporated the initial renal assault, the primary immunologic
response and the peaks of both the heterologous and autologous phases of the
disease.
It has been shown that a number of leukocyte adhesion molecules, pro-inflammatory
cytokines and chemokines facilitate the infdtration of glomeruli (and/or tubulo-
interstitum) by mononuclear cells in experimental nephrotoxic nephritis (100-104).
Nephrotoxic GN in WKY rats is associated with infdtration of leukocytes
(predominantly monocytes/macrophages and CD8+ lymphocytes) within 2.5 hr p. i.,
reaching a peak between day 4 and day 8. CD8+ cells (which at their day 4
maximum represent 20-25% of the total infdtrate) appear to play a pivotal role in the
pathogenesis of this model. Depletion of CD8+ cells has been shown to significantly
reduce glomerular monocyte/macrophage accumulation (100, 105) and to completely
prevent proteinuria and crescent formation (105). It has been speculated that CD8+
cells act to promote monocyte/macrophage accumulation and, hence, the
pathogenesis of GN via their production of pro-inflammatory and chemotactic
cytokines. CD8+ cell depletion has been shown to reduce the early glomerular
expression of a number of cytokines and it has been proposed that CD8+-derived
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mediators facilitate monocyte/macrophage infiltration in part through their induction
of glomerular cytokine/chemokine and intercellular adhesion molecule-1 (ICAM-1)
expression. Indeed, glomerular ICAM-1 levels are markedly reduced in
CD8+depleted nephritic WKY rats, in tandem with a reduced monocyte/macrophage
infiltrate (100). The temporal profile of glomerular pro-inflammatory cytokine
(namely TNF-a, ILl-p, INF-y) and chemokine induction in the WKY model
parallels that of ICAM-1; expression is apparent within 1 hr and significantly
elevated at day 3. It is not surprising therefore, that the current study found CIS-1
and SOCS-3 levels to be maximal at day 7, since logic dictates that stimulated levels
of these species should kinetically trail the peak of cytokine expression.
Glomerular expression of SOCS-3 and CIS-1, as detected by RT-PCR, was reduced
in animals receiving IL-4. In contrast, no definite difference in the glomerular
expression of SOCS-3 could be detected using immunohistochemistry.
Immunoperoxidase staining is, however, a relatively insensitive technique for the
assessment ofmoderate expression differences and therefore, small changes between
the treated and untreated animals might not be readily apparent. The ability to detect
basal glomerular SOCS-3 expression in normal glomeruli by semi-quantitative RT-
PCR but not immunohistochemistry supports this contention.
A detailed immunohistological analysis of renal sections in this model has been
previously performed by other investigators. These studies indicated that in animals
receiving IL-4 the number of infiltrating macrophages were not reduced over control.
There was, however, significantly fewer iNOS positive cells and markedly reduced
staining for sialoadhesin, markers of macrophage activation (99). These results
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suggest that the upregulation of SOCS-3 and CIS-1 at day 7 arises as a consequence
of increased production and activity of cytokines within the inflammatory site.
Conversely, the blunting of macrophage activity following IL-4 administration is
likely to result in reduced ambient cytokine levels and hence reduced SOCS-3 and
CIS-1 expression.
In summary the up-regulation of SOCS, namely SOCS-3 and CIS-1, in renal cells in
vitro has been demonstrated in response to both pro- and anti-inflammatory
cytokines. In keeping with these observations, increases in SOCS-3 and CIS-1 have
been demonstrated in rat nephrotoxic nephritis. In this model it appears that SOCS
expression correlates with disease activity, providing evidence that these proteins
may represent a pleiotropic negative feedback mechanism by which the JAK/STAT-
dependent actions of cytokines are blunted. To-date, SOCS expression has not been
reported in other inflammatory renal diseases. However, it will be intriguing to
determine their pathophysiological role and potential therapeutic targets in cytokine-
driven renal disease.
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3.8. SOCS expression in cardiac transplant rejection and correlation with
cytokine levels and immune cell infiltration
3.8.1. Introduction
Having studied SOCS in autoimmune inflammation, the profile of SOCS expression
in an animal model of alloantigen-driven inflammation was next examined. Since I
am a cardiologist an animal model of experimental acute cardiac transplant rejection
was chosen.
The development of microsurgical techniques has provided a potent tool in the study
of whole organ allograft immunobiology in rodents. Studies in such models have
greatly expanded the knowledge of transplant immunology and have been a driving
force in the development of the now commonly used various immunosuppressive
regimes (106). One of the most technically feasible models that facilitates studies
into cardiac rejection is the heterotopic cardiac allograft (107). Here the donor graft
is transplanted infrarenally into the pelvis of the recipient by anastomosis to aorta
and inferior vena cava and the native heart is left in situ. A cervical accessory model
with anastomosis to recipient carotid artery and jugular vein also exists but this is
used less frequently. In such models the transplanted heart can be easily palpated,
with rejection defined as complete cessation of palpable heart beat (and confirmed at
laporatomy). Loss of pulsation in the first 48 hours however is regarded as an
indicator of operative failure and can be confirmed by the presence of thrombus at
anastomotic sites. Once the animal is sacrificed both native and donor heart can be
retrieved ensuring the easy availability of suitable controls in these studies. The
degree of MHC mismatch between donor and recipient, in addition to the
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administration (or not) of immunosuppressive therapy, determines whether the model
is one of acute or chronic rejection (108).
Heterotopic cardiac allografts exchanged across the MHC in terms of complete Class
I and Class II mismatch provide a highly reproducible and rigidly controlled model
for studies of acute rejection. Immunohistochemistry in such models has confirmed
progressive mononuclear cell (CD4+, CD8+ and macrophages) infiltration into
allograft tissue (109, 110). In addition there is severe diffuse loss of integrity of the
microvascular endothelium providing strong evidence that the allograft
microcirculation is a central target of graft destruction. The central role of T cells in
acute graft rejection has been shown conclusively in athymic mice, which fail to
produce mature T cells (111). These mice accept grafts from syngeneic, allogeneic or
even xenogeneic donors, without evidence of rejection. The CD4+ and CD8+ T cell
subset are independently capable of mediating graft rejection. Studies have shown
that administration of monoclonal antibody to either CD4+ or CD8+ cells is
ineffective in preventing graft rejection confirming the functional overlap of these
lymphocyte subsets (112). Similarly, the experimental elimination of either MHC
Class I or Class II molecules by gene inactivation using homologous recombination
("knock-out") technology in mice has shown that grafts expressing only Class I
(predominantly recognised by CD8+ T cells) or Class II (predominantly recognised
by CD4+ T cells) are both readily rejected (113).
The first experimental studies which analysed the molecular pathways involved in
acute rejection and graft acceptance provided evidence that these mechanisms were
dominated by intragraft production of either Thl or Th2 cytokines, respectively.
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Studies to date in these models have demonstrated the consistent upregulation of
various cytokines and chemokines. The temporal nature of these responses varies
slightly, depending on the animal used and MHC mismatch.
It has become evident using genetically manipulated animals, however, that rejection
and acceptance are not exclusively restricted to the typel/type 2 dichotomy. IL-2 and
IFN-y "knockout" mice reject their transplants in the presence of Th2 cytokines and
IL-4 knockout mice accept their transplants in the presence of Thl cytokines (114).
In addition to the upregulation of cytokines and chemokines, the upregulation of
adhesion molecules, MHC molecules, complement and the molecules implicated in
cell-mediated cytotoxicity (perforin, granzyme) have been demonstrated in these
models and evidence provided for their functional roles in the allogeneic immune
response (115-119).
Mechanisms of immunosuppression
In the last decade, aided by such work in experimental transplant settings, there has
been remarkable developments in the field of immunosuppression with the result that
the transplant physician now has an expanding portfolio of immunosuppressive
agents for the prevention and treatment of rejection (120). Most regimens employ a
corticosteroid which blocks T cell activation and proliferation. Azathioprine also
blocks lymphocyte proliferation following antigenic stimulation, possibly by
blocking DNA replication. Mycophenolate mofetil is a novel immunosuppressive
drug which also has a potent cytostatic effect (predominantly on lymphocytes), again
by interfering with DNA synthesis (121). The demonstration in some experimental
models of its ability to inhibit vascular smooth muscle proliferation may offer
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potential in the treatment of chronic rejection. Cyclosporin, a small cyclic peptide of
fungal origin, remains the basis for all current immunosuppressive protocols. By
■ji
blocking the Ca dependent component of the T cell receptor signal transduction
pathway, it blocks the expression of cytokines produced by T cells including IL-2,
IL-3, IL-4, IFN-y and TNF-a (122). It does not, however, interfere with IL-1 or TNF
production by APC or macrophages. FK 506, although differing in structure to
cyclosporin, acts through the same final common pathway to block the induction of
cytokine RNA and indirectly inhibit T cell proliferation (123). Rapamycin is a potent
immunosuppressive agent which is currently undergoing clinical trials. In contrast to
cyclosporin and FK 506 which inhibit an early signal in T cell activation, rapamycin
inhibits late signals in T cell activation by preventing phosphorylation of p70 kinase
in the CD28 co-stimulatory and IL-2R signal transduction pathways (124).
Combination therapy with cyclosporin and rapamycin has been shown to
synergistically increase immunosuppression in experimental models.
Administration of polyclonal anti-lymphocyte globulin results in the elimination of
circulating T cells and resolution of acute graft rejection episodes; however, in
addition to profound immunosuppression, the heterogeneity of the antibody mixture
can lead to variable efficacy as well as adverse reactions. The development of
monoclonal antibodies to T cell surface molecules offers the advantage of more
predictable therapeutic agents (120). The monoclonal antibody OKT3 which is
routinely used in clinical practice binds the T cell receptor and blocks both CD4+
and CD8+ T cell function. A number of other antibodies such as anti-leukocyte
function-associated antigen-1 (LFA-1), anti-ICAM-1, anti-CD4 and anti-CD25 have
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been shown to reduce rejection in animal models and are currently being tested in
clinical trials (125).
Tolerance induction
The incidence of organ rejection, and of death from infection, have decreased over
time, primarily as a result of improvements in immunosuppression and in the
prevention and treatment of infection. These advances not with-standing,
immunological rejection and its sequlae - toxicity from immunosuppressive regimes
and graft dysfunction - remain the major cause of morbidity and mortality in
transplant patients. The increased incidence of cancers such as lymphoma secondary
to prolonged immunosuppression is also a concern. The ultimate goal of clinical
transplantation is to induce donor-specific unresponsiveness in the recipient while
maintaining responsiveness to donor antigens. Most approaches to tolerance
induction to an allograft in the experimental model involve pretreatment or treatment
with antigen in one form or another, usually in association with immunosuppressive
therapies. Intrathymic immune modulation with donor antigens in the form of donor
cells, purified MHC antigens, synthetic allopeptides, in addition to donor specific
blood transfusion, have been demonstrated to be effective means of inducing long
term allograft survival in various experimental systems (126-130). The exact
mechanisms induced using this approach are not yet well defined. An alternative
strategy has been to inhibit the costimulatory signal during T cell encounter with
donor antigen and induce non- specific tolerance. Blockade of CD28-B7 binding by
CTLA4Ig in combination with donor specific lymphocytes, indefinitely prolonged
graft survival in a heterotopic transplant model (131). Recently in human bone
marrow transplantation, donor bone marrow was co-cultured with irradiated cells
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from the recipient in the presence ofCTLA4-Ig and then transfused into the recipient
following conventional myeloablation (132). This resulted in anergy to alloantigens
with a low risk of graft versus host disease, while responsiveness to other unrelated
alloantigens was unaffected. The widespread applicability of this procedure to bone
marrow transplantation, and indeed other organ transplantation, remains to be seen.
In summary then, allograft rejection, both acute and chronic, represents the end result
of a complex set of immunological processes arising from the recognition of non-self
antigens on transplanted tissues. The alloreactive phenotype is discussed in detail in
section 1.3.5. Cytokines sustain and amplify the allograft-directed immune response
by promoting lymphocyte activation, increasing adhesion molecule expression, and
regulating MHC expression. Cytokine elaboration, and consequently cytokine-
activated JAK/STAT mobilisation, is therefore a critical determinant of graft
rejection. The suppressors of cytokine signalling (SOCS) proteins function as
negative regulators of cytokine-activated JAK/STAT signal transduction. Animal
heterotopic cardiac allografts exchanged across the MHC in terms of complete Class
I and Class II mismatch provide a highly reproducible and rigidly controlled model
for studies of acute rejection. The aim of this study therefore was to examine the
expression of SOCS in this experimental setting. In addition, the temporal expression
of cytokines and leukocyte trafficking determinants were also investigated in this
model.
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3.8.2. Materials and Methods
Animals and grafting techniques
Inbred Lewis (LEW RT1L) and Wistar-Furth (WF RT1U) rats weighing 200-250g
were purchased from Harlan Sprague-Dawley (Indianapolis, IN). LEW to WF
heterotopic cardiac allografting was performed as previously described (107). Donor
hearts were transplanted to the recipients abdomen by anastomising donor and
recipient aorta, and donor pumonary artery to inferior vena cava. These cardiac
allografts show an irreversible rejection 7-10 days post-transplantation. LEW to
LEW transplants and native hearts served as isograft/ischaemia-reperfusion controls.
Rejection was defined as complete cessation of palpable heart beat. Animals were
sacrificed at days 1, 3, 5 and 7 post transplantation and both native (N) and donor
heart (T) retrieved. A portion of each tissue was frozen in liquid nitrogen and stored
at -80°C for subsequent RNA extraction. The remaining portion was embedded in
Cryo-gel (Instrumedics Inc., Hakensack, NJ) and immediately snap frozen in liquid
nitrogen in preparation for immunohistologic studies.
Immunohistology
Cryostat sections were blocked with normal horse serum. Sections were also blocked
for endogenous peroxidase using 0.3% H2O2 in methanol for 20 minutes. Sections
were then stained with the following primary antibodies: CD 45 (mouse anti-rat CD
45, Serotec UK) 10-20 jig/ml for 1 hour at room temperature and EDI (mouse anti-
rat ED 1, Serotec UK) 10-20 pg/ml for 1 hour at room temperature. CD 45 (often
referred to as common leukocyte antigen (CLA)) is a universal antigen present on all
leukocytes, while ED-1 is a cytoplasmic antigen present in monocytes, macrophages
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and dendritic cells. The secondary antibody in all cases was biotinylated anti-mouse
IgG (affinity purified and not absorbed) 10 pg/ml for 30 minutes (Vector Labs, CA
94010). Detection system for all antibodies was Vectastain ABC System (Vector
Labs, CA). Expression of both antigens on cardiac sections was graded
semiquantitatively and reflected changes in the intensity of staining.
RT-PCR
Total RNA from cardiac tissue was isolated using Trizol reagent (Gibco Life
Technologies, Paisley, Scotland) according to the manufacturers' instructions. Total
RNA (2pg) was treated with DNase I and 01igo(dt)i2-i8 was then used to generate first
strand cDNA. Reverse transcription was carried out using Superscript II RNase H (all
from Gibco). Sequence specific primer pairs were designed for each gene studied and
obtained from Sigma-Genoys (Cambridge, UK). (Table 3.3). Amplification was as
previously described, typically 94°C for 3 minutes; 35-40 cycles of 94°C for 30
seconds (denaturing), 55°C-60°C for 1 minute (annealing) and 72°C for 1 minute
(extension); followed by a final extension step of 72°C for 7 minutes. cDNA samples
were subjected to parallel PCR reactions with primers for GAPDH to control for
equivalency of loading. The presence of genomic DNA was determined by control
reactions in which amplification was conducted in complete reaction mixture lacking
template cDNA or with RNA samples from RT reactions carried out in the absence of
Superscript II. PCR products were visualised by ethidium bromide staining following
electrophoresis on 1.2% agarose gels. Subsequent quantification for each gene
studied in comparison to the GAPDH loading control was conducted using the










P1= Primer 1 P2= Primer 2
SOCS
SOCS-1 55 273
P1 5'-TCC GOT CCC ACT CTG ATT AC-3'
P2 5'-CGA AGA GGC AGT CGA AGG T-3'
SOCS-2 55 333
P1 5'-AAA TTA AAA GAG GCG CCA GA-3'
P2 5'-AAT GCT GAG TCG GCA GAA GT-3'
SOCS-3 55 200
P1 5'-GCT ACC CTC CAG CAT CTT TG-3'
P2 5'-GGC TGG ATT TTT GTG CTT GT-3'
CIS-1 55 201
P1 5'-TCT CCT ACC TCC GGG AAT CT-3'
P2 5'-CCA GTC GGA AGC TAG AGT CG-3'
GAPDH 60 495
P1 5-ACC ACA GTC CAT GCC ATC AC-3'
P2 5'-TCC ACC ACC CTG TTG CTG TA-3'
CYTOKINES
IL-1 p 60 510
P1 5'-TCA TTG TGG CTG TGG AGA AG- 3'
P2 5-AGT TGG GGA ACT GTG CAG AC-3'
TNF-a 60 489
P1 5'-GCT CCC TCT CAT CAG TTC CA-3'
P2 5'-AAG TAG ACC TGC CCG GAC TC-3'
IL-2 60 388
P1 5'-CAG CTC GCA TCC TGT GTT GCA C-3'
P2 5-'CAC AGT TGC TGG CTC ATC ATC G-3'
IFN-y 60 299
P1 5'-TTA CTG CCA AGG CAC ACT CA-3'
P2 5'-ACT TGG CGA TGC TCA TGA AT-3'
IL-4 60 204
P1 5'-TCC TTA CGG CAA CAA GGA AC-3'
P2 5'-TTG TGA GCG TGG ACT CAT TC-3'
IL-10 60 450
P1 5'-CCT GCT CTT ACT GGC TGG AG-3'
P2 5'-TTC ATG GCC TTG TAG ACA CCT-3'
TGFp 60 552
P1 5'- GTC AAC TGT GGA GCA ACA CG-3'
P2 5-TGG TTG TAG AGG GCA AGG AC -3'
CTGF 60 400
P1 5'-CTA AGA CCT GTG GAA TGG GC-3'
P2 5'-CTC AAG ATG TCA TTG TCC CC-3'
CHEMOKIN ES
GRO-a 60 180
P1 5'-AGA CAG TGG CAG GGA TTC AC-3'
P2 5'-ACT TGG GGA CAC CCT TTA GC-3'
MCP-1 60 266






P1 5'- AAA CCT ACC CCA CAA CCA CA-3'
P2 5'-CTG GGC CTT GAA AAA GCA TA -3'
CCR2 60 350
P1 5-TTT GAT CCT GCC CCT ACT TG-3'
P2 5'-TTT TGG CAA TGT GCT TTC TG-3'
CXCR2 60 197
P1 5-AGT TCT GAC CCG CCC TTT AC-3'
P2 5'-GCC AGG TTC AGC AGG TAG AC-3'
CXCR4 60 501
P1 5'-GCC ATG GCT GAC TGG TAC TT-3'
P2 5'-GAA GGA ATC GAT GCT GAT CC-3'
ADHESION MOLECULES
ICAM-1 60 600
P1 5-TTC TGC CAC CAT CAC TGT GT-3'
P2 5'-TTC TCC ATC TCC AGG GTC TG-3'
VCAM-1 60 451
P1 5-GAC CTG TCA GCG AAG GAA AC-3'
P2 5'-TGA GCA GGT CAG GTT CAC AG-3'
Table 3.3. Rat primer sequences and product sizes.
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3.8.3. Results and Discussion
In the current study the expression of SOCS, cytokines, leukocyte trafficking
determinants in a rat model of acute experimental cardiac rejection was assessed. In
the model chosen for analysis, for allogeneic grafts Lewis rats serve as recipients for
Wistar Furth cardiac transplants (W->L); for syngeneic grafts Lewis rats are used as
both donors and recipients (L-*L). The combination ofWistar Furth to Lewis is fully
mismatched for both MHC class I and class II antigens and thus serves as a model of
acute cardiac transplant rejection: cardiac allografts reproducibly undergo
irreversible rejection 7-10 days post-transplantation. An animal from each group was
sacrificed at days 1, 3, 5, and 7 post-transplantation and both the native (N) and
donor (T) heart retrieved, i.e. for each time point post-transplantation 4 hearts were
analysed (W—>L, N and T; L~»L, N and T).
It is important to note that, since intact hearts were used for total RNA extraction,
mRNA levels of the species examined reflect all cells present in the organ, both
resident and infiltrating. In agreement with the current paradigm of acute transplant
rejection, the upregulation of immune mediators in the present study was almost
exclusively restricted to allogeneic graft tissue. Spleen and lymph nodes were not
harvested from the animals, but it has been confirmed in similar models that the
temporal expression of immune mediators in these organs is similar to those in
acutely rejecting allografts. mRNA levels for many of the key determinants in this
process were elevated one day following surgery and most remained above control
levels throughout the time course studied, confirming that the immune response is
rapid and sustained in this scenario.
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Immunohistology
Cryostat sections from native and transplanted hearts were stained for the common
leukocyte antigen (CLA, CD45 - a universal marker present on all leukocytes) and
the macrophage marker EDI at all time points. In common with previous reports
(109, 133) the current model of unmodified cardiac rejection was characterised by
progressive mononuclear cell infiltration. The number of CLA positive and EDI
positive cells in transplanted hearts, both syngeneic and allogeneic, was elevated
from day 1 as compared with the native controls - most probably as a consequence
of post-operative ischaemia-reperfusion. By day 3 however, marked infiltration of
the acutely rejecting mismatched heart by ED1+ cells was found, with the numbers
of these cells in these organs, as compared with native hearts and syngeneic controls,
remaining elevated over the time course studied (Fig. 3.19a-g). Likewise,
pronounced infiltration of allogeneic organs by CLA positive cells, as compared to
the matched controls, was apparent from day 5 onwards (Fig. 3.20a-d).
These results confirm that in the current model immune cell infiltration of the
rejecting organ is rapid and sustained. Thus having established, in agreement with
previous studies, that immunological rejection of allograft tissue occurred throughout
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Table 3.5 Graft tissue graded for positivity following IHC staining with anti-CD 45.
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Figure 3.19a EDI staining in the native heart at day 1 following allogeneic transplant
Figure 3.19b EDI staining at day 1 in allogeneic heart
Sinificant infiltration ofEDI positive cells into the allogeneic organ occurs at day 1, as compared with
native heart.
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Figure 3.19c EDI staining in the native heart at day 5 following allogeneic transplant
Figure 3.19d EDI staining at day 5 in allogeneic heart
Marked infiltration of EDI positive cells into the allogeneic organ occurs at day 5, as compared with
native heart.
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Figure 3.19fEDI staining at day 5 in allogeneic heart
Marked infiltration of EDI positive cells into the allogeneic organ occurs at day 5, as compared with
syngeneic heart.
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Figure 3.19g EDI staining in the allogeneic heart at day 7.
Ongoing infiltration by EDI positive cells occurs at day 7 in the allogenic organ
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Figure 3.20a CD 45 staining in the native heart at day 1 following allogeneic
transplant
Figure 3.20b CD45 staining at day 1 in allogeneic heart
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Figure 3.20c CD 45 staining in syngeneic organ at day 5 following transplant
Figure 3.20d CD45 staining at day 5 in allogeneic heart




Cytokines are central to the generation of the allogeneic immune response. These
mediators are produced by multiple different cell types including T cells, B cells,
monocytes/macrophages and antigen presenting cells as well as various non-immune
cells including endothelial cells. Cytokines initiate their pleiotropic cellular effects
through their interactions with specific receptors on the surface of target cells. Once
bound to the surface receptor various intracellular signal transduction pathways are
activated and ultimately these lead to the transcription of new genes. The importance
of the JAK/STAT signal transduction cascade in linking activation of cytokine
receptors to gene transcription has been established. Recently a family of inhibitors
of JAK/STAT signalling have been reported, the suppressors of cytokine signalling
(SOCS) family. These are discussed in detail in section 3.6 and their profile in an
experimental model of glomerulonephritis is detailed in section 3.7. We sought
therefore to examine the expression of the SOCS family members in another model
of acute inflammation - acute transplant rejection.
Levels of SOCS-3 mRNA were elevated specifically in allogeneic transplants on
days 1-7. No SOCS-3 expression could be detected in native hearts or syngeneic
controls (Fig. 3.21). CIS-1 expression occurred in all specimens, but at day 5 levels
in the allogeneic graft, as compared to the control tissues were elevated (Fig 3.22).
SOCS-1 was weakly expressed in rejecting organ at day 5 only (Fig 3.23). RT-PCR
analysis of SOCS-2 revealed constitutive expression but no allogeneic-specific
upregulation of this species (Fig 3.24).
331
Day 1 Day 3 Day 5 Day 7




Day 1 Day 3 Day 5 Day 7






































Figure 3.21. SOCS-3 expression in experimental acute cardiac transplant rejection
Levels of SOCS-3 mRNA were elevated specifically in allogeneic transplants on days 1-7. No SOCS-
3 expression could be detected in native hearts or syngeneic controls
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Figure 3.22. CIS-1 expression in experimental acute cardiac transplant rejection
CIS-l expression occurred in all specimens, but at day 5 levels in the allogeneic graft, as compared to
the control tissues were elevated
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Figure 3.23 SOCS-1 expression in experimental acute cardiac transplant rejection
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Figure 3.24 SOCS-2 expression in experimental acute cardiac transplant rejection




Having confirmed the presence of SOCS in this model, we then sought to establish
the simultaneous presence of a variety of representative cytokines known to be
important in the rejection process. mRNA for the cytokine TNF-a was present in all
specimens at day 1, but more pronounced in the transplanted hearts (allogeneic and
syngeneic). After day 1 however mRNA for this species declined in control tissues
while levels in the mismatched grafts continued to increase and remained elevated
compared to the control at all time points (Fig 3.25). Similarly, IL-ip was detected in
native hearts, syngeneic transplants and allogeneic transplants at day 1. On days 3, 5
and 7, however, expression levels for this cytokine rose markedly in mismatched
transplants when compared to native hearts and syngeneic controls. (Fig 3.26) The
universal expression of these mRNA species on day 1 was most probably a post¬
operative phenomenon and, in particular, increased expression of TNF-a in the
transplanted hearts on day 1, and its subsequent decline in syngeneic tissue, is most
likely secondary to ischaemia-reperfusion injury occurring specifically in the
transplanted hearts. The expression of IL-2 and IFN-y was identified only in
allogeneic transplants. mRNA for IL-2 was apparent from day 3 onwards while that
for IFN-y was detectable at days 5 and 7 only (Fig. 3.27, Fig. 3.28). In contrast,
expression of the Th2 cytokine IL-4 was not detected in native hearts, isograft
controls or allogeneic hearts over the time course studied, while IL-10 mRNA was
apparent only in allogeneic organs from day 3 onwards (Fig. 3.29).
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Figure 3.25 TNF-a expression in experimental acute cardiac transplant rejection
mRNA for the cytokine TNF-a was present in all specimens at day 1, but more pronounced in the
transplanted hearts (allogeneic and syngeneic). After day 1 however mRNA for this species declined
in control tissues while levels in the mismatched grafts continued to increase and remained elevated
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Figure 3.26 IL-ip expression in experimental acute cardiac transplant rejection
IL-ip was detected in native hearts, syngeneic transplants and allogeneic transplants at day 1. On days
3, 5 and 7, however, expression levels for this cytokine rose markedly in mismatched transplants when
compared to native hearts and syngeneic controls
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Figure 3.27 IL-2 expression in experimental acute cardiac transplant rejection
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Figure 3.28 IFN-y expression in experimental acute cardiac transplant rejection




























Figure 3.29 IL-10 expression in experimental acute cardiac transplant rejection
The expression of IL-10 was identified only in allogeneic transplants at days 5 and 7.
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T cells and their products are critical in the acute rejection event. Two major subsets
of T cells, the CD8+ cytotoxic T cells and CD4+ T helper (Th) cells recognise
processed antigen on MHC class I and class II, respectively. Subsets of Th cells,
namely Thl and Th2, which exhibit characteristic cytokine production profiles are
central to the immune response (section 1.3.5). Thl cells exert broadly pro¬
inflammatory actions via their secretion of IL-2, TNF-a and IFN-y, while Th2
cytokines (principally IL-4, IL-6, IL-10 and IL-13) exert mainly anti-inflammatory
effects via their suppression of macrophage and Thl cell activation. IL-2 is a
powerful autocrine T cell growth factor, activating T cells, stimulating their growth
and giving rise to clonal expansion. In addition, this cytokine facilitates the effector
function of cytotoxic T cells. TNF-a and IFN-y, secreted both by Thl cells and
macrophages, exert activating effects on monocytes and resident cells. These
cytokines induce class I and class II antigen expression, modulate adhesion molecule
expression and stimulate the release of further cytokines, chemokines and growth
factors from monocytes, T cells and endothelial cells. IL-lp production by antigen-
activated macrophages further enhances the immune response by stimulating growth
factor and chemokine production by resident cells thus promoting further infiltration
of lymphocytes and macrophages into the allograft. IL-lp also acts in an autocrine
fashion to induce its own synthesis.
The cytokines IL-4 and IL-10 are produced mainly by Th2 cells. These cytokines
have multifunctional roles, the most important of which is the modulation of
macrophage function (3). Th2 cytokines have been shown to inhibit macrophage
release of reactive oxygen species (ROS), proinflammatory cytokines and
chemokines. In addition, these anti-inflammatory mediators down-regulate leukocyte
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growth factors, including granulocyte macrophage colony-stimulating factor (GM-
CSF) and granulocyte colony stimulating stimulating factor (G-CSF). All of these
effects result in a marked attenuation of the inflammatory process. The role of IL-10,
however, is particularly complex in that its effects are not uniformly
immunosuppressive or anti-inflammatory: IL-10 augments IL-2-driven proliferation
of cytotoxic T cells and enhances IL-2 induced cytotoxicity by these cells. In
addition this cytokine stimulates antibody dependent cellular cytotoxicity. Thus,
depending on the nature of the APC and the local microenvironment, IL-10 may
exert anti- or pro-inflammatory effects. The presence of IL-10, and its related
cytokines, is well-documented in experimental transplant models treated with
immunosuppression or manipulated to induce tolerance where immune deviation
from a Thl to a Th2 phenotype occurs. Conflicting reports exist as to the expression
of this cytokine in models such as the one examined. Our observation that IL-10, but
not IL-4, is expressed in the allogeneic transplants may indicate that in this scenario
IL-10 is behaving as a pro-inflammatory cytokine or indeed raises the possibility that
the IL-10 transcripts observed were not derived from Th2 lymphocytes, but from
cells of a monocyte lineage (134).
The observations in the current study that expression of pro-inflammatory cytokines
is restricted to mismatched allografts confirms that in acute cardiac rejection, the
inflammatory response is largely confined to the graft tissue and implicates these
cytokines in the promotion and amplification of this response. These results are in
broad agreement with those of other investigators using other experimental acute
transplant rejection models including murine heterotopic cardiac transplantation
models, alternative rat heterotopic cardiac transplantation models exchanged over
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different MHC mismatches and, indeed, acutely rejecting renal allografts in rats
(117, 135, 136). Analyses in these experimental settings have demonstrated that
acute rejection is dominated by intragraft production of pro-inflammatory cytokines
(IL-2, IFN-y, TNF-a, IL-ip) while graft acceptance, in general, is associated with
diminished type 1 and enhanced type 2 cytokine production (137).
The complex actions of the cytokine TGF-p are essential in a wide range of
pathophysiological processes. Constitutive expression is essential for the
maintenance of normal immune and tissue function; TGF-p "knock-out" mice
demonstrate immune dysregulation, multiorgan inflammation and early death (53).
TGF-P is upregulated in many diseases particularly autoimmune disorders where it
appears to exert anti-inflammatory actions (3). In this model, TGF-P expression was
detected only in allogenic transplants from day 3 onwards and remained elevated
over the time course studied (Fig. 3.30). Connective tissue growth factor (CTGF) is a
downstream mediator of TGF-P action on connective tissue cells, where it stimulates
cell proliferation and synthesis of ECM (138). Studies have demonstrated that CTGF
is coordinately expressed with TGF-p in every fibrotic disorder examined to date. In
the current model CTGF, although constitutive in all specimens, was not specifically
upregulated in mismatched transplants (Fig 3.31). The upregulation of TGF-p during
cardiac allograft rejection most likely represents endogenous immunosuppression by
infiltrating lymphocytes. TGF-P also mediates potent fibrogenic effects which can be
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Figure 3.30. TGF-P expression in experimental acute cardiac transplant rejection
TGF-P expression was detected only in allogeneic transplants from day 3 onwards and remained
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Figure 3.31 CTGF expression in experimental acute cardiac transplant rejection
CTGF, was constitutive in all specimens but not specifically upregulated in mismatched transplants
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In acute allograft rejection, and certainly over the time course studied here, fibrosis is
not a prominent feature (confirmed by histology) and therefore the failure to
demonstrate increased mRNA for CTGF in allogeneic transplants is not unexpected.
It would be interesting however to profile the expression of this mediator in an
experimental model of chronic cardiac rejection or indeed in human chronic cardiac
rejection in which fibrosis is a more prominent feature.
SOCS, cytokines and immune cell infiltration
The current findings that SOCS-2 and CIS-1 are constitutively expressed are in broad
agreement with previous studies which have reported basal SOCS-2 and CIS-1
expression in murine heart. SOCS-3 expression in bone marrow is increased by a
wide range of pro-inflammatory cytokines including IL-1 (3, IL-2, TNF-a and IFN-y,
so it is not unexpected that increased levels of this mRNA species were detected in
the mismatched transplants where the ambient levels of these cytokines are elevated
as a consequence of the activation of the inflammatory response. The mechanisms by
which SOCS-3 inhibits the JAK/STAT cascade are currently unknown. Although
SOCS-3 interacts with JAK-2 in vitro, it suppresses JAK activity only weakly,
despite a pronounced inhibition of cytokine bioactivity (80, 83). The cytokines
upregulated in the current study signal through multiple JAKS and STATs (or
STAT-like factors), any number ofwhich are potential targets for SOCS-3 activity.
In contrast with the other SOCS family members, SOCS-1 is only faintly detected in
allogeneic tissue at day 5. Previous investigators have shown that basal SOCS-1
expression was not detected in murine heart and that SOCS-1 expression in bone
marrow increases in response to IFN-y but not in response to other pro-inflammatory
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cytokines such as IL-2, TNF-ot or IL-ip (60). In murine cell lines SOCS-1 is an
interferon-y inducible gene while overexpression of SOCS-1 in these cell lines
confers IFN-y resistance (88). Furthermore, SOCS-1 knock-out mice exhibit
excessive responses typical of those induced by IFN-y (hyper-responsiveness to viral
infection and enhanced IFN-y-dependent macrophage function) (139). This was
prevented by the administration of anti-IFN-y antibodies and did not occur in SOCS
V1' mice also lacking the IFN-y gene. On the basis of these observations it has been
speculated that SOCS-1 is a key modulator of IFN-y actions and may allow the
protective effects of this cytokine to occur without the risk of associated pathological
responses. In the context of the current study IFN-y expression in allogeneic organs,
like SOCS-1 expression, does not occur until day 5. It has been previously shown
that the upregulation of SOCS-1 in murine liver in response to IL-6 was rapid and
declined to basal levels within 4 hours. SOCS-1 contains a potential PEST sequence;
pest sequence containing proteins are predisposed to enhanced ubiquitination and
degradation. Indeed difficulties encountered by other investigators in reproducibly
expressing SOCS-1 to a moderate level in mammalian cells in vitro were overcome
by the addition of a GST-tag to the NH2 terminal of SOCS-1, hence conferring
resistance to degradation (82). These observations may explain the presence of
SOCS-1 in only the day 5 allogeneic organ and why, even on this day, expression
was only barely apparent.
The upregulation of CIS-1, as compared to its expression in native hearts and
syngeneic control, occurred only at day 3. Negative regulation of the JAK/STAT
pathway by CIS-1, at least in part, occur via its inhibition of STAT 5 proteins in a
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number of in vitro models. (73). Activation and recruitment of STAT 5 occurs in
response to multiple cytokines including IL-2, IL-3, IL-5, GM-CSF and
erythropoietin (57). In the current study IL-2 expression was only detectible in
allogeneic organ at day 5, and the expression of these other known STAT 5
activators was not investigated. Other studies, however, in murine systems have
documented increased expression of IL-3, IL-5 and GM-CSF in allogeneic organs
(135). The upregulation of CIS-1 at day 3 in the mismatched organ may reflect the
presence of such STAT 5-activating cytokines.
SOCS-2, although present in all organs, demonstrated no allogeneic-specific
upregulation. While SOCS-2 has been previously been demonstrated to be
constitutive in murine heart, expression in bone marrow was increased in response
various cytokines including IL-1 and IFN-y (60). The findings of the present study
may reflect both species and tissue differences in the nature of cytokine-induced
SOCS-2 upregulation.
The sustained rise of SOCS-3 in allogeneic organs as compared with increases of
CIS-1 and SOCS-1 at days 3 and 5 respectively is intriguing. Basal and cytokine-
induced SOCS expression exhibits striking tissue- and cell-type specificity (section
3.6). Recent evidence suggests that certain chemokines such as RANTES and MIP-
la may also activate the JAK/STAT pathway and indeed many of the mechanisms of
chemokine receptor-chemokine signal transduction are still unknown (140, 141). The
upregulation of multiple cytokines has been demonstrated in this model. In addition,
by virtue of the fact that whole organ was used for RNA analysis, these results reflect
a heterogeneous cell population. We cannot speculate, therefore, on the basis of these
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results as to which particular cytokines induce expression of particular SOCS
species. Profiling the expression of SOCS in mice in which "knock-out" technology
has deleted the gene for a particular cytokine and who subsequently undergo organ
transplantation would undoubtedly clarify this. To our knowledge this is the first
report of SOCS expression in animal transplant rejection. These findings raise the
tantalising possibility that SOCS-3, and indeed the specific cytokines which induce
its upregulation, may be important determinants in the process of acute cardiac
rejection.
Chemokine/chemokine receptor expression
The leukocyte population infiltrating the allograft is defined both by the nature of the
chemokines secreted by, as well the specific chemokine receptors expressed on, the
cytokine-activated allograft cells and the infiltrating cells themselves. Given the
central role of the nature of this infiltrating leukocyte population in promoting and
sustaining the alloreactive immune response, the expression of a variety of
representative C-C and C-X-C chemokines and their corresponding receptors was
profiled in this model.
While expression of RANTES was constitutive in all specimens, mRNA levels for
this chemokine was elevated in allogeneic allografts as compared to controls on days
3, 5 and 7 (Fig 3.32). mRNA for GRO was detected, allbeit at low levels, in control
specimens at day 1, while levels in the mismatched transplant at this time-point were
markedly elevated. On days 3-7, GRO expression was largely confined to allogeneic
tissue. (Fig 3.33). MCP-1 and MlP-la expression occurred in mismatched
transplants only (Days 1-7). (Fig 3.34, Fig. 3.35) In contrast, MIP-2 mRNA was
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Figure 3.32 RANTES expression in experimental acute cardiac transplant rejection
Expression of RANTES was constitutive in all specimens. mRNA levels for this chemokine were
elevated in allogeneic allografts as compared to controls on days 3, 5 and 7
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Figure 3.33 GRO-a expression in experimental acute cardiac transplant rejection
.mRNA for GRO-a was detected in control specimens at day 1, while levels in the mismatched
transplant at this time-point were markedly elevated. On days 3-7, GRO expression was largely
confined to allogeneic tissue.
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Figure 3.34 MCP-1 expression in experimental acute cardiac transplant rejection
MCP-l expression was largely confined to mismatched transplants on days 1, 3, 5 and 7.
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Figure 3.35 MIP-loc expression in experimental acute cardiac transplant rejection
MlP-la expression occurred in mismatched transplants on days 1, 3, 5 and 7.
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Figure 3.36 MIP-2 expression in experimental acute cardiac transplant rejection
MIP-2 mRNA was detected in all specimens but was not upregulated in acutely rejecting organs
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MCP-1 and MlP-la are monocyte/macrophage chemoattractants, while RANTES is
produced by T cells and draws both monocytes and T cells to the target tissue. The
C-X-C chemokines GRO-a and MIP-2 are predominantly neutrophil
chemoattractants, although GRO has been implicated in atherogenic
monocyte/macrophage accumulation. Cells migrating within tissues encounter
multiple chemoattractant signals in complex spatial and temporal patterns. There is
evidence that certain chemokines exert specificity for overlapping leukocyte
subpopulations e.g MCP-1, MlP-la, RANTES and GRO-a are all, to varying
degrees, monocyte chemoattractants. It may be, however, that the chemokines
demonstrated to be upregulated in the current study, over varying time courses,
participate in different ways to guide leukocyte subsets to their tissue destination and
ensure ongoing leukocyte recruitment (as evidenced by ongoing cellular infiltration
in the immunohistochemical studies). Some support for this theory comes from a
recent in vitro study in which it was demonstrated that GRO-a and its receptor
CXCR2, but not MCP-1 (or its receptor CCR1), mediated the conversion of
monocyte rolling into firm shear-resistant arrest on activated endothelium under
conditions of physiological flow. In contrast, MCP-1 and CCR2, but not GRO-
a/CXCR2 mediated spreading, shape change and subsequent transendothelial
migration (142).
The expression of the chemokine MIP-2 has been implicated in ischaemia-
reperfusion injury (143). Although constitutive expression ofMIP-2 was detected in
the current study, there was no evidence of increased expression in any organs in the
early days following surgery. Since MIP-2 is predominantly a neutrophil
chemoattractant, and given that these cells do not feature predominantly in the acute
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rejection process, it is not surprising that upregulation of this chemokine was not
detected in allogeneic organs. Conversely, the observations that T cell and
monocyte/macrophage chemoattractants are upregulated in this model concurs with
studies implicating these leukocyte subpopulations as the principal immune cell
mediators of acute transplant rejection.
Having demonstrated the upregulation of various chemokines in the allogeneic
organs, the expression of their corresponding receptors was next investigated. The
chemokine receptor CCR1 was detected in all specimens and upregulated in
allogeneic organs compared to control on days 1-7. (Fig. 3.37) CCR2 was detected in
rejecting hearts only (Fig. 3.38). CXCR2 was detected in all specimens at days 1 and
3, but was consistently elevated above control levels in the mismatched transplants.
At days 5 and 7 expression occurred exclusively in allogeneic organs. (Fig 3.39)
There was no evidence of expression of the chemokine receptor CXCR4 in any
specimens. CXCR4 and its corresponding ligand have been discussed in detail in
previous sections. To date only one study has documented CXCR4 expression in
human allograft kidneys undergoing severe rejection (144). This was not the case in





























Figure 3.37 CCR1 expression in experimental acute cardiac transplant rejection
CCRl was detected in all specimens but upregulated in allogeneic organs compared to control on days
1-7. In two samples while PCR fragments were apparent, these proved to be below the sensitivity
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Figure 3.38 CCR2 expression in experimental acute cardiac transplant rejection





























Figure 3.39 CXCR2 expression in experimental acute cardiac transplant rejection
CXCR2 was detected in all specimens at days 1 and 3, but was consistently elevated above control
levels in the mismatched transplants. At days 5 and 7 expression occurred exclusively in allogeneic
organs. At day 7 a PCR fragment of the expected size was apparent, but this proved to be below the
sensitivity threshold of the imaging/quantifying equipment.
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Chemokine receptor genes are expressed in a cell-type specific manner and it has
been speculated that this may be the basis for the specificity of chemokines for
leukocyte subsets. Although predominantly restricted to leukocytes, these receptors
have also been demonstrated on other cell types such as VSMC or endothelial cells,
either constitutively or in response to inflammatory stimuli. Most chemokine
receptors recognise more than one ligand and several chemokines bind to more than
one receptor. In relation to the chemokines relevant to the present study, CCR1 binds
MlP-la and RANTES; CCR2 is a receptor for MCP-1 while CXCR2 binds GRO-a
and MIP-2. The results of the current study confirm that the upregulation of
chemokine expression is paralleled by a concomitant upregulation in cognate
receptor expression, for example, increases in MCP-1 mRNA levels occur in tandem
with increases in CCR2 mRNA.
Progressive leukocyte infiltration of acutely rejecting hearts has been demonstrated
by immunohistology in the current model. Although broadly speaking the expression
of the chemokine receptors occur in tandem with increasing immune cell infiltration,
it should be noted that chemokine receptor expression is not necessarily restricted to
leukocytes as previously discussed. CXCR2 is detected in all organs at days 1 and 3,
but after this time expression occurs exclusively in allogeneic organs. This
expression pattern suggests that CXCR2 positive cells may be of particular
importance in the immune response associated with ischaemia-reperfiision injury.
Little is known about the regulation of chemokine receptor expression in vivo.
Studies in vitro have demonstrated that TNF-a results in downregulation of
neutrophil CXC chemokine receptors (145, 146). Increased mRNA levels for TNF-a
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in the allogeneic transplants over the time course studied appears to occur in parallel
with decreases in CXCR2 expression in these organs. In contrast, interferon-y and
IL-2 have been shown to increase the expression of CCR1 and CCR2 on T
lymphocytes and monocytes (147, 148). It is possible that the expression of these
cytokines in allogeneic organs at days 5 and 7 may sustain expression of these
chemokine receptors. It must be noted that the limitations of semiquantiative RT-
PCR prevent a definitive correlation between chemokine receptor expression and
cytokine expression.
The importance of the chemokine receptors in leukocyte trafficking and host defence
has been illustrated by targeted disruption of these genes in mice. Mice deficient in
CCR1 demonstrate impaired host defence, haematopoiesis and granulomatous
inflammation (149), while CCR2 deficiency results in impaired monocyte migration
and reduced Thl cytokine responses (150). Binding of a chemokine to its receptor
activates the intracellular pathways necessary to propel the cell towards the source of
chemoattractant. Activation of the leukocyte also ensues, as evidenced by rises in
intracellular calcium, production of microbicidal oxygen radicals and bioactive
lipids, and release of lytic enzymes from intracellular granules (Section 1.2.4). These
processes are facilitated by each of the many chemoattractant receptors expressed on
the leukocyte surface. In the context of allograft rejection, the current model has
demonstrated the upregulation of the chemokines RANTES, MCP-1, MlP-la and
GRO-a in allogeneic organs. This is in agreement with the results of other
investigators using similar models (143). We have also demonstrated the
upregulation of the chemokine receptors CCR1, CCR2 and CXCR2 in the allogeneic
organs, and to our knowledge this is the first report of upregulation of these receptors
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in this particular model. While we fully accept that the presence of a particular
chemokine receptor (or cytokine/chemokine) is not direct evidence of its
participation in the rejection response, these novel results raise exciting possibilities.
It has become clear, however, from the recent explosive growth in information
concerning chemokines and their functions that multiple chemokines can (1) bind to
a single chemokine receptor and (2) attract the same leukocyte subpopulations. It
may be therefore that immunomodulation at the level of chemokine gene expression
could be difficult and possibly ineffective. The discovery that chemokine receptors
act as cofactors for HIV infection has boosted the search for therapeutic strategies
targeting chemokine receptors and a number of chemokine receptor antagonists now
exist which are undergoing preliminary evaluation (151). For example, a truncated
form ofMCP-1 acts as an antagonist at the CCR2 receptor and prevents the chronic
inflammatory arthritis that develops in MRL-lpr mice. In a murine model of acute
inflammation, CXCR2 antagonists inhibit neutrophil recruitment. A recent study has
demonstrated for the first time that inbred mice with a targeted deletion of CCR1
resulted in a prolongation of cardiac allograft survival exchanged across a MHC
class II mismatch. In addition, levels of cyclosporin that had marginal effects in
CCR1+/+ mice resulted in permanent allograft acceptance in the CCR/_ recipients
(152). In light of the results presented here, it would be interesting to examine the
influence of chemokine receptor antagonists in the current model both on the
temporal nature of allograft rejection and on the expression profile of the immune
mediators found to be upregulated in the current study.
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Adhesion molecule expression
As has been described previously, while increasing gradients of chemokines attract
immune cells to the endothelium, and hence to the target tissue, the successful
extravasation of these cells absolutely requires their firm attachment to endothelium
via interactions between leukocyte integrins and endothelial expressed VCAM-1 and
ICAM-1. Given the crucial role of these adhesion molecules in the paradigm of
leukocyte trafficking, we evaluated their expression profile in this model. Although
mRNA for VCAM-1 was expressed constitutively, mRNA levels for this leukocyte
adhesion molecule and its related molecule ICAM-1 were elevated in rejecting
organs as compared to control over the time course studied (Fig. 3.41, Fig. 3.42).
Another study of rat cardiac allografts (Dark Agouti donors to WF recipients) has
also demonstrated that that ICAM-1 and VCAM-1 expression were markedly
upregulated in the acutely rejecting hearts (116). The same study, however, failed to
identify VCAM-1 expression on the vascular endothelium in native hearts and
demonstrated only weak expression in syngeneic grafts using immunohistochemical
techniques. Rat myocytes express VCAM-1 in vitro (153) and the observation that
VCAM-1 is constitutively expressed in the current study may reflect the fact that
whole hearts were used for RNA extraction and that a relatively sensitive detection
method i.e. RT-PCR was employed. The crucial role of ICAM-1 in the rejection
process has been confirmed in similar experimental models when administration of
monoclonal antibodies specific for this adhesion molecule resulted in significant
increases in allograft survival (154, 155). Whether such techniques will prove of
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Figure 3.40 VCAM-1 expression in experimental acute cardiac transplant rejection
mRNA for VCAM-1 was expressed constitutively in most specimens but mRNA levels for this
leukocyte adhesion molecule were elevated in rejecting organs as compared to controls over the time
course studied
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Figure 3.41 ICAM-1 expression in experimental acute cardiac transplant rejection
ICAM-l expression was detected in mismatched transplants only at days 1,3,5 and 7.
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Cyclooxygenase II
The role of arachidonic acid metabolites in the inflammatory response is well-
established. Arachiodonic acid, released from cellular phospholipase by the actions
of phospholipase A2 is converted to prostaglandins and thromboxane eicosanoids by
the actions of cyclooxygenase (COX). This enzyme exists in two isoforms, one
present in most cells under basal conditions - COX-1 and one which is rapidly and
transiently induced in response to a diverse range of stimuli - COX-2. As discussed
in detail in 2.4.3, depending on the inflammatory setting, COX-2 can be potentially
deleterious or protective. The role of COX-2 in the allogeneic immune response is
currently unknown and on this basis we chose to profile its expression in this model.
mRNA levels for COX-2 were markedly elevated in the mismatched rejecting organs
at days 1 and 3 (Fig 3.42). After this time point, expression levels fell markedly with
faint and no expression at days 5 and 7 respectively. Weak COX-2 expression was
detected in the syngeneic organ at days 1 and 5 only.
The regulation of COX-2 expression is the focus of intense research, most
particularly given its pathologic constitutive expression in colon cancer (156). To
date, the precise mechanisms underlying its expression in vivo have not been
elucidated. Broadly speaking, COX-2 expression is regulated by both transcriptional
and post-transcriptional mechanisms; the former involves classic transcription factor-
dependent promoter activation; the latter, regulation of mRNA translation.
Adenosine- and/or uridine-rich - AUUUA/AUn - elements (AREs) are found in the
3' untranslated (UTR) region of labile mRNA species encoding transiently expressed
proteins and have been shown to mediate selective translation-dependent
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Fig.3.42. mRNA levels for COX-2 were markedly elevated in the mismatched rejecting organs at
days 1 and 3. After this time point, expression levels fell markedly with faint and no expression at
days 5 and 7 respectively. Weak COX-2 expression was detected in the syngeneic organ at days 1 and
5 only.
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destabilization/degradation of such mRNAs (157). A number of ARE motifs are
located in the 3'-untranslated region of the human, rat and murine COX-2 genes;
moreover, studies have demonstrated that post-transcriptional regulation of human
COX-2 expression is mediated by its ARE-rich 3' UTR (158). It is necessary to
note, however, that in vitro, cytokine stimulation of various cell types results in
stabilization of COX-2 mRNA via a p38 MAPK-dependent mechanism (159, 160).
Our finding that COX-2 expression was transient and did not persist for the entire
time course of the study is, therefore, not wholly unexpected and is probably due to
the inherent lability of its mRNA. Moreover, while we have confirmed that increases
in the expression of a number of cytokine mRNAs is sustained in the current model,
in vitro cytokine-stimulation extends COX-2 mRNA half-life from minutes to hours
and, therefore, COX-2 expression in the current setting may be viewed, relatively
speaking, as prolonged.
Recently another group, using a similar model, have demonstrated that COX-2
expression is upregulated in the rejecting cardiac allografts (161). These authors also
demonstrated that increases in COX-2 mRNA levels are paralleled by increases in
COX-2 protein and prostaglandin production. Immunostaining revealed increases in
COX-2 protein expression in endothelial cells, vascular smooth muscle cells,
infiltating macrophages and damaged cardiac myocytes. Interestingly, in animals
treated with a selective COX-2 inhibitor, while there was a significant reduction in
COX-2 mRNA levels, this was not paralleled by a reduction in myocardial
inflammation or rejection grade in allogeneic organs. There was only a slight
increase in graft survival from 5.4 to 6.4 days.
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It is apparent therefore that COX-2 expression is induced in models of alloantigen-
driven inflammation, not altogether surprising given the high levels of infiltrating
leukocytes and ambient cytokines in acutely rejecting organs. The exact nature of its
role, however, remains unclear. As has previously been discussed, in carrageenin-
induced pleurisy in rats, selective COX-2 inhibitors, while inhibiting inflammation at
2 hours, result in a significant exacerbation in inflammation at 48 hours (162). This
model at 48 hours is dominated by mononuclear cell recruitment and these authors
have suggested that COX-2 expression at this time-point may aid inflammatory
resolution by the generation of anti-inflammatory prostaglandins. Likewise the
immune response in transplant rejection is dominated by mononuclear cell
recruitment and it could be argued that COX-2 production in this scenario is a
protective response designed to limit tissue damage. Studies in vitro have also
demonstrated that COX-2 induction in VSMC in response to cytokines limits their
adhesion molecule expression and cytokine release (163). Furthermore in animal
blood vessels following injury increases in VSMC COX-2 are associated with
increases in PGL and PGE2 production that compensates for the loss of PG synthesis
via constitutive COX-1 in endothelial cells. On this basis it was proposed that COX-
2 expression in VSMC may represent a defence mechanism which limits further
vessel damage. These observations could potentially explain the lack of response in
animals treated with the COX-2 inhibitor.
Alternatively if the induction of COX-2 is viewed as deleterious and responsible for
the promotion of tissue damage, it could be argued that the immune response
associated with allograft rejection is overwhelming. Often a combination of powerful
immunosuppressive agents is needed to ameliorate allograft survival. It might not be
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surprising that COX-2 inhibitors alone do not seem to alter this process. However it
might be that such treatment in combination with immunosuppressive agents may
improve outcomes or indeed reduce the doses of such agents required to suppress
rejection. We await with interest further developments in this field.
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Summary
The current study examined the expression of SOCS in an experimental model of
acute cardiac transplant rejection. In addition, we sought to correlate SOCS
expression with immune cell infiltration and the temporal expression of cytokines,
chemokines, chemokine receptors and adhesion molecules in this model.
Immunohistology confirmed that, in agreement with the current paradigm of acute
allograft rejection, immune cell infiltration of the rejecting hearts was rapid and
sustained over the time course studied. This occurred in tandem with increased
expression of cytokines (IL-ip, TNF-a, IL-2, IFN-y, TGF-p and IL-10), chemokines
(GRO-a, RANTES, MCP-1, MlP-la), adhesion molecules (ICAM-1 and VCAM-1)
and COX-2 in these organs. Of particular interest is the novel finding that increased
chemokine receptor (CCR1, CCR2 and CXCR2) expression occured in allogeneic
grafts, suggesting that chemokine receptor antagonists could potentially modify the
rejection process in this model.
In addition, allogeneic-specific upregulation of SOCS-3 occurred at all time points.
In contrast, increases in CIS-1 and SOCS-1 expression occurred in the mismatched
organs at days 3 and 5, respectively. The identify of the particular cytokines (or
chemokines) inducing the expression of these SOCS species is as yet unknown. To
our knowledge, this is the first report of SOCS expression in experimental cardiac
transplant rejection. These findings raise the possibility that these proteins may be
important in the modulation of the immune response leading to allograft rejection.
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Exposure ofmesangial cells to cyclic mechanical strain results in increases in mRNA
for TGF-J3 and CTGF. It has been demonstrated by other investigators in our group
that high glucose stimulates mesangial CTGF expression in vitro by TGF-p
dependent and protein kinase C-dependent pathways. The use of anti-TGF-p
antibodies will establish whether cyclic mechanical strain induces CTGF through
similar mechanisms. Stretch-induced increases in protein surface
expression/secretion may occur independently of transcriptional/translational
mechanisms; it will be important to investigate whether the surface expression of
leukocyte trafficking determinants, such as the chemokine receptors are increased in
response to cyclic mechanical strain in this manner.
To our knowledge, this is the first report of SOCS expression in experimental animal
models of inflammation. Current work in our laboratory is using dual staining
techniques is attempting to define the cell types expressing SOCS in these models. It
will be of great interest to define the physiological roles of these proteins in
inflammatory diseases since, given their ability to modulate cytokine bioactivity in
vitro. In particular, it will be intriguing to explore the possibility that SOCS mimetics
could be used as novel anti-inflammatory agents in vivo.
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Appendix 1.
Quantification data (raw volumes) for each gene studied in comparison to the
GAPDH loading control is detailed below for individual experiments.
Appendix 1A - Influence of mechanical strain on cytokine-adhesion molecule
networks in ECV-304 cells
ICAM-1
C24 S24 C48 S48
ICAM-1 25715.42 214291.77 46156.00 201790.59
GAPDH 71149.72 58299.69 68286.09 57266.47
RATIO 0.36 3.68 0.68 3.52
C24 S24 C48 S48
EXPT2
ICAM-1 23814.36 208876.43 36554.87 236753.95
GAPDH 89567.34 64509.74 88564.45 76439.65
RATIO 0.27 3.24 0.41 3.10
C24 S24 C48 S48
EXPT3
ICAM-1 15743.96 165964.97 21754.39 98765.66
GAPDH 98677.34 56743.95 76849.49 65976.99
RATIO 0.16 2.92 0.28 1.50
MCP-1
EXPT1
C24 S24 C48 S48
MCP-1 153067.78 77536.18 118979.50 640521.52
GAPDH 71149.72 58299.69 68286.09 57266.47
RATIO 2.15 1.33 1.74 11.18
C24 S24 C48 S48
EXPT2
MCP-1 180749.57 94632.12 145389.09 498543.44
GAPDH 61900.26 44890.76 62823.20 48103.83
RATIO 2.92 2.11 2.31 10.36
C24 S24 C48 S48
EXPT 3
MCP-1 232701.47 158721.23 153340.85 577045.84
GAPDH 95340.62 86283.54 101746.27 86472.37
RATIO 2.44 1.84 1.51 6.67
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IL-8
C24 S24 C48 S48
EXPT 1
IL-8 98279.00 214449.00 60667.00 101290.00
GAPDH 76005.50 83697.50 78310.00 86487.50
RATIO 1.29 2.56 0.77 1.17
C24 S24 C48 S48
EXPT 2
IL-8 73709.25 145825.32 43680.24 95212.60
GAPDH 41803.03 51222.87 37588.80 58811.50
RATIO 1.76 2.85 1.16 1.62
C24 S24 C48 S48
EXPT 3
IL-8 131693.86 330251.46 107380.59 189412.30
GAPDH 77197.99 81806.44 79264.03 84249.79
RATIO 1.71 4.04 1.35 2.25
RANTES
C24 S24 C48 S48
EXPT 1
RANTES 160404.07 101633.00 121402.00 138645.00
GAPDH 105558.15 108007.00 91798.17 102977.33
RATIO 1.52 0.94 1.32 1.35
C24 S24 C48 S48
EXPT 2
RANTES 135076.27 83875.29 104423.05 130360.39
GAPDH 132094.41 142582.70 121266.59 139232.01
RATIO 1.02 0.59 0.86 0.94
C24 S24 C48 S48
EXPT 3
RANTES 150908.15 90275.41 116886.45 123623.42
GAPDH 118272.35 132045.84 101804.05 123063.13
RATIO 1.28 0.68 1.15 1.00
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CXCR4
C24 S24 C48 S48
EXPT 1
CXCR4 84258.49 34847.33 23824.31 41067.50
GAPDH 71149.72 58299.69 68286.09 57266.47
RATIO 1.18 0.60 0.35 0.72
C24 S24 C48 S48
EXPT 2
CXCR4 98579.85 54168.45 31626.30 52486.20
GAPDH 59052.76 54589.47 73129.29 63172.72
RATIO 1.67 0.99 0.43 0.83
C24 S24 C48 S48
EXPT 3
CXCR4 75364.80 22542.15 26579.55 37009.50
GAPDH 95318.97 81669.11 74115.85 72742.53
RATIO 0.79 0.28 0.36 0.51
COX-1
C24 S24 C48 S48
EXPT-1
COX-1 217918.00 140977.50 132892.50 134140.00
GAPDH 71149.72 58299.69 68286.09 57266.47
RATIO 3.06 2.42 1.95 2.34
C24 S24 C48 S48
EXPT-2
COX-1 187652.29 140739.22 130831.18 153336.25
GAPDH 66190.58 54088.02 72316.58 61049.65
RATIO 2.84 2.60 1.81 2.51
C24 S24 C48 S48
EXPT-3
COX-1 206847.77 122060.87 122060.87 152033.11
GAPDH 60745.92 55734.38 66061.19 52848.95
RATIO 3.41 2.19 1.85 2.88
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COX-2
C24 S24 C48 S48
EXPT 1
COX-2 124875.00 44512.97 22162.60 49422.00
GAPDH 71149.72 58299.69 68286.09 57266.47
RATIO 1.76 0.76 0.32 0.86
C24 S24 C48 S48
EXPT 2
COX-2 130332.04 51728.79 29559.31 65139.95
GAPDH 67535.31 54536.26 72615.40 53829.80
RATIO 1.93 0.95 0.41 1.21
C24 S24 C48 S48
EXPT 3
COX-2 116047.65 40780.89 30927.79 58844.91
GAPDH 68621.56 55964.69 63741.80 60386.97
RATIO 1.69 0.73 0.49 0.97
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Appendix IB - Influence of cyclic mechanical strain on glomerular endothelial
and mesangial cell activation in vitro
TGF-P
EXPT 1
C24 S24 C48 S48 C72 S72
TGF 39129.40 58606.00 53572.00 51270.00 63717.20 67160.40
GAPDH 68158.33 77431.86 71314.69 33534.10 80867.00 32562.45
RATIO 0.57 0.76 0.75 1.53 0.79 2.06
EXPT 2
C24 S24 C48 S48 C72 S72
TGF 37913.66 62685.94 55133.42 44710.93 71928.79 62197.25
GAPDH 74706.45 81627.00 66366.30 43475.25 82514.25 40281.15
RATIO 0.51 0.77 0.83 1.03 0.87 1.54
EXPT 3
C24 S24 C48 S48 C72 S72
TGF 45768.29 65102.75 60722.28 53622.91 62232.79 64045.39
GAPDH 63527.10 67785.90 62994.75 37087.05 76126.05 26794.95
RATIO 0.72 0.96 0.96 1.45 0.82 2.39
CTGF
EXPT 1
C24 S24 C48 S48 C72 S72
CTGF 244920.04 220133.00 121290.96 267014.98 131979.24 233941.77
GAPDH 68158.33 77431.86 71314.69 33534.10 80867.00 32562.45
RATIO 3.59 2.84 1.70 7.96 1.63 7.18
EXPT 2
C24 S24 C48 S48 C72 S72
CTGF 232142.82 197938.20 142425.79 239432.33 163172.85 266908.17
GAPDH 77098.60 86608.56 76024.99 43286.96 91302.74 41414.92
RATIO 3.01 2.29 1.87 5.53 1.79 6.44
EXPT 3
C24 S24 C48 S48 C72 S72
CTGF 329149.37 272338.19 185245.26 288927.31 127183.31 277176.68
GAPDH 64039.74 67682.72 64039.74 28185.16 74585.21 25884.33




C24 S24 C48 S48 C72 S72
IL-8 197735.00 124588.93 185158.56 34798.40 209078.33 73014.00
GAPDH 68158.33 77431.86 71314.69 33534.10 80867.00 32562.45
RATIO 2.90 1.61 2.60 1.04 2.59 2.24
EXPT 2
C24 S24 C48 S48 C72 S72
IL-8 126011.51 72006.58 131280.28 18879.77 146647.54 43028.32
GAPDH 58927.78 68437.74 63343.12 31416.83 73532.36 24454.18
RATIO 2.14 1.05 2.07 0.60 1.99 1.76
EXPT 3
C24 S24 C48 S48 C72 S72
IL-8 171235.15 116791.16 162453.86 34798.40 193188.38 78153.48
GAPDH 70985.05 79306.27 77345.09 36563.89 90684.25 39039.57
RATIO 2.41 1.47 2.10 0.95 2.13 2.00
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Appendix 1C - Regulation of SOCS expression in glomerular endothelial and
mesangial cells in vitro
SOCS-3 (glomerular endothelial cells).
EXPT 1
Control IL-1 IL-4 IL-6 TNF IFN
SOCS-3 50272.00 107759.00 95750.00 109201.00 113574.00 156926.00
GAPDH 92783.00 95524.00 97147.00 97951.00 99987.00 96405.00
RATIO 0.54 1.13 0.99 1.11 1.14 1.63
EXPT 2
Control IL-1 IL-4 IL-6 TNF IFN
SOCS-3 59782.99 94249.76 80738.43 95238.39 107761.08 170253.12
GAPDH 94430.00 100440.00 101240.00 100800.00 104570.00 99310.00
RATIO 0.63 0.94 0.80 0.94 1.03 1.71
EXPT 3
Control IL-1 IL-4 IL-6 TNF IFN
SOCS-3 77556.32 119058.01 87654.80 124000.00 133703.86 159555.96
GAPDH 92110.00 93200.00 99410.00 103340.00 98400.00 95280.00
RATIO 0.84 1.28 0.88 1.20 1.36 1.67
CIS-1 (glomerular endothelial cells).
EXPT 1
Control IL-1 IL-4 IL-6 TNF IFN
CIS-1 14272.13 27431.86 34322.50 26575.50 45172.50 80392.50
GAPDH 92783.00 95524.00 97147.00 97951.00 99987.00 96405.00
RATIO 0.15 0.29 0.35 0.27 0.45 0.83
EXPT 2
Control IL-1 IL-4 IL-6 TNF IFN
CIS-1 21609.50 37816.63 35621.92 31063.66 54699.06 98762.19
GAPDH 96650.00 102650.00 107936.75 107888.99 112427.59 127728.98
RATIO 0.22 0.37 0.33 0.29 0.49 0.77
EXPT 3
Control IL-1 IL-4 IL-6 TNF IFN
CIS-1 10992.23 21569.66 36754.56 36502.50 47079.93 73627.21
GAPDH 54182.63 64643.64 70276.49 78591.64 94149.03 110242.89




Control IL-1 IL-4 IL-6 TNF IFN
SOCS 3 231220.20 247985.40 134606.00 131617.40 161477.20 307627.00
GAPDH 80538.50 78161.00 77489.00 74323.50 57933.50 87024.50
RATIO 2.87 3.17 1.74 1.77 2.79 3.53
EXPT 2
Control IL-1 IL-4 IL-6 TNF IFN
SOCS 3 244840.33 286831.41 167964.34 175716.54 211247.46 416839.69
GAPDH 101853.93 98390.89 99032.57 66948.59 65879.12 97963.11
RATIO 2.40 2.92 1.70 2.62 3.21 4.26
EXPT 3
Control IL-1 IL-4 IL-6 TNF IFN
SOCS 3 190829.21 201333.57 122550.87 103292.88 182075.58 281867.00
GAPDH 75290.42 62029.04 85129.51 81279.43 69729.20 80637.75
RATIO 2.53 3.25 1.44 1.27 2.61 3.50
CIS-1 (mesangial cells)
EXPT 1
Control IL-1 IL-4 IL-6 TNF IFN
CIS-1 29834.69 35250.19 30201.85 22275.12 40108.77 38442.42
GAPDH 80538.50 78161.00 77489.00 74323.50 57933.50 87024.50
RATIO 0.37 0.45 0.39 0.30 0.69 0.44
EXPT 2
Control IL-1 IL-4 IL-6 TNF IFN
CIS-1 46157.17 53408.46 46769.79 41161.90 51753.11 60687.62
GAPDH 67800.79 60400.00 74928.09 67983.54 47698.13 79131.38
RATIO 0.68 0.88 0.62 0.61 1.09 0.77
EXPT 3
Control IL-1 IL-4 IL-6 TNF IFN
CIS-1 39578.88 37773.53 36801.42 31524.23 54577.20 46800.29
GAPDH 72004.07 73283.33 73831.59 72186.82 50987.65 76755.61
RATIO 0.55 0.52 0.50 0.44 1.07 0.61
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